"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CN,U,CN 208583198 U,142-558-754-391-717,2019-03-08,2019,CN 201721339440 U,2017-10-17,US 201662409172 P,2016-10-17,Hybrid tube controller and hybrid tube subassembly,"The utility model provides a hybrid tube controller and hybrid tube subassembly, hybrid tube controller are used for the distributor including the frozen food of hybrid tube subassembly, and the hybrid tube subassembly has the base and follows the air hose that the base extends, and the base has the product annular ring, and the hybrid tube controller includes: the board, the central opening and the first and second product openings are injectd to the board, and wherein first open -ended area is different from second open -ended area, and central open -ended size is set to makes the air hose of hybrid tube subassembly can pass this center opening, be connected to the handle of board is worked as the hoarding winds during the air hose of hybrid tube subassembly location, the handle is allowwed the board for the first and second at least angular positions are arrived in the air hose rotation, wherein the handle is rotatory will to make the first opening in the board aim at with the product annular ring basically to first angular position to rotate handle will make the second opening in the board aim at with the product annular ring basically to the second angular position.",FBD PARTNERSHIP LP,CARLOS ACOSTA,,https://lens.org/142-558-754-391-717,Limited Patent,no,0,0,5,5,0,A23G9/28;;A23G9/222;;A23G9/28;;A23G9/222,B01F23/10,,0,0,,,,INACTIVE
2,CN,U,CN 207999985 U,035-635-659-349-745,2018-10-23,2018,CN 201721364668 U,2017-10-17,US 201662409172 P,2016-10-17,Frozen food distributor and division board thereof,"Frozen food distributor and division board thereof is disclosed, the drive shaft of frozen food distributor in extending to freezing bucket, freezing bucket has the roughly circular shape cross section of limited diameter, the division board includes: the design is for the drive shaft that is connected to the food distributor and the roughly circular shape board in freezing bucket, and wherein thedistance between the inboard of outward flange and the refrigeration bucket of division board is in between 2% and 7% of diameter of freezing bucket.",FBD PARTNERSHIP LP,CARLOS ACOSTA,,https://lens.org/035-635-659-349-745,Limited Patent,no,0,0,5,5,0,A23G9/28;;A23G9/222;;A23G9/28;;A23G9/222,F25D23/00;;B01F23/10,,0,0,,,,INACTIVE
3,CA,C,CA 2948927 C,185-452-586-192-94X,2020-12-15,2020,CA 2948927 A,2014-05-16,CL 2014000024 W,2014-05-16,"ROBOTIC MACHINE FOR REMOVING AND INSERTING TROMMEL SCREENS, AND OPERATING METHOD THEREOF","The invention relates to a robotic machine for removing and inserting trommel screens or panels (19), said machine comprising: a tool for grabbing the panel; a robotic arm with 6 degrees of freedom which manipulates the tool and which permits the panel to be removed and replaced; and a mobile main beam which is anchored to the structure of the building or site of installation or assembly, and which permits the manipulator or robotic arm to be moved and inserted inside the trommel, in order to carry out the operation. The invention also relates to the method for operating said robotic machine.",CARMONA ACOSTA CARLOS;;MI ROBOTIC SOLUTIONS S A,CARMONA ACOSTA CARLOS,,https://lens.org/185-452-586-192-94X,Granted Patent,no,0,0,6,6,0,B25J5/02;;B25J13/085;;B25J15/0052,B25J11/00;;B25J15/10;;E21D11/40,,0,0,,,,ACTIVE
4,CL,A1,CL 2016002914 A1,044-319-827-335-45X,2017-04-28,2017,CL 2016002914 A,2016-11-16,CL 2014000024 W,2014-05-16,Máquina robótica para el retiro e inserción de parrillas trommel y su método de operación.,"Máquina robótica para el retiro e inserción de parrillas o palmetas del Trommel, caracterizada porque comprende una herramienta para la toma de la palmeta, un brazo robótico de 6 grados de libertad que manipula la herramienta y que permite retirar y reponer la palmeta y una viga principal móvil que se ancla a la estructura del edificio o lugar de instalación o de montaje y que permite desplazar el manipulador o brazo robótico e introducirlo al interior del Trommel para desarrollar la operación.",MI ROBOTIC SOLUTIONS S A,CARMONA ACOSTA CARLOS,,https://lens.org/044-319-827-335-45X,Patent Application,no,0,0,6,6,0,B25J15/0052;;B25J5/02;;B25J13/085,B23P19/00;;B23P19/02;;B23P19/04;;B25J9/00,,0,0,,,,PENDING
5,WO,A1,WO 2012/055378 A1,013-009-121-667-331,2012-05-03,2012,CR 2010000002 W,2010-10-28,CR 2010000002 W,2010-10-28,WIND-TURBINE ROTOR,"A windmill-style wind-turbine rotor, the axis of which is substantially aligned with the wind direction, characterized in that the blades thereof have a truncated conical surface shape with curved edges approximately perpendicular to the generator of said surface.",UNIV COSTA RICA;;ACOSTA NASSAR CARLOS,ACOSTA NASSAR CARLOS,,https://lens.org/013-009-121-667-331,Patent Application,yes,5,1,1,1,0,F03D1/00;;F05B2240/2211;;Y02E10/72,F03D1/06,,0,0,,,,PENDING
6,WO,A1,WO 2015/081455 A1,094-057-116-365-333,2015-06-11,2015,CL 2013000087 W,2013-12-02,CL 2013000087 W,2013-12-02,"ROBOTISED AND/OR REMOTE-CONTROLLED MACHINE FOR REMOVING AND INSERTING SWITCHGEAR EQUIPMENT, COMPRISING A CHASSIS, WHEELS, A SUPPORT, A STRUCTURE, A CAMERA, AND CONTROLS, AND METHOD FOR SAME","The invention relates to a robotised and/or remote-controlled machine for removing and inserting switchgear equipment, which eliminates the risk of electric arc to the operator, comprising: a main chassis (1) which provides the structure for the whole machine; a drivetrain which allows the machine to move over the entire plane; a supporting system (5) which allows the drivetrain to be connected to the chassis; an upper structure (6) which supports a traction mechanism so that the switchgear equipment can be removed or inserted; at least one viewing camera; and a power panel, a control panel and a man-machine interface, the function of which is to provide the robotic machine with power and control. The invention further relates to the method for removing and inserting the switchgear equipment.",MI ROBOTIC SOLUTIONS S A;;CARMONA ACOSTA CARLOS,CARMONA ACOSTA CARLOS,,https://lens.org/094-057-116-365-333,Patent Application,yes,4,16,1,1,0,B25J5/007;;B25J15/0293;;H02B3/00,B25J9/16;;B25J5/00;;B25J19/04;;G05B15/02,,1,0,,,"MINORU MIDA ET AL.: ""A Task Analysis and a Controller System Design for a Power Distribution Line Maintenance Rbot''."", 2ND INTERNATIONAL CONFERENCE ON APPLIED ROBOTICS FOR THE POWER INDUSTRY (CARPI) ETH ZURICH, 11 September 2012 (2012-09-11)",PENDING
7,US,A1,US 2006/0144441 A1,080-915-251-158-820,2006-07-06,2006,US 2839805 A,2005-01-03,US 2839805 A,2005-01-03,Inflation device with automatic disconnect,"An apparatus that injects fluid into an inflatable device, dynamically monitors the pressure inside the device, and automatically terminates the inflation and disconnects from the inflatable device when the pressure inside the device reaches a predetermined value preset by the operator. After securing a chuck to the valve of an inflatable device by simply pulling a trigger similar to that of a pistol, the operator initiates the inflation and does not need to intervene further.",ACOSTA CARLOS R,ACOSTA CARLOS R,,https://lens.org/080-915-251-158-820,Patent Application,yes,18,11,2,2,0,F16K11/0716;;F16K11/161;;Y10T137/3584;;Y10T137/3724;;Y10T137/3584;;Y10T137/3724;;F16K11/161;;F16K11/0716,F16K11/14,137/223,0,0,,,,INACTIVE
8,WO,A1,WO 2015/172262 A1,145-464-776-481-571,2015-11-19,2015,CL 2014000024 W,2014-05-16,CL 2014000024 W,2014-05-16,"ROBOTIC MACHINE FOR REMOVING AND INSERTING TROMMEL SCREENS, AND OPERATING METHOD THEREOF","The invention relates to a robotic machine for removing and inserting trommel screens or panels (19), said machine comprising: a tool for grabbing the panel; a robotic arm with 6 degrees of freedom which manipulates the tool and which permits the panel to be removed and replaced; and a mobile main beam which is anchored to the structure of the building or site of installation or assembly, and which permits the manipulator or robotic arm to be moved and inserted inside the trommel, in order to carry out the operation. The invention also relates to the method for operating said robotic machine.",MI ROBOTIC SOLUTIONS S A;;CARMONA ACOSTA CARLOS,CARMONA ACOSTA CARLOS,,https://lens.org/145-464-776-481-571,Patent Application,yes,5,8,6,6,0,B25J15/0052;;B25J5/02;;B25J13/085,B25J11/00;;B25J15/10;;E21D11/40,,0,0,,,,PENDING
9,PE,A1,PE 20170725 A1,141-796-783-413-185,2017-07-04,2017,PE 2016002234 A,2014-05-16,PE 2016002234 A,2014-05-16,MAQUINA ROBOTICA PARA EL RETIRO E INSERCION DE PARRILLAS TROMMEL Y SU ME TODO DE OPERACION,"COMPRENDE UNA HERRAMIENTA PARA LA TOMA DE LA PALMETA, UN BRAZO ROBOTICO DE 6 GRADOS DE LIBERTAD QUE MANIPULA LA HERRAMIENTA Y QUE PERMITE RETIRAR Y REPONER LA PALMETA Y UNA VIGA PRINCIPAL MOVIL QUE SE ANCLA A LA ESTRUCTURA DEL EDIFICIO O LUGAR DE INSTALACION O DE MONTAJE Y QUE PERMITE DESPLAZAR EL MANIPULADOR O BRAZO ROBOTICA E INTRODUCIRLO AL INTERIOR DEL TROMMEL PARA DESARROLLAR LA OPERACION; ADEMAS, SE DESCRIBE EL METODO DE OPERACION DE DICHA MAQUINA ROBOTICA",MI ROBOTIC SOLUTIONS S A,CARMONA ACOSTA CARLOS,,https://lens.org/141-796-783-413-185,Patent Application,no,0,0,1,1,0,,B25J11/00;;B25J15/10;;E21D11/40,,0,0,,,,PENDING
10,AU,A1,AU 2014/394044 A1,114-560-645-241-979,2016-12-01,2016,AU 2014/394044 A,2014-05-16,CL 2014000024 W,2014-05-16,"Robotic machine for removing and inserting trommel screens, and operating method thereof","The invention relates to a robotic machine for removing and inserting trommel screens or panels (19), said machine comprising: a tool for grabbing the panel; a robotic arm with 6 degrees of freedom which manipulates the tool and which permits the panel to be removed and replaced; and a mobile main beam which is anchored to the structure of the building or site of installation or assembly, and which permits the manipulator or robotic arm to be moved and inserted inside the trommel, in order to carry out the operation. The invention also relates to the method for operating said robotic machine.",MI ROBOTIC SOLUTIONS S A;;CARMONA ACOSTA CARLOS,CARMONA ACOSTA CARLOS,,https://lens.org/114-560-645-241-979,Patent Application,no,0,0,6,6,0,B25J15/0052;;B25J5/02;;B25J13/085,B25J11/00;;B25J15/10;;E21D11/40,,0,0,,,,ACTIVE
11,AU,B2,AU 2014/394044 B2,158-208-660-301-144,2019-04-04,2019,AU 2014/394044 A,2014-05-16,CL 2014000024 W,2014-05-16,"Robotic machine for removing and inserting trommel screens, and operating method thereof","The invention relates to a robotic machine for removing and inserting trommel screens or panels (19), said machine comprising: a tool for grabbing the panel; a robotic arm with 6 degrees of freedom which manipulates the tool and which permits the panel to be removed and replaced; and a mobile main beam which is anchored to the structure of the building or site of installation or assembly, and which permits the manipulator or robotic arm to be moved and inserted inside the trommel, in order to carry out the operation. The invention also relates to the method for operating said robotic machine.",CARMONA ACOSTA CARLOS;;MI ROBOTIC SOLUTIONS S A,CARMONA ACOSTA CARLOS,,https://lens.org/158-208-660-301-144,Granted Patent,no,5,0,6,6,0,B25J5/02;;B25J13/085;;B25J15/0052,B25J11/00;;B25J15/10;;E21D11/40,,0,0,,,,ACTIVE
12,CA,A1,CA 2948927 A1,163-832-512-029-636,2015-11-19,2015,CA 2948927 A,2014-05-16,CL 2014000024 W,2014-05-16,"ROBOTIC MACHINE FOR REMOVING AND INSERTING TROMMEL SCREENS, AND OPERATING METHOD THEREOF","The invention relates to a robotic machine for removing and inserting trommel screens or panels (19), said machine comprising: a tool for grabbing the panel; a robotic arm with 6 degrees of freedom which manipulates the tool and which permits the panel to be removed and replaced; and a mobile main beam which is anchored to the structure of the building or site of installation or assembly, and which permits the manipulator or robotic arm to be moved and inserted inside the trommel, in order to carry out the operation. The invention also relates to the method for operating said robotic machine.",CARMONA ACOSTA CARLOS;;MI ROBOTIC SOLUTIONS S A,CARMONA ACOSTA CARLOS,,https://lens.org/163-832-512-029-636,Patent Application,no,0,0,6,6,0,B25J15/0052;;B25J5/02;;B25J13/085,B25J11/00;;B25J15/10;;E21D11/40,,0,0,,,,ACTIVE
13,CR,A,CR 11090 A,011-025-821-293-542,2010-01-19,2010,CR 11090 A,2009-11-03,CR 11090 A,2009-11-03,ROTOR PARA TURBINA EOLICA,"Un rotor para turbina eolica del tipo de molino de viento, cuyo eje se encuentra sustancialmente alineado con la direccion del viento, caracterizado por sus alabes tienen forma de superficie conica recortada con bordes curvos aproximadamente perpendiculares a al generatriz de dicha superficie.",UNIV COSTA RICA,CARLOS ACOSTA NASSAR,,https://lens.org/011-025-821-293-542,Patent Application,no,0,0,1,1,0,Y02E10/72,F03D1/06,,0,0,,,,PENDING
14,US,B2,US 7270142 B2,104-086-726-573-635,2007-09-18,2007,US 2839805 A,2005-01-03,US 2839805 A,2005-01-03,Inflation device with automatic disconnect,"An apparatus that injects fluid into an inflatable device, dynamically monitors the pressure inside the device, and automatically terminates the inflation and disconnects from the inflatable device when the pressure inside the device reaches a predetermined value preset by the operator. After securing a chuck to the valve of an inflatable device by simply pulling a trigger similar to that of a pistol, the operator initiates the inflation and does not need to intervene further.",ACOSTA CARLOS R,ACOSTA CARLOS R,,https://lens.org/104-086-726-573-635,Granted Patent,yes,19,13,2,2,0,F16K11/0716;;F16K11/161;;Y10T137/3584;;Y10T137/3724;;Y10T137/3584;;Y10T137/3724;;F16K11/161;;F16K11/0716,F16K15/20,137/223;;137/231;;141/392;;152/415,0,0,,,,INACTIVE
15,MX,A,MX 2014011888 A,035-641-488-741-312,2016-03-17,2016,MX 2014011888 A,2014-09-18,MX 2014011888 A,2014-09-18,CORE LIAISON SYSTEM (PROENLACE NUCLEO).,"The liaison process between Government and Citizens used by the Proenlace system makes use of a plurality of advanced technologies to provide means for different governments to have a closer relationship with its citizens. Moreover, it is worth mentioning that the Proenlace system consists of a set of technological tools that allow different government entities to establish a direct co-relation to solve first and foremost, the main complaints regarding the public services provided, through software that facilitates the management and treatment thereof. It also allows governments to have a more direct approach with citizens through tools that facilitate sending customized messages, thus strengthening the field of social communication. Likewise, public security will be benefited as well, since every citizen with a smartphone will be able to send a customized and geo-referenced alert (panic, fire or medical). This will be supported by a dispatch unit system that will be included in Proen lace, this will allow public and social security forces to act quickly and efficiently in order to address the citizens’ needs.",MORALES CARLOS HUMBERTO ACOSTA,MORALES CARLOS HUMBERTO ACOSTA,,https://lens.org/035-641-488-741-312,Patent Application,no,0,0,1,1,0,,G06Q30/02,,0,0,,,,PENDING
16,ES,A1,ES 2953761 A1,015-247-190-200-328,2023-11-15,2023,ES 202230320 A,2022-04-08,ES 202230320 A,2022-04-08,"PLASTIC RING FOR PROTECTION OF CONSTRUCTION GAPS (Machine-translation by Google Translate, not legally binding)","It is an industrial piece to provide a stable surface of exact size to be placed or integrated into a work opening, in such a way that a firm edge would be achieved in a work opening with an exact deviation and in accordance with the required needs in the necessary work spaces. A piece formed by a single ring-shaped assembly, from which extensions start so that it can be fixed by itself in a work space. If the hole were made precisely, this piece would be perfectly integrated into the hole. In the event that the gap does not have a circular shape, this piece can be integrated into the gap using putty or some material to fill the gaps between the surface and this piece, and it can later be sanded and repaired so that it is fully integrated into the gap. gap. The extensions are wedge-shaped at the ends in the direction of introduction of the piece into the hole, and in the opposite direction to extraction, in such a way that once introduced it remains installed and is not easy to remove. (Machine-translation by Google Translate, not legally binding)",RENOVA540 SL,ALVAREZ ACOSTA ROBERTO CARLOS,,https://lens.org/015-247-190-200-328,Patent Application,no,6,0,1,1,0,E04F13/06;;E04F13/074;;F16C33/20,E04F13/06;;F16C33/20,,0,0,,,,PENDING
17,US,S,US D0848060 S,128-807-148-865-190,2019-05-07,2019,US 201729630051 F,2017-12-19,US 201729630051 F,2017-12-19,Makeup sponge,,LUDERT CARLOS;;ACOSTA MONICA,LUDERT CARLOS;;ACOSTA MONICA,,https://lens.org/128-807-148-865-190,Design Right,no,19,14,1,1,0,,,2802;;D28/7,3,0,,,"20061001 Sugar Cookies, https://commons.wikimedia.org/wiki/File:20061001_sugar_cookies.jpg (Nov. 12, 2018).;;Viola Sugar Cookies, http://almostunschoolers.blogspot.com/2012/05/viola-sugar-cookies.html (Nov. 12, 2018).;;Jumbo Flower Foam Shapes, https://www.orientaltrading.com/jumbo-flower-shapes-a2-13673899.fltr (Nov. 12, 2018).",ACTIVE
18,US,A1,US 2015/0322919 A1,187-501-381-351-354,2015-11-12,2015,US 201514705963 A,2015-05-06,US 201514705963 A;;US 201461989465 P,2014-05-06,Electricity Generating Wind Turbine,"The invention relates to a wind turbine rotor comprising of a central warhead, blades with asymmetrical conical geometry and an external girth. The warhead distributes air from to a central section aerodynamically to the blades, which together account for more area than an area of a circle described by an outer girth or cinch around all said blades, so they produce more torque than conventional turbines. The outer girth eliminates friction between the blades and the wind and also stiffens the whole rotor. There is also a stiffening polygon between the blades. Being a multi-blade turbine together with the geometrical form of the blades makes the turbine starts generating at 3 to 4 m/s wind speed. The present invention is good looking and silent.",ACOSTA-NASSAR CARLOS ALBERTO;;CORPORACIÓN SKYTWISTER S A,ACOSTA-NASSAR CARLOS ALBERTO,CORPORACIÓN SKYTWISTER S. A (2015-05-06),https://lens.org/187-501-381-351-354,Patent Application,yes,1,3,1,1,0,F03D1/0625;;F03D1/0633;;F05B2240/2211;;F05B2240/33;;F05B2250/232;;F05B2250/24;;F03D80/82;;F03D9/25;;Y02E10/72;;F03D1/0625;;F03D1/0691;;F03D7/0204;;F03D9/25;;F03D80/82;;F03D1/0633;;F05B2250/232;;F05B2240/33;;F05B2250/24;;F05B2240/2211;;Y02E10/72;;F03D1/0675,F03D1/06;;F03D7/02;;F03D9/00;;F03D11/00,,0,0,,,,DISCONTINUED
19,US,S,US D0703811 S,187-335-623-012-662,2014-04-29,2014,US 201229427328 F,2012-07-17,US 201229427328 F,2012-07-17,Female urine funnel,,LUDERT CARLOS;;ACOSTA MONICA,LUDERT CARLOS;;ACOSTA MONICA,,https://lens.org/187-335-623-012-662,Design Right,no,0,6,1,1,0,,,2404;;D24/122,0,0,,,,ACTIVE
20,AR,A1,AR 000434 A1,048-224-859-143-130,1997-06-18,1997,AR 33714796 A,1996-06-20,AR 33714796 A,1996-06-20,Mejoras en estructuras de soporte para la conformación de estanterías cerramientos interiores y similares,"Mejoras en estructuras de soporte para la conformación de estanterías, cerramientos interiores y similares, del tipo que comprenden en combinación, almenos un parante o columna vertical, que sostiene, al menos una viga horizontal que es dondese instalan los paneles de cerramiento, estantes, etc; estandoambos unidos entre sí, a través de un medio de unión, que se aloja en el interior de la viga (en su extremo de unión) y se proyecta hacia afuera paraanclarse en la columna;teniendo l a columna canales longitudinales exteriores previstos para estos anclajes, que incluyen recursos de traba cooperantes conel medio de unión, en tanto que dicho medio de unión está constituido por dos plaquetas enfrentadas que, por laacción de un perno roscado de empuje, queatraviesa una pared de la viga, producen la retención de la viga y su anclaje en la columna, caracterizadas las mejoras por el hecho de que los canaleslongitudinales exteriores de la columna, son definidospor pares de n ervios longitudinales rectos y divergentes que incluyen, cada uno de ellos, dos paresde pestanas transversales, orientadas, dos a dos, hacia el interior de los canales en tanto que, cada medio de unión está constituido por unpar deplaquetas , iguales, y unidas entre sí, por un borde vertical, a través de un perno de abisagramiento, mientras que, por su borde opuesto, presentanrespectivamente, pares de dientes, orientados hacia afuera, de acción de traba cooperantecon las pestanas d e los canales definidos en la columna.",SUAREZ DIEGO GUSTAVO;;ACOSTA JUAN CARLOS,SUAREZ DIEGO GUSTAVO;;ACOSTA JUAN CARLOS,,https://lens.org/048-224-859-143-130,Patent Application,no,0,0,1,1,0,,A47F7/00;;E04B2/74,,0,0,,,,PENDING
21,US,A1,US 2017/0027185 A1,074-752-705-249-452,2017-02-02,2017,US 201615220837 A,2016-07-27,US 201615220837 A;;US 201562199423 P,2015-07-31,FROZEN BEVERAGE DISPENSER,An improved frozen product dispenser wherein a product is placed into a cooled hopper and the product is then fed from the hopper into a freezing and dispensing chamber where it is frozen and dispensed.,FBD PARTNERSHIP LP,ACOSTA CARLOS;;GRACZYK ANDREW;;SALAZAR GILBERT,FBD PARTNERSHIP LP (2016-07-29),https://lens.org/074-752-705-249-452,Patent Application,yes,14,12,17,17,0,A23G9/281;;F25B39/02;;A23G9/22;;A23G9/28;;B67D1/0801;;B67D1/0858;;F25D23/00;;F25D31/002;;F25B2339/02;;F16J15/061;;F16J15/064;;F16J15/3268;;A23G9/045;;A23G9/281;;F16J15/3236;;A23G9/045;;A23G9/224;;A23G9/281;;F16J15/061;;F16J15/064;;F16J15/3268;;F16J15/3236;;A23G9/222;;F25D11/022;;F25D29/003;;F25D31/002;;F25D2600/02;;F25D2600/04,A23G9/04;;A23G9/28;;F25B41/20;;F25B41/31;;F25B41/37,,0,0,,,,DISCONTINUED
22,US,B2,US 9646129 B2,107-116-357-513-525,2017-05-09,2017,US 201514726304 A,2015-05-29,US 201514726304 A;;US 201414225379 A;;US 201361804919 P,2013-03-25,Notch detection and correction in mask design data,"Mask data is analyzed for the presence of a notch. A notch candidate on a polygon boundary of mask data is defined as a plurality of line segments that includes an initial line segment, a final line segment and at least two line segments therebetween. The initial and final line segments define adjacent edges of the notch candidate. A direction of each line segment is a direction of travel from the initial line segment to the final line segment.",SYNOPSYS INC,ACOSTA CARLOS;;SALAZAR DANIEL;;MORALES DOMINGO,SYNOPSYS INC (2015-01-20),https://lens.org/107-116-357-513-525,Granted Patent,yes,5,0,3,3,0,G03F1/36;;G03F1/36;;G06F30/398,G06F17/50;;G03F1/36,,2,0,,,"U.S. Appl. No. 14/225,379, Non-Final Office Action mailed Sep. 30, 2014.;;U.S. Appl. No. 14/225,379, Notice of Allowance mailed Feb. 10, 2015.",ACTIVE
23,CN,A,CN 106403469 A,158-779-969-746-570,2017-02-15,2017,CN 201610621730 A,2016-08-01,US 201562199423 P;;US 201615220837 A,2015-07-31,FROZEN BEVERAGE DISPENSER and Feed hopper assembly,"A fronzen beverage dispenser and a feed hopper assembly for use in a dispensing device comprising: a hopper configured to receive and store a product defining at least a first side wall, a second side wall, a vertical dimension And a horizontal dimension; and a tube configured to allow the refrigerant to flow therethrough, thermally connecting to the first and second side walls of the hopper, the tube having a substantially vertical A first portion extending in a straight dimension and a second portion extending substantially along a horizontal dimension of the hopper, wherein the length of the first portion of the tube is greater than the length of the second portion of the tube.",FBD PARTNERSHIP LP,GILBERT SALAZAR;;CARLOS ACOSTA;;ANDREW GRACZYK,,https://lens.org/158-779-969-746-570,Patent Application,no,0,0,17,17,0,A23G9/281;;F25B39/02;;A23G9/22;;A23G9/28;;B67D1/0801;;B67D1/0858;;F25D23/00;;F25D31/002;;F25B2339/02;;F16J15/061;;F16J15/064;;F16J15/3268;;A23G9/045;;A23G9/281;;F16J15/3236;;A23G9/045;;A23G9/224;;A23G9/281;;F16J15/061;;F16J15/064;;F16J15/3268;;F16J15/3236;;A23G9/222;;F25D11/022;;F25D29/003;;F25D31/002;;F25D2600/02;;F25D2600/04,F25D23/00;;F25B41/20;;F25B41/31;;F25B41/37;;F25D31/00,,0,0,,,,DISCONTINUED
24,CN,U,CN 205939897 U,019-430-944-711-134,2017-02-08,2017,CN 201620824717 U,2016-08-01,US 201562199423 P;;US 201615220837 A,2015-07-31,Freeze beverage distributor and send hopper assembly,"Freeze beverage distributor and send hopper assembly should send hopper assembly to be used for distributor, included: the feeding funnel, it is configured as receives and saves the product, and at least the first side wall, second lateral wall, vertical size and horizontal size are injectd to this feeding funnel, and the pipe, it is configured as and is used for letting the refrigerant flow through from it, and the hot link is extremely first and second lateral walls of feeding funnel, the pipe have basic along first portion that the vertical size of feeding funnel is extended with basic along the second portion of the horizontal size extension of feeding funnel, wherein the length of the first portion of pipe is greater than the length of the second portion of pipe.",FBD PARTNERSHIP LP,CARLOS ACOSTA;;ANDREW GRACZYK;;GILBERT SALAZAR,,https://lens.org/019-430-944-711-134,Limited Patent,no,0,0,17,17,0,A23G9/281;;F25B39/02;;A23G9/22;;A23G9/28;;B67D1/0801;;B67D1/0858;;F25D23/00;;F25D31/002;;F25B2339/02;;F16J15/061;;F16J15/064;;F16J15/3268;;A23G9/045;;A23G9/281;;F16J15/3236;;A23G9/045;;A23G9/224;;A23G9/281;;F16J15/061;;F16J15/064;;F16J15/3268;;F16J15/3236;;A23G9/222;;F25D11/022;;F25D29/003;;F25D31/002;;F25D2600/02;;F25D2600/04,F25D23/00;;F25B41/20;;F25B41/31;;F25B41/37;;F25D31/00,,0,0,,,,INACTIVE
25,US,B1,US 9053287 B1,198-287-086-913-38X,2015-06-09,2015,US 201414225379 A,2014-03-25,US 201414225379 A;;US 201361804919 P,2013-03-25,Notch detection and correction in mask design data,"Mask data is analyzed for the presence of a notch. A notch candidate on a polygon boundary of mask data is defined as a plurality of line segments that includes an initial line segment, a final line segment and at least two line segments therebetween. The initial and final line segments define adjacent edges of the notch candidate and have an angle therebetween within a defined range. A direction of each line segment is a direction of travel from the initial line segment to the final line segment. A plurality of conditions is applied to the plurality of line segments and the direction of travel, and the notch candidate is a notch when all conditions are satisfied. The notch may be removed from the data before mask writing.",SYNOPSYS INC,ACOSTA CARLOS;;SALAZAR DANIEL;;MORALES DOMINGO,SYNOPSYS INC (2015-01-20),https://lens.org/198-287-086-913-38X,Granted Patent,yes,4,5,3,3,0,G03F1/36;;G03F1/36;;G06F30/398,G06F17/50,,0,0,,,,ACTIVE
26,US,A1,US 2015/0261909 A1,017-952-331-661-803,2015-09-17,2015,US 201514726304 A,2015-05-29,US 201514726304 A;;US 201414225379 A;;US 201361804919 P,2013-03-25,NOTCH DETECTION AND CORRECTION IN MASK DESIGN DATA,"Mask data is analyzed for the presence of a notch. A notch candidate on a polygon boundary of mask data is defined as a plurality of line segments that includes an initial line segment, a final line segment and at least one line segment therebetween. The initial and final line segments define adjacent edges of the notch candidate and have an angle therebetween within a defined range. A direction of each line segment is a direction of travel from the initial line segment to the final line segment. A plurality of conditions is applied to the plurality of line segments and the direction of travel, and the notch candidate is a notch when all conditions are satisfied. The notch may be removed from the data before mask writing.",SYNOPSYS INC,ACOSTA CARLOS;;SALAZAR DANIEL;;MORALES DOMINGO,SYNOPSYS INC (2015-01-20),https://lens.org/017-952-331-661-803,Patent Application,yes,5,0,3,3,0,G03F1/36;;G03F1/36;;G06F30/398,G06F17/50,,0,0,,,,ACTIVE
27,CU,A1,CU 21574 A1,093-649-531-330-51X,1987-07-22,1987,CU 1985012 A,1985-01-18,CU 1985012 A,1985-01-18,REACT COMBINATION FOR THE CONTROL OF TICK-KILLER BATH,,CTRO NAC SANIDAD AGROPECUARIA,ACOSTA REYMUNDEZ ALFONSO JOSE;;MELLA LIZAMA CARLOS MANUEL,,https://lens.org/093-649-531-330-51X,Limited Patent,no,0,0,1,1,0,,C12Q1/46,,0,0,,,,EXPIRED
28,WO,A1,WO 2018/122675 A1,069-886-010-558-796,2018-07-05,2018,IB 2017058078 W,2017-12-18,CO 2016005798 A,2016-12-26,FLUIDISED-BED REACTOR WITH MULTIPHASE SEPARATION,"The invention relates to a fluidised-bed reactor with multiphase separation, and to a unit for reaction by fluidisation with multiphase separation. The reactor comprises a tank with a liquid level and a liquid-gas distributor arranged at the bottom of the tank; and includes a solid-liquid-gas separation unit arranged inside the tank, above the liquid-gas distributor. The solid-liquid-gas separation unit comprises a liquid inlet arranged below the liquid level and a liquid outflow pipe arranged between the liquid level and the liquid inlet. The solid-liquid-gas separation unit has an outlet for solids arranged at the bottom of the solid-liquid-gas separation unit and a gas outlet arranged above the liquid level. In addition, the reactor includes a pump with a suction pipe connected to the liquid outflow pipe, and a discharge pipe connected to the liquid-gas distributor. Furthermore, the reactor has a gas supply unit connected to the discharge pipe by means of a gas-transporting pipe that has a Venturi; and has a gas outflow pipe connected to the tank, arranged above the liquid level. Moreover, the reaction unit comprises a first fluidised-bed reactor and a second fluidised-bed reactor that can be interconnected for the co-current, counter-current, serial or parallel circulation of at least two phases (liquid, solid or gas) that react in said reactors.",UNIV EAFIT,GONZÁLEZ MEJÍA CARLOS ALBERTO;;ACOSTA MAYA DIEGO ANDRÉS,,https://lens.org/069-886-010-558-796,Patent Application,yes,5,0,2,2,0,B01J8/00;;C02F3/00;;C02F3/08;;C02F3/28;;Y02W10/10,C02F3/00;;B01J8/00,,0,0,,,,PENDING
29,CO,A1,CO 2016005798 A1,140-826-339-721-665,2018-07-19,2018,CO 2016005798 A,2016-12-26,CO 2016005798 A,2016-12-26,Reactor de lecho fluidizado con separación multifásica,"La presente invención corresponde a un reactor de lecho fluidizado con separación multifásica, y a una unidad de reacción por fluidización con separación multifásica. El reactor comprende un tanque con un nivel de líquido y un distribuidor liquido-gas localizado en el fondo del tanque; e incluye una unidad de separación sólido-líquido-gas localizada dentro del tanque encima del distribuidor líquido-gas. La unidad de separación sólido-líquido-gas comprende una entrada de líquido localizada debajo del nivel de líquido y una tubería de salida de líquido localizada entre el nivel de líquido y la entrada de líquido. También, la unidad de separación sólido-líquido-gas tiene una salida para sólidos localizada en el fondo de la unidad de separación sólido-líquido-gas y una salida de gas localizada encima del nivel del líquido. Adicionalmente, el reactor incluye una bomba con una tubería de succión conectada a la tubería de salida de líquido, y una tubería de descarga conectada al distribuidor líquido-gas. Además, el reactor tiene una unidad de suministro de gas conectada a la tubería de descarga a través de una tubería para transporte de gas que tiene un Venturi; y tiene una tubería de salida para gas conectada al tanque localizada encima del nivel de líquido. Por otro lado, la unidad de reacción comprende un primer reactor de lecho fluidizado y un segundo reactor de lecho fluidizado que pueden conectarse entre sí, para que fluyan al menos dos fases (líquido, sólido o gas) que reaccionan en dichos reactores, en co-corriente, en contracorriente, en serie, o en paralelo.",UNIV EAFIT,ACOSTA MAYA DIEGO ANDRÉS;;GONZÁLEZ MEJIA CARLOS ALBERTO,,https://lens.org/140-826-339-721-665,Patent Application,no,0,0,2,2,0,B01J8/00;;C02F3/00;;C02F3/08;;C02F3/28;;Y02W10/10,C02F3/28;;C02F3/08,,0,0,,,,PENDING
30,WO,A1,WO 2017/212398 A1,017-467-477-223-196,2017-12-14,2017,IB 2017053321 W,2017-06-06,CO 16148876 A,2016-06-07,DISPENSING DEVICE,"The present invention relates to a dispensing device comprising a tank, a pressure regulator, a dispensing mechanism and a pump. The tank is connected to a supply of liquid by means of a pipeline. The pressure regulator and the tank are connected by means of tubes. Connected to the tank is an outlet line having a discharge line connected to the dispensing mechanism. The suction side of the pump is connected to the outlet line, downstream of the discharge line. The discharge side of the pump is connected to a discharge line that exits the battery limits of the process and has a return to the dispensing mechanism.",UNIV EAFIT,ACOSTA MAYA DIEGO ANDRÉS;;GONZALEZ MEJÍA CARLOS ALBERTO,,https://lens.org/017-467-477-223-196,Patent Application,yes,6,0,1,1,0,C22B3/00;;C22B3/02;;C22B3/22;;C22B11/00;;C22B11/12;;G05B1/00;;G05B1/01;;Y02P10/20,C22B3/00;;C22B3/02;;C22B3/22;;C22B11/00;;C22B11/12;;G05B1/00;;G05B1/01,,0,0,,,,PENDING
31,MX,A,MX 2018002800 A,082-541-466-710-968,2019-08-22,2019,MX 2018002800 A,2018-02-21,MX 2018002800 A,2018-02-21,METHOD FOR DETERMINING SIZE AND NUMBER OF WHEAT GRAINS BY DIGITAL IMAGE ANALYSIS.,"The present invention relates to a method for determining the size and number of wheat grains by digital image processing. The method consists of the selection of the wheat sample, digitization, color segmentation of the images, differentiation, separation of the grains, analysis of digital images, registration of the number of grains by an AID, and evaluation of the weight of the grain wheat. The acquisition of the images can be done with a flatbed scanner, in which the grain samples are placed on the glass with black foamy paper (ethyl vinyl acetate), to avoid noise. Herein, the projection of shadows caused by ambient light can penetrate because the lid is raised due to the volume of the grains. Also, the black background allows a better contrast of the grains and facilitates the segmentation of the image.",UNIV AUTONOMA DE SINALOA,CARLOS PATRICIO SAUCEDA ACOSTA;;GABRIEL ANTONIO LUGO GARCÍA,,https://lens.org/082-541-466-710-968,Patent Application,no,0,2,1,1,0,,G01N33/10,,0,0,,,,PENDING
32,US,A,US 3367133 A,014-345-101-073-375,1968-02-06,1968,US 49467865 A,1965-10-11,US 49467865 A,1965-10-11,Bottled-water cooler with two faucets,,HANES CORP,DREIS DARBY H;;SANDS LOUIS T;;ACOSTA CARLOS E,,https://lens.org/014-345-101-073-375,Granted Patent,no,2,10,1,1,0,B67D3/0009;;F25D31/002;;B67D3/0035;;B67D3/0038;;B67D3/0009;;F25D31/002,B67D3/00;;F25D31/00,62/390,0,0,,,,EXPIRED
33,WO,A1,WO 2005/056113 A1,055-279-271-308-522,2005-06-23,2005,ES 2004000549 W,2004-12-09,ES 200302898 A,2003-12-09,COMPOUNDS FOR THE TREATMENT OF OCULAR DRYNESS CAUSED BY PHOTOREFRACTIVE SURGERY,"The invention relates to compounds for the treatment of ocular dryness caused by photorefractive surgery. Agents which block the electric activity of injured nerve endings of the neuroma can be used for the treatment of ocular dryness caused by photorefractive surgery, such as excimer laser photorefractive keractomy or laser-assisted in-situ keratomileusis. The administration of said blocking agents effectively reduces the sensations of ocular dryness, said agents including antiepileptics, anticonvulsants, antiarrhythmics, tricyclic antidepressants and local anaesthetics and, in particular, licodaine, tocainidine, phenytoin, carbamazepine, lamotrigine, mexiletine and pregabaline.",UNIV MIGUEL HERNANDEZ;;BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MACARMEN,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MACARMEN,,https://lens.org/055-279-271-308-522,Patent Application,yes,4,2,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61K9/00;;A61K9/08;;A61P27/02,,0,0,,,,PENDING
34,CN,A,CN 114746610 A,139-526-451-798-603,2022-07-12,2022,CN 201980102942 A,2019-11-12,ES 2019070776 W,2019-11-12,Structure for supporting offshore installation and method of implementation,"The invention relates to a structure (2) for supporting a wind turbine tower (1), provided with a housing (7) for placing the bottom of the tower (1) therein, a main axis (gamma) defined on the platform (2) coinciding with the main axis of the tower (1), and comprising a body having a constant cross-section and an inner wall (8) and an intermediate wall (10) joined by an inner radial rib (11) perpendicular to the plane of the inner wall (8) passing through the main axis (gamma), such that at the intermediate wall (10), a first joining node (12) is defined between the intermediate wall (10) and the radial rib (11), the intermediate wall (10) and the outer wall (9) being joined by mesh ribs (14 and 15). The structure provides optimal force transmission. The invention also relates to a method for manufacturing, assembling and installing the structure.",BRADY MARINE LTD,CORBIANBABE IRENE;;ACOSTA GUTIERREZ CARLOS;;BERENGUER PEREZ JOSE MANUEL,,https://lens.org/139-526-451-798-603,Patent Application,no,0,1,10,10,0,E02D27/06;;E02D27/42;;B63B75/00;;Y02B10/30;;Y02E10/728;;B63B2231/64;;B63B2035/446;;B63B77/10;;Y02E10/727;;Y02E10/72;;E02D27/52;;E02D23/02;;E02D15/08;;F03D13/25;;E02B2017/0091;;F03D13/10;;E02D27/06;;E02D27/42;;B63B75/00;;Y02B10/30;;B63B75/00;;B63B77/10;;B63B2035/446;;F03D13/256,E02D27/42;;B63B75/00;;E02D27/06,,0,0,,,,PENDING
35,ES,A1,ES 2234428 A1,068-667-588-693-728,2005-06-16,2005,ES 200302898 A,2003-12-09,ES 200302898 A,2003-12-09,COMPOUNDS FOR THE TREATMENT OF OCULAR DRYNESS CAUSED BY PHOTOREFRACTIVE SURGERY,"The blocking agents of the electrical activity of the damaged nerve endings of the neuroma can be used for the treatment of dryness of the ocular surface caused by photorefractive surgery, such as excimer laser photorefractive keratectomy or laser-assisted in situ keratomileusis. The administration of said blocking agents, which include antiepileptics, anticonvulsants, anti-arrhythmic drugs, tricyclic antidepressants and local anaesthetics and, in particular, include lidocaine, tocainide, phenytoin, carbamazepine, lamotrigine, mexiletine and pregabalin, effectively reduce the sensations of ocular dryness.",UNIV MIGUEL HERNANDEZ,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ M CARMEN,,https://lens.org/068-667-588-693-728,Patent Application,no,4,0,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61K9/00;;A61K9/08;;A61P27/02,,0,0,,,,EXPIRED
36,EP,A1,EP 1700616 A1,127-744-525-764-896,2006-09-13,2006,EP 04805092 A,2004-12-09,ES 2004000549 W;;ES 200302898 A,2003-12-09,COMPOUNDS FOR THE TREATMENT OF OCULAR DRYNESS CAUSED BY PHOTOREFRACTIVE SURGERY,"The blocking agents of the electrical activity of the damaged nerve endings of the neuroma can be used for the treatment of dryness of the ocular surface caused by photorefractive surgery, such as excimer laser photorefractive keratectomy or laser-assisted in situ keratomileusis. The administration of said blocking agents, which include antiepileptics, anticonvulsants, anti-arrhythmic drugs, tricyclic antidepressants and local anaesthetics and, in particular, include lidocaine, tocainide, phenytoin, carbamazepine, lamotrigine, mexiletine and pregabalin, effectively reduce the sensations of ocular dryness.",UNIV MIGUEL HERNANDEZ DE ELCHE,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ M CARMEN,,https://lens.org/127-744-525-764-896,Patent Application,yes,0,1,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61P27/02;;A61K9/00;;A61K9/08,,0,0,,,,DISCONTINUED
37,US,A1,US 2007/0135412 A1,056-839-715-378-599,2007-06-14,2007,US 58132104 A,2004-12-09,ES 200302898 A;;ES 2004000549 W,2003-12-09,Compounds for the treatment of ocular dryness caused by photorefractive surgery,"The blocking agents of the electrical activity of the damaged nerve endings of the neuroma can be used for the treatment of dryness of the ocular surface caused by photorefractive surgery, such as excimer laser photorefractive keratectomy or laser-assisted in situ keratomileusis. The administration of said blocking agents, which include antiepileptics, anticonvulsants, anti-arrhythmic drugs, tricyclic antidepressants and local anaesthetics and, in particular, include lidocaine, tocainide, phenyloin, carbamazepine, lamotrigine, mexiletine and pregabalin, effectively reduce the sensations of ocular dryness.",MARTINEZ CARLOS B;;MARTINEZ JUANA G;;ACOSTA BOJ MA CARMEN,MARTINEZ CARLOS B;;MARTINEZ JUANA G;;ACOSTA BOJ MA CARMEN,UNIVERSIDAD MIGUEL HERNANDEZ (2006-07-18),https://lens.org/056-839-715-378-599,Patent Application,yes,6,1,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61K31/55;;A61K9/00;;A61K9/08;;A61K31/137;;A61K31/195;;A61K31/24;;A61P27/02,514/217;;514/534;;514/561;;514/649,0,0,,,,DISCONTINUED
38,TW,A,TW 200800261 A,094-170-397-413-016,2008-01-01,2008,TW 95120797 A,2006-06-12,ES 200302898 A;;ES 2004000549 W;;CN 200480036796 A;;AU 2004/296566 A;;MX PA06006516 A,2003-12-09,Compounds for the treatment of dryness of the ocular surface caused by photorefractive surgery,"The blocking agents of the electrical activity of the damaged nerve endings of the neuroma can be used for the treatment of dryness of the ocular surface caused by photorefractive surgery, such as excimer laser photorefractive keratectomy or laser-assisted in situ keratomileusis. The administration of said blocking agents, which include antiepileptics, anticonvulsants, anti-arrhythmic drugs, tricyclic antidepressants and local anaesthetics and, in particular, include lidocaine, tocainide, phenytoin, carbamazepine, lamotrigine, mexiletine and pregabalin, effectively reduce the sensations of ocular dryness.",UNIV MIGUEL HERNANDEZ,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MA CARMEN,,https://lens.org/094-170-397-413-016,Patent of Addition,no,0,0,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61K45/06;;A61K9/00;;A61K9/08;;A61P27/02,,0,0,,,,PENDING
39,UY,A1,UY 28972 A1,141-633-949-819-518,2006-04-28,2006,UY 28972 A,2005-06-20,UY 28972 A,2005-06-20,VACUNAS CONTRA FASCIOLA HEPATICA UTILIZANDO MOLÉCULAS DE ADN RECOMBINANTES CODIFICANTES PARA LEUCIN AMINOPEPTIDASAS.,"Fasciola hepatica es un helminto parásito que afecta fundamentalmente al ganado ovino y bovino. El tema de la invención es un polipéptido producido en un microorganismo genéticamente modificado que contienen la secuencia completa de amino ácidos correspondiente a la leucin aminopeptidasa de Fasciola hepatica, una enzima proteolítica localizada en el tubo digestivo del gusano; y su aplicación a la inmunización contra la infección producida por el parásito en rumiantes.",CARMONA CARLOS,CARMONA CARLOS;;ACOSTA DANIEL;;TORT JOSE;;ROCHE LEDA;;CANCELA MARTIN,,https://lens.org/141-633-949-819-518,Patent Application,no,0,0,1,1,0,,A61K39/00;;A61P33/10;;C07K14/435;;C07K14/44;;C12N9/48;;C12N15/70,,0,0,,,,DISCONTINUED
40,BR,A,BR PI0417474 A,083-835-114-076-545,2007-05-08,2007,BR PI0417474 A,2004-12-09,ES 200302898 A;;ES 2004000549 W,2003-12-09,compostos para o tratamento de ressecamento da superfìcie ocular causado por cirurgia fotorrefrativa,"COMPOSTOS PARA O TRATAMENTO DE RESSECAMENTO DA SUPERFìCIE OCULAR CAUSADO POR CIRURGIA FOTORREFRATIVA. Os agentes bloqueadores da atividade elétrica das terminações nervosas lesadas do neuroma podem ser usados para o tratamento do ressecamento da superfície ocular causado pela cirurgia fotorrefrativa, tais como ceratotomia fotorrefrativa com laser excímero ou ceratomileuse laser assistida in situ. A administração dos ditos agentes bloqueadores, que incluem fármacos antiepiléticos, anticonvulsivantes, antiarrítmicos, antidepressivos tricíclicos e anestésicos locais e, em particular, incluem lidocaína, tocainida, fenitoína, carbamazepina, lamotrigina, mexiletina e pregabalina, reduz eficazmente as sensações de ressecamento ocular.",UNIV MIGUEL HERNANDEZ,MARTINEZ CARLOS BELMONT;;MARTINEZ JUANA GALLA;;BOJ M CARMEN ACOSTA,,https://lens.org/083-835-114-076-545,Patent Application,no,0,0,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61P27/02;;A61K9/00;;A61K9/08,,0,0,,,,DISCONTINUED
41,WO,A1,WO 2023/086084 A1,093-627-957-490-193,2023-05-19,2023,US 2021/0058801 W,2021-11-10,US 2021/0058801 W,2021-11-10,BUILD VOLUME PORTIONS,"Examples of methods are described herein. In some examples, a method includes determining a first portion within a build volume. In some examples, the method includes packing first objects in the first portion. In some examples, the method includes packing using a genetic procedure. In some examples, the method includes packing, using the genetic procedure, second objects in the build volume.",HEWLETT PACKARD DEVELOPMENT CO,CATANA SALAZAR JUAN CARLOS;;MEDRANO ACOSTA MARCO ANTONIO;;ZENG JUN,,https://lens.org/093-627-957-490-193,Patent Application,yes,4,0,1,1,0,B29C64/171;;B33Y10/00;;B29C64/386;;B33Y50/00;;B29C64/153;;B29C64/165;;B22F10/28;;B22F10/80,B29C64/171;;B29C64/25;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02,,0,0,,,,PENDING
42,US,A1,US 2018/0103656 A1,161-193-994-583-937,2018-04-19,2018,US 201715785599 A,2017-10-17,US 201715785599 A;;US 201662409172 P,2016-10-17,FROZEN PRODUCT DISPENSING SYSTEMS AND METHODS,An improved frozen product dispenser wherein a product is placed into a cooled hopper and the product is then fed from the hopper into a freezing and dispensing chamber where it is frozen and dispensed.,FBD PARTNERSHIP LP,ACOSTA CARLOS;;LASCH MICHAEL RYAN;;SALAZAR GILBERT;;WARD JOSHUA GARY,FBD PARTNERSHIP LP (2016-11-01),https://lens.org/161-193-994-583-937,Patent Application,yes,10,10,5,5,0,A23G9/28;;A23G9/222;;A23G9/28;;A23G9/222,A23G9/22;;A23G9/28;;B01F23/10,,0,0,,,,DISCONTINUED
43,CA,A1,CA 2548446 A1,167-486-507-796-212,2005-06-23,2005,CA 2548446 A,2004-12-09,ES 200302898 A;;ES 2004000549 W,2003-12-09,COMPOUNDS FOR THE TREATMENT OF OCULAR DRYNESS CAUSED BY PHOTOREFRACTIVE SURGERY,"The invention relates to compounds for the treatment of ocular dryness cause d by photorefractive surgery. Agents which block the electric activity of injured nerve endings of the neuroma can be used for the treatment of ocular dryness caused by photorefractive surgery, such as excimer laser photorefractive keractomy or laser-assisted in-situ keratomileusis. The administration of said blocking agents effectively reduces the sensations of ocular dryness, said agents including antiepileptics, anticonvulsants, antiarrhythmics, tricyclic antidepressants and local anaesthetics and, in particular, licodaine, tocainidine, phenytoin, carbamazepine, lamotrigine, mexiletine and pregabaline.",UNIV MIGUEL HERNANDEZ,BELMONTE MARTINEZ CARLOS;;ACOSTA BOJ MOERDF CARMEN;;GALLAR MARTINEZ JUANA,,https://lens.org/167-486-507-796-212,Patent Application,no,0,0,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61P27/02;;A61K9/00;;A61K9/08,,0,0,,,,DISCONTINUED
44,CN,A,CN 115279185 A,191-708-062-718-369,2022-11-01,2022,CN 202180017858 A,2021-02-26,US 202062983283 P;;IB 2021051647 W,2020-02-28,Micellar disinfectant,"The present invention relates to micellar compositions consisting, in other ingredients, of a biomimetic phospholipid and a non-ionic surfactant for scavenging one or more types of microorganisms, including mycobacteria, bacteria, fungi and viruses, from a surface within a surface contact time of less than about 1 minute and a pH in the range of about 0.3 to 8. It is an object of the present invention to be applicable not only to hard inanimate surfaces but also to tissues for endodontic applications using 100% bio-based (renewable) biodegradable non-toxic ingredients.",CONTE SWITZERLAND AG,BOSA TRONCOSO ANTONIO CARLOS;;ACOSTA SALA EDUARDO JAVIER;;CRIOLAKA DIEGO,,https://lens.org/191-708-062-718-369,Patent Application,no,6,0,7,7,0,A01N59/00;;A01N25/30;;A61L2/186;;A61P31/02;;A01P3/00;;A01P1/00;;A01N25/04;;A01N25/30;;A01N31/14;;A01N37/10;;A01N59/00;;A61K9/0063;;A61K9/1075;;A61K33/40;;A61K47/24,A01N25/30;;A01N59/00;;A61L2/18,,1,0,,,"H.MARTIN等: ""Synergism between hydrogen peroxide and seventeen acids against six bacterial strains"", 《JOURNAL OF APPLIED MICROBIOLOGY》, vol. 133, no. 3, pages 578 - 590, XP055765234, DOI: 10.1111/j.1365-2672.2012.05364.x",PENDING
45,AU,A1,AU 2004/296566 A1,101-928-832-785-737,2005-06-23,2005,AU 2004/296566 A,2004-12-09,ES 200302898 A;;ES 2004000549 W,2003-12-09,Compounds for the treatment of ocular dryness caused by photorefractive surgery,,UNIV MIGUEL HERNANDEZ,BOJ M CARMEN ACOSTA;;MARTINEZ CARLOS BELMONTE;;MARTINEZ JUANA GALLAR,,https://lens.org/101-928-832-785-737,Patent Application,no,0,0,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61K9/08;;A61K9/00;;A61P27/02,,0,0,,,,DISCONTINUED
46,ES,B1,ES 2234428 B1,118-914-299-882-562,2006-11-01,2006,ES 200302898 A,2003-12-09,ES 200302898 A,2003-12-09,COMPUESTOS PARA EL TRATAMIENTO DE LA SEQUEDAD DE LA SUPERFICIE OCULAR PROVOCADA POR LA CIRUGIA FOTORREFRACTIVA.,"Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugía fotorrefractiva. Los agentes bloqueantes de la actividad eléctrica de las terminaciones nerviosas lesionadas del neuroma son útiles para el tratamiento de la sequedad de la superficie ocular provocada por la cirugía fotorrefractiva, como la queractomía fotorrefractiva con láser excimer o la queratomileusis in situ asistida con láser. La administración de dichos agentes bloqueantes, que incluyen antiepilépticos, anticonvulsivantes, antiarrítmicos, antidepresivos tricíclicos y anestésicos locales y en particular, incluyen la lidocaina, la tocainida, la fenitoina, la carbamazepina la lamotrigina y la mexiletina, reducen de manera efectiva las sensaciones de sequedad ocular.",UNIV MIGUEL HERNANDEZ,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ M CARMEN,,https://lens.org/118-914-299-882-562,Granted Patent,no,0,0,12,12,0,A61K9/0048;;A61P27/02;;A61K9/08;;A61K9/0048,A61P27/02;;A61K9/00;;A61K9/08,,0,0,,,,EXPIRED
47,BR,A2,BR 102018011737 A2,142-687-281-652-999,2019-12-24,2019,BR 102018011737 A,2018-06-11,BR 102018011737 A,2018-06-11,kit modular acoplável em máquinas processadoras de fraldas descartáveis,"trata-se de um kit modular acoplável em máquinas processadoras, pertencente ao campo de aplicação dos equipamentos de porte destinados à fabricação de fraldas descartáveis, cujo kit modular possibilita a produção versátil de fraldas descartáveis modelo ?pull up? (fralda calça) em vários tamanhos / modelos de produtos, tanto de uso infantil como adulto, permitindo o acoplamento do sistema em qualquer máquina, de qualquer fabricante, aplicando-se os mesmos inversores de produto e os equipamentos de solda dos materiais, sem que se faça necessária a substituição dos mesmos, dito kit (1) abrangendo faca ?pad? (2), rotator ?pad? (3), laminação das cintas (4), meio corte (5), corte anatômico (6), ?lycra®? zig-zag (7), rotação 900 (8), fitilho de descarte (9), solda das cintas (10), corte final (11), rotator de produto (12), dobra das cintas geriátricas (13), dobra final geriátrica.",CARLOS DOROTEO ORTEGA ACOSTA;;HERIBERTO BARBOSA ROCHA JUNIOR;;RENATO SERGIO NAZAR,CARLOS DOROTEO ORTEGA ACOSTA;;HERIBERTO BARBOSA ROCHA JUNIOR;;RENATO SÉRGIO NAZAR,,https://lens.org/142-687-281-652-999,Patent Application,no,0,0,1,1,0,,A61F13/15;;A61F13/49;;B26D7/20;;B29C65/00,,0,0,,,,DISCONTINUED
48,CL,A1,CL 2016002979 A1,174-130-573-432-00X,2017-07-14,2017,CL 2016002979 A,2016-11-21,CL 2016002979 A,2016-11-21,"Herramienta de torque para extracción de tuercas, que comprende un sistema continuo de extracción y expulsión de tuercas","<p>UNA HERRAMIENTA DE TORQUE (100) PARA LA EXTRACCION DE FIJACIONES, POR EJEMPLO TUERCAS, DE MANERA CONTINUA, QUE COMPRENDE DOS SUBSISTEMAS: UN EJE CENTRAL (1) Y UNA CARCASA (2, 3), EL PRIMERO DE ELLOS EXTRAE Y GUIA LA FIJACION A TRAVÉS DE ELLA PARA SER EXPULSADA POR UN LUGAR DISTINTO AL QUE ENTRÓ Y ESTÁ CONSTRUIDO EN UNA ALEACION DE ACERO Y COMPRENDE TRES SEGMENTOS DEFINIDOS: EXTREMO PARA INSERCIÓN DE FIJACIONES (4), SECCION INTERMEDIA (5) PARA EXTRACCION CONTINUA DE FIJACIONES Y UN EXTREMO PARA CONEXIÓN EN HERRAMIENTAS ROTATORIAS (6), LA CARCASA (2, 3) SE POSICIONA ALREDEDOR DEL EJE CENTRAL (1) Y ES DESMONTABLE PARA LA MANTENCION DE LA HERRAMIENTA DE TORQUE (100), CUMPLIENDO LA FUNCION DE MANTENER A LAS FIJACIONES DENTRO DE LA HERRARRIIENTA GUIANDOLAS HACIA UN CONDUCTO MEDIANTE GRAVEDAD.</p>",UNIV TÉCNICA FEDERICO SANTA MARÍA,CARMONA ACOSTA CARLOS JESÚS;;PIÑONES ZULETA EDUARDO ANDRÉS;;NIKULIN CHANDÍA CHRISTOPHER NIK,,https://lens.org/174-130-573-432-00X,Patent Application,no,0,0,1,1,0,,B25B21/00,,0,0,,,,PENDING
49,ES,B2,ES 2837548 B2,064-388-832-813-254,2022-04-18,2022,ES 201931176 A,2019-12-31,ES 201931176 A,2019-12-31,Procedimiento y dispositivo para producir una secreción lagrimal refleja y un kit para la medición de la magnitud de flujo lagrimal generado,,UNIV MIGUEL HERNANDEZ DE ELCHE UMH;;CONSEJO SUPERIOR INVESTIGACION,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MARÍA CARMEN;;MERINO SUAREZ MARÍA,,https://lens.org/064-388-832-813-254,Granted Patent,no,0,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61B3/10,,0,0,,,,ACTIVE
50,CO,A1,CO 2022007669 A1,002-309-851-757-991,2023-12-20,2023,CO 2022007669 A,2022-06-16,CO 2022007669 A,2022-06-16,Método automatizado para la detección de anomalías en pruebas de pcr para el diagnóstico del covid-19,"la invención presentada resuelve el problema a partir de la implementación de una inteligencia artificial para facilitar la verificación, al detectar perfiles atípicos en la curva de PCR causados por la contaminación o artefactos/eventos ajenos a la prueba.",UNIV SIMON BOLIVAR,VILLARREAL GONZÁLEZ REYNALDO;;ACOSTA HOYOS ANTONIO;;GALÁN FREYLE NATALY;;PACHECO LONDOÑO LEONARDO CARLOS,,https://lens.org/002-309-851-757-991,Patent Application,no,0,0,1,1,0,,C12Q1/68;;A61B5/00;;G06N3/02,,0,0,,,,PENDING
51,ES,A1,ES 2837548 A1,029-166-804-356-671,2021-06-30,2021,ES 201931176 A,2019-12-31,ES 201931176 A,2019-12-31,"Procedure and device to produce a reflex tear secretion and a kit to measure the magnitude of tear flow generated (Machine-translation by Google Translate, not legally binding)","Procedure for the generation of a reflex tear secretion, which includes chemical stimulation of the cornea of the eye of a subject by applying a controlled murmur of a gas with a high content of CO2 to said cornea, of at least 80% CO2 . Compact device (1, 1') for the generation of a reflex tear secretion, comprising a gas source (7) in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 80% of CO2 ; and a pneumatic circuit that connects an outlet mouth of said gas source (7) with a gas outlet nozzle (3) of the device (1, 1'), the circuit comprising pressure regulation means (8) and flow rate (17) suitable for ejecting puffs of gas through the outlet nozzle (3) at a predetermined pressure and flow rates. (Machine-translation by Google Translate, not legally binding)",UNIV MIGUEL HERNANDEZ DE ELCHE UMH;;CONSEJO SUPERIOR INVESTIGACION,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MARÍA CARMEN;;MERINO SUAREZ MARÍA,,https://lens.org/029-166-804-356-671,Patent Application,no,5,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61B3/10,,1,1,008-169-091-506-546,15223813;;10.1167/iovs.03-1366,"M. CARMEN ACOSTA ET AL. ""Tear Secretion Induced by Selective Stimulation of Corneal and Conjunctival Sensory Nerve Fibers"". Investigative Ophthalmology & Visual Science, 30/07/2004, Vol. 45, Páginas 2333-2336 Recuperado de Internet (URL:https://doi.org/10.1167/iovs.03-1366), (DOI: https://doi.org/10.1167/iovs.03-1366)M. CARMEN ACOSTA ET AL. ""Tear Secretion Induced by Selective Stimulation of Corneal and Conjunctival Sensory Nerve Fibers"". Investigative Ophthalmology & Visual Science, 30/07/2004, Vol. 45, Páginas 2333-2336 Recuperado de Internet (URL:https://doi.org/10.1167/iovs.03-1366), (DOI: https://doi.org/10.1167/iovs.03-1366)",ACTIVE
52,ES,A1,ES 2446719 A1,102-789-441-769-819,2014-03-10,2014,ES 201200883 A,2012-09-07,ES 201200883 A,2012-09-07,"System for the increase of the efficiency in the production of hydrogen through the photolysis of water in a photo-electrochemical cell expanding the range of spectral response of the catalytic semiconductor. (Machine-translation by Google Translate, not legally binding)","System for the increase of the efficiency in the production of hydrogen through the photolysis of water in a photo-electrochemical cell expanding the range of spectral response of the catalytic semiconductor. A system for the increase of the efficiency in the production of hydrogen through the photolysis of water in a photo-electrochemical cell is proposed, extending the range of spectral response of the catalytic semiconductor, by means of a photoconversion of incident solar radiation towards wavelengths short, using transparent nano-ceramic materials composed of a silicon oxide matrix containing fluoride nanocrystals (PbF2, NaYF4, YF3, KYF4) doped with rare earth ions (Nd3 +, Tm3 +, Ho3 +, Er3 +, Yb3 + . In this way, a system capable of absorbing and taking advantage of a wide range of energy from the sun in the red and infrared is achieved and converted efficiently, through ""up-conversion"" processes, to the blue and UV range, optimizing the water rupture in hydrogen and oxygen. (Machine-translation by Google Translate, not legally binding)",UNIV LA LAGUNA,MENDEZ RAMOS JORGE;;DEL CASTILLO VARGAS FRANCISCO JAVIER;;RUIZ MORALES JUAN CARLOS;;YANES HERNANDEZ ANGEL CARLOS;;ACOSTA MORA PABLO,,https://lens.org/102-789-441-769-819,Patent Application,no,0,0,2,2,0,C03C10/16;;C25B1/55;;C25B11/091;;Y02E60/36;;Y02P20/133,C03C10/16;;C25B1/04;;C25B11/04,,6,0,,,"MENDEZ-RAMOS J et al. Rare-earth doped YF3 nanocrystals embedded in sol-gel silica glass matrix for white light generation.Journal of Luminescence, 2010, Vol.130, Nº12, páginas: 2508 - 2511. Resumen, Introducción, Punto 3.2, Conclusiones.;;SANTANA-ALONSO A et al. White light up-conversion in transparent sol-gel derived glass-ceramics containing Yb3+-Er3+-Tm3+ triply-doped YF3 nanocrystals.Materials Chemistry and Physics, 2010, Vol. 124, Nº1, páginas: 699 - 703. Resumen, Introducción, Punto 3.2, Conclusiones;;CHEN et al. Strong cooperative upconversion luminescence of ytterbium doped oxyfluoride nanophase vitroceramics. Solid state communications, Vol.136, Nº 6, páginas: 313 - 317. Páginas 313 y 314;;WANG Y et al. New transparent vitroceramics codoped with Er3+ and Yb3+ for efficient frequency upconversion. Applied Physics Letters. Diciembre 1993, Vol. 63, Nº 24, páginas 3268 - 3270. Páginas 3268 y 3270.;;QUIN W et al. Near-infrared photocatalysis based on YF3: Yb3+, Tm3+/TiO2 core/shell nanoparticles. Chemical Communications, 2010, Vol. 46, páginas: 2304-2306. Todo el documento.;;LI C et al. NaYF4:Yb,Tm/CdS composite as a novel near-infrared-driven photocatalyst. Applied Catalysis B: Environmental, 2010, Vol. 100, Nº: 3-4, páginas: 433 - 439. Resumen, 1. Introducción, 2.4 Preparación de compuesto NaYF4:Yb,Tm/CdS.",ACTIVE
53,ES,B1,ES 2446719 B1,148-526-035-837-227,2015-03-10,2015,ES 201200883 A,2012-09-07,ES 201200883 A,2012-09-07,Sistema para el aumento de la eficiencia en la producción de hidrógeno a través de la fotólisis del agua en una célula foto-electroquímica ampliando el rango de respuesta espectral del semiconductor catalítico.,,UNIV LA LAGUNA,MENDEZ RAMOS JORGE;;DEL CASTILLO VARGAS FRANCISCO JAVIER;;RUIZ MORALES JUAN CARLOS;;YANES HERNANDEZ ANGEL CARLOS;;ACOSTA MORA PABLO,,https://lens.org/148-526-035-837-227,Granted Patent,no,0,1,2,2,0,C03C10/16;;C25B1/55;;C25B11/091;;Y02E60/36;;Y02P20/133,C03C10/16;;C25B1/04;;C25B11/04,,0,0,,,,ACTIVE
54,EP,A1,EP 4084748 A1,037-432-518-738-010,2022-11-09,2022,EP 20842246 A,2020-12-30,ES 201931176 A;;EP 2020088057 W,2019-12-31,PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW,,UNIV MIGUEL HERNANDEZ DE ELCHE UMH;;CONSEJO SUPERIOR INVESTIGACION,BELMONTE MARTÍNEZ CARLOS;;GALLAR MARTÍNEZ JUANA;;ACOSTA BOJ MARÍA CARMEN;;MERINO SUÁREZ MARÍA LUISA,,https://lens.org/037-432-518-738-010,Patent Application,yes,0,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61F9/00;;A61B3/10;;A61F9/02;;A61H35/02;;A61M11/00;;A61M11/02;;A61M16/00;;A61M16/16,,0,0,,,,PENDING
55,WO,A1,WO 2021/136820 A1,060-806-907-412-943,2021-07-08,2021,EP 2020088057 W,2020-12-30,ES 201931176 A,2019-12-31,PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW,"Procedure for the generation of a reflex tear secretion, which comprises the chemical stimulation of the cornea of the eye of a subject by applying a controlled jet of a gas with a high CO 2 content, of at least 80% of CO 2 . Compact device (1,1') for the generation of a reflex tear secretion, comprising a gas source (7) in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 80% of CO 2 ; and a pneumatic circuit connecting an outlet mouth of said gas source (7) with a gas outlet nozzle (3) of the device (1,1'), the circuit comprising pressure regulation means (8) and flow rate (17) regulation means suitable for ejecting puffs of gas through the outlet nozzle (3) at a predetermined pressure and flow rates.",UNIV MIGUEL HERNANDEZ DE ELCHE UMH;;CONSEJO SUPERIOR INVESTIGACION,BELMONTE MARTÍNEZ CARLOS;;GALLAR MARTÍNEZ JUANA;;ACOSTA BOJ MARÍA CARMEN;;MERINO SUÁREZ MARÍA LUISA,,https://lens.org/060-806-907-412-943,Patent Application,yes,5,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61F9/00;;A61B3/10;;A61F9/02;;A61H35/02;;A61M11/00;;A61M11/02;;A61M16/00;;A61M16/16,,6,5,008-169-091-506-546;;038-017-327-134-909;;065-519-371-665-757;;147-985-277-710-479;;008-169-091-506-546,15223813;;10.1167/iovs.03-1366;;11481273;;8762770;;10.1046/j.1475-1313.1996.95001026.x;;10.1016/0275-5408(95)00102-6;;9950612;;15223813;;10.1167/iovs.03-1366,"M. CARMEN ACOSTA ET AL: ""Tear Secretion Induced by Selective Stimulation of Corneal and Conjunctival Sensory Nerve Fibers"", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, vol. 45, no. 7, 1 July 2004 (2004-07-01), pages 2333 - 2336, XP055771372, ISSN: 1552-5783, DOI: 10.1167/iovs.03-1366;;ACOSTA MCTAN MEBELMONTE CGALLAR J.: ""Sensations evoked by selective mechanical, chemical, and thermal stimulation of the conjunctiva and cornea"", INVEST OPHTHALMOL VIS SCI., vol. 42, 2001, pages 2063 - 7;;MURPHY PJPATEL SMARSHALL JA: ""new non-contact corneal aesthesiometer (NCCA"", OPHTHALMIC PHYSIOL OPT, vol. 16, 1996, pages 101 - 7;;BELMONTE CACOSTA MCSCHMELZ MGALLAR J.: ""Measurement of corneal sensitivity to mechanical and chemical stimulation with a C0 esthesiometer"", INVEST OPHTHALMOL VIS SCI., vol. 40, 1999, pages 513 - 9;;ACOSTA MCTAN MEBELMONTE CGALLAR J.: ""Sensations evoked by selective mechanical, chemical, and thermal stimulation of the conjunctiva and cornea"", INVEST OPHTHALMOL VIS SCI, vol. 42, 2001, pages 2063 - 7;;ACOSTA MCPERAL ALUNA CPINTOR JBELMONTE CGALLAR J.: ""Tear secretion induced by selective stimulation of corneal and conjunctival sensory nerve fibers"", INVEST OPHTHALMOL VIS SCI., vol. 45, 2004, pages 2333 - 2336",PENDING
56,CO,A2,CO 6251214 A2,154-193-293-014-383,2011-02-21,2011,CO 09148919 A,2009-12-30,ES 200702142 A,2007-07-28,FORMULACION DE CAROTENOIDES DISPERSABLE EN AGUA,"1.- Formulación dispersable en agua de carotenoidesen forma de líquido, constituida por una mezcla deCantaxantina y de un extracto de marigold saponificado,que contiene entre 1 y 500 partes de carotenoides totalespor cada 1000 partes de disolución apta para su utilizacióncomo agente pigmentante en la industria de la alimentaciónanimal.2.- Formulación de carotenoides de acuerdo con lareivindicación 1 en la que extracto de marigold utilizado hasido sometido a un proceso de saponificación parcial o totalde los ésteres de las xantofilas.3.- Formulación de acuerdo con la reivindicación 1 enla que la Cantaxantina de partida se obtiene por síntesis, obien por extracción a partir de fuentes de origen natural.4.- Procedimiento para la elaboración de la formulacióndescrita en la reivindicación 1 que consta de las siguientesfases:- Obtención del jabón por saponificación parcial ototal del extracto de marigold.- Preparación de la formulación de la Cantaxantinadispersable en agua.- Mezcla de ambos productos en condicionescontroladas de agitación y temperatura.5.- Procedimiento de acuerdo con la reivindicación 4 enel que el extracto de marigold se somete a unasaponificación parcial o total de sus ésteres de xantofilas,por acción de un reactivo alcalino, tal como hidróxidosalcalinos o alcalino-térreos o alcóxidos metálicos, en unmedio acuoso o hidroalcohólico.6.- Procedimiento de acuerdo con la reivindicación 4en el que el producto dispersable que contiene laCantaxantina está elaborado en forma demicroencapsulado dispersión, gel o cualquier otraformulación que permita la dispersión homogénea de laxantofila en un medio acuoso.7.- Procedimiento según la reivindicación 4 en el que lamezcla del jabón de marigold y la Cantaxantina dispersableen agua se lleva a cabo con fuerte agitación hasta alcanzaruna mezcla homogénea.8.- Procedimiento según las reivindicaciones 4 a 7 enel que la agitación de la mezcla se mantiene durante untiempo entre 1 minuto y varias horas, dependiendo de lascondiciones de agitación utilizadas, hasta alcanzar unamezcla totalmente homogénea",INVEST QUIMICAS Y FARMACEUTICAS S A,FERRATER MARTORELL JOAN CARLOS;;FERNANDEZ MARTIN JUAN ANTONIO;;RIBERA RUIZ DAVID;;VISO ACOSTA ANTONIO,,https://lens.org/154-193-293-014-383,Patent Application,no,0,0,17,17,0,A23K20/179;;A23K20/179;;A23L5/44;;A23L5/44;;C07C49/603;;C09B61/00;;C07C403/24;;C09B61/00,A23K1/16;;A23L1/275;;C07C49/603;;C09B61/00,,0,0,,,,ACTIVE
57,BR,B1,BR 112019020789 B1,192-679-318-906-192,2023-11-28,2023,BR 112019020789 A,2017-07-20,MX 2017000081 W;;MX 2017004430 A,2017-04-05,Aditivos nanoestruturados de baixo ponto de fusão e seus processos de preparação,"a presente invenção refere-se a um processo para a fabricação, o acondicionamento e a estabilização de uma família de aditivos à base de óxidos de sódio, potássio, boro, silício, zinco e cálcio, entre outros, preparada com o uso de métodos físico-químicos e de síntese química, que forma estruturas manométricas, e que é reformulada com aditivos defloculantes, sequestrantes e dispersantes que permitem obter uma dispersão ou pó capaz de diminuir a temperatura de sinterização de um corpo de cerâmica devido a seu alto poder de fusão, que é maximizado com o uso da nanotecnologia nas estruturas obtidas. o processo consiste na preparação de sementes de nucleação de óxidos metálicos, silicatos e carbonatos, que permitem, por meio de um processo químico, desenvolver estruturas de natureza nanométrica em um processo de síntese química em via úmida de óxidos de sódio, boro, silício, zinco, potássio e cálcio.",NANOMATERIALES QUIM AVANZADOS S A DE C V;;NANOMATERIALES SA DE CV,CARLOS FIX FIERRO;;GUILLERMO ENRIQUE ACOSTA GONZÁLEZ;;JOEL GUTIÉRREZ ANTONIO;;MÓNICA IBETH AGUILERA BUSTOS,"NANOMATERIALES QUIMICOS AVANZADOS, S.A. DE C.V. (MX) (2021-11-16)",https://lens.org/192-679-318-906-192,Granted Patent,no,0,0,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B35/64,,0,0,,,,ACTIVE
58,US,A1,US 2017/0286547 A1,030-764-080-183-271,2017-10-05,2017,US 201615085638 A,2016-03-30,US 201615085638 A,2016-03-30,USING RELEVANT OBJECTS TO ADD CONTENT TO A COLLABORATIVE REPOSITORY,"Techniques are described herein that are capable of using relevant objects to add content to a collaborative repository. The relevant objects are selected from URI-addressable objects based on each relevant object satisfying one or more relevance criteria. The relevant objects are recommended via a user interface. A determination is made that a specified relevant object is selected from the relevant objects. In one example, the content may be added to (e.g., created in) the collaborative repository based on the specified relevant object. In another example, the specified relevant object may be used to represent a new object type in a new content menu. For instance, the new object type may be selectable to cause an object of the new object type to be created in the collaborative repository.",MICROSOFT TECHNOLOGY LICENSING LLC,TORRES ACOSTA MELISSA;;TRUELOVE BENJAMIN N;;POZNANSKI VICTOR;;DEMARIS JOHN L;;PEREZ CARLOS G,MICROSOFT TECHNOLOGY LICENSING LLC (2016-03-28),https://lens.org/030-764-080-183-271,Patent Application,yes,0,2,3,3,0,G06F16/94;;G06F16/9535;;G06F16/93;;G06F16/958;;G06F16/9535;;G06F16/93;;G06F16/958;;G06F16/94;;G06F3/0482;;G06F3/04842;;H04L65/403,G06F17/30;;G06F3/0482;;G06F3/0484;;H04L29/06,,0,0,,,,ACTIVE
59,US,B2,US 11339098 B2,184-195-112-196-892,2022-05-24,2022,US 201716603131 A,2017-07-20,MX 2017004430 A;;MX 2017000081 W,2017-04-05,"Preparation method of nanometric size metal oxide additives that reduce the temperature of sinterized and/or increase productivity in the manufacture of ceramic parts, improving mechanical properties without affecting the gresification properties of ceramic bodies, tiles or coatings","The object of this invention is a process for manufacturing, conditioning and stabilization of a family of base additives sodium, potassium, boron, silicon, zinc, calcium oxides, among others, prepared by physicochemical and chemical synthesis methods that form nanometric structures, reformulated with deflocculant, sequestrants and dispersants additives that allow to obtain a dispersion or powder capable to decrease the sintering temperature of a ceramic body due to the high fluxing power, which is maximized by the use of nanotechnology in the structures obtained. The process consists in the preparation of nucleation seeds of metal, silicates and carbonates oxides by means of a physicochemical process, and which allow nanometric structures to grow by means of a chemical process in a chemical synthesis process wet basis of sodium, boron, silicon, zinc, potassium and calcium oxides. The combination of these oxides allows structuring elements of high fluxing power due to their high surface area and physicochemical composition. The additives prepared in this invention are chemically stabilized with deflocculating agents, which allow the additives to be incorporated into the aqueous medium grinding process of the ceramic body. Applications made with the additives of this invention allow the sintering temperature of a red body to be reduced from 1150° C. to 1000° C. and in porcelain bodies from 1180° C. to 1050° C., with the use of 0.2 to 5% of the additive, or increasing the speed of the heat treatment by up to 20%, and it can be used in the manufacture of bathroom fittings, molding parts, components for tooling, coatings, valances, enamels, vitrified pastes and other ceramic components. The present invention proposes several nanostructured additive formulations with high performance fluxing properties, which allow to optimize and standardize the sintering process and to improve the mechanical properties of the ceramic body. It also proposes different methods of application of the additive in ceramic formulations.",NANOMATERIALS QUIM AVANZADOS S A DE C V,FIX FIERRO CARLOS;;ACOSTA GONZÁLEZ GUILLERMO ENRIQUE;;AGUILERA BUSTOS MÓNICA IBETH;;GUTIÉRREZ ANTONIO JOEL,NANOMATERIALES QUIMICOS AVANZADOS S.A. DE C.V (2021-05-11),https://lens.org/184-195-112-196-892,Granted Patent,yes,6,0,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B35/64;;B82Y30/00;;B82Y40/00;;C04B35/626,,0,0,,,,ACTIVE
60,WO,A1,WO 2018/186729 A1,113-953-259-755-69X,2018-10-11,2018,MX 2017000081 W,2017-07-20,MX 2017004430 A,2017-04-05,"METHOD FOR THE PREPARATION OF NANOMETRIC METAL OXIDE ADDITIVES THAT REDUCE SINTERING TEMPERATURE AND/OR INCREASE PRODUCTIVITY IN THE MANUFACTURE OF CERAMIC PIECES, IMPROVING MECHANICAL PROPERTIES WITHOUT AFFECTING THE VITRIFICATION PROPERTIES OF CERAMIC BODIES, TILES OR COATINGS","The present invention relates to a process for manufacturing, conditioning and stabilising a family of additives based on oxides of sodium, potassium, boron, silicon, zinc and calcium, inter alia, prepared using physicochemical methods and chemical synthesis methods, which form nanometric structures and are reformulated with deflocculant additives, sequesterants and dispersants that allow the production of a dispersion or powder able to reduce the sintering temperature of a ceramic body, owing to the high melting capacity thereof, which is maximised by the use of nanotechnology in the structures obtained. The method consists of preparing nucleation seeds of metal oxides, silicate and carbonates by means of a physicochemical process, which allow, by means of a chemical process, the growth of nanometric structures in a wet chemical synthesis process for synthesising oxides of sodium, boron, silicon, zinc, potassium and calcium. The combination of these oxides allows the structuring of elements having a high melting capacity owing to the high surface area and physicochemical composition thereof. The additives produced in the present invention are chemically stabilised with deflocculant agents that allow the additives to be incorporated in the process of grinding the ceramic body in an aqueous medium. The uses developed with the additives of the present invention allow of the sintering temperature of a red body to be reduced from 1150 to 1000°C and the sintering temperature of porcelain bodies to be reduced from 1180 to 1050°C, with the use of 0.2 to 5% of the additive, or by increasing the thermal treatment speed by 20%. The method can be used in the manufacture of bathrooms, moulding pieces, components for tools, coatings, border tiles, enamels, slips and other ceramic components. The present invention proposes several formulations of nanostructured additives with high-performance melting properties, which allow the sintering process to be optimised and standardised and the mechanical properties of the ceramic body to be improved. It also proposes various methods for using the ceramic formulation additive.",NANOMATERIALES SA DE CV,FIX FIERRO CARLOS;;ACOSTA GONZÁLEZ GUILLERMO ENRIQUE;;AGUILERA BUSTOS MÓNICA IBETH;;GUTIÉRREZ ANTONIO JOEL,,https://lens.org/113-953-259-755-69X,Patent Application,yes,8,3,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B35/64,,4,0,,,DATABASE WPI Derwent World Patents Index; AN 2015-029442;;DATABASE WPI Derwent World Patents Index; AN 2016-51122B;;DATABASE WPI Derwent World Patents Index; AN 2015-420721;;See also references of EP 3608299A4,PENDING
61,CN,A,CN 114929168 A,154-369-464-009-279,2022-08-19,2022,CN 202080091433 A,2020-12-30,ES 201931176 A;;EP 2020088057 W,2019-12-31,Method and device for generating reflective tear secretion and kit for measuring magnitude of induced tear flow,"A method for generating reflective tear secretion includes chemically stimulating the cornea of an eye of a subject by applying a controlled gas jet having a high CO2 content, at least 80% CO2. A compact device (1, 1 ') for generating reflective tear secretion comprises: a gas source (7) in the form of a cartridge of the disposable type containing a pressurized gas having a CO2 component of at least 80%; and a pneumatic circuit connecting the outlet nozzle of the gas source (7) with the gas outlet nozzle (3) of the device (1, 1 '), the circuit comprising a pressure regulating device (8) and a flow rate (17) regulating device, which are adapted to eject a gas jet through the outlet nozzle (3) at a predetermined pressure and flow rate.",UNIV DE MIGUEL HERN ¨ ¢ LCE UMH;;CONSEJO SUPERIOR INVESTIG,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JORGE;;ACOSTA BOCHE MAURO CESAR;;MERINO SUAREZ MARIA LUCIA,,https://lens.org/154-369-464-009-279,Patent Application,no,0,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61F9/00;;A61B3/10;;A61F9/02;;A61H35/02;;A61M11/00;;A61M11/02;;A61M16/00;;A61M16/16,,0,0,,,,PENDING
62,US,A1,US 2023/0035094 A1,072-878-654-060-772,2023-02-02,2023,US 202017790029 A,2020-12-30,ES 201931176 A;;EP 2020088057 W,2019-12-31,PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW,"Procedure for the generation of a reflex tear secretion, which comprises the chemical stimulation of the cornea of the eye of a subject by applying a controlled jet of a gas with a high CO 2 content, of at least 80% of CO 2 . Compact device ( 1,1 ′) for the generation of a reflex tear secretion, comprising a gas source ( 7 ) in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 80% of CO 2 ; and a pneumatic circuit connecting an outlet mouth of said gas source ( 7 ) with a gas outlet nozzle ( 3 ) of the device ( 1,1 ′), the circuit comprising pressure regulation means ( 8 ) and flow rate ( 17 ) regulation means suitable for ejecting puffs of gas through the outlet nozzle ( 3 ) at a predetermined pressure and flow rates.",UNIV MIGUEL HERNANDEZ DE ELCHE UNH;;CONSEJO SUPERIOR INVESTIGACION,BELMONTE MARTÍNEZ CARLOS;;GALLAR MARTÍNEZ JUANA;;ACOSTA BOJ MARIA CARMEN;;MERINO SUÁREZ MARIA LUISA,CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (2022-06-09);;UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (UMH) (2022-06-09),https://lens.org/072-878-654-060-772,Patent Application,yes,0,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61B3/10,,0,0,,,,PENDING
63,BR,A2,BR 112019020789 A2,075-711-918-932-496,2020-04-28,2020,BR 112019020789 A,2017-07-20,MX 2017000081 W;;MX 2017004430 A,2017-04-05,"método para a preparação de aditivos de óxidos metálicos de tamanho nanométrico que reduzem a temperatura de sinterização e/ou incrementam a produtividade na fabricação de peças de cerâmica, aperfeiçoando as propriedades mecânicas sem afetar as propriedades de gresificação de corpos de cerâmica, placas ou revestimentos","a presente invenção refere-se a um processo para a fabricação, o acondicionamento e a estabilização de uma família de aditivos à base de óxidos de sódio, potássio, boro, silício, zinco e cálcio, entre outros, preparada com o uso de métodos físico-químicos e de síntese química, que forma estruturas manométricas, e que é reformulada com aditivos defloculantes, sequestrantes e dispersantes que permitem obter uma dispersão ou pó capaz de diminuir a temperatura de sinterização de um corpo de cerâmica devido a seu alto poder de fusão, que é maximizado com o uso da nanotecnologia nas estruturas obtidas. o processo consiste na preparação de sementes de nucleação de óxidos metálicos, silicatos e carbonatos, que permitem, por meio de um processo químico, desenvolver estruturas de natureza nanométrica em um processo de síntese química em via úmida de óxidos de sódio, boro, silício, zinco, potássio e cálcio.",NANOMATERIALES SA DE CV,CARLOS FIX FIERRO;;GUILLERMO ENRIQUE ACOSTA GONZÁLEZ;;JOEL GUTIÉRREZ ANTONIO;;MÓNICA IBETH AGUILERA BUSTOS,"NANOMATERIALES QUIMICOS AVANZADOS, S.A. DE C.V. (MX) (2021-11-16)",https://lens.org/075-711-918-932-496,Patent Application,no,0,0,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B35/64,,0,0,,,,ACTIVE
64,MX,A,MX 2015017441 A,031-454-976-071-275,2017-06-15,2017,MX 2015017441 A,2015-12-16,MX 2015017441 A,2015-12-16,FORMULATION BASED ON ROSELLE PLANT CALICES COMPOUNDS FOR DISINFECTING OR PRESERVING AVOCADO.,"The present disclosure is related to compositions or formulations for the disinfection and/or effective fruit preservation and which are contaminated with pathogenic and deteriorating bacteria. The disclosed formulations contain hibiscus acid derivatives, such as the methyl monoester and the methyl diester of the hibiscus acid obtained from the Roselle plant (Hibiscus sabdariffa) chalices, which can act alone or in combination with other disinfectant agents, such as organic acids and chlorine compounds, and surfactants such as the polysorbate 80. The compositions object of the present invention, are capable of eliminating or inactivating bacteria, including pathogenic bacteria of all types in raw fruits and vegetables; but the highest effectiveness is for the avocado (Persea americana), without altering the nutritional and/or sensitive properties of the same.",UNIV AUTÓNOMA DEL ESTADO DE HIDALGO *,JAVIER CASTRO ROSAS;;CARLOS ALBERTO GÓMEZ ALDAPA;;HUMBERTO CORTÉS LÓPEZ;;MARIEL ALEJANDRA AMAYA ACOSTA,,https://lens.org/031-454-976-071-275,Patent Application,no,0,0,1,1,0,,A01P1/00;;A01N65/00,,0,0,,,,PENDING
65,CA,A1,CA 3160701 A1,116-614-790-272-927,2021-07-08,2021,CA 3160701 A,2020-12-30,ES 201931176 A;;EP 2020088057 W,2019-12-31,PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW,"Procedure for the generation of a reflex tear secretion, which comprises the chemical stimulation of the cornea of the eye of a subject by applying a controlled jet of a gas with a high CO2 content, of at least 80% of CO2. Compact device (1,1') for the generation of a reflex tear secretion, comprising a gas source (7) in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 80% of CO2; and a pneumatic circuit connecting an outlet mouth of said gas source (7) with a gas outlet nozzle (3) of the device (1,1'), the circuit comprising pressure regulation means (8) and flow rate (17) regulation means suitable for ejecting puffs of gas through the outlet nozzle (3) at a predetermined pressure and flow rates.",UNIV MIGUEL HERNANDEZ DE ELCHE UMH;;CONSEJO SUPERIOR INVESTIGACION,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MARIA CARMEN;;MERINO SUAREZ MARIA LUISA,,https://lens.org/116-614-790-272-927,Patent Application,no,0,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61B3/10;;A61F9/00;;A61F9/02;;A61H35/02;;A61M11/00;;A61M11/02;;A61M16/00;;A61M16/16,,0,0,,,,PENDING
66,WO,A1,WO 2017/172558 A1,114-630-040-257-450,2017-10-05,2017,US 2017/0024217 W,2017-03-27,US 201615085638 A,2016-03-30,USING RELEVANT OBJECTS TO ADD CONTENT TO A COLLABORATIVE REPOSITORY,"Techniques are described herein that are capable of using relevant objects to add content to a collaborative repository. The relevant objects are selected from URI-addressable objects based on each relevant object satisfying one or more relevance criteria. The relevant objects are recommended via a user interface. A determination is made that a specified relevant object is selected from the relevant objects. In one example, the content may be added to (e.g., created in) the collaborative repository based on the specified relevant object. In another example, the specified relevant object may be used to represent a new object type in a new content menu. For instance, the new object type may be selectable to cause an object of the new object type to be created in the collaborative repository.",MICROSOFT TECHNOLOGY LICENSING LLC,TORRES ACOSTA MELISSA;;TRUELOVE BENJAMIN N;;POZNANSKI VICTOR;;DEMARIS JOHN L;;PEREZ CARLOS G,,https://lens.org/114-630-040-257-450,Patent Application,yes,1,0,3,3,0,G06F16/94;;G06F16/9535;;G06F16/93;;G06F16/958;;G06F16/9535;;G06F16/93;;G06F16/958;;G06F16/94;;G06F3/0482;;G06F3/04842;;H04L65/403,G06F17/30,,1,0,,,"ANONYMOUS: ""Template Creation Basics in Google Docs - Gone Google!"", WEB ARCHIVE COPY OF WEBPAGE, 22 December 2010 (2010-12-22), pages 1 - 3, XP055102812, Retrieved from the Internet <URL:http://web.archive.org/web/20101222004317/http://google.rubissolutions.com/docs/template-creation-basics-in-google-docs> [retrieved on 20140218]",PENDING
67,KR,A,KR 20220123247 A,156-178-521-258-003,2022-09-06,2022,KR 20227025525 A,2020-12-30,ES 201931176 A;;EP 2020088057 W,2019-12-31,반사 눈물 분비를 생성하는 방법 및 디바이스 및 유발된 눈물 유동의 크기를 측정하는 키트,"반사 눈물 분비를 생성하는 방법으로서, 적어도 80% 의 CO2 라는 높은 CO2 함량을 갖는 제어된 기체 제트를 적용함으로써 대상자의 눈의 각막의 화학적 자극을 포함한다. 반사 눈물 분비를 생성하기 위한 컴팩트 디바이스 (1, 1') 로서, 적어도 80% 의 CO2 조성을 갖는 가압 기체를 함유하는 일회용 유형의 카트리지 형태의 기체 공급원 (7); 및 상기 기체 공급원 (7) 의 출구를 상기 디바이스 (1, 1') 의 기체 출구 노즐 (3) 과 연결하는 공압식 회로를 포함하고, 상기 공압식 회로는 미리 결정된 압력 및 유량으로 출구 노즐 (3) 을 통해 기체 퍼프들을 배출하기에 적합한 압력 조절 수단 (8) 및 유량 조절 수단 (17) 을 포함한다.",UNIV MIGUEL HERNANDEZ DE ELCHE UMH;;CONSEJO SUPERIOR INVESTIGACION,BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MARIA CARMEN;;MERINO SUAREZ MARIA LUISA,,https://lens.org/156-178-521-258-003,Patent Application,no,0,0,9,9,0,A61F9/0008;;A61H33/14;;A61H2033/145;;A61H35/02;;A61H2201/0157;;A61H2201/0153;;A61H2201/5097;;A61H2205/024;;A61H2230/205;;A61H2230/206;;A61B3/101;;A61F9/0008;;A61B3/101;;A61B10/0045;;A61H35/02;;A61H2033/145;;A61H2201/0153;;A61H2201/0157;;A61H2201/5097;;A61H2205/024;;A61B2010/0067;;A61B3/101;;A61B2560/0214;;A61B2560/0425;;A61B2560/0431;;A61B2560/0462,A61F9/00;;A61B10/00;;A61H33/14;;A61H35/02,,0,0,,,,PENDING
68,US,B2,US 10289741 B2,190-650-100-014-413,2019-05-14,2019,US 201615085638 A,2016-03-30,US 201615085638 A,2016-03-30,Using relevant objects to add content to a collaborative repository,"Techniques are described herein that are capable of using relevant objects to add content to a collaborative repository. The relevant objects are selected from URI-addressable objects based on each relevant object satisfying one or more relevance criteria. The relevant objects are recommended via a user interface. A determination is made that a specified relevant object is selected from the relevant objects. In one example, the content may be added to (e.g., created in) the collaborative repository based on the specified relevant object. In another example, the specified relevant object may be used to represent a new object type in a new content menu. For instance, the new object type may be selectable to cause an object of the new object type to be created in the collaborative repository.",MICROSOFT TECHNOLOGY LICENSING LLC,TORRES ACOSTA MELISSA;;TRUELOVE BENJAMIN N;;POZNANSKI VICTOR;;DEMARIS JOHN L;;PEREZ CARLOS G,MICROSOFT TECHNOLOGY LICENSING LLC (2016-03-28),https://lens.org/190-650-100-014-413,Granted Patent,yes,17,0,3,3,0,G06F16/94;;G06F16/9535;;G06F16/93;;G06F16/958;;G06F16/9535;;G06F16/93;;G06F16/958;;G06F16/94;;G06F3/0482;;G06F3/04842;;H04L65/403,G06F3/0482;;G06F3/0484;;H04L29/06,,8,0,,,"“Template Creation Basics in Google Docs”, Retrieved from <<http://web.archive.org/web/20101222004317/http://google.rubissolutions.com/docs/template-creation-basics-in-google-docs>>, Dec. 22, 2010, 3 Pages.;;“International Search Report and Written Opinion Issued in PCT Application No. PCT/US2017/024217”, dated May 29, 2017, 14 Pages.;;“M-Files”, Published on: Mar. 25, 2015, 2 pages, Available at: http://www.m-files.com/en/top-ecm-features-new.;;Linder, Josh, “Dropbox for Business Review”, Published on: Apr. 28, 2015, 7 pages, Available at: http://www.tomsitpro.com/articles/dropbox-for-business-review,2-852.html.;;“FileCloud provides Secure Access to Enterprise Data from Any Device”, Retrieved on: Dec. 24, 2015, 1 page, Available at: https://www.getfilecloud.com/enterprise-file-synchronization-and-sharing/.;;“OmniDocs Enterprise Content Management (ECM) Suite”, Published on: Mar. 18, 2015, 8 pages, Available at: http://www.newgensoft.com/products/enterprise-content-management-omnidocs/.;;“IBM Knowledge Center”, Retrieved on: Dec. 24, 2015, 6 pages, Available at: https://www-01.ibm.com/support/knowledgecenter/SSEUEX_2.0.3/com.ibm.installingeuc.doc/eucao009.htm.;;Swanson, et al., “Integrating External Document Repositories with SharePoint Server 2007”, Published on: Feb. 2009, 11 pages, Available at: https://msdn.microsoft.com/en-us/library/office/dd440954%28v=office.12%29.aspx.",ACTIVE
69,MX,B,MX 371325 B,010-907-834-109-597,2020-01-27,2020,MX 2014007303 A,2014-06-17,MX 2014007303 A,2014-06-17,FIREPROOF AND HEAT-STABLE AQUEOUS SUSPENSIONS IN THE FORM OF COATINGS APPLIED OVER CELLULOSE DERIVATIVES INTENDED TO WRAP FOOD AND MANUFACTURE BOXES.,"The purpose of the present invention is to provide aqueous suspensions of ions, functionalized silicon oxide nanoparticles and calcium carbonate nanoparticles, which are intended to cover products derived from cellulose used in the manufacture of food wraps for the fast food sector and in the manufacture of cardboard boxes. The superficial functionalization of the silicon oxide nanoparticles plays an important role in the result of the fireproof capacity of the coating, contributing in different aspects during the application of the same. The paper manufactured with the process of the present inventions allows food to be heated in different heat sources without removing the wrap and preventing the formation of a carbon layer, avoiding the paper flavor to be transmitted to the food during heating. In the case of the cardboard boxes, this prevents fire propagation in places where these are stored. The invention proposes several formulations of nanoparticle suspensions with fireproof cha racteristics and resistance to thermo-degradation. Moreover, the invention proposes different methods for applying the coatings over the cellulose derivatives.",NANOMATERIALES S A DE C V,JOEL GUTIERREZ ANTONIO;;CARLOS ENRIQUE FIX FIERRO;;FATIMA PEREZ RODRIGUEZ;;GUILLERMO ENRIQUE ACOSTA GONZALEZ,LEONIDES HERNANDEZ ESCALANTE (2021-10-15),https://lens.org/010-907-834-109-597,Granted Patent,no,0,0,2,2,0,,D21H21/34;;C09D5/18;;D21H17/11;;D21H17/13,,0,0,,,,ACTIVE
70,EP,A1,EP 3608299 A1,073-267-852-467-892,2020-02-12,2020,EP 17904875 A,2017-07-20,MX 2017004430 A;;MX 2017000081 W,2017-04-05,"METHOD FOR THE PREPARATION OF NANOMETRIC METAL OXIDE ADDITIVES THAT REDUCE SINTERING TEMPERATURE AND/OR INCREASE PRODUCTIVITY IN THE MANUFACTURE OF CERAMIC PIECES, IMPROVING MECHANICAL PROPERTIES WITHOUT AFFECTING THE VITRIFICATION PROPERTIES OF CERAMIC BODIES, TILES OR COATINGS","The object of this invention is a process for manufacturing, conditioning and stabilization of a family of base additives sodium, potassium, boron, silicon, zinc, calcium oxides, among others, prepared by physicochemical and chemical synthesis methods that form nanometric structures, reformulated with deflocculant, sequestrants and dispersants additives that allow to obtain a dispersion or powder capable to decrease the sintering temperature of a ceramic body due to the high fluxing power, which is maximized by the use of nanotechnology in the structures obtained. The process consists in the preparation of nucleation seeds of metal, silicates and carbonates oxides by means of a physicochemical process, and which allow nanometric structures to grow by means of a chemical process in a chemical synthesis process wet basis of sodium, boron, silicon, zinc, potassium and calcium oxides. The combination of these oxides allows structuring elements of high fluxing power due to their high surface area and physicochemical composition. The additives prepared in this invention are chemically stabilized with deflocculating agents, which allow the additives to be incorporated into the aqueous medium grinding process of the ceramic body. Applications made with the additives of this invention allow the sintering temperature of a red body to be reduced from 1150 °C to 1000 °C and in porcelain bodies from 1180 °C to 1050 °C, with the use of 0.2 to 5% of the additive, or increasing the speed of the heat treatment by up to 20%, and it can be used in the manufacture of bathroom fittings, molding parts, components for tooling, coatings, valances, enamels, vitrified pastes and other ceramic components. The present invention proposes several nanostructured additive formulations with high performance fluxing properties, which allow to optimize and standardize the sintering process and to improve the mechanical properties of the ceramic body. It also proposes different methods of application of the additive in ceramic formulations.",NANOMATERIALES SA DE CV,FIX FIERRO CARLOS;;ACOSTA GONZÁLEZ GUILLERMO ENRIQUE;;AGUILERA BUSTOS MÓNICA IBETH;;GUTIÉRREZ ANTONIO JOEL,"NANOMATERIALES QUIMICOS AVANZADOS, S.A. DE C.V. (2021-12-08)",https://lens.org/073-267-852-467-892,Patent Application,yes,0,0,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B35/64,,0,0,,,,PENDING
71,PE,A1,PE 20090117 A1,083-848-164-452-687,2009-03-30,2009,PE 2007000710 A,2007-06-07,PE 2007000710 A,2007-06-07,"MATERIALES COMPUESTOS DE MATRIZ DE CEMENTO, FIBRAS DE CELULOSA Y QUITOSANO REFORZADOS OPCIONALMENTE CON FIBRAS NATURALES TRATADAS CON QUITOSANO, PROCEDIMIENTO PARA EL TRATAMIENTO DE FIBRAS CON QUITOSANO, PROCEDIMIENTOS PARA FABRICAR MATERIALES COMPUE","SE REFIERE A UN MATERIAL COMPUESTO QUE COMPRENDE CEMENTO REFORZADO CON FIBRAS DE CELULOSA OBTENIDAS A PARTIR DE PAPEL RECICLADO, CARACTERIZADO PORQUE: A) EL QUITOSANO PUEDE ESTAR PRESENTE EN LAS SIGUIENTES OPCIONES, i) EN LA MEZCLA DE CEMENTO Y FIBRA DE CELULOSA, ii) COMO UNA PELICULA QUE RECUBRE LA SUPERFICIE DE LAS FIBRAS DE CELULOSA, O iii) EN AMBAS FORMAS A LA VEZ; B) EL GRADO DE DESACETILACION DEL QUITOSANO ES DE POR LO MENOS 60%, EL QUITOSANO SE DILUYE EN ACIDO ACETICO DILUIDO EN UNA PROPORCION DE 0,5% A 5% VOLUMEN/VOLUMEN, ESTANDO PRESENTE EL QUITOSANO EN UNA PROPORCION MAXIMA DE 10% EN PESO DE LA MEZCLA TOTAL; C) LAS FIBRAS DE CELULOSA ANTES DE SER MEZCLADAS CON EL CEMENTO SE ENCUENTRAN COMO PASTA DE PAPEL EN UNA PROPORCION EN PESO DE PAPEL ENTRE 40% Y 70% DE LA MEZCLA TOTAL DE CEMENTO, PASTA DE PAPEL Y SOLUCION DE QUITOSANO, Y VARIANDO LAS LONGITUDES DE LAS FIBRAS DE CELULOSA ENTRE 0,15mm Y 15mm DE LARGO. SE REFIERE ADEMAS, A UN PROCEDIMIENTO QUE INCLUYE LOS PASOS DE: i) PREPARAR PREVIAMENTE LAS FIBRAS, DE ACUERDO A SI SON DE CELULOSA O NATURALES; ii) INTRODUCIR LAS FIBRAS EN UNA SOLUCION DE QUITOSANO EN ACIDO ACETICO PARA PRODUCIR UNA IMPREGNACION DEL QUITOSANO EN LA FIBRA; Y iii) RETIRAR LA FIBRA DE LA SOLUCION Y SECARLA A UNA TEMPERATURA MAXIMA DE 80ºC DURANTE UN TIEMPO NO MAYOR A 30 MINUTOS, PARA FORMAR UNA PELICULA DE QUITOSANO SOBRE LA SUPERFICIE DE LA FIBRA",UNIV PONTIFICIA CATOLICA PERU,ACOSTA SULLCAHUAMAN JULIO ARNALDO;;FUENTES ROJAS CARLOS ANIBAL;;PASTOR REVOREDO DE ABRAM ANA VIRGINIA,,https://lens.org/083-848-164-452-687,Patent Application,no,0,0,1,1,0,,C04B16/00;;C04B24/00,,0,0,,,,ACTIVE
72,US,A1,US 2020/0115287 A1,117-018-292-424-348,2020-04-16,2020,US 201716603131 A,2017-07-20,MX 2017004430 A;;MX 2017000081 W,2017-04-05,"PREPARATION METHOD OF NANOMETRIC SIZE METAL OXIDE ADDITIVES THAT REDUCE THE TEMPERATURE OF SINTERIZED AND/OR INCREASE PRODUCTIVITY IN THE MANUFACTURE OF CERAMIC PARTS, IMPROVING MECHANICAL PROPERTIES WITHOUT AFFECTING THE GRESIFICATION PROPERTIES OF CERAMIC BODIES, TILES OR COATINGS","The object of this invention is a process for manufacturing, conditioning and stabilization of a family of base additives sodium, potassium, boron, silicon, zinc, calcium oxides, among others, prepared by physicochemical and chemical synthesis methods that form nanometric structures, reformulated with deflocculant, sequestrants and dispersants additives that allow to obtain a dispersion or powder capable to decrease the sintering temperature of a ceramic body due to the high fluxing power, which is maximized by the use of nanotechnology in the structures obtained. The process consists in the preparation of nucleation seeds of metal, silicates and carbonates oxides by means of a physicochemical process, and which allow nanometric structures to grow by means of a chemical process in a chemical synthesis process wet basis of sodium, boron, silicon, zinc, potassium and calcium oxides. The combination of these oxides allows structuring elements of high fluxing power due to their high surface area and physicochemical composition. The additives prepared in this invention are chemically stabilized with deflocculating agents, which allow the additives to be incorporated into the aqueous medium grinding process of the ceramic body. Applications made with the additives of this invention allow the sintering temperature of a red body to be reduced from 1150° C. to 1000° C. and in porcelain bodies from 1180° C. to 1050° C., with the use of 0.2 to 5% of the additive, or increasing the speed of the heat treatment by up to 20%, and it can be used in the manufacture of bathroom fittings, molding parts, components for tooling, coatings, valances, enamels, vitrified pastes and other ceramic components. The present invention proposes several nanostructured additive formulations with high performance fluxing properties, which allow to optimize and standardize the sintering process and to improve the mechanical properties of the ceramic body. It also proposes different methods of application of the additive in ceramic formulations.",NANOMATERIALES SA DE CV,FIX FIERRO CARLOS;;ACOSTA GONZÁLEZ GUILLERMO ENRIQUE;;AGUILERA BUSTOS MÓNICA IBETH;;GUTIÉRREZ ANTONION JOEL,NANOMATERIALES QUIMICOS AVANZADOS S.A. DE C.V (2021-05-11),https://lens.org/117-018-292-424-348,Patent Application,yes,0,2,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B35/626;;C04B35/64,,0,0,,,,ACTIVE
73,MX,A,MX 2014007303 A,143-918-012-559-472,2015-12-17,2015,MX 2014007303 A,2014-06-17,MX 2014007303 A,2014-06-17,FIREPROOF AND HEAT-STABLE AQUEOUS SUSPENSIONS IN THE FORM OF COATINGS APPLIED OVER CELLULOSE DERIVATIVES INTENDED TO WRAP FOOD AND MANUFACTURE BOXES.,"The purpose of the present invention is to provide aqueous suspensions of ions, functionalized silicon oxide nanoparticles and calcium carbonate nanoparticles, which are intended to cover products derived from cellulose used in the manufacture of food wraps for the fast food sector and in the manufacture of cardboard boxes. The superficial functionalization of the silicon oxide nanoparticles plays an important role in the result of the fireproof capacity of the coating, contributing in different aspects during the application of the same. The paper manufactured with the process of the present inventions allows food to be heated in different heat sources without removing the wrap and preventing the formation of a carbon layer, avoiding the paper flavor to be transmitted to the food during heating. In the case of the cardboard boxes, this prevents fire propagation in places where these are stored. The invention proposes several formulations of nanoparticle suspensions with fireproof cha racteristics and resistance to thermo-degradation. Moreover, the invention proposes different methods for applying the coatings over the cellulose derivatives.",NANOMATERIALES S A DE C V,ANTONIO JOEL GUTIERREZ;;FIERRO CARLOS ENRIQUE FIX;;RODRIGUEZ FATIMA PEREZ;;GONZALEZ GUILLERMO ENRIQUE ACOSTA,LEONIDES HERNANDEZ ESCALANTE (2021-10-15),https://lens.org/143-918-012-559-472,Patent Application,no,0,1,2,2,0,,A23P1/08;;C08J3/00;;C08J5/00;;C09D101/02,,0,0,,,,ACTIVE
74,EP,A4,EP 3608299 A4,191-944-043-705-014,2021-01-13,2021,EP 17904875 A,2017-07-20,MX 2017004430 A;;MX 2017000081 W,2017-04-05,"METHOD FOR THE PREPARATION OF NANOMETRIC METAL OXIDE ADDITIVES THAT REDUCE SINTERING TEMPERATURE AND/OR INCREASE PRODUCTIVITY IN THE MANUFACTURE OF CERAMIC PIECES, IMPROVING MECHANICAL PROPERTIES WITHOUT AFFECTING THE VITRIFICATION PROPERTIES OF CERAMIC BODIES, TILES OR COATINGS",,NANOMATERIALES SA DE CV,FIX FIERRO CARLOS;;ACOSTA GONZÁLEZ GUILLERMO ENRIQUE;;AGUILERA BUSTOS MÓNICA IBETH;;GUTIÉRREZ ANTONIO JOEL,"NANOMATERIALES QUIMICOS AVANZADOS, S.A. DE C.V. (2021-12-08)",https://lens.org/191-944-043-705-014,Search Report,no,2,0,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B33/13;;C04B35/626,,2,1,142-982-408-383-936,10.1080/02726351.2014.978425,"CHETAN M. PATEL ET AL: ""Influence of pH on the Stability of Alumina and Silica Nanosuspension Produced by Wet Grinding"", PARTICULATE SCIENCE AND TECHNOLOGY, vol. 33, no. 3, 6 January 2015 (2015-01-06), US, pages 240 - 245, XP055757039, ISSN: 0272-6351, DOI: 10.1080/02726351.2014.978425;;See also references of WO 2018186729A1",PENDING
75,US,A1,US 2023/0186524 A1,022-814-642-469-072,2023-06-15,2023,US 202117552219 A,2021-12-15,US 202117552219 A,2021-12-15,OBJECT MODEL ENCODINGS,"Examples of methods are described herein. In some examples, a method includes determining a quantity of inner voxels in a canonical direction from each surface voxel of a set of surface voxels of a three-dimensional (3D) object model. In some examples, the method includes generating an encoded representation of the 3D object model, the encoded representation indicating a location of each surface voxel and the quantity of inner voxels for each surface voxel.",HEWLETT PACKARD DEVELOPMENT CO;;INST ATLANTICO,CATANA SALAZAR JUAN CARLOS;;MEDRANO ACOSTA MARCO ANTONIO;;GOMES SOARES CANTAL ALYNE;;ZENG JUN,INSTITUTO ATLANTICO (2021-12-10);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2021-12-08),https://lens.org/022-814-642-469-072,Patent Application,yes,11,0,1,1,0,G06T9/001;;G06T9/40;;G06T17/005;;G06T9/001,G06T9/00;;G06T17/00,,0,0,,,,PENDING
76,BR,A,BR 0003091 A,080-338-463-029-812,2001-10-16,2001,BR 0003091 A,2000-07-05,MX 9906308 A;;MX 9906309 A,1999-07-06,Artigo absorvente descartável com sistema anti-escorrimento e processo para sua fabricação,"""ARTIGO ABSORVENTE DESCARTáVEL COM SISTEMA ANTI- ESCORRIMENTO E PROCESSO PARA SUA FABRICAçãO"", tal como uma fralda descartável para bebes, uma fralda descartável para adultos incontinentes, um calção preparador ou uma toalha sanitária feminina, que tem colocadas e fixadas de forma simultaneamente durante o processo de fabricação do artigo absorvente descartável, mediante extrusão, aspergindo ou untando duas barreiras longitudinais de um material impermeável sobre a parte interna da capa superior permeável, a ambos lados da mesma, de modo que ao colocar a capa superior sobre o núcleo absorvente, se formam as barreiras internas longitudinais. As barreiras mantém-se unidas em sua totalidade por sua face interna da capa superior, enquanto que a parte interna das barreiras em sua parte superior mantém-se montada sobre o núcleo absorvente, a parte média da barreira mantém-se adjacente a borda longitudinal do núcleo absorvente ao menos na seção dos fundilhos e a parte inferior da barreira mantém-se aderida com a parte interna da capa inferior impermeável. Se crê ademais um sistema integral anti-escorrimento ao atuar em conjunto as barreiras internas longitudinais extrusadas e as barreiras laterais externas.",GRUPO P I MABE SA DE C V,CARLOS ALBERTO CORONA;;MONTEROS CARLOS CANALES ESPINO;;FERNANDEZ LUCIA SANCHEZ;;HERRERA GUSTAVO TORRES;;ACOSTA JUAN FRANCISCO GALVAN;;MARTINEZ RAUL GONZALEZ,,https://lens.org/080-338-463-029-812,Patent Application,no,0,0,5,5,0,,A61F13/475;;A61F13/494;;A61L15/42,,0,0,,,,EXPIRED
77,AU,A1,AU 2003/226028 A1,087-126-971-086-813,2003-11-10,2003,AU 2003/226028 A,2003-03-26,US 13396102 A;;US 0309360 W,2002-04-26,AUTOMATIC WAVEFORM OUTPUT ADJUSTMENT FOR AN IMPLANTABLE MEDICAL DEVICE,,MEDTRONIC INC,BRIGHT KEVIN L;;HESTER RICHARD E;;ACOSTA CARLOS C;;PERZ LEROY L;;JURAN CARLEEN J,,https://lens.org/087-126-971-086-813,Patent Application,no,0,0,7,7,0,A61N1/36125;;A61N1/36125,A61N1/08;;A61N1/36,,0,0,,,,DISCONTINUED
78,WO,A3,WO 2003/090609 A3,180-694-261-288-986,2003-12-11,2003,US 0309360 W,2003-03-26,US 13396102 A,2002-04-26,AUTOMATIC WAVEFORM OUTPUT ADJUSTMENT FOR AN IMPLANTABLE MEDICAL DEVICE,"Apparatus and method assure electrical characteristics of a stimulation waveform to an electrode of an Implantable Neuro Stimulator. The embodiment comprises a regulator, a measurement module, a generator, and a processor. The generator provides an input signal to the regulator. The regulator consequently regulates the input signal in order to form a pulse that is applied to the electrode. The processor instructs the measurement module to perform an electrical measurement that is indicative of an amplitude of the pulse. If the electrical measurement is sufficiently different from a desired value, the processor instructs the generator to be reconfigured in order that the amplitude of the pulse is within an acceptable value. A redundant capacitor pair may be inserted in a capacitor arrangement in order to compensate for a reduced battery voltage, or a detected faulty component such as a capacitor or a regulator may be replaced with a redundant component.",MEDTRONIC INC,ACOSTA CARLOS C;;PERZ LEROY L;;JURAN CARLEEN J;;BRIGHT KEVIN L;;HESTER RICHARD E,,https://lens.org/180-694-261-288-986,Search Report,yes,5,0,7,7,0,A61N1/36125;;A61N1/36125,A61N1/08;;A61N1/36,,0,0,,,,PENDING
79,US,A1,US 2003/0204226 A1,035-602-554-187-187,2003-10-30,2003,US 13396102 A,2002-04-26,US 13396102 A,2002-04-26,Automatic waveform output adjustment for an implantable medical device,"
   Apparatus and method assure the electrical characteristics of a stimulation waveform to an electrode of an Implantable Neuro Stimulator. The embodiment comprises a regulator, a measurement module, a generator, and a processor. The generator provides an input signal to the regulator. The regulator consequently regulates the input signal in order to form a pulse that is applied to the electrode. The processor instructs the measurement module to perform an electrical measurement that is indicative of an amplitude of the pulse. If the electrical measurement is sufficiently different from a desired value, the processor instructs the generator to be reconfigured in order that the amplitude of the pulse is within an acceptable value. A redundant capacitor pair may be inserted in a capacitor arrangement in order to compensate for a reduced battery voltage, or a detected faulty component such as a capacitor or a regulator may be replaced with a redundant component. 
",MEDTRONIC INC,ACOSTA CARLOS C;;PERZ LEROY L;;JURAN CARLEEN J;;BRIGHT KEVIN L;;HESTER RICHARD E,MEDTRONIC INC (2002-04-24),https://lens.org/035-602-554-187-187,Patent Application,yes,13,35,7,7,0,A61N1/36125;;A61N1/36125,A61N1/08;;A61N1/36,607/48,0,0,,,,EXPIRED
80,AU,A8,AU 2003/226028 A8,106-242-259-183-260,2003-11-10,2003,AU 2003/226028 A,2003-03-26,US 13396102 A;;US 0309360 W,2002-04-26,Automatic waveform output adjustment for an implantable medical device,,MEDTRONIC INC,JURAN CARLEEN J;;PERZ LEROY L;;BRIGHT KEVIN L;;HESTER RICHARD E;;ACOSTA CARLOS C,,https://lens.org/106-242-259-183-260,Patent Application,no,0,0,7,7,0,A61N1/36125;;A61N1/36125,A61N1/08;;A61N1/36,,0,0,,,,DISCONTINUED
81,WO,A2,WO 2003/090609 A2,163-388-594-648-271,2003-11-06,2003,US 0309360 W,2003-03-26,US 13396102 A,2002-04-26,AUTOMATIC WAVEFORM OUTPUT ADJUSTMENT FOR AN IMPLANTABLE MEDICAL DEVICE,"Apparatus and method assure electrical characteristics of a stimulation waveform to an electrode of an Implantable Neuro Stimulator. The embodiment comprises a regulator, a measurement module, a generator, and a processor. The generator provides an input signal to the regulator. The regulator consequently regulates the input signal in order to form a pulse that is applied to the electrode. The processor instructs the measurement module to perform an electrical measurement that is indicative of an amplitude of the pulse. If the electrical measurement is sufficiently different from a desired value, the processor instructs the generator to be reconfigured in order that the amplitude of the pulse is within an acceptable value. A redundant capacitor pair may be inserted in a capacitor arrangement in order to compensate for a reduced battery voltage, or a detected faulty component such as a capacitor or a regulator may be replaced with a redundant component.",MEDTRONIC INC,ACOSTA CARLOS C;;PERZ LEROY L;;JURAN CARLEEN J;;BRIGHT KEVIN L;;HESTER RICHARD E,,https://lens.org/163-388-594-648-271,Patent Application,yes,0,0,7,7,0,A61N1/36125;;A61N1/36125,A61N1/08;;A61N1/36,,0,0,,,,PENDING
82,EP,A2,EP 1501590 A2,118-895-565-542-472,2005-02-02,2005,EP 03747256 A,2003-03-26,US 0309360 W;;US 13396102 A,2002-04-26,AUTOMATIC WAVEFORM OUTPUT ADJUSTMENT FOR AN IMPLANTABLE MEDICAL DEVICE,,MEDTRONIC INC,ACOSTA CARLOS C;;PERZ LEROY L;;JURAN CARLEEN J;;BRIGHT KEVIN L;;HESTER RICHARD E,,https://lens.org/118-895-565-542-472,Patent Application,yes,0,0,7,7,0,A61N1/36125;;A61N1/36125,A61N1/08;;A61N1/36,,1,0,,,See references of WO 03090609A3,DISCONTINUED
83,US,B2,US 7024246 B2,065-957-129-399-972,2006-04-04,2006,US 13396102 A,2002-04-26,US 13396102 A,2002-04-26,Automatic waveform output adjustment for an implantable medical device,"Apparatus and method assure the electrical characteristics of a stimulation waveform to an electrode of an Implantable Neuro Stimulator. The embodiment comprises a regulator, a measurement module, a generator, and a processor. The generator provides an input signal to the regulator. The regulator consequently regulates the input signal in order to form a pulse that is applied to the electrode. The processor instructs the measurement module to perform an electrical measurement that is indicative of an amplitude of the pulse. If the electrical measurement is sufficiently different from a desired value, the processor instructs the generator to be reconfigured in order that the amplitude of the pulse is within an acceptable value. A redundant capacitor pair may be inserted in a capacitor arrangement in order to compensate for a reduced battery voltage, or a detected faulty component such as a capacitor or a regulator may be replaced with a redundant component.",MEDTRONIC INC,ACOSTA CARLOS C;;PERZ LEROY L;;JURAN CARLEEN J;;BRIGHT KEVIN L;;HESTER RICHARD E,MEDTRONIC INC (2002-04-24),https://lens.org/065-957-129-399-972,Granted Patent,yes,14,210,7,7,0,A61N1/36125;;A61N1/36125,A61N1/36;;A61N1/08,607/46,0,0,,,,EXPIRED
84,BR,B1,BR 0003091 B1,045-042-261-475-935,2009-01-13,2009,BR 0003091 A,2000-07-05,MX 9906308 A;;MX 9906309 A,1999-07-06,artigo absorvente descartÁvel com sistema anti-escorrimento e processo para sua fabricaÇço.,,,CARLOS ALBERTO CORONA;;DE LOS MONTEROS CARLOS CANALES ESPINOSA;;FERNANDEZ LUCIA SANCHEZ;;HERRERA GUSTAVO TORRES;;ACOSTA JUAN FRANCISCO GALVAN;;MARTINEZ RAUL GONZALEZ,,https://lens.org/045-042-261-475-935,Granted Patent,no,0,0,5,5,0,,A61L15/42;;A61F13/475;;A61F13/494,,0,0,,,,EXPIRED
85,WO,A1,WO 2021/216573 A1,028-935-026-223-895,2021-10-28,2021,US 2021/0028192 W,2021-04-20,US 202063012810 P;;US 202063036024 P,2020-04-20,"SCALABLE, EASY-TO-DEPLOY SYSTEM AND REAGENTS THEREOF FOR CRISPR-ASSOCIATED NUCLEASE-BASED DETECTION OF PATHOGEN GENETIC MATERIAL","Scalable testing of a disease or pathogenic infection is limited by hurdles in cost of reagents, instrument accessibility, availability of highly trained personnel, and large upfront investment. Herein, systems and methods for use of CRISPR-associated nuclease-based, Rugged, Equitable, Scalable Testing (CREST) are provided. CREST pairs reliable polymerase chain reaction (PCR) with low-cost instrumentation without sacrificing detection sensitivity, and allows for a binary interpretation of detection results. A new lysis solution for extraction of nucleic acids and/or protein is also provided and can be used to prepare nucleic acid sample in CREST assay. The systems and reagents disclosed provide for a point-of-care solution to increase distribution of COVID-19 surveillance.",UNIV CALIFORNIA,ARIAS GONZALEZ CAROLINA;;ACOSTA-ALVEAR DIEGO;;WILSON MAX;;KOSIK KENNETH;;COSTELLO MICHAEL;;PONCE ROJAS JOSE CARLOS,,https://lens.org/028-935-026-223-895,Patent Application,yes,4,2,1,1,16,A61P35/00;;C12N2310/20;;C12N15/1003;;G01N33/54388;;G01N33/54346;;C12Q1/6816,A61P35/00;;C07H21/00;;C07H21/04;;C07K14/47;;C12N1/21;;C12N5/10,,4,3,042-584-044-209-208;;142-017-493-396-461;;198-900-840-071-675,10.2139/ssrn.3562504;;10.1101/789164;;pmc8092748;;10.37473/dac/10.1101/2020.04.20.052159;;10.1128/jcm.02402-20;;33478979,"CHATTERJEE S.: ""Understanding the Nature of Variations in Structural Sequences coding for Coronavirus Spike, Envelope, Membrane and Nucleocapsid Proteins of SARS-CoV-2"", SSRN, 9 July 2021 (2021-07-09), pages 2 - 12, XP055868139;;KUZNIEWSKA BOZENA, CYSEWSKI DOMINIK, WASILEWSKI MICHAL, SAKOWSKA PAULINA, MILEK JACEK, KULINSKI TOMASZ M., KOZIELEWICZ PAWEL, DADL: ""Mitochondria biogenesis in the synapse is supported by local translation"", BIORXIV, 1 October 2019 (2019-10-01), pages 1 - 24, XP055868144, [retrieved on 20211201], DOI: 10.1101/789164;;DONG TIANYU: ""Development of Field-deployable Nucleic Acid Testing Platforms"", MASTER'S THESIS, FACULTY OF MATHEMATICS AND SCIENCE, BROCK UNIVERSITY, 1 January 2019 (2019-01-01), pages 1 - 105, XP055812207;;RAUCH JENNIFER N., VALOIS ERIC, SOLLEY SABRINA C., BRAIG FRIEDERIKE, LACH RYAN S., AUDOUARD MORGANE, PONCE-ROJAS JOSE CARLOS, COST: ""A Scalable, Easy-to-Deploy Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material"", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 59, no. 4, 19 March 2021 (2021-03-19), US , pages 1 - 8, XP055868173, ISSN: 0095-1137, DOI: 10.1128/JCM.02402-20",PENDING
86,US,A1,US 2019/0070643 A1,055-637-581-511-662,2019-03-07,2019,US 201816124701 A,2018-09-07,US 201816124701 A;;US 201762555117 P,2017-09-07,BEVERAGE DISPENSER CLEANING METHODS AND APPARATUS,"The present disclosure provides systems and methods for automating the cleaning and sanitizing processes of a food dispensing machine. The systems and methods may be set to run automatically and may keep a dispensing system cleaned and sanitized for an extended time. The systems and methods disclosed are designed to make cleaning easier for the operator, shorten the overall cleaning time, reduce the amount of labor involved, and improve the convenience, reliability, and repeatability of the cleaning processes.",FBD PARTNERSHIP LP,WONG ELGIN W;;GATES MATHEW G;;BLESSING JR WILLIAM R;;TRENT NOAH G;;ACOSTA CARLOS A,FBD PARTNERSHIP LP (2020-01-08),https://lens.org/055-637-581-511-662,Patent Application,yes,0,12,3,3,0,B67D1/07;;B08B9/0321;;B67D2001/075;;B08B9/0325;;B67D1/07;;B08B9/0328;;B08B9/0325;;B08B3/102;;B08B2203/007;;B67D1/07;;B08B9/0328;;B08B9/0321;;B67D2001/075;;A23G9/28;;A23G9/30;;A23G9/00,B08B9/032;;B08B3/10;;B67D1/07,,0,0,,,,PENDING
87,CO,A1,CO 2022007149 A1,114-163-475-231-890,2022-10-31,2022,CO 2022007149 A,2022-05-26,CO 2022007149 A,2022-05-26,Simulador de mediana fidelidad para punción lumbar,"La presente invención pertenece al campo de la física, como material educativo o de demostración en medios de enseñanza o de comunicación destinados a modelos para usos científicos, médicos por Ej. Dispositivos a escala real para la demostración en la medicina: particularmente se refiere a simulador de mediana fidelidad para punción lumbar para identificar con precisión los puntos de referencia anatómicos que en este caso se relacionan con las crestas iliacas, por lo que se presenta un torso sintético de látex que es la base del simulador donde se ubica la zona de punción lumbar, la cual se compone de las vértebras lumbares que están sobre la manguera de látex por la cual atraviesa el líquido cefalorraquídeo que se conecta con el equipo de macro goteo para generar presión al momento de la salida del fluido, donde las vértebras se encuentran recubiertas por pintura conductiva y una placa flexible de aluminio para detectar la zona errónea de punción, a través de un sensor de continuidad.",UNIV COOPERATIVA DE COLOMBIA SEDE PASTO,INSUASTY ORTIZ HECTOR ARMANDO;;ESTRADA VALLEJO DAVID ESTEBAN;;DIAZ PINTO CARLOS LEOPOLDO;;CHAVES ACOSTA JORGE DARIO,,https://lens.org/114-163-475-231-890,Patent Application,no,0,0,1,1,0,,G09B23/00;;G09B23/28;;G09B23/30,,0,0,,,,PENDING
88,CA,C,CA 2809027 C,009-435-822-466-898,2018-01-02,2018,CA 2809027 A,2011-01-06,US 68327910 A;;US 2011/0020405 W,2010-01-06,MULTIMEDIA TRAINING SYSTEM AND APPARATUS AND METHOD THEREFOR,"A system and method for providing interactive training, whereby a video display and a base station are coupled in communication with a computer. A plurality of wireless handheld remotes are configured for wirelessly communicating with the base station, and each of the remotes is operable by a respective trainee of a group of trainees. Each remote has a remote ID unique from all other remotes and is stored in a memory of the computer; and the base station includes a base station ID code unique from all other base stations, and the base station ID is stored in a memory of each remote. Each remote remains in an inactive state and is operable to be activated via a respective ACTIVATE signal transmitted from the base station, and the base station is operable to transmit an ACTIVATE signal to one or more of the remotes, the ACTIVATE signal being effective for enabling the remote to transmit a signal, wherein the remote is preferably deactivated upon completion of transmission of signal. Using unique IDs prevents interference from other wireless devices including remotes bound with other base stations. It also makes it unnecessary for one training system to operate on a different channel from another training system.",ALCHEMY SYSTEMS L P,ACOSTA CARLOS;;BARRETT ARCHIE D JR;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID;;EASTMAN JEFFREY;;DONELSON ROBIN,,https://lens.org/009-435-822-466-898,Granted Patent,no,0,0,7,7,0,G09B5/00;;G09B7/00;;H04W52/0225;;Y02D30/70;;G09B5/00;;G09B7/00;;Y02D30/70;;G09B5/10;;G09B5/12;;G09B5/14;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/0225;;H04W84/12,G09B5/00;;H04L12/12;;H04L12/28;;H04L12/46;;H04L29/12,,0,0,,,,ACTIVE
89,WO,A1,WO 2011/085119 A1,132-351-053-660-856,2011-07-14,2011,US 2011/0020405 W,2011-01-06,US 68327910 A,2010-01-06,MULTIMEDIA TRAINING SYSTEM AND APPARATUS AND METHOD THEREFOR,"A system and method for providing interactive training, whereby a video display and a base station are coupled in communication with a computer. A plurality of wireless handheld remotes are configured for wirelessly communicating with the base station, and each of the remotes is operable by a respective trainee of a group of trainees. Each remote has a remote ID unique from all other remotes and is stored in a memory of the computer; and the base station includes a base station ID code unique from all other base stations, and the base station ID is stored in a memory of each remote. Each remote remains in an inactive state and is operable to be activated via a respective ACTIVATE signal transmitted from the base station, and the base station is operable to transmit an ACTIVATE signal to one or more of the remotes, the ACTIVATE signal being effective for enabling the remote to transmit a signal, wherein the remote is preferably deactivated upon completion of transmission of signal. Using unique IDs prevents interference from other wireless devices including remotes bound with other base stations. It also makes it unnecessary for one training system to operate on a different channel from another training system.",ALCHEMY SYSTEMS L P;;ACOSTA CARLOS;;BARRETT ARCHIE D JR;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID;;EASTMAN JEFFREY;;DONELSON ROBIN,ACOSTA CARLOS;;BARRETT ARCHIE D JR;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID;;EASTMAN JEFFREY;;DONELSON ROBIN,,https://lens.org/132-351-053-660-856,Patent Application,yes,5,0,7,7,0,G09B5/00;;G09B5/10;;G09B5/00;;G09B5/12;;G09B5/14;;G09B7/00;;G09B7/00;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/0225;;H04W52/0225;;H04W84/12;;Y02D30/70;;Y02D30/70,G09B5/00;;H04L12/12;;H04L12/28;;H04L12/46;;H04L29/12,,1,0,,,See also references of EP 2543029A1,PENDING
90,US,A1,US 2023/0149984 A1,145-842-798-704-540,2023-05-18,2023,US 202318157954 A,2023-01-23,US 202318157954 A;;US 201816124701 A;;US 201762555117 P,2017-09-07,Systems and methods for cleaning food product forming and dispensing devices,"The present disclosure provides systems and methods for automating the cleaning and sanitizing processes of a food dispensing machine. The systems and methods may be set to run automatically and may keep a dispensing system cleaned and sanitized for an extended time. The systems and methods disclosed are designed to make cleaning easier for the operator, shorten the overall cleaning time, reduce the amount of labor involved, and improve the convenience, reliability, and repeatability of the cleaning processes.",FBD PARTNERHSIP LP,WONG ELGIN W;;GATES MATHEW G;;BLESSING JR WILLIAM R;;TRENT NOAH G;;ACOSTA CARLOS A,,https://lens.org/145-842-798-704-540,Patent Application,yes,0,3,3,3,0,B67D1/07;;B08B9/0321;;B67D2001/075;;B08B9/0325;;B67D1/07;;B08B9/0328;;B08B9/0325;;B08B3/102;;B08B2203/007;;B67D1/07;;B08B9/0328;;B08B9/0321;;B67D2001/075;;A23G9/28;;A23G9/30;;A23G9/00,B08B9/032;;B08B3/10;;B67D1/07,,0,0,,,,PENDING
91,CA,A1,CA 2809027 A1,011-899-611-353-823,2012-07-14,2012,CA 2809027 A,2011-01-06,US 68327910 A;;US 2011/0020405 W,2010-01-06,MULTIMEDIA TRAINING SYSTEM AND APPARATUS AND METHOD THEREFOR,"A system and method for providing interactive training, whereby a video display and a base station are coupled in communication with a computer. A plurality of wireless handheld remotes are configured for wirelessly communicating with the base station, and each of the remotes is operable by a respective trainee of a group of trainees. Each remote has a remote ID unique from all other remotes and is stored in a memory of the computer; and the base station includes a base station ID code unique from all other base stations, and the base station ID is stored in a memory of each remote. Each remote remains in an inactive state and is operable to be activated via a respective ACTIVATE signal transmitted from the base station, and the base station is operable to transmit an ACTIVATE signal to one or more of the remotes, the ACTIVATE signal being effective for enabling the remote to transmit a signal, wherein the remote is preferably deactivated upon completion of transmission of signal. Using unique IDs prevents interference from other wireless devices including remotes bound with other base stations. It also makes it unnecessary for one training system to operate on a different channel from another training system.",ALCHEMY SYSTEMS L P,ACOSTA CARLOS;;BARRETT ARCHIE D JR;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID;;EASTMAN JEFFREY;;DONELSON ROBIN,,https://lens.org/011-899-611-353-823,Patent Application,no,0,0,7,7,0,G09B5/00;;G09B5/10;;G09B5/00;;G09B5/12;;G09B5/14;;G09B7/00;;G09B7/00;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/0225;;H04W52/0225;;H04W84/12;;Y02D30/70;;Y02D30/70,G09B5/00;;H04L12/12;;H04L12/28;;H04L12/46;;H04L29/12,,0,0,,,,ACTIVE
92,CO,A1,CO 2020012373 A1,086-138-395-848-382,2022-04-08,2022,CO 2020012373 A,2020-09-30,CO 2020012373 A,2020-09-30,Composición para fabricar elementos no estructurales para mampostería,"La composición para fabricar elementos no estructurales para mampostería de la presente divulgación comprende cemento entre 5% y 25% p/p; agregados gruesos entre 5% y 35% p/p; agregados finos entre 30% y 80% p/p; desechos hospitalarios entre 0,1% y 5% p/p y agua entre 1% y 5% p/p. Los desechos hospitalarios son esterilizados y triturados hasta obtener una granulometría inferior a 20mm. Luego los desechos hospitalarios son secados hasta obtener un porcentaje de humedad entre el 0,1% y 80%. Posteriormente, los desechos hospitalarios son mezclados junto con el cemento, los agregados pétreos, y agua en las dosificaciones mencionadas. La composición es dispuesta en moldes para bloques de concreto y pasan por un proceso de curado hasta obtener un bloque de concreto con la composición para fabricar elementos no estructurales para mampostería.",UNIV FRANCISCO DE PAULA SANTANDER,PEÑA SOTO CARLOS ALBERTO;;GAMBOA SUÁREZ JAVIER CAMILO;;ARÉVALO VERJEL ALBA NELY;;ACOSTA MÉNDEZ JESÚS SANTIAGO,,https://lens.org/086-138-395-848-382,Patent Application,no,0,0,1,1,0,Y02W30/91,C04B18/04;;C04B18/30,,0,0,,,,PENDING
93,CN,A,CN 116264548 A,196-981-067-528-58X,2023-06-16,2023,CN 202210399674 A,2022-04-15,US 202117551136 A,2021-12-14,In-service software upgrade with active service monitoring,"The embodiment of the invention relates to in-service software upgrade with active service monitoring. A system for performing an in-service software upgrade on a network device is provided. In response to a software upgrade command, the system generates an upgrade database based on a state database storing data plane states and control plane states associated with the network device. The network device is managed by a management unit, the management unit comprising a data plane management sub-unit and a control plane sub-unit, and the upgrade database stores at least a data plane state to allow the data plane management sub-unit to operate based on the upgrade database. The system respectively upgrades the data plane management subunit and the control plane subunit under the condition of not interrupting the service provided by the network equipment. The system monitors the status database and the upgrade database to detect events associated with the network device. In response to determining that the trigger condition is satisfied, the system performs an action to prevent a network failure or error.",HEWLETT PACKARD ENTPR DEV LP,ROJAS FONSECA FRANCISCO JOSE;;SHOMA VARGAS JOSE ANTONIO;;RAMIREZ ACOSTA EDUARDO FRANCISCO;;BALANTES CHAVEZ PEDRO CARLOS,,https://lens.org/196-981-067-528-58X,Patent Application,no,0,0,5,5,0,H04L41/082;;H04L41/0866;;G06F8/656;;G06F8/656,H04L41/082;;H04L41/0866,,0,0,,,,PENDING
94,EP,A1,EP 2543029 A1,068-009-535-220-105,2013-01-09,2013,EP 11701568 A,2011-01-06,US 68327910 A;;US 2011/0020405 W,2010-01-06,MULTIMEDIA TRAINING SYSTEM AND APPARATUS AND METHOD THEREFOR,,ALCHEMY SYSTEMS L P,ACOSTA CARLOS;;BARRETT ARCHIE D JR;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID;;EASTMAN JEFFREY;;DONELSON ROBIN,,https://lens.org/068-009-535-220-105,Patent Application,yes,0,0,7,7,0,G09B5/00;;G09B5/10;;G09B5/00;;G09B5/12;;G09B5/14;;G09B7/00;;G09B7/00;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/0225;;H04W52/0225;;H04W84/12;;Y02D30/70;;Y02D30/70,G09B5/00;;H04L12/12;;H04L12/28;;H04L12/46;;H04L29/12,,2,0,,,"CARLOS A ACOSTA: ""Alchemy Systems L SISTEM Radio Frequency Remote Control(8015-2R) & receiver(8015-2B) User Guide"", 16 July 2008 (2008-07-16), XP055411607, Retrieved from the Internet <URL:https://fccid.io/V6Q8015-2R/User-Manual/User-manual-971491.pdf> [retrieved on 20170929];;See also references of WO 2011085119A1",DISCONTINUED
95,ES,B2,ES 2615602 B2,033-337-820-237-005,2018-02-01,2018,ES 201500878 A,2015-12-07,ES 201500878 A,2015-12-07,"Protector versátil apto para portar defensas de uso policial y otros accesorios, y para uso de técnicas de bloqueo defensivo. métodos de empleo",,UNIV CADIZ;;VERA JIMENEZ JOSÉ CARLOS,FERNANDEZ ZACARIAS FRANCISCO;;VERA JIMENEZ JOSÉ CARLOS;;AYUSO VILACIDES JESÚS;;LORENTE ACOSTA JOSÉ ANTONIO;;GONZALEZ HERRERA LUCAS,,https://lens.org/033-337-820-237-005,Granted Patent,no,0,0,2,2,0,F41B15/02;;F41H5/08;;F41B13/04;;F41H1/02;;F41H5/08;;F41H13/00,F41B15/02;;F41B13/04;;F41H1/02;;F41H5/08;;F41H13/00,,0,0,,,,INACTIVE
96,ES,A1,ES 2442968 A1,139-803-297-672-174,2014-02-14,2014,ES 201231302 A,2012-08-14,ES 201231302 A,2012-08-14,"BURNER COVER AND PAN SUPPORT FOR A GAS COOKING ZONE, GAS COOKING ZONE AND GAS HOB",The invention relates to easy-to-clean and correspondingly aesthetic vitro-ceramic burner covers and/or pan supports. Said disclosed vitro-ceramic material is advantageous in that it is easy to work with and enables complex three-dimensional forms to be produced. The invention also relates to gas cooking zones and a gas hob which are characterized in that they comprise the above-mentioned burner cover and/or pan support.,BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO,,https://lens.org/139-803-297-672-174,Patent Application,no,4,0,3,3,0,C03C3/085;;C03C10/0045;;F24C15/10;;F24C3/08;;F23D2212/10;;F23D2900/00001;;F23D14/06;;F24C15/10,F23D14/06;;F24C15/10,,0,0,,,,DISCONTINUED
97,CN,A,CN 117241810 A,073-687-953-866-041,2023-12-15,2023,CN 202280032407 A,2022-03-03,US 202163156328 P;;IB 2022000099 W,2021-03-03,"Vaginal microbiota related methods, compositions, and devices","The present invention relates to a pharmaceutical composition for use in the treatment of inflammation in the female urogenital tract of a human subject, wherein the female subject exhibits a microbiota of dysbiosis in the urogenital tract. The pharmaceutical composition comprises a substantially intact vaginal microbiota preparation wherein the preparation (i) comprises one, two, three or four bacterial species from the genus Lactobacillus, selected from the group consisting of Lactobacillus crispatus, Lactobacillus inericius, Lactobacillus jensenii, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus acidophilus, the bacterial species comprise from about 80% to 99.9% of all detectable bacterial species of the preparation; and (ii) comprises less than 5% of certain species of the genus gardnerella, certain species of the genus Atortoria and certain species of the genus Prevotella; wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent. The invention also relates to methods of making the compositions, and devices comprising and/or using the compositions.",FREA LIFE SCIENCES INC,ACOSTA CARLOS DANIEL;;VAN HELKMAVERLIGH JOHANNES EDUARDUS THEODORUS;;RASMUSSEN TORBEN G;;BOSMA ERWIN F;;MORTENSEN BJU RN,,https://lens.org/073-687-953-866-041,Patent Application,no,0,0,8,8,0,A61K35/747;;A61P15/02;;A61K9/0034;;A61K47/36;;A61K47/32;;A61M31/00;;A61K47/46;;A61K47/10;;A61K47/38;;A61K9/2054;;A61K9/2027;;A61K9/7007;;A61K47/42;;A61K35/747;;A61K9/2054;;A61K47/10;;A61K47/46;;A61K47/36;;A61K47/42;;A61K9/7007;;A61K9/2027;;A61P15/02;;A61K47/32;;A61K47/38;;A61K9/0034;;A61M31/00;;A61K35/747;;A61K9/0034;;A61K47/38;;A61K47/32;;A61P15/02;;A61P29/00,A61K35/747,,0,0,,,,PENDING
98,ES,A1,ES 2442969 A1,186-597-961-339-688,2014-02-14,2014,ES 201231303 A,2012-08-14,ES 201231303 A,2012-08-14,"COVER PLATE WITH INTEGRATED PAN SUPPORT FOR A GAS COOKING ZONE, GAS COOKING ZONE AND GAS HOB",The invention relates to easy-to-clean and correspondingly aesthetic vitro-ceramic cover plates with integrated pan supports. The disclosed vitro-ceramic material is advantageous due to the fact that it is easy to work with and complex three-dimensional shaping is possible. The invention also relates to a gas hob and a gas cooking zone which are characterized in that they comprise the above-mentioned cover plates.,BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO,,https://lens.org/186-597-961-339-688,Patent Application,no,3,0,3,3,0,C03C3/085;;C03C10/0045;;F24C3/02;;F24C15/10;;F24C15/10,F24C3/02;;F24C15/10,,0,0,,,,DISCONTINUED
99,MX,A,MX 2017004430 A,041-951-029-005-237,2018-11-09,2018,MX 2017004430 A,2017-04-05,MX 2017004430 A,2017-04-05,"METHOD FOR THE PREPARATION OF NANOMETRIC METAL OXIDE ADDITIVES THAT REDUCE SINTERING TEMPERATURE AND/OR INCREASE PRODUCTIVITY IN THE MANUFACTURE OF CERAMIC PIECES, IMPROVING MECHANICAL PROPERTIES WITHOUT AFFECTING THE VITRIFICATION PROPERTIES OF CERAMIC BODIES, TILES OR COATINGS.","The present invention relates to a process for manufacturing, conditioning and stabilising a family of additives based on oxides of sodium, potassium, boron, silicon, zinc and calcium, inter alia, prepared using physicochemical methods and chemical synthesis methods, which form nanometric structures and are reformulated with deflocculant additives, sequesterants and dispersants that allow the production of a dispersion or powder able to reduce the sintering temperature of a ceramic body, owing to the high melting capacity thereof, which is maximised by the use of nanotechnology in the structures obtained. The method consists of preparing nucleation seeds of metal oxides, silicate and carbonates by means of a physicochemical process, which allow, by means of a chemical process, the growth of nanometric structures in a wet chemical synthesis process for synthesising oxides of sodium, boron, silicon, zinc, potassium and calcium. The combination of these oxides allows the structuring of elements having a high melting capacity owing to the high surface area and physicochemical composition thereof. The additives produced in the present invention are chemically stabilised with deflocculant agents that allow the additives to be incorporated in the process of grinding the ceramic body in an aqueous medium. The uses developed with the additives of the present invention allow of the sintering temperature of a red body to be reduced from 1150 to 1000°C and the sintering temperature of porcelain bodies to be reduced from 1180 to 1050°C, with the use of 0.2 to 5% of the additive, or by increasing the thermal treatment speed by 20%. The method can be used in the manufacture of bathrooms, moulding pieces, components for tools, coatings, border tiles, enamels, slips and other ceramic components. The present invention proposes several formulations of nanostructured additives with high-performance melting properties, which allow the sintering process to be optimised and standardised and the mechanical properties of the ceramic body to be improved. It also proposes various methods for using the ceramic formulation additive.",NANOMATERIALES S A DE C V,JOEL GUTIERREZ ANTONIO;;CARLOS FIX FIERRO;;GUILLERMO ENRIQUE ACOSTA GONZALEZ;;JAIME PARADA AVILA;;MONICA IBETH AGUILERA BUSTOS,,https://lens.org/041-951-029-005-237,Patent Application,no,0,0,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C01B13/14,,0,0,,,,PENDING
100,CO,A1,CO 2022011594 A1,162-071-838-203-315,2024-02-26,2024,CO 2022011594 A,2022-08-17,CO 2022011594 A,2022-08-17,Dispositivo de detección de la enfermedad hlb,"El dispositivo funciona a partir de la detección del espectro de fluorescencia producida por la bacteria en las hojas en un rango de 500-1000 nm. Lo que permite hacer una prueba rápida en campo y es capaz de diferenciar la planta enferma con HLB de aquella que tiene otras enfermedades o desnutrición, debido al rango específico de espectro de luz que analiza. Asimismo, se puede realizar un mayor número de pruebas a mayor cantidad de plantas en un cultivo, lo que permite tomar acciones preventivas reales.",UNIV SIMON BOLIVAR,VILLARREAL GONZÁLEZ REYNALDO;;ACOSTA HOYOS ANTONIO;;GALÁN FREYLE NATALY;;PACHECO LONDOÑO LEONARDO CARLOS;;MACHADO ELWI;;ARANGUREN YANI,,https://lens.org/162-071-838-203-315,Patent Application,no,0,0,2,2,0,,G01N21/00;;G01N21/64;;G01N21/77;;G01N21/78;;G01N33/48;;G01N33/569,,0,0,,,,PENDING
101,WO,A3,WO 2014/027270 A3,103-684-964-950-76X,2014-07-24,2014,IB 2013056289 W,2013-07-31,ES 201231302 A,2012-08-14,"BURNER COVER AND PAN SUPPORT FOR A GAS COOKING ZONE, GAS COOKING ZONE AND GAS HOB",The invention relates to easy-to-clean and correspondingly aesthetic vitro-ceramic burner covers and/or pan supports. Said disclosed vitro-ceramic material is advantageous in that it is easy to work with and enables complex three-dimensional forms to be produced. The invention also relates to gas cooking zones and a gas hob which are characterized in that they comprise the above-mentioned burner cover and/or pan support.,BSH BOSCH & SIEMENS HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO,,https://lens.org/103-684-964-950-76X,Search Report,yes,5,0,3,3,0,C03C3/085;;C03C10/0045;;F24C15/10;;F24C3/08;;F23D2212/10;;F23D2900/00001;;F23D14/06;;F24C15/10,C03C3/085;;C03C10/00;;F24C15/10,,0,0,,,,PENDING
102,CO,A1,CO 2022011608 A1,058-914-285-090-631,2024-02-26,2024,CO 2022011608 A,2022-08-17,CO 2022011608 A,2022-08-17,Método para pronosticar nefritis lúpica a partir de espectroscopia raman aumentada,El análisis de muestras de orina por espectroscopía Raman con nanopartículas de oro brinda una oportunidad para ser aplicada en el análisis de muestras de orina de pacientes con lupus que puede diferenciar de manera rápida y efectiva a pacientes con nefritis lúpica gracias a la identificación de metabolitos urinarios.,UNIV SIMON BOLIVAR,PACHECO LUGO LISANDRO ALFONSO;;NAVARRO QUIROZ ELKIN ANTONIO;;ACOSTA HOYOS ANTONIO;;GALÁN FREYLE NATALY;;PACHECO LONDOÑO LEONARDO CARLOS;;ESPINOSA GARAVITO ALBERTO CARLOS;;CARMONA ADA,,https://lens.org/058-914-285-090-631,Patent Application,no,0,0,1,1,0,,G01N33/00;;G01N1/00;;G01N3/00;;G01N21/00;;G01N35/00,,0,0,,,,PENDING
103,WO,A2,WO 2014/027270 A2,174-553-153-569-100,2014-02-20,2014,IB 2013056289 W,2013-07-31,ES 201231302 A,2012-08-14,"BURNER COVER AND PAN SUPPORT FOR A GAS COOKING ZONE, GAS COOKING ZONE AND GAS HOB",The invention relates to easy-to-clean and correspondingly aesthetic vitro-ceramic burner covers and/or pan supports. Said disclosed vitro-ceramic material is advantageous in that it is easy to work with and enables complex three-dimensional forms to be produced. The invention also relates to gas cooking zones and a gas hob which are characterized in that they comprise the above-mentioned burner cover and/or pan support.,BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO,,https://lens.org/174-553-153-569-100,Patent Application,yes,2,0,3,3,0,C03C3/085;;C03C10/0045;;F24C15/10;;F24C3/08;;F23D2212/10;;F23D2900/00001;;F23D14/06;;F24C15/10,C03C3/085,,0,0,,,,PENDING
104,CO,A2,CO 2019011965 A2,084-077-188-812-409,2020-02-18,2020,CO 2019011965 A,2019-10-25,MX 2017000081 W;;MX 2017004430 A,2017-04-05,"Método para la preparación de aditivos de óxidos metálicos de tamaño nanométrico que reducen la temperatura de sinterizado y/o incrementan la productividad en la fabricación de piezas cerámicas, mejorando propiedades mecánicas sin afectar las propiedades de gresificación de cuerpos cerámicos, losetas o revestimientos","RESUMEN El objeto de la presente invención es un proceso para la fabricación, acondicionamiento y estabilización de una familia de aditivos base óxidos de sodio, potasio, boro, silicio, zinc, calcio, entre otros, preparados por métodos fisicoquímicos y de síntesis química que forman estructuras nanométricas, reformulados con aditivos defloculantes, secuestrantes y dispersantes que permiten obtener una dispersión o polvo con la capacidad de disminuir la temperatura de sinterizado de un cuerpo cerámico por su alto poder de fundencia, que se maximiza por el uso de la nanotecnología en las estructuras obtenidas, el proceso consiste en la preparación de semillas de nucleación de óxidos metálicos, silicatos y carbonatos mediante un proceso fisicoquímico, y los cuales permiten crecer mediante un proceso químico estructuras de índole nanométrico en un proceso de síntesis química en vía húmeda de óxidos de sodio, boro, silicio, zinc, potasio y calcio. La combinación de estos óxidos permite estructurar elementos de alto poder fundente por su alta área superficial y su composición fisicoquímica. Los aditivos elaborados en la presente invención se estabilizan químicamente con agentes defloculantes, que permiten a los aditivos ser incorporados en el proceso de molienda en medio acuoso del cuerpo cerámico. Las aplicaciones elaboradas con los aditivos de la presente invención permiten disminuir la temperatura de sinterizado de un cuerpo rojo desde 1150°C hasta 1000°C y en cuerpos porcelánicos gres de 1180°C a 1050°C, con el uso de 0.2 a 5 % del aditivo, o bien incrementando la velocidad del tratamiento térmico hasta en un 20%, pudiendo ser utilizado en la fabricación de sanitarios, piezas de moldeo, componentes para herramentales, revestimientos, cenefas, esmaltes, engobes y otros componentes cerámicos. La presente invención propone varias formulaciones de aditivos nanoestructurados con propiedades fundentes de alto desempeño, que permiten optimizar y uniformizar el proceso de sinterizado y mejorar las propiedades mecánicas del cuerpo cerámico. Así mismo propone diferentes métodos de aplicación del aditivo en formulaciones cerámicas.",NANOMATERIALES SA DE CV,FIX FIERRO CARLOS;;ACOSTA GONZÁLEZ GUILLERMO ENRIQUE;;AGUILERA BUSTOS MÓNICA IBETH;;GUTIÉRREZ ANTONIO JOEL;;PARADA AVILA JAIME,,https://lens.org/084-077-188-812-409,Patent Application,no,0,0,9,9,0,C04B33/131;;C04B2235/5454;;C04B2235/365;;C04B35/62615;;C04B2235/5436;;C04B2235/9615;;C04B2235/96;;B82Y30/00;;B82Y40/00;;C04B35/62615;;C04B35/64;;C04B2235/3201;;C04B2235/3208;;C04B2235/3284;;C04B2235/3409;;C04B2235/3418;;C04B2235/407;;C04B2235/408;;C04B2235/5454,C04B35/64,,0,0,,,,PENDING
105,WO,A3,WO 2014/027274 A3,158-362-439-345-063,2014-07-24,2014,IB 2013056406 W,2013-08-05,ES 201231303 A,2012-08-14,"COVER PLATE WITH INTEGRATED PAN SUPPORT FOR A GAS COOKING ZONE, GAS COOKING ZONE AND GAS HOB",The invention relates to easy-to-clean and correspondingly aesthetic vitro-ceramic cover plates with integrated pan supports. The disclosed vitro-ceramic material is advantageous due to the fact that it is easy to work with and complex three-dimensional shaping is possible. The invention also relates to a gas hob and a gas cooking zone which are characterized in that they comprise the above-mentioned cover plates.,BSH BOSCH & SIEMENS HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO,,https://lens.org/158-362-439-345-063,Search Report,yes,5,0,3,3,0,C03C3/085;;C03C10/0045;;F24C15/10;;F24C3/02;;F24C15/10,C03C3/085;;C03C10/00;;F24C15/10,,0,0,,,,PENDING
106,WO,A2,WO 2014/027274 A2,005-538-999-263-507,2014-02-20,2014,IB 2013056406 W,2013-08-05,ES 201231303 A,2012-08-14,"COVER PLATE WITH INTEGRATED PAN SUPPORT FOR A GAS COOKING ZONE, GAS COOKING ZONE AND GAS HOB",The invention relates to easy-to-clean and correspondingly aesthetic vitro-ceramic cover plates with integrated pan supports. The disclosed vitro-ceramic material is advantageous due to the fact that it is easy to work with and complex three-dimensional shaping is possible. The invention also relates to a gas hob and a gas cooking zone which are characterized in that they comprise the above-mentioned cover plates.,BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO,,https://lens.org/005-538-999-263-507,Patent Application,yes,2,0,3,3,0,C03C3/085;;C03C10/0045;;F24C3/02;;F24C15/10;;F24C15/10,C03C3/085,,0,0,,,,PENDING
107,ES,A1,ES 2615602 A1,149-327-165-702-966,2017-06-07,2017,ES 201500878 A,2015-12-07,ES 201500878 A,2015-12-07,"Versatile protector suitable for carrying defenses for police use and other accessories, and for the use of defensive blocking techniques. Methods of employment (Machine-translation by Google Translate, not legally binding)","Versatile protector suitable for carrying defenses for police use and other accessories, and for the use of defensive blocking techniques. Methods of employment. The invention relates to a versatile protective system housed in the forearms of a rigid but light and ergonomic nature that has assembled a removable police defense, and the option of coupling other utensils. The versatile protector consists of at least one external rigid part with a protective function as an extensive arm cuff, and a padded inner part where a semi-long-length police defense is housed perfectly, although it can be unfolded and/or detached at will. (Machine-translation by Google Translate, not legally binding)",UNIV CADIZ;;VERA JIMENEZ JOSÉ CARLOS,FERNANDEZ ZACARIAS FRANCISCO;;VERA JIMENEZ JOSÉ CARLOS;;AYUSO VILACIDES JESÚS;;LORENTE ACOSTA JOSÉ ANTONIO;;GONZALEZ HERRERA LUCAS,,https://lens.org/149-327-165-702-966,Patent Application,no,5,0,2,2,0,F41B15/02;;F41H5/08;;F41B13/04;;F41H1/02;;F41H5/08;;F41H13/00,F41B15/02;;F41B13/04;;F41H1/02;;F41H5/08;;F41H13/00,,0,0,,,,INACTIVE
108,CO,A2,CO 2023004840 A2,131-954-707-657-610,2023-05-29,2023,CO 2023004840 A,2023-04-18,IB 2020062551 W,2020-12-30,Formulación de ivermectina en solución oral,"La presente invención se refiere a una formulación de Ivermectina en solución oral que permite la correcta absorción, permitiendo que el medicamento puede ser consumido en cualquier momento. Particularmente, la composición lipídica oral está diseñada con la selección adecuada de un aceite de triglicérido de cadena media, un cosolvente hidrofílico y un antioxidante, para influenciar la absorción/digestibilidad del activo pobremente soluble en agua y facilitar la biodisponibilidad y bioactividad para la administración de la solución oral en gotas. La formulación incluye Ivermectina en un medio lipídico que incluye un co-solvente y un antioxidante en combinación con un solvente oleoso para conformar una solución oral de suministro en gotas. El campo de la invención esta relacionado con mejorar la biodisponibilidad de fármacos insolubles tal como la Ivermectina para su entrega en formas orales en gotas basada principalmente en lípidos sin comprometer su estabilidad y sin la creación de impurezas.",PROCAPS SA,PADILLA BOTETT CARLOS MANUEL;;MONTERROZA HERNANDEZ DIEGO RAFAEL;;GARCIA VERA JANICE;;ACOSTA URREA JOSE ALFREDO;;BERTHEL BELEÑO ALFREDO,,https://lens.org/131-954-707-657-610,Patent Application,no,0,0,2,2,0,A61K33/10;;A61K31/7048,A61K31/7048;;A61K33/10,,0,0,,,,PENDING
109,WO,A1,WO 2022/144575 A1,117-018-868-796-372,2022-07-07,2022,IB 2020062551 W,2020-12-30,IB 2020062551 W,2020-12-30,FORMULATION OF IVERMECTIN IN ORAL SOLUTION,"The present invention relates to a formulation of Ivermectin in oral solution which allows proper absorption, enabling the drug to be consumed at any time. In particular, the oral lipid composition is designed with the appropriate selection of a medium-chain triglyceride oil, a hydrophilic cosolvent and an antioxidant, so as to influence the absorption/digestibility of the poorly water-soluble active ingredient and facilitate bioavailability and bioactivity for the administration of the oral solution in drops. The formulation includes Ivermectin in a lipid medium including a cosolvent and an antioxidant in combination with an oily solvent to form an oral solution for administration in drops. The field of the invention is related to improving the bioavailability of insoluble drugs such as Ivermectin for administration in oral drop forms based mainly on lipids without compromising stability or creating impurities.",PROCAPS S A,PADILLA BOTETT CARLOS MANUEL;;MONTERROZA HERNANDEZ DIEGO RAFAEL;;GARCIA VERA JANICE;;ACOSTA URREA JOSE ALFREDO;;BERTHEL BELEÑO ALFREDO,,https://lens.org/117-018-868-796-372,Patent Application,yes,5,0,2,2,0,A61K33/10;;A61K31/7048,A61K31/7048;;A61K33/10,,0,0,,,,PENDING
110,MX,A,MX 2020010485 A,162-583-230-063-763,2022-04-06,2022,MX 2020010485 A,2020-10-05,MX 2020010485 A,2020-10-05,SYSTEM AND METHOD OF MECHANICAL DEFORMATION MEASUREMENT USING AN OPTICAL FIBER WITH SMS STRUCTURE.,"The present invention relates to a measurement system for the experimental analysis of mechanical deformations, formed by an optical method that consists of optical fiber with SMS structure, establishing its operating principle on multimodal interference technique. Also, it relates to an instrumentation and measurement methodology on a mechanical element, monitoring the optic fiber with SMS structure and the deformation of the part subjected to uniaxial stress in tension or compression. Further, it possesses the advantage of instrumenting it in elements that are in environments with hostile conditions and having a remote monitoring system.",UNIV AUTONOMA DEL ESTADO DE MORELOS,BASURTO PENSADO MIGUEL ÁNGEL;;GARCÍA CASTREJÓN JUAN CARLOS;;PALILLERO SANDOVAL OMAR;;RAMÍREZ DOMÍNGUEZ MIREYA ELIZABETH;;ACOSTA FLORES MARIO,,https://lens.org/162-583-230-063-763,Patent Application,no,0,0,1,1,0,,G01B11/16,,0,0,,,,PENDING
111,WO,A1,WO 2020/193301 A1,020-773-470-265-936,2020-10-01,2020,EP 2020057396 W,2020-03-18,ES 201930267 A,2019-03-25,GAS HOB,"A gas hob (1) comprising a top sheet (2), a connection rail (3) having a plurality of ports (6a) and arranged on the top sheet (2), and gas burners (7) arranged on the top sheet (2) and releasably connected to the ports (6a) of the connection rail (3), the ports (6a) being configured to supply the gas burners (7) with fuel gas.",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/020-773-470-265-936,Patent Application,yes,5,2,3,3,0,F24C3/085;;F24C3/10;;F23K5/005;;F23N1/02;;F23N2239/04;;F23N2241/08;;F24C3/082;;F24C3/085;;F24C3/103;;F24C3/126;;F24C15/00;;F24C15/107,F24C3/08;;F24C3/12,,0,0,,,,PENDING
112,CN,A,CN 113330253 A,130-373-870-866-525,2021-08-31,2021,CN 202080010107 A,2020-01-15,ES 201930038 A;;EP 2020050906 W,2019-01-21,"PAN SUPPORT FOR A GAS HOB, GAS HOB AND METHOD FOR MANUFACTURING A PAN SUPPORT","A pan support (2) for a gas hob (1), the pan support (2) comprising: a pan support structure (4) configured for supporting a pan (6), and a gas burner body (5) comprising gas openings (7) for burning an air-fuel-gas-mixture, wherein the pan support structure (4) and the gas burner body (5) are joined in a joining process to form an integral unit (37).",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;ALONSO LOPEZ JOSE MANUEL;;GUTIERREZ HUMARA MELCA;;LOPEZ ORTIZ ALBERTO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/130-373-870-866-525,Patent Application,no,8,0,2,2,0,F23D14/06;;F24C15/107;;F24C3/085,F23D14/06;;F24C15/10,,0,0,,,,PENDING
113,ES,A1,ES 2244301 A1,174-464-108-689-264,2005-12-01,2005,ES 200302834 A,2003-12-02,ES 200302834 A,2003-12-02,Low-cost localization device for autonomous robots has portable computer that outputs localization and orientation data after making final calculation,"Low cost device for the localisation of autonomous robots. This invention refers to a low cost device for measuring the position and direction of indoor mobile robots. The device comprises a transmitter placed on a wall within the area and a receiver on the upper part of the robot. The transmitter is a laser pointer which acts like a revolving beacon and the receiver is a combination of photocells which form a cylinder. The robot's position and direction is obtained by measuring the times at which the laser hits each of the photocells. The device consists principally of three very distinct blocks: 1) Subsystem transmitter which generates laser beams which move in a horizontal plane. 2) A receiver subsystem. This consists of a collection of sensors grouped in the form of a cylinder in order to cover all possible directions from which the laser beam might hit. The collection of sensors has to be at the same height as the transmitter so that the laser beam makes contact with the sensors. Within the cylinder, formed by sensors, are the electronics that identify which cells the laser beam has made contact with as well as the instant and the duration of the laser contact on each cell. 3) A portable computer on the robot makes the final calculations and provides the localisation and direction information.",UNIV LA LAGUNA,HERNANDEZ ALONSO SERGIO ELIAS;;TORRES JORGE JESUS MIGUEL;;ACOSTA SANCHEZ LEOPOLDO;;MORALES DIAZ CARLOS ALBERTO;;TOLEDO CARRILLO JONAY TOMAS,,https://lens.org/174-464-108-689-264,Patent Application,no,6,0,2,2,0,G05D1/0236,G05D1/02,,0,0,,,,EXPIRED
114,ES,B2,ES 2244301 B2,011-032-659-460-36X,2008-02-16,2008,ES 200302834 A,2003-12-02,ES 200302834 A,2003-12-02,DISPOSITIVO DE BAJO COSTE PARA LA LOCALIZACION DE ROBOTS AUTONOMOS.,"Dispositivo de bajo coste para la localización de robots autónomos. La presente invención se refiere a un dispositivo de bajo coste para medir la posición y orientación de robos móviles en interiores. El dispositivo se compone de un emisor localizado en una pared del entorno y un receptor en la parte superior del robot. El emisor es un puntero láser que actúa como un faro giratorio y el receptor es una combinación de fotocélulas que forman un cilindro. La posición del robot y su orientación se obtiene tomando los tiempos en los que la luz del láser impacta en cada una de las fotocélulas. El dispositivo consiste principalmente en tres bloques bien diferenciados: 1) Subsistema emisor que genera la luz láser que se mueve en el plano horizontal. 2) Un subsistema receptor. El cual consiste en un conjunto de sensores agrupados formando un cilindro para cubrir todas las posibles direcciones de impacto de la luz láser. El conjunto de sensores tiene que estar a la misma altura que el emisor para quela luz del láser incida en los sensores. Dentro del cilindro, formado por los sensores, se encuentra la electrónica que identifica las células en las que incide el láser así como el momento y duración de la incidencia del láser en cada célula. 3) Un ordenador portátil sobre el robot hace los cálculos finales y da los datos de localización y orientación.",UNIV LA LAGUNA,HERNANDEZ ALONSO SERGIO ELIAS;;TORRES JORGE JESUS MIGUEL;;ACOSTA SANCHEZ LEOPOLDO;;MORALES DIAZ CARLOS ALBERTO;;TOLEDO CARRILLO JONAY TOMAS,,https://lens.org/011-032-659-460-36X,Granted Patent,no,0,0,2,2,0,G05D1/0236,G05D1/02,,0,0,,,,EXPIRED
115,MX,A,MX 2015017899 A,026-954-824-655-175,2017-06-20,2017,MX 2015017899 A,2015-12-21,MX 2015017899 A,2015-12-21,"THE USE OF CMY GENE (BOS TAURUS CHYMOSIN) OPTIMIZED WITH A SYNTHETIC SEQUENCE FOR THE PRODUCTION OF RECOMBINANT CHYMOSIN, FOR ITS EXPRESSION IN PICHIA PASTORIS.","The present invention relates to the study in the bovine prochymosin gene codon optimization, performed for its expression in Pichia Pastoris. Specifically, related to an artificial gene coding designed from a wild chymosin gene for the same amino-acid sequence (aa), thereby replacing atypical or low-frequency codons use in Pichia Pastoris (<15%), by those using preferably high-frequency yeast. The modified nucleotides of up to 332, therefore, optimizing up to 286 codons and the designed gene cloned into the expression vector pPICZa and transformed into P. pastoris. The strains transformed with the gene cultured in artificial media enriched with 1% yeast extract, 2% peptone and 1% glycerol, thereby increasing the biomass to subsequently being cultured in a similar way, thus replacing glycerol with methanol of up to 0.5% as a carbon source to initiate gene induction. Furthermore, the chymosin activation of prochymosin synthesized with the designed gene by acidification-neutralization, thus showing coagulant activity directly from the supernatant of up to 146.11 U/mL, representing an approximate increase of up to 12 times, comparable to the wild gene corresponding to 12.2 U/ml. Said chymosin activation, showed a stability range of up 25°C to 50°C with an optimum of up 35°C to 40°C and a range of up 5pH to 6.9pH with an optimum of up to 5.0. These results show that codon optimization in the bovine prochymosin gene is a viable alternative to improve expression levels in P. pastoris.",CENTRO DE INVESTIGACIÓN EN ALIMENTACIÓN Y DESARROLLO A C,PAUL BARUK ZAMUDIO FLORES;;CARLOS HORACIO ACOSTA MUÑIZ;;DAVID ROBERTO SEPÚLVEDA AHUMADA;;CLAUDIO RIOS VELASCO;;JOSÉ ALBERTO ESPINOZA MOLINA,,https://lens.org/026-954-824-655-175,Patent Application,no,0,0,1,1,0,,A23C19/00;;C12N15/09,,0,0,,,,PENDING
116,WO,A1,WO 2020/152008 A1,163-262-158-307-055,2020-07-30,2020,EP 2020050906 W,2020-01-15,ES 201930038 A,2019-01-21,"PAN SUPPORT FOR A GAS HOB, GAS HOB AND METHOD FOR MANUFACTURING A PAN SUPPORT","A pan support (2) for a gas hob (1), the pan support (2) comprising: a pan support structure (4) configured for supporting a pan (6), and a gas burner body (5) comprising gas openings (7) for burning an air-fuel-gas-mixture, wherein the pan support structure (4) and the gas burner body (5) are joined in a joining process to form an integral unit (37).",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;ALONSO LOPEZ JOSE MANUEL;;GUTIERREZ HUMARA MELCA;;LOPEZ ORTIZ ALBERTO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/163-262-158-307-055,Patent Application,yes,4,0,2,2,0,F23D14/06;;F24C3/085;;F24C15/107,F23D14/06;;F24C15/10,,0,0,,,,PENDING
117,US,B2,US 8356068 B2,026-047-935-739-401,2013-01-15,2013,US 68327910 A,2010-01-06,US 68327910 A,2010-01-06,Multimedia training system and apparatus,"A method for providing interactive training, whereby a video display and a base station are coupled in communication with a computer. A plurality of wireless handheld remotes are configured for wirelessly communicating with the base station, and each of the remotes is operable by a respective trainee of a group of trainees. Each remote has a remote ID unique from all other remotes and is stored in non-volatile memory of the computer; and the base station includes a base station ID code unique from all other base stations, and the base station ID is stored in non-volatile memory of each remote. Each remote remains in an inactive state and is operable to be activated via a respective activate signal transmitted from the base station, and the base station is operable to transmit an activate signal to one or more of the remotes, the activate signal being effective for enabling the remote to transmit a signal, wherein the remote is deactivated upon completion of transmission of signal. Using unique IDs prevents interference from other wireless devices including remotes paired with other base stations. It also makes it unnecessary for one training system to operate on a different channel from another training system.",ALCHEMY SYSTEMS L P;;ACOSTA CARLOS A;;BARRETT JR ARCHIE D;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID I;;EASTMAN JEFFERY A;;DONELSON ROBIN,ACOSTA CARLOS A;;BARRETT JR ARCHIE D;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID I;;EASTMAN JEFFERY A;;DONELSON ROBIN,ALCHEMY SYSTEMS L.P (2010-03-19),https://lens.org/026-047-935-739-401,Granted Patent,yes,51,0,7,7,0,G09B5/00;;G09B5/10;;G09B5/00;;G09B5/12;;G09B5/14;;G09B7/00;;G09B7/00;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/0225;;H04W52/0225;;H04W84/12;;Y02D30/70;;Y02D30/70,G06F15/16,709/203;;709/224;;709/204;;434/350,1,0,,,"http://en.wikipedia.org/wiki/Carrier-sense-multiple-access-with-collision-detection, Apr. 2012.",ACTIVE
118,US,A1,US 2011/0167103 A1,165-548-052-127-263,2011-07-07,2011,US 68327910 A,2010-01-06,US 68327910 A,2010-01-06,MULTIMEDIA TRAINING SYSTEM AND APPARATUS,"A method for providing interactive training, whereby a video display and a base station are coupled in communication with a computer. A plurality of wireless handheld remotes are configured for wirelessly communicating with the base station, and each of the remotes is operable by a respective trainee of a group of trainees. Each remote has a remote ID unique from all other remotes and is stored in non-volatile memory of the computer; and the base station includes a base station ID code unique from all other base stations, and the base station ID is stored in non-volatile memory of each remote. Each remote remains in an inactive state and is operable to be activated via a respective activate signal transmitted from the base station, and the base station is operable to transmit an activate signal to one or more of the remotes, the activate signal being effective for enabling the remote to transmit a signal, wherein the remote is deactivated upon completion of transmission of signal. Using unique IDs prevents interference from other wireless devices including remotes paired with other base stations. It also makes it unnecessary for one training system to operate on a different channel from another training system.",ACOSTA CARLOS A;;BARRETT JR ARCHIE D;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID I;;EASTMAN JEFFERY A;;DONELSON ROBIN,ACOSTA CARLOS A;;BARRETT JR ARCHIE D;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID I;;EASTMAN JEFFERY A;;DONELSON ROBIN,ALCHEMY SYSTEMS L.P (2010-03-19),https://lens.org/165-548-052-127-263,Patent Application,yes,51,15,7,7,0,G09B5/00;;G09B5/10;;G09B5/00;;G09B5/12;;G09B5/14;;G09B7/00;;G09B7/00;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/0225;;H04W52/0225;;H04W84/12;;Y02D30/70;;Y02D30/70,G06F15/16;;G06F1/12;;G06F1/26;;G09B7/00,709/203;;434/350;;713/310;;709/248;;709/204;;709/224,0,0,,,,ACTIVE
119,ES,A1,ES 2784536 A1,182-591-736-746-495,2020-09-28,2020,ES 201930267 A,2019-03-25,ES 201930267 A,2019-03-25,"GAS HOB (Machine-translation by Google Translate, not legally binding)","Gas hob. The present invention refers to a gas hob (1), which comprises a top plate (2), a connection rail (3) with multiple ports (6a) and arranged on the top plate (2), and burners gas (7) arranged on the top plate (2) and detachably connected to the ports (6a) of the connection rail (3), where the ports (6a) are configured to supply fuel gas to the gas burners (7). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA SA;;BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/182-591-736-746-495,Patent Application,no,5,0,3,3,0,F24C3/085;;F24C3/10;;F23K5/005;;F23N1/02;;F23N2239/04;;F23N2241/08;;F24C3/082;;F24C3/085;;F24C3/103;;F24C3/126;;F24C15/00;;F24C15/107,F24C3/10;;F23N1/02;;F24C3/08;;F24C15/00,,0,0,,,,DISCONTINUED
120,CN,A,CN 113631862 A,179-248-855-008-421,2021-11-09,2021,CN 202080024284 A,2020-03-18,ES 201930267 A;;EP 2020057396 W,2019-03-25,GAS HOB,"A gas hob (1) comprising a top sheet (2), a connection rail (3) having a plurality of ports (6a) and arranged on the top sheet (2), and gas burners (7) arranged on the top sheet (2) and releasably connected to the ports (6a) of the connection rail (3), the ports (6a) being configured to supply the gas burners (7) with fuel gas.",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/179-248-855-008-421,Patent Application,no,4,0,3,3,0,F24C3/085;;F24C3/126;;F23K5/005;;F24C3/10;;F24C3/103;;F24C3/082;;F24C3/085;;F24C15/00;;F24C15/107;;F23N1/02;;F23N2239/04;;F23N2241/08,F24C3/08;;F24C3/12,,0,0,,,,PENDING
121,US,B1,US 9691292 B1,179-787-491-294-094,2017-06-27,2017,US 201213725453 A,2012-12-21,US 201213725453 A;;US 68327910 A,2010-01-06,Multimedia training system and apparatus,"A method for providing interactive training, whereby a video display and a base station are coupled in communication with a computer. A plurality of wireless handheld remotes are configured for wirelessly communicating with the base station, and each of the remotes is operable by a respective trainee of a group of trainees. Each remote has a remote ID unique from all other remotes and is stored in non-volatile memory of the computer; and the base station includes a base station ID code unique from all other base stations, and the base station ID is stored in non-volatile memory of each remote. Unique IDs prevents interference from other wireless devices including remotes paired with other base stations. It also makes it unnecessary for one training system to operate on a different channel from another training system.",ACOSTA CARLOS A;;BARRETT JR ARCHIE D;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID I;;EASTMAN JEFFREY A;;DONELSON ROBIN;;ALCHEMY SYSTEMS L P,ACOSTA CARLOS A;;BARRETT JR ARCHIE D;;MERKORD BRANDON;;SILVER ERIN;;PERL DAVID I;;EASTMAN JEFFREY A;;DONELSON ROBIN,,https://lens.org/179-787-491-294-094,Granted Patent,yes,53,1,7,7,0,G09B5/00;;G09B5/10;;G09B5/00;;G09B5/12;;G09B5/14;;G09B7/00;;G09B7/00;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/0225;;H04W52/0225;;H04W84/12;;Y02D30/70;;Y02D30/70,G09B5/10;;G09B5/00;;G09B5/12;;G09B5/14;;G09B7/00;;G09B7/02;;G09B7/04;;H04L12/12;;H04W24/00;;H04W52/02;;H04W84/12,,2,0,,,"Aztech, “WL830RT4 Wireless G Broadband Router User Manual Version 1.0”, Copyright 2007, www.aztech.com, pp. 1-102.;;http://en.wikipedia.org/wiki/Carrier—sense—multiple—access—with—collision—detection, Apr. 2012.",ACTIVE
122,BR,A2,BR 112015032281 A2,033-592-607-799-576,2017-07-25,2017,BR 112015032281 A,2014-06-23,CU 2014000003 W;;CU 20130086 A,2013-06-24,sistema de posicionamento dos pés para estudos de ressonância magnética,"a presente invenção refere-se a um sistema e a um método que garantem a reprodutibilidade da posição dos pés, e das partes baixas das pernas, durante estudos com imagens de ressonância magnética (irm), para obter informação quantitativa robusta ao longo do tempo. o sistema compreende um dispositivo que é incorporado às bobinas de radiofrequência de qualquer equipamento de irm. o dito dispositivo compreende uma seção de suporte de pé, uma seção de suporte para a perna e uma base adaptada para que sejam fixadas na mesma as seções anteriormente mencionadas. com este dispositivo e método, através de marcadores externos e internos, são realizadas determinações quantitativas da evolução de fenômenos fisiopatológi-cos que afetam a anatomia e a fisiologia dos pés e das partes baixas das pernas.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CARLOS ALBERTO CABAL MIRABAL;;EVELIO RAFAEL GONZÁLEZ DALMAU;;JORGE AMADOR BERLANGA ACOSTA;;LUIS MANUEL FLORES DÍAZ;;LUIS SATURNINO HERRERA MARTINEZ,,https://lens.org/033-592-607-799-576,Patent Application,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61G13/12;;A61N5/10,,0,0,,,,DISCONTINUED
123,US,B2,US 10765341 B2,075-857-287-460-569,2020-09-08,2020,US 201414900244 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,Feet positioning system for magnetic resonance imaging studies,"The present invention is related to a system and method to ensure the reproducibility of the position of the feet and lower parts of the legs during Magnetic Resonance Imaging (MRI) studies, and to obtain robust quantitative information through the time. The system includes a device that is inserted into the radiofrequency coils of any MRI equipment. The device includes a foot support section, a leg support section and a base adapted to allow that the abovementioned sections be fixed in it. With this device and method, and through external and internal markers, quantitative studies of the evolution of pathophysiological phenomena that affect the anatomy and physiology of the feet and lower parts of the legs are performed.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;FLORES DÍAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA (2018-04-17),https://lens.org/075-857-287-460-569,Granted Patent,yes,14,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B90/00;;A61G13/12;;A61N5/10,,24,21,010-769-526-733-280;;115-132-543-497-485;;067-215-734-694-531;;065-980-674-620-842;;001-282-687-394-629;;044-571-468-585-776;;069-190-827-895-791;;076-997-683-023-10X;;008-776-374-807-28X;;012-316-418-405-475;;005-562-517-621-763;;084-287-648-321-367;;050-982-579-725-632;;007-959-462-338-079;;071-288-508-079-153;;038-962-968-489-407;;037-273-481-680-576;;019-995-060-658-524;;007-790-910-377-426;;012-751-065-510-240;;051-731-561-357-958,10.2214/ajr.07.2229;;17715077;;10.1001/archinte.167.2.125;;17242312;;21645348;;pmc3121660;;10.1186/1471-2474-12-128;;10.1053/j.jfas.2012.05.009;;22727342;;10.2337/diacare.28.6.1425;;pmc1224714;;15920063;;10.2214/ajr.08.1376;;19098186;;19280173;;10.1007/s00125-009-1320-0;;10.1007/s11604-012-0119-y;;22965582;;10.1016/j.clinbiomech.2006.05.006;;16844273;;10753037;;10.1007/s001250050025;;10.1086/424846;;15472838;;10.1046/j.1525-1497.1997.07108.x;;pmc1497159;;9294787;;10.1302/0301-620x.91b1.21196;;19091997;;10.1186/1758-5996-2-25;;pmc2873248;;20412561;;19241076;;10.1007/s00256-009-0663-4;;16687463;;10.1259/bjr/30036666;;10.2214/ajr.185.2.01850386;;16037509;;10.1148/radiology.203.3.9169715;;9169715;;19545417;;pmc2714150;;10.1186/ar2737;;10.1055/s-2007-972001;;17387644;;22619270;;pmc3364457;;10.1136/bmjopen-2012-001118,"Recht et al., “Selective Atrophy of the Abductor Digiti Quinti” An MRI Study, Musculoskeletal Imaging, American Roentgen Ray Society, Sep. 2007.;;Kapoor et al., “Magnetic Resonance Imaging for Diagnosing Foot Osteomyelitis,” Arch Intern Med., vol. 167, p. 125-132, Jan. 2007.;;Sormaala et al., “Comparison of 1.5T and 3T MRI scanners in evaluation of acute bone stress in the foot,” BMC Musculosketal Disorders, 2011.;;Sung et al., “Diagnosis of Plantar Plate Injury by Magnetic Resonance Imaging with Reference to Intraoperative Findings,” The Journal of Foot & Ankle Surgery, vol. 51, p. 570-574, 2012.;;Greenman et al., “Foot Small Muscle Atrophy Is Present Before the Detection of Clinical Neuropathy,” Diabetes Care, vol. 28, No. 6, p. 1425-1430, Jun. 2005.;;Johnson et al., “Diagnostic Utility of T1-Weighted MRI Characteristics in Evaluation of Osteomyelitis of the Foot,” Musculoskeletal Imaging, American Roentgen Ray Society, Jan. 2009.;;Andreassen et al., “Accelerated atrophy of lower leg and foot muscles—a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI),” Diabetologia vol. 52, p. 1182-1191, Mar. 2009.;;Kudo et al., “Round cell liposarcoma arising in the left foot: MRI and PET findings,” Japan Radiological Society, vol. 30, p. 852-857, 2012.;;Sangeux et al., “Quantification of the 3D relative movement of external marker sets vs. bones based on magnetic resonance imaging,” ScienceDirect, Clinical Biomechanics 21, p. 984-991, 2006.;;Suzuki et al., “1H- and 31P-magnetic resonance spectroscopy and imaging as a new diagnostic tool to evaluate neuropathic foot ulcers in Type II diabetic patients,” Diabetologia vol. 43, p. 165-172, 2000.;;Lipsky et al., “Diagnosis and Treatment of Diabetic Foot Infections,” Guideline for Diabetic Foot Infections, Clinical Infectious Diseases, vol. 39, p. 885-910, 2004.;;Edelman et al., “Prognostic Value of the Clinical Examination of the Diabetic Foot Ulcer,” J Gen Intern Med, vol. 12, p. 537-543, 1997.;;Robinson et al., “Surgical aspects of the diabetic foot,” Bone and Joint Surgery, vol. 91-B, No. 1, p. 1-7, Jan. 2009.;;Poll et al., “Routine MRI findings of the asymptomatic foot in diabetic patients with unilateral Charcot foot,” BioMed Central, Diabetology & Metabolic Syndrome, 2010.;;Thomas et al., “Osteomyelitis and Lower Extremity Amputations in the Diabetic Population,” The Journal of Diabetic Foot Complications, vol. 2, Issue 1, No. 4, p. 18-27, 2010.;;Moholkar et al., “Imaging benign soft tissue lesions of the foot,” Applied Radiology, p. 10-21, 2009.;;Vartanians et al., “Is there a role for imaging in the management of patients with diabetic foot?,” Skeletal Radial., vol. 38, p. 633-636, 2009.;;Moreno Casado et al., “Diabetic foot. Findings on MR Imaging,” Revista Internacional de Ciencias Podologicas, vol. 4, No. 1, p. 45-53, 2010.;;Tan et al., “MRI of the diabetic foot: differentiation of infection from neuropathic change,” The British Journal of Radiology, vol. 80, p. 939-948, 2007.;;Collins et al., “T1-Weighted MRI Characteristics of Pedal Osteomyelitis,” Musculoskeletal Imaging—Clinical Observations, p. 386-393, 2005.;;Craig et al., “Osteomyelitis of the Diabetic Foot: MR Imaging-Pathologic Correlation,” Radiology, vol. 203, p. 849-855, 1997.;;Mundwiler et al., “The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study,” Arthritis Research & Therapy, p. 1-10, 2009.;;Kavanagh et al., “MRI of Trauma to the Foot and Ankle,” Semin Musculoskelet Radiol, p. 308-327, 2006.;;Freund et al, “The foot in multistage ultra-marathon runners: experience in a cohort study of 22 participants of the Trans Europe Footrace Project with mobile MRI,” BMJ Open, p. 1-8, 2012.",ACTIVE
124,AR,A1,AR 096616 A1,086-176-521-296-898,2016-01-20,2016,AR P140102272 A,2014-06-13,CU 20130086 A,2013-06-24,SISTEMA DE POSICIONAMIENTO DE LOS PIES PARA ESTUDIOS DE RESONANCIA MAGNÉTICA,"La presente se relaciona con un sistema y un método que garantizan la reproducibilidad de la posición de los pies, y de las partes bajas de las piernas, durante los estudios con Imágenes de Resonancia Magnética (IRM), para obtener información cuantitativa robusta a lo largo del tiempo. El sistema comprende un dispositivo que se incorpora a las bobinas de radiofrecuencia de cualquier equipo de IRM. Dicho dispositivo comprende una sección de soporte del pie, una sección de soporte para la pierna y una base adaptada para que se fijen en ella las secciones antes mencionadas. Con este dispositivo y método, a través de marcadores externos e internos, se realizan determinaciones cuantitativas de la evolución de fenómenos fisiopatológicos que afectan la anatomía y la fisiología de los pies y las partes bajas de las piernas.",CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA,EVELIO RAFAEL GONZLEZ DALMAU;;JORGE AMADOR BERLANGA ACOSTA;;LUIS SATURNINO HERRERA MARTINEZ;;CARLOS ALBERTO CABAL MIRABAL;;LUIS MANUEL FLORES DIAZ,,https://lens.org/086-176-521-296-898,Patent Application,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/00;;A61B5/055;;A61B6/04;;A61G13/12;;A61N5/10,,0,0,,,,ACTIVE
125,ES,R1,ES 2426318 R1,155-169-750-570-243,2014-01-23,2014,ES 201231672 A,2012-10-31,DE 102012206507 A,2012-04-20,Quemador para un aparato de cocción calentado a gas,"Quemador para un aparato de cocción calentado a gas. La presente invención crea un quemador (1) para un aparato de cocción calentado a gas (2), con un tubo (14) para mezclar gas combustible (28) con aire primario (29), y con un elemento de desviación (23) que está dispuesto en el espacio interior (24) delimitado por el tubo (14).",BSH ELECTRODOMÉSTICOS ESPANA S A,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,,https://lens.org/155-169-750-570-243,Unknown,no,3,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F23D14/02;;F24C3/08;;F24C15/10,,0,0,,,,DISCONTINUED
126,US,A1,US 2016/0157750 A1,136-744-137-712-978,2016-06-09,2016,US 201414900244 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,"The present invention is related to a system and method to ensure the reproducibility of the position of the feet and lower parts of the legs, during the Magnetic Resonance Imaging (MRI) studies, to obtain robust quantitative information through the time. The system comprises a device that is inserted into the radiofrequency coils of any MRI equipment. Said device comprises a foot support section, a leg support section and a base adapted to allow that the abovementioned sections be fixed in it. With this device and method, through external and internal markers, quantitative studies of the evolution of pathophysiological phenomena that affect the anatomy and physiology of the feet and lower parts of the legs are performed.",CT INGENIERIA GENETICA BIOTECH,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;FLORES DÍAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA (2018-04-17),https://lens.org/136-744-137-712-978,Patent Application,yes,14,4,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B90/00,,0,0,,,,ACTIVE
127,CN,A,CN 105431083 A,012-741-607-090-596,2016-03-23,2016,CN 201480043321 A,2014-06-23,CU 2014000003 W;;CU 20130086 A,2013-06-24,Feet positioning system for magnetic resonance imaging studies,"The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/012-741-607-090-596,Patent Application,no,7,1,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61G13/12;;A61N5/10,,1,1,008-776-374-807-28X,10.1016/j.clinbiomech.2006.05.006;;16844273,"M. SANGEUX, F. MARIN, F. CHARLEUX, L. DURSELEN: ""Quantification of the 3D relative movement of external marker sets vs. bones based on magnetic resonance imaging"", 《CLINICAL BIOMECHANICS》",INACTIVE
128,MX,A,MX 2016000135 A,090-084-572-203-571,2016-03-01,2016,MX 2016000135 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES.,"The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.",CT INGENIERIA GENETICA BIOTECH,MIRABAL CARLOS ALBERTO CABAL;;DALMAU EVELIO RAFAEL GONZÁLEZ;;ACOSTA JORGE AMADOR BERLANGA;;DÍAZ LUIS MANUEL FLORES;;MARTINEZ LUIS SATURNINO HERRERA,,https://lens.org/090-084-572-203-571,Patent Application,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61G13/12;;A61N5/10,,0,0,,,,ACTIVE
129,EP,B1,EP 3015065 B1,187-976-025-795-767,2018-10-17,2018,EP 14744427 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,,CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;FLORES DÍAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/187-976-025-795-767,Granted Patent,yes,5,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61B90/00;;A61G13/12;;A61N5/10,,1,1,008-776-374-807-28X,10.1016/j.clinbiomech.2006.05.006;;16844273,"SANGEUX M ET AL: ""Quantification of the 3D relative movement of external marker sets vs. bones based on magnetic resonance imaging"", CLINICAL BIOMECHANICS, BUTTERWORTH SCIENTIFIC LTD, GUILDFORD, GB, vol. 21, no. 9, 1 November 2006 (2006-11-01), pages 984 - 991, XP028011516, ISSN: 0268-0033, [retrieved on 20061101], DOI: 10.1016/J.CLINBIOMECH.2006.05.006",ACTIVE
130,CU,A7,CU 20130086 A7,134-262-044-181-624,2015-02-26,2015,CU 20130086 A,2013-06-24,CU 20130086 A,2013-06-24,SISTEMA DE POSICIONAMIENTO DE LOS PIES PARA ESTUDIOS DE RESONANCIA MAGNÉTICA,"La presente invención se relaciona con un sistema que garantiza la reproducibilidad de la posición del pie, y de la parte baja de la pierna, durante los estudios con Imágenes de Resonancia Magnética (IRM), para obtener información cuantitativa robusta a lo largo del tiempo. El sistema comprende un dispositivo que se incorpora a las bobinas de radiofrecuencia de cualquier equipo de IRM. Dicho dispositivo comprende una sección de soporte del pie, una sección de soporte para la pierna y una base adaptada para que se fijen en ella las secciones antes mencionadas. Con este dispositivo, a través de marcadores externos e internos, se realizan determinaciones cuantitativas de la evolución de fenómenos fisiopatológicos que afectan la anatomía y la fisiología de los pies y las partes bajas de las piernas.",CT DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;FLORES DÍAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTÍNEZ LUIS SATURNINO,,https://lens.org/134-262-044-181-624,Patent Application,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B6/04,,0,0,,,,PENDING
131,DE,A1,DE 102012206507 A1,178-635-029-860-325,2013-10-24,2013,DE 102012206507 A,2012-04-20,DE 102012206507 A,2012-04-20,Brenner für ein gasbeheiztes Gargerät,"Die vorliegende Erfindung schafft einen Brenner (1) für ein gasbeheiztes Gargerät (2), mit einem Rohr (14) zum Mischen von Brenngas (28) mit Primärluft (29) und einem Ablenkelement (23), welches in dem von dem Rohr (14) begrenzten Innenraum (24) angeordnet ist.",BSH BOSCH SIEMENS HAUSGERAETE,HERRERA ESTRADA PEDRO;;TRIGUEROS PRECIADO SARA;;ACOSTA HERRERO LUIS;;CARLOS NEGRO AINHOA DE;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO,,https://lens.org/178-635-029-860-325,Patent Application,no,1,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F24C3/08;;F23D14/02;;F24C15/10,,0,0,,,,DISCONTINUED
132,WO,A3,WO 2013/156902 A3,010-457-656-826-079,2014-02-06,2014,IB 2013052850 W,2013-04-10,DE 102012206507 A;;ES 201231672 A,2012-04-20,BURNER FOR A GAS-HEATED COOKING APPLIANCE,"The present invention provides a burner (1) for a gas-heated cooking appliance (2), with a pipe (14) for mixing burnable gas (28) with primary air (29), and with a deflecting element (23) which is arranged in the interior space (24) which is bounded by the pipe (14).",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,,https://lens.org/010-457-656-826-079,Search Report,yes,3,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F24C3/08;;F23D14/06;;F24C15/10,,0,0,,,,PENDING
133,ES,T3,ES 2697400 T3,028-614-587-984-988,2019-01-23,2019,ES 14744427 T,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,Sistema de posicionamiento de los pies para estudios de imágenes de resonancia magnética,"La presente invención se relaciona con un sistema y un método que garantizan la reproducibilidad de la posición de los pies, y de las partes bajas de las piernas, durante los estudios con Imágenes de Resonancia Magnética (IRM), para obtener información cuantitativa robusta a lo largo del tiempo. El sistema comprende un dispositivo que se incorpora a las bobinas de radiofrecuencia de cualquier equipo de IRM. Dicho dispositivo comprende una sección de soporte del pie, una sección de soporte para la pierna y una base adaptada para que se fijen en ella las secciones antes mencionadas. Con este dispositivo y método, a través de marcadores externos e internos, se realizan determinaciones cuantitativas de la evolución de fenómenos fisiopatológicos que afectan la anatomía y la fisiología de los pies y las partes bajas de las piernas.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/028-614-587-984-988,Granted Patent,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61B90/00;;A61G13/12;;A61N5/10,,0,0,,,,ACTIVE
134,CA,A1,CA 2916112 A1,054-175-351-349-129,2014-12-31,2014,CA 2916112 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,"The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.",CT INGENIERIA GENETICA BIOTECH,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/054-175-351-349-129,Patent Application,no,0,1,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61G13/12;;A61N5/10,,0,0,,,,DISCONTINUED
135,US,B2,US 10317086 B2,125-670-588-751-548,2019-06-11,2019,US 201314390799 A,2013-04-10,DE 102012206507 A;;ES 201231672 A;;IB 2013052850 W,2012-04-20,Burner for a gas-heated cooking appliance,"A burner for a gas-heated cooking appliance includes a pipe for mixing burnable gas with primary air, and a deflecting element which is arranged in an interior space which is bounded by the pipe. The pipe has one end which points toward a nozzle of the burner and another end which points toward a cover of the burner. The deflecting element is arranged in the interior space between a center of the pipe in respect of a longitudinal direction thereof and the one end of the pipe.",BSH BOSCH & SIEMENS HAUSGERAETE GMBH;;BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,BSH BOSCH UND SIEMENS HAUSGERAETE GMBH (2014-09-18);;BSH HAUSGERÄTE GMBH (2015-03-23),https://lens.org/125-670-588-751-548,Granted Patent,yes,88,2,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F24C3/08;;F23D14/06;;F24C15/10,,2,0,,,"Report of Examination CN 201380020803.7 dated May 5, 2016.;;International Search Report PCT/IB2013/052850 dated Nov. 20, 2013.",ACTIVE
136,ES,T3,ES 2887216 T3,067-101-154-616-611,2021-12-22,2021,ES 13726022 T,2013-04-10,DE 102012206507 A;;ES 201231672 A;;IB 2013052850 W,2012-04-20,Quemador para un aparato de cocción calentado a gas,"Quemador (1) para un aparato de cocción calentado a gas (2), con una tapa (6), un inyector (11), un tubo (14) para mezclar gas combustible (28) con aire primario (29), y un elemento de desviación (23) que está dispuesto en un espacio interior (24) delimitado por el tubo (14), donde el tubo (14) señala con un extremo (15) hacia el inyector (11), y con su otro extremo (16), hacia la tapa (6), caracterizado por que el elemento de desviación (23) está dispuesto entre un centro del tubo (14) inclusive, con respecto a una dirección longitudinal (34) del mismo, y el extremo (15) que señala hacia el inyector (11), y donde el elemento de desviación (23) presenta al menos un fragmento de filamento (25, 26).",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,,https://lens.org/067-101-154-616-611,Granted Patent,no,0,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F23D14/06;;F24C3/08;;F24C15/10,,0,0,,,,ACTIVE
137,ES,A1,ES 2340647 A1,082-269-547-313-606,2010-06-07,2010,ES 200800901 A,2008-03-18,ES 200800901 A,2008-03-18,"Control element and spring element for fixing the elementode control (Machine-translation by Google Translate, not legally binding)","Control element and spring element for fixing the control element. To perfect a control element (100) for the control of at least one domestic appliance, having an axis (30), on which the control element (100) is insertable, and at least one spring element (40; 42; 44) configured for fixing the control element (100) on the shaft (30), where the spring element (40; 42; 44) is available between the control element (100) and the shaft (30) in such a way that the spring element (40; 42; 44) in its use position is bent towards the axis (30) or towards the control element (100), in its area directed towards the control element (100) or the shaft (30) is in contact at least by areas (10) with the control element (100) and with the shaft (30) respectively and fix the control element (100) by pressing pressure to the shaft (30), so that the contact between the spring element (40; 42; 44) and the shaft (30) or between the spring element (40; 42; 44) and the control element (100) is improved and the tightening pressure be increased compared to the state of the art. (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO,,https://lens.org/082-269-547-313-606,Patent Application,no,4,0,2,2,0,G05G1/12,G05G1/12,,0,0,,,,INACTIVE
138,WO,A2,WO 2013/156902 A2,017-259-158-111-756,2013-10-24,2013,IB 2013052850 W,2013-04-10,DE 102012206507 A;;ES 201231672 A,2012-04-20,BURNER FOR A GAS-HEATED COOKING APPLIANCE,"The present invention provides a burner (1) for a gas-heated cooking appliance (2), with a pipe (14) for mixing burnable gas (28) with primary air (29), and with a deflecting element (23) which is arranged in the interior space (24) which is bounded by the pipe (14).",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,,https://lens.org/017-259-158-111-756,Patent Application,yes,1,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F23D14/06,,0,0,,,,PENDING
139,EP,A1,EP 3015065 A1,057-744-908-024-265,2016-05-04,2016,EP 14744427 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,"The present invention is related to a system and method to ensure the reproducibility of the position of the feet and lower parts of the legs, during the Magnetic Resonance Imaging (MRI) studies, to obtain robust quantitative information through the time. The system comprises a device that is inserted into the radiofrequency coils of any MRI equipment. Said device comprises a foot support section, a leg support section and a base adapted to allow that the abovementioned sections be fixed in it. With this device and method, through external and internal markers, quantitative studies of the evolution of pathophysiological phenomena that affect the anatomy and physiology of the feet and lower parts of the legs are performed.",CT INGENIERIA GENETICA BIOTECH,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;FLORES DÍAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/057-744-908-024-265,Patent Application,yes,0,1,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61B90/00;;A61G13/12;;A61N5/10,,0,0,,,,ACTIVE
140,US,A1,US 2015/0090249 A1,088-240-792-733-232,2015-04-02,2015,US 201314390799 A,2013-04-10,DE 102012206507 A;;ES 201231672 A;;IB 2013052850 W,2012-04-20,BURNER FOR A GAS-HEATED COOKING APPLIANCE,"A burner for a gas-heated cooking appliance includes a pipe for mixing burnable gas with primary air, and a deflecting element which is arranged in an interior space which is bounded by the pipe. The pipe has one end which points toward a nozzle of the burner and another end which points toward a cover of the burner. The deflecting element is arranged in the interior space between a center of the pipe in respect of a longitudinal direction thereof and the one end of the pipe.",BSH BOSCH & SIEMENS HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,BSH BOSCH UND SIEMENS HAUSGERAETE GMBH (2014-09-18);;BSH HAUSGERÄTE GMBH (2015-03-23),https://lens.org/088-240-792-733-232,Patent Application,yes,41,2,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F24C3/08,126 39 E,0,0,,,,ACTIVE
141,WO,A1,WO 2014/206379 A1,011-485-567-208-716,2014-12-31,2014,CU 2014000003 W,2014-06-23,CU 20130086 A,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,"The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.",CT INGENIERIA GENETICA BIOTECH,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;FLORES DÍAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/011-485-567-208-716,Patent Application,yes,7,3,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61B19/00;;A61G13/12;;A61N5/10,,30,18,008-776-374-807-28X;;012-316-418-405-475;;001-282-687-394-629;;012-751-065-510-240;;115-132-543-497-485;;069-190-827-895-791;;007-959-462-338-079;;076-997-683-023-10X;;065-980-674-620-842;;005-562-517-621-763;;071-288-508-079-153;;010-769-526-733-280;;084-287-648-321-367;;019-995-060-658-524;;005-562-517-621-763;;037-273-481-680-576;;038-962-968-489-407;;050-982-579-725-632,10.1016/j.clinbiomech.2006.05.006;;16844273;;10753037;;10.1007/s001250050025;;10.2337/diacare.28.6.1425;;pmc1224714;;15920063;;10.1055/s-2007-972001;;17387644;;10.1001/archinte.167.2.125;;17242312;;19280173;;10.1007/s00125-009-1320-0;;10.1186/1758-5996-2-25;;pmc2873248;;20412561;;10.1007/s11604-012-0119-y;;22965582;;10.1053/j.jfas.2012.05.009;;22727342;;10.1086/424846;;15472838;;19241076;;10.1007/s00256-009-0663-4;;10.2214/ajr.07.2229;;17715077;;10.1046/j.1525-1497.1997.07108.x;;pmc1497159;;9294787;;10.1148/radiology.203.3.9169715;;9169715;;10.1086/424846;;15472838;;10.2214/ajr.185.2.01850386;;16037509;;16687463;;10.1259/bjr/30036666;;10.1302/0301-620x.91b1.21196;;19091997,"SANGEUX M ET AL: ""Quantification of the 3D relative movement of external marker sets vs. bones based on magnetic resonance imaging"", CLINICAL BIOMECHANICS, BUTTERWORTH SCIENTIFIC LTD, GUILDFORD, GB, vol. 21, no. 9, 1 November 2006 (2006-11-01), pages 984 - 991, XP028011516, ISSN: 0268-0033, [retrieved on 20061101], DOI: 10.1016/J.CLINBIOMECH.2006.05.006;;SUZUKI E., DIABETOLOGIA, vol. 43, 2000, pages 165 - 172;;GREENMAN R L., DIABETES CARE, vol. 28, no. 6, 2005, pages 1425 - 30;;E.C KAVANAGH; A. C ZOGA, SEMINARS IN MUSCULOSKELETAL RADIOL, vol. 10, no. 4, 2006, pages 308 - 27;;KAPOOR A, ARCH INTERN MED., vol. 167, 2007, pages 125 - 132;;JOHNSON P. W, AJR, vol. 192, 2009, pages 96 - 100;;ANDREASSEN C. S., DIABETOLOGIA, vol. 52, 2009, pages 1182 - 1191;;MORENO CASADO M.J, REVISTA INTERN. CIENCIAS PODOLÓGICAS, vol. 4, 2010, pages 45 - 53;;POLL L. W, DIABETOLOGY & METABOLIC SYNDROME, vol. 2, 2010, pages 2 - 5, Retrieved from the Internet <URL:http-//www.dmsjournal.com/content/2/1/25>;;RAMOUTAR CT, THE J OF DIABETIC FOOT COMPLICATIONS, vol. 2, 2010, pages 18 - 27;;M.J. SORMAALA ET AL., MUSCULOSKELETAL DISORDERS, vol. 12, 2011, pages 1 - 6;;H. KUDO ET AL., JPN. J. RADIOL, vol. 30, 2012, pages 852 - 857;;W L. SUNG ET AL., THE J. OF FOOT AND ANKLE SURGERY, vol. 50, 2012, pages 570 - 574;;FREUD W, BMJ OPEN, vol. 2, 2012, pages 1 - 8;;BA LIPSKY ET AL., CLINICAL INFECTIOUS DISEASES, vol. 39, 2004, pages 885 - 910;;MOHOLKAR S, APPL. RADIOLOGY, October 2009 (2009-10-01), Retrieved from the Internet <URL:www.appIiedradiology.com>;;VARTANIANS V.M ET AL., SKELETAL RADIOL, vol. 38, 2009, pages 633 - 636;;THOMAS-RAMOUTAR C, THE J OF DIABETIC FOOT COMPLICATIONS, vol. 2, 2010, pages 18 - 27;;M.L MUNDWILER ET AL., ARTHRITIS RESEARCH AND THERAPY, vol. 11, no. 3, 2009, pages 1 - 10;;VARTANIANS V. M ET AL., SKELETAL RADIOL, vol. 38, 2009, pages 633 - 636;;M.P. RECHT ET AL., AJR, vol. 189, 2007, pages W123 - W127;;EDELMAN, D., J. GEN INTERN MED, vol. 12, 1997, pages 537 - 543;;CRAIG JC, RADIOL., vol. 203, 1997, pages 849 - 855;;BA LIPSKY ET AL., INFECTIONS CLINICAL INFECTIOUS DISEASES, vol. 39, 2004, pages 885 - 910;;COLLINS MS, AJR, vol. 185, 2005, pages 386 - 393;;TAN, PL; TEH J., THE BRITÍSH J. OF RADIOL, vol. 80, 2007, pages 939 - 948;;ROBINSON A.H.N, J BONE JOINT SURG, vol. 91-B, 2009, pages 1 - 7;;CRAIG J C, RADIOL, vol. 203, 1997, pages 849 - 855;;COLLINS M.S, AJR, vol. 185, 2005, pages 386 - 393;;JOHNSON P.W, AJR, vol. 192, 2009, pages 96 - 100",PENDING
142,EP,A2,EP 2839215 A2,154-976-831-288-260,2015-02-25,2015,EP 13726022 A,2013-04-10,DE 102012206507 A;;ES 201231672 A;;IB 2013052850 W,2012-04-20,BURNER FOR A GAS-HEATED COOKING APPLIANCE,,BSH BOSCH & SIEMENS HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/154-976-831-288-260,Patent Application,yes,0,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F23D14/06;;F24C3/08;;F24C15/10,,0,0,,,,ACTIVE
143,CN,A,CN 104246368 A,033-495-812-193-990,2014-12-24,2014,CN 201380020803 A,2013-04-10,IB 2013052850 W;;DE 102012206507 A;;ES 201231672 A,2012-04-20,Burner for a gas-heated cooking appliance,"The present invention provides a burner (1) for a gas-heated cooking appliance (2), with a pipe (14) for mixing burnable gas (28) with primary air (29), and with a deflecting element (23) which is arranged in the interior space (24) which is bounded by the pipe (14).",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,,https://lens.org/033-495-812-193-990,Patent Application,no,6,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F23D14/06;;F24C3/08;;F24C15/10,,0,0,,,,ACTIVE
144,CU,B1,CU 24138 B1,188-261-095-104-447,2015-12-23,2015,CU 20130086 A,2013-06-24,CU 20130086 A,2013-06-24,SISTEMA DE POSICIONAMIENTO DE LOS PIES PARA ESTUDIOS DE RESONANCIA MAGNÉTICA,,CT DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;FLORES DÍAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTÍNEZ LUIS SATURNINO,,https://lens.org/188-261-095-104-447,Unknown,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,,,0,0,,,,PENDING
145,KR,A,KR 20160023875 A,007-618-412-542-332,2016-03-03,2016,KR 20167002047 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,"본 발명은 시간을 통해 강력한 정량적 정보를 얻기 위해서 자기 공명 영상(MRI) 연구 동안, 발과 다리의 하부의 위치의 재현 가능성을 보장하는 시스템과 방법에 관련된 것이다. 시스템은 임의의 MRI 장비의 무선주파수 코일 내로 삽입되는 장치를 포함한다. 상기 장치는 발 지지부, 다리 지지부 및 상술한 부분들이 그 내부에 고정되는 것을 가능하게 하도록 채용된 베이스를 포함한다. 이러한 장치와 방법으로, 외부 및 내부 마커를 통해서, 발과 다리의 하부의 해부학적 구조(anatomy)와 생리(physiology)에 영향을 주는 병리생리학 현상들의 진전의 정량적 연구가 수행된다.",CT INGENIERIA GENETICA BIOTECH,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/007-618-412-542-332,Patent Application,no,0,1,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/00;;A61B90/00;;A61G13/12;;A61N5/10,,0,0,,,,DISCONTINUED
146,EP,B1,EP 2839215 B1,168-237-440-246-441,2021-06-30,2021,EP 13726022 A,2013-04-10,DE 102012206507 A;;ES 201231672 A;;IB 2013052850 W,2012-04-20,BURNER FOR A GAS-HEATED COOKING APPLIANCE,,BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/168-237-440-246-441,Granted Patent,yes,3,0,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F23D14/06;;F24C3/08;;F24C15/10,,0,0,,,,ACTIVE
147,ES,A2,ES 2426318 A2,179-379-537-396-035,2013-10-22,2013,ES 201231672 A,2012-10-31,DE 102012206507 A,2012-04-20,BURNER FOR A GAS-HEATED COOKING APPLIANCE,"The present invention provides a burner (1) for a gas-heated cooking appliance (2), with a pipe (14) for mixing burnable gas (28) with primary air (29), and with a deflecting element (23) which is arranged in the interior space (24) which is bounded by the pipe (14).",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;TRIGUEROS PRECIADO SARA,,https://lens.org/179-379-537-396-035,Patent Application,no,0,1,12,12,0,F24C15/10;;F23D14/06;;F24C3/085;;F23D14/02;;F24C3/08;;F24C15/10;;F23D14/06;;F24C15/10;;F24C3/085;;F24C3/08,F23D14/00,,0,0,,,,DISCONTINUED
148,MX,B,MX 351561 B,100-649-477-524-007,2017-10-18,2017,MX 2016000135 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES.,"The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CARLOS ALBERTO CABAL MIRABAL;;EVELIO RAFAEL GONZÁLEZ DALMAU;;JORGE AMADOR BERLANGA ACOSTA;;LUIS MANUEL FLORES DÍAZ;;LUIS SATURNINO HERRERA MARTINEZ,,https://lens.org/100-649-477-524-007,Granted Patent,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61G13/12;;A61N5/10,,0,0,,,,ACTIVE
149,US,B2,US 9939837 B2,139-718-478-505-256,2018-04-10,2018,US 201314405552 A,2013-06-04,ES 201200608 A;;ES 2013000134 W,2012-06-04,Method for generating piecewise-affine multivariable functions with on-line computation of the search tree and device for implementing same,"Method for generating piecewise-affine multivariate functions, wherein the online computation of the search tree is performed in order to locate the input value in the polytopes of the partition, and the subsequent generation of the corresponding affine function. It also proposes a configurable and programmable device for generating piecewise-affine multivariate functions composed of an architecture with four functional blocks namely: a control unit block ( 1 ), a tree memory block, a parameter memory block and an arithmetic unit block; and it has at least three operating modes which can be selected using different values of a bus (config): writing of the tree memory, writing of the parameter memory and evaluating the affine function. It may include a fourth operating mode, which is the test mode.",UNIV SEVILLA;;CONSEJO SUPERIOR INVESTIGACION;;CONSEJO SUPERIOR DE INVESTIG CIENTFICAS,ACOSTA JIMENEZ ANTONIO JOSE;;BATURONE CASTILLO ILUMINADA;;CASTRO RAMIREZ JAVIER;;JIMENEZ FERNANDEZ CARLOS JESUS;;BROX JIMENEZ PIEDAD;;MARTINEZ RODRIGUEZ MACARENA CRISTINA,CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (2015-01-07);;UNIVERSIDAD DE SEVILLA (2015-01-07),https://lens.org/139-718-478-505-256,Granted Patent,yes,2,1,7,7,0,G06F1/02;;G06F17/175;;G05B15/02;;G06F16/9027;;G06F16/9027;;G06F16/951;;G06F16/951;;G06F17/175;;G06N20/00;;G06N20/00,G06F1/02;;G05B15/02;;G06F17/17;;G06F17/30;;G06N99/00,,13,12,109-260-195-322-978;;118-242-877-825-457;;014-244-040-332-499;;019-226-752-178-63X;;073-862-089-193-82X;;115-132-167-327-537;;011-599-497-847-533;;006-866-052-551-994;;182-532-346-411-489;;055-566-327-761-134;;003-264-261-705-438;;014-503-167-077-951,10.1109/isie.2011.5984382;;10.1109/tie.2007.896547;;10.1201/9781315274249;;10.1109/fpt.2011.6132696;;10.1109/tcst.2006.883206;;10.1109/ecctd.2011.6043625;;10.1109/ecctd.2009.5274957;;10.1007/978-1-4615-4090-8_7;;10.1016/s0165-1684(00)00013-x;;10.1109/tie.2007.898292;;10.1002/cta.610;;10.1016/s0005-1098(02)00308-4,"Baturone, Digital Implementation of Hierarchical Piecewise-Affine Controllers, symposium, 2011, p. 1497-1502, IEEE.;;Baturone, Design of Embedded DSP-Based Fuzzy Controllers for Autonomous Mobile Robots, IEEE Transactions on Industrial Electronics, Feb. 2008, p. 928-936, vol. 55, Issue 2, IEEE.;;Baturone, Microelectronic Design of Fuzzy Logic-Based Systems, 2000, p. 1-336, CRC Press.;;Echevarria, Digital Hardware Implementation of High Dimensional Fuzzy Systems, Applications of Fuzzy Sets Theory, 2007, p. 245-252, vol. 4578, Springer.;;Martinez-Rodriguez, Design Methodology for FPGA Implementation of Lattice Piecewise-Affine Functions, Field-Programmable Technology (FPT) International Conference, 2011, p. 1-4, IEEE.;;Johansen, Hardware Synthesis of Explicit Model Predictive Controllers, IEEE Transactions on Control Systems Technology, Jan. 2007, p. 191-197, vol. 15, Issue 1, IEEE.;;Martinez-Rodriguez, Circuit Implementation of Piecewise-Affine Functions Based on Lattice Representation, 2011 20th European Conference on Circuit Theory and Design, Aug. 2011, p. 644-647, IEEE.;;Oliveri, Circuit implementation of piece-wise athne functions based on a binary search tree, 2009 European Conference on Circuit Theory and Design, Aug. 2009, p. 145-148, IEEE.;;Rovatti, Automatic Implementation of Piecewise-Linear Fuzzy Systems Addressing Memory-Performance Trade-Off, Fuzzy Hardware: Architectures and Applications, 1998, p. 159-179, Kluwer Academic Publishers, Norwell, MA.;;Rovatti, High-speed DSP-based implementation of piecewise-affine and piecewise-quadratic fuzzy systems, Signal Processing, 2000, p. 951-963, vol. 80, Elsevier Science B.V.;;Sanchez-Solano, FPGA Implementation of Embedded Fuzzy Controllers for Robotic Applications, IEEE Transactions on Industrial Electronics, Aug. 2007, p. 1937-1945, vol. 54, Issue 4, IEEE.;;Storace, Digital architectures realizing piecewise-linear multivariate functions: Two FPGA implementations, International Journal of Circuit Theory and Applications, 2009, p. 1-15, vol. 39, Issue 1, John Wiley & Sons, Ltd.;;Tondel, Evaluation of piecewise affine control via binary search tree, Automatica, May 2003, p. 945-950, vol. 39, Issue 5, Elsevier Science Ltd.",INACTIVE
150,EP,A1,EP 2857981 A1,014-840-928-727-670,2015-04-08,2015,EP 13801227 A,2013-06-04,ES 201200608 A;;ES 2013000134 W,2012-06-04,METHOD FOR GENERATING PIECEWISE-AFFINE MULTIVARIABLE FUNCTIONS WITH ON-LINE COMPUTATION OF THE SEARCH TREE AND DEVICE FOR IMPLEMENTING SAME,"The invention relates to a method for generating piecewise-affine multivariable functions, comprising the on-line computation of the search tree in order to locate the input value in the polytopes of the partition, and the subsequent generation of the corresponding affine function. The invention also relates to a configurable and programmable device for generating piecewise-affine multivariable functions, formed by an architecture having four functional blocks, namely a control unit block (1), a tree memory block, a parameter memory block and an arithmetic unit block, as well as having at least three operating modes that can be selected using different values of a bus (config): writing of the tree memory, writing of the parameter memory and evaluating the affine function. The device can also have a fourth operating mode, i.e. the test mode.",UNIV SEVILLA;;CONSEJO SUPERIOR INVESTIGACION,ACOSTA JIMÉNEZ ANTONIO JOSÉ;;BATURONE CASTILLO ILUMINADA;;CASTRO RAMÍREZ JAVIER;;JIMÉNEZ FERNÁNDEZ CARLOS JESÚS;;BROX JIMÉNEZ PIEDAD;;MARTÍNEZ RODRÍGUEZ MACARENA CRISTINA,,https://lens.org/014-840-928-727-670,Patent Application,yes,0,0,7,7,0,G06F1/02;;G06F17/175;;G05B15/02;;G06F16/9027;;G06F16/9027;;G06F16/951;;G06F16/951;;G06F17/175;;G06N20/00;;G06N20/00,G06F17/17;;G06F1/02;;G06F17/30;;G06N99/00,,0,0,,,,DISCONTINUED
151,CO,A1,CO 2022011605 A1,071-659-648-806-615,2024-02-26,2024,CO 2022011605 A,2022-08-17,CO 2022011605 A,2022-08-17,Sistema portátil isotermal para medir fluorescencia través de imágenes,"El sistema propuesto, comprende un gabinete portátil, dividido en tres zonas o recámaras, conectado a un computador u otro dispositivo con un procesador de datos, donde cada zona o recámara comprende una serie de dispositivos o componentes que en su conjunto permiten la cuantificación de la fluorescencia del material analizado. Se puede conectar a la corriente o trabajar con batería. Asimismo, comprende una tapa frontal, que en la modalidad provista de la solución, está unida al borde inferior del gabinete por intermedio de un sistema de bisagras y que permite acceder al gabinete para ajustar los componentes, dar mantenimiento al sistema e introducir o extraer una estructura de pozos. Todo el dispositivo es activado y controlado desde el computador o dispositivo con procesador de datos. El procesamiento de las imágenes obtenidas también se realiza desde el dispositivo por medio del mismo software que controla y activa el sistema.",UNIV SIMON BOLIVAR,NAVARRO QUIROZ ELKIN ANTONIO;;VILLARREAL GONZÁLEZ REYNALDO;;ACOSTA HOYOS ANTONIO;;GALÁN FREYLE NATALY;;PACHECO LONDOÑO LEONARDO CARLOS;;MACHADO ELWI;;ARANGUREN YANI,,https://lens.org/071-659-648-806-615,Patent Application,no,0,0,1,1,0,,B01L3/00;;A61B5/00;;G01N15/00;;G01N21/00;;G01N33/00,,0,0,,,,PENDING
152,ES,A1,ES 2176087 A1,186-172-062-345-01X,2002-11-16,2002,ES 200001680 A,2000-07-06,MX 9906308 A;;MX 9906309 A,1999-07-06,Disposable absorbent element with anti-leak system and procedure for its manufacture,"Disposable absorbent element with anti-leak system and procedure for its manufacture.Disposable absorbent element with anti-leak system and procedure for its manufacture.This invention relates to a disposable absorbent element with anti-leak system and procedure for its manufacture, such as a baby nappy, a disposable incontinence pad for adults, a sports training garment, or feminine sanitary towel, which has simultaneously placed and fixed during the manufacturing process of the disposable absorbent element, using extrusion, spraying, or soaking of the two longitudinal barriers of a waterproof material on the internal part of the permeable top layer, to both sides of the latter, so that when placing the top layer on the absorbent nucleus, the longitudinal internal barriers are formed. The barriers are joined completely by their eternal sides to the internal part of the top layer, whilst the internal part of the barriers along its top part is mounted on the absorbent nucleus; the middle part of the barriers is adjacent to the longitudinal edge of the absorbent nucleus at least in the section to be placed between the user's legs and the lower part of the barrier is adhered to the internal part of the waterproof lower layer. A complete anti-leak system is also created by the fact that the extruded internal longitudinal barriers act together with the external side barriers.<IMAGE>",GRUPO P I MABE SA DE C V,CORONA CARLOS ALBERTO;;SANCHES FERNANDEZ LUCIA;;CANALES ESPINOSA DE LOS MONTER;;GALVAN ACOSTA JUAN FRANCISCO;;GONZALEZ MARTINEZ RAUL;;TORRES HERRERA GUSTAVO,,https://lens.org/186-172-062-345-01X,Patent Application,no,3,2,5,5,0,,A61F13/475;;A61F13/494;;A61L15/42,,0,0,,,,EXPIRED
153,ES,B1,ES 2176087 B1,056-863-776-596-581,2004-01-16,2004,ES 200001680 A,2000-07-06,MX 9906308 A;;MX 9906309 A,1999-07-06,ARTICULO ABSORBENTE DESECHABLE CON SISTEMA ANTIESCURRIMIENTOS Y PROCEDIMIENTO PARA SU FABRICACION.,"Artículo absorbente desechable con sistema antiescurrimientos y proceso para su fabricación. La presente invención se refiere a un artículo absorbente desechable con sistema anti-escurrimientos y proceso para su fabricación, tal como un pañal desechable para bebés, un pañal desechable para adultos incontinentes, un calzón entrenador o una toalla sanitaria femenina, que tiene colocadas y fijadas de forma simultáneamente, durante el proceso de fabricación del artículo absorbente desechable, mediante extrusión, espreado o embarramiento de dos barreras longitudinales de un material impermeable sobre la parte interna de la capa superior permeable, a ambos lados de la misma, de modo que al colocar la capa superior sobre el núcleo absorbente, se forman las barreras internas longitudinales. Las barreras quedan unidas en su totalidad por su cara externa a la parte interna de la capa superior, mientras que la parte interna de las barreras en su parte superior queda montada sobre el núcleo absorbente,la parte media de barrera queda adyacente a la orilla longitudinal del núcleo absorbente al menos en la sección de entrepierna y la parte inferior de barrera queda adherida con la parte interna de la capa inferior impermeable. Se crea además un sistema integral anti-escurrimientos al actuar en conjunto las barreras internas longitudinales extruidas y las barreras laterales externas.",GRUPO P I MABE SA DE C V,CORONA CARLOS ALBERTO;;SANCHES FERNANDEZ LUCIA;;CANALES ESPINOSA DE LOS MONTER;;GALVAN ACOSTA JUAN FRANCISCO;;GONZALEZ MARTINEZ RAUL;;TORRES HERRERA GUSTAVO,,https://lens.org/056-863-776-596-581,Granted Patent,no,0,0,5,5,0,,A61F13/475;;A61F13/494;;A61L15/42,,0,0,,,,EXPIRED
154,EP,A4,EP 2857981 A4,193-815-125-538-514,2016-05-11,2016,EP 13801227 A,2013-06-04,ES 201200608 A;;ES 2013000134 W,2012-06-04,METHOD FOR GENERATING PIECEWISE-AFFINE MULTIVARIABLE FUNCTIONS WITH ON-LINE COMPUTATION OF THE SEARCH TREE AND DEVICE FOR IMPLEMENTING SAME,,UNIV SEVILLA;;CONSEJO SUPERIOR INVESTIGACION,ACOSTA JIMÉNEZ ANTONIO JOSÉ;;BATURONE CASTILLO ILUMINADA;;CASTRO RAMÍREZ JAVIER;;JIMÉNEZ FERNÁNDEZ CARLOS JESÚS;;BROX JIMÉNEZ PIEDAD;;MARTÍNEZ RODRÍGUEZ MACARENA CRISTINA,,https://lens.org/193-815-125-538-514,Search Report,no,0,0,7,7,0,G06F1/02;;G06F17/175;;G05B15/02;;G06F16/9027;;G06F16/9027;;G06F16/951;;G06F16/951;;G06F17/175;;G06N20/00;;G06N20/00,G06F17/17;;G06F1/02;;G06F17/30;;G06N99/00,,9,7,014-503-167-077-951;;011-599-497-847-533;;035-335-067-787-712;;115-132-167-327-537;;019-226-752-178-63X;;186-397-459-021-723;;110-966-557-299-112,10.1016/s0005-1098(02)00308-4;;10.1109/ecctd.2009.5274957;;10.1109/tcsii.2010.2040316;;10.1109/ecctd.2011.6043625;;10.1109/fpt.2011.6132696;;10.1109/tcsi.2013.2265962;;10.1109/tcst.2014.2345094,"P. TØNDEL ET AL: ""Evaluation of piecewise affine control via binary search tree"", AUTOMATICA, vol. 39, no. 5, May 2003 (2003-05-01), pages 945 - 950, XP055178937, ISSN: 0005-1098, DOI: 10.1016/S0005-1098(02)00308-4;;ALBERTO OLIVERI ET AL: ""Circuit implementation of piecewise-affine functions based on a binary search tree"", CIRCUIT THEORY AND DESIGN, 2009. ECCTD 2009. EUROPEAN CONFERENCE ON, IEEE, PISCATAWAY, NJ, USA, 23 August 2009 (2009-08-23), pages 145 - 148, XP031537950, ISBN: 978-1-4244-3896-9;;TOMASO POGGI: ""Circuit Implementation of Piecewise-Affine Functions and Applications"", PHD THESIS, 2010, Genoa, Italy, pages 1 - 163, XP055259821, Retrieved from the Internet <URL:http://ncas.dibe.unige.it/people/poggi/PhD_Thesis_Poggi_Tomaso.pdf> [retrieved on 20160318];;POGGI T ET AL: ""Digital Circuit Realization of Piecewise-Affine Functions With Nonuniform Resolution: Theory and FPGA Implementation"", IEEE TRANSACTIONS ON CIRCUITS AND SYSTEMS II: EXPRESS BRIEFS, IEEE, US, vol. 57, no. 2, February 2010 (2010-02-01), pages 131 - 135, XP011334162, ISSN: 1549-7747, DOI: 10.1109/TCSII.2010.2040316;;MARTINEZ-RODRIGUEZ M C ET AL: ""Circuit implementation of piecewise-affine functions based on lattice representation"", CIRCUIT THEORY AND DESIGN (ECCTD), 2011 20TH EUROPEAN CONFERENCE ON, IEEE, 29 August 2011 (2011-08-29), pages 644 - 647, XP031975636, ISBN: 978-1-4577-0617-2, DOI: 10.1109/ECCTD.2011.6043625;;MARTINEZ-RODRIGUEZ M C ET AL: ""Design methodology for FPGA implementation of lattice piecewise-affine functions"", FIELD-PROGRAMMABLE TECHNOLOGY (FPT), 2011 INTERNATIONAL CONFERENCE ON, IEEE, 12 December 2011 (2011-12-12), pages 1 - 4, XP032096847, ISBN: 978-1-4577-1741-3, DOI: 10.1109/FPT.2011.6132696;;PIEDAD BROX ET AL: ""A Programmable and Configurable ASIC to Generate Piecewise-Affine Functions Defined Over General Partitions"", IEEE TRANSACTIONS ON CIRCUITS AND SYSTEMS I: REGULAR PAPERS, vol. 60, no. 12, December 2013 (2013-12-01), US, pages 3182 - 3194, XP055259819, ISSN: 1549-8328, DOI: 10.1109/TCSI.2013.2265962;;MARTINEZ-RODRIGUEZ MACARENA CRISTINA ET AL: ""Digital VLSI Implementation of Piecewise-Affine Controllers Based on Lattice Approach"", IEEE TRANSACTIONS ON CONTROL SYSTEMS TECHNOLOGY, IEEE SERVICE CENTER, NEW YORK, NY, US, vol. 23, no. 3, May 2015 (2015-05-01), pages 842 - 854, XP011579046, ISSN: 1063-6536, [retrieved on 20150416], DOI: 10.1109/TCST.2014.2345094;;See also references of WO 2013182717A1",DISCONTINUED
155,WO,A1,WO 2013/182717 A1,028-172-796-521-685,2013-12-12,2013,ES 2013000134 W,2013-06-04,ES 201200608 A,2012-06-04,METHOD FOR GENERATING PIECEWISE-AFFINE MULTIVARIABLE FUNCTIONS WITH ON-LINE COMPUTATION OF THE SEARCH TREE AND DEVICE FOR IMPLEMENTING SAME,"The invention relates to a method for generating piecewise-affine multivariable functions, comprising the on-line computation of the search tree in order to locate the input value in the polytopes of the partition, and the subsequent generation of the corresponding affine function. The invention also relates to a configurable and programmable device for generating piecewise-affine multivariable functions, formed by an architecture having four functional blocks, namely a control unit block (1), a tree memory block, a parameter memory block and an arithmetic unit block, as well as having at least three operating modes that can be selected using different values of a bus (config): writing of the tree memory, writing of the parameter memory and evaluating the affine function. The device can also have a fourth operating mode, i.e. the test mode.",UNIV SEVILLA;;CONSEJO SUPERIOR INVESTIGACION,ACOSTA JIMENEZ ANTONIO JOSE;;BATURONE CASTILLO ILUMINADA;;CASTRO RAMIREZ JAVIER;;JIMENEZ FERNANDEZ CARLOS JESUS;;BROX JIMENEZ PIEDAD;;MARTINEZ RODRIGUEZ MACARENA CRISTINA,,https://lens.org/028-172-796-521-685,Patent Application,yes,0,0,7,7,0,G06F1/02;;G06F17/175;;G05B15/02;;G06F16/9027;;G06F16/9027;;G06F16/951;;G06F16/951;;G06F17/175;;G06N20/00;;G06N20/00,G06F17/00,,15,13,014-503-167-077-951;;006-866-052-551-994;;182-532-346-411-489;;055-566-327-761-134;;118-242-877-825-457;;055-043-657-808-81X;;003-264-261-705-438;;019-226-752-178-63X;;115-132-167-327-537;;109-260-195-322-978;;073-862-089-193-82X;;011-599-497-847-533;;014-503-167-077-951,10.1016/s0005-1098(02)00308-4;;10.1007/978-1-4615-4090-8_7;;10.1016/s0165-1684(00)00013-x;;10.1109/tie.2007.898292;;10.1109/tie.2007.896547;;10.1007/978-3-540-73400-0_30;;10.1002/cta.610;;10.1109/fpt.2011.6132696;;10.1109/ecctd.2011.6043625;;10.1109/isie.2011.5984382;;10.1109/tcst.2006.883206;;10.1109/ecctd.2009.5274957;;10.1016/s0005-1098(02)00308-4,"P. TØNDEL ET AL.: ""Evaluation of piecewise affine control via binary search tree"", AUTOMATICA, vol. 39, 1 May 2003 (2003-05-01), pages 945 - 950, XP055178937;;See also references of EP 2857981A4;;R. ROVATTI; A. FERRARI; M. BORGATTI: ""Fuzzy hardware: architectures and applications"", 1998, KLUWER ACADEMIC PUBLISHERS, article ""Automatic implementation of piecewise-linear fuzzy systems addressing memory-performance tradeoff"", pages: 159 - 179;;R. ROVATTI; C. FANTUZZI; S. SIMANI: ""High-speed DSP-based implementation of piecewise-affine and piecewise-quadratic fuzzy systems"", SIGNAL PROCESSING, vol. 80, 2000, pages 951 - 963;;S. SANCHEZ-SOIANO; A. CABRERA; I. BATURONE; F. J. MORENO-VELO; M. BROX: ""FPGA implementation of embedded fuzzy controllers for robotic applications"", IEEE TRANS. ON INDUSTRIAL ELECTRONICS, vol. 54, no. 4, August 2007 (2007-08-01), pages 1937 - 1945;;I. BATURONE; F. J. MORENO-VELO; V. BLANCO; J. FERRUZ: ""Design of embedded DSP-based fuzzy controllers for autonomous robots"", IEEE TRANS. ON INDUSTRIAL ELECTRONICS, vol. 55, February 2008 (2008-02-01), pages 928 - 936;;I. BATURONE; A. BARRIGA; S. SANCHEZ SOLANO; C.J. JIMENEZ FERNANDEZ; D.R. LOPEZ: ""Microelectronic design of fuzzy logic-based systems"", March 2000, CRC PRESS;;P. ECHEVARRIA; M. MARTINEZ; J. ECHANOBE; I. OF THE CAMPO; J. TARELA: ""Applications of Fuzzy Sets Theory, ser. Lecture Notes in Computer Science"", 2007, SPRINGER, article ""Digital hardware implementation of high dimensional fuzzy systems"", pages: 245 - 252;;M. STORACE; T. POGGI: ""Digital architectures realizing piecewise-linear multi-variate functions: two FPGA implementations"", INT. JOURNAL OF CIRCUIT THEORY AND APPLICATIONS, vol. 39, no. 1, 2011, pages 1 - 15;;M. C. MARTINEZ-RODRIGUEZ; I. BATURONE; P. BROX: ""Design Methodology for FPGA Implementation of Lattice Piecewise-Affine Functions"", PROC. 2011 INT. CONF. ON FIELD-PROGRAMMABLE TECHNOLOGY (FPT), NEW DELHI (INDIA, 14 December 2011 (2011-12-14), pages 1 - 4;;M. C. MARTINEZ-RODRIGUEZ; I. BATURONE; P. BROX: ""Circuit Implementation of Piecewise-Affine Functions Based on Lattice Representation"", PROCEEDINGS OF THE 2011 EUROPEAN CONFERENCE ON CIRCUIT THEORY AND DESIGN (ECCTD), LINK6PING, SWEDEN, 29 August 2011 (2011-08-29), pages 644 - 647;;I. BATURONE; M. C. MARTINEZ-RODRIGUEZ; P. BROX; A. GERSNOVIEZ; S. SANCHEZ-SOIANO: ""Digital implementation of hierarchical piecewise-affine controllers"", PROC. OF THE 21TH IEEE INTERNATIONAL SYMPOSIUM ON INDUSTRIAL ELECTRONICS (ISIE), GDARISK, POLAND, 27 June 2011 (2011-06-27), pages 1497 - 1502;;T. JOHANSEN; W. JACKSON; R. SCHREIBER; P. TONDEL: ""Hardware synthesis of explicit model predictive controllers"", IEEE TRANS. ON CONTROL SYSTEMS TECHNOLOGY, vol. 15, no. 1, January 2007 (2007-01-01), pages 191 - 197;;A. OLIVERI; T. POGGI; M. STORACE: ""Circuit implementation of piecewise-affine functions based on a binary search tree"", PROC. EUROPEAN CONFERENCE ON CIRCUIT THEORY AND DESIGN (ECCTD), ANTALYA (TURKEY, 23 August 2009 (2009-08-23), pages 145 - 148;;P. TONDEL; T. JOHANSEN; A. BEMPORAD: ""Evaluation of piecewise-affine control via binary search tree"", AUTOMATICA, vol. 39, no. 5, May 2003 (2003-05-01), pages 945 - 950",PENDING
156,DE,D1,DE 602006019458 D1,097-473-539-822-526,2011-02-17,2011,DE 602006019458 T,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,MODULATION DER TRPV-EXPRESSIONSMENGEN,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/097-473-539-822-526,Granted Patent,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
157,US,A1,US 2015/0301555 A1,020-746-251-495-500,2015-10-22,2015,US 201314405552 A,2013-06-04,ES 201200608 A;;ES 2013000134 W,2012-06-04,Method for Generating Piecewise-Affine Multivariable Functions with On-Line Computation of the Search Tree and Device for Implementing Same,"Method for generating piecewise-affine multivariate functions, wherein the online computation of the search tree is performed in order to locate the input value in the polytopes of the partition, and the subsequent generation of the corresponding affine function. It also proposes a configurable and programmable device for generating piecewise-affine multivariate functions composed of an architecture with four functional blocks namely: a control unit block ( 1 ), a tree memory block, a parameter memory block and an arithmetic unit block; and it has at least three operating modes which can be selected using different values of a bus (config): writing of the tree memory, writing of the parameter memory and evaluating the affine function. It may include a fourth operating mode, which is the test mode.",UNIV SEVILLA;;CONSEJO SUPERIOR INVESTIGACION,ACOSTA JIMENEZ ANTONIO JOSE;;BATURONE CASTILLO ILUMINADA;;CASTRO RAMIREZ JAVIER;;JIMENEZ FERNANDEZ CARLOS JESUS;;BROX JIMENEZ PIEDAD;;MARTINEZ RODRIGUEZ MACARENA CRISTINA,CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (2015-01-07);;UNIVERSIDAD DE SEVILLA (2015-01-07),https://lens.org/020-746-251-495-500,Patent Application,yes,2,3,7,7,0,G06F1/02;;G06F17/175;;G05B15/02;;G06F16/9027;;G06F16/9027;;G06F16/951;;G06F16/951;;G06F17/175;;G06N20/00;;G06N20/00,G06F1/02;;G05B15/02;;G06F17/30,,0,0,,,,INACTIVE
158,ES,T3,ES 2157060 T3,133-791-038-766-674,2001-08-01,2001,ES 97901516 T,1997-01-17,CU 1996010 A,1996-01-17,SISTEMA DE EXPRESION DE ANTIGENOS HETEROLOGOS COMO PROTEINAS DE FUSION.,"LA PRESENTE INVENCION SE REFIERE A LA BIOTECNOLOGIA Y A LA INGENIERIA GENETICA, ESPECIALMENTE A LA EXPRESION DE PROTEINAS HETEROLOGAS EN MICROORGANISMOS A TRAVES DE SU FUSION MEDIANTE LA APLICACION DE LA TECNOLOGIA DEL ADN RECOMBINANTE A LOS PEPTIDOS BACTERIANOS. LA PRESENTE INVENCION PROPORCIONA UN PROCEDIMIENTO EFICAZ PARA LA EXPRESION EN ESCHERICHIA COLI DE PROTEINAS HETEROLOGAS COMO POLIPEPTIDOS DE FUSION CON EL OBJETIVO DE OBTENER ESTAS CON UN ALTO GRADO DE PUREZA, EN CANTIDADES COMERCIALMENTE UTILES Y EN UNA FORMA APROPIADA PARA SU INCLUSION EN PREPARACIONES DE VACUNAS PREVISTAS PARA USO HUMANO. PARA ELLO, LO QUE SE UTILIZA ESENCIALMENTE ES UNA SECUENCIA ESTABILIZANTE DERIVADA DE LOS 47 PRIMEROS AMINOACIDOS DEL ANTIGENO P64K DE NEISSERIA MENINGITIDIS B:4:P1.15. EN PARTICULAR, SE UTILIZA UN PLASMIDO RECOMBINANTE QUE CONTIENE DICHA SECUENCIA BAJO EL CONTROL DEL PROMOTOR DEL TRIPTOFANO DE E. COLI Y DEL TERMINADOR DE LA TRANSCRIPCION DEL FAGO T4, INCLUYENDO LOS SITIOS DE RESTRICCION, QUEPROPORCIONA LA CLONACION EN FASE DE FRAGMENTOS DE ADN QUE CODIFICAN PARA LOS POLIPEPTIDOS DE INTERES. EL PROCEDIMIENTO DE LA INVENCION ES APLICABLE A LA INDUSTRIA FARMACEUTICA PARA EL DESARROLLO DE SISTEMAS DIAGNOSTICOS, PREPARACIONES DE VACUNA Y EN CUALQUIER SITUACION DONDE SE REQUIERA PARA OBTENER ELEVADAS CANTIDADES DE PROTEINAS HETEROLOGAS COMO POLIPEPTIDOS DE FUSION EN E. COLI.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA,,https://lens.org/133-791-038-766-674,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
159,ES,B1,ES 2458215 B1,007-929-293-904-940,2015-02-12,2015,ES 201200608 A,2012-06-04,ES 201200608 A,2012-06-04,Dispositivo para generar funciones multivariables afines a tramos con computación on-line del árbol de búsqueda,,UNIV SEVILLA;;CONSEJO SUPERIOR INVESTIGACION,ACOSTA JIMENEZ ANTONIO JOSÉ;;BATURONE CASTILLO MARÍA ILUMINADA;;CASTRO RAMIREZ JAVIER;;JIMENEZ FERNANDEZ CARLOS JESÚS;;BROX JIMENEZ PIEDAD;;MARTINEZ RODRIGUEZ MACARENA CRISTINA,,https://lens.org/007-929-293-904-940,Granted Patent,no,0,0,7,7,0,G06F1/02;;G06F17/175;;G05B15/02;;G06F16/9027;;G06F16/9027;;G06F16/951;;G06F16/951;;G06F17/175;;G06N20/00;;G06N20/00,G06F17/10,,0,0,,,,INACTIVE
160,SI,T1,SI 1937281 T1,023-718-812-124-752,2011-09-30,2011,SI 200630965 T,2006-10-20,GB 0521351 A;;GB 2006050342 W;;EP 06794999 A,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/023-718-812-124-752,Granted Patent,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/00;;A61P27/00;;C12N15/113,,0,0,,,,ACTIVE
161,EP,A2,EP 1937281 A2,063-252-195-375-271,2008-07-02,2008,EP 06794999 A,2006-10-20,GB 2006050342 W;;GB 0521351 A,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/063-252-195-375-271,Patent Application,yes,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
162,US,A1,US 2010/0286230 A1,176-250-353-735-42X,2010-11-11,2010,US 9042606 A,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL;;JIMENEZ GOMEZ MARIA CONCEPCION,SYLENTIS S.A.U (2008-06-19),https://lens.org/176-250-353-735-42X,Patent Application,yes,53,4,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61K31/7105;;A61P27/02;;C07H21/02;;C12N5/00;;C12N15/113,514 44 A;;536/24.5;;435/325,4,4,037-101-743-841-229;;018-351-655-903-314;;016-670-235-376-074;;004-876-714-261-109,10.1124/jpet.104.079855;;15615864;;10.1093/nar/gkg409;;12799446;;pmc162243;;10.1038/35078175;;11373658;;10.1016/s1046-2023(02)00023-3;;12054897,"Gavva et al. (J. of Pharmacology & Experimental Therapeutics 2005, Vol. 313:474-484).;;Grunweller, et al. (2003, Nuc. Acids Res., v.31 :3185-93).;;Bass (2001, Nature, v.411:428-9).;;Elbashir, et al. (2002, Methods, v.26 :199-213).",ACTIVE
163,PL,T3,PL 1937281 T3,000-594-689-873-873,2011-06-30,2011,PL 06794999 T,2006-10-20,GB 0521351 A;;EP 06794999 A;;GB 2006050342 W,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMÉNEZ GÓMEZ MARIA CONCEPCIÓN;;BELMONTE MARTINEZ CARLOS;;JIMÉNEZ ANTÓN ANA ISABEL,,https://lens.org/000-594-689-873-873,Patent Application,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/11;;C12N15/113,,0,0,,,,PENDING
164,AU,B2,AU 2006/305657 B2,087-739-408-112-56X,2011-10-20,2011,AU 2006/305657 A,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,Modulation of TRPV expression levels,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/ or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ISABEL JIMENEZ ANTON ANA;;CARMEN ACOSTA BOJ MARIA DEL;;CONCEPCION JIMENEZ GOMEZ MARIA;;CARLOS BELMONTE MARTINEZ;;ANGELA SESTO YAGUE;;JUANA GALLAR MARTINEZ,,https://lens.org/087-739-408-112-56X,Granted Patent,no,4,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,3,2,048-116-857-026-485;;018-351-655-903-314,10.1016/j.jmb.2005.03.011;;15843020;;10.1093/nar/gkg409;;12799446;;pmc162243,"SCHUBERT, S. et al. ""Local RNA Target Structure Influences siRNA Efficacy: Systematic Analysis of Intentionally Designed Binding Regions"" Journal of Molecular Biology. 2005. Vol. 348, No. 4, pages 883-893.;;CHRISTOPH, T. et al. "" RNA Interference Approaches for Target Validation in Pain Research"" Jornal of Neurochemistry. 2005. Vol. 94, No. Suppl.2, page 142;;GRUNWELLER, A. et al. ""Comparison of Different Antisense Strategies in Mammalian Cells Using Locked Nucleic Acids, 2'-0-methyl RNA, Phosphorothioates and Small Interfering RNA"". Nucleic Acids Research. 2003. Vol. 31, No. 12, pages 3185-3193",ACTIVE
165,US,B2,US 8354385 B2,075-705-998-379-254,2013-01-15,2013,US 9042606 A,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,Modulation of TRPV expression levels,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU;;BOJ MARIA DEL CARMEN ACOSTA;;MARTINEZ JUANA GALLAR;;YAGUE ANGELA SESTO;;MARTINEZ CARLOS BELMONTE;;ANTON ANA ISABEL JIMENEZ;;GOMEZ MARIA CONCEPCION JIMENEZ,BOJ MARIA DEL CARMEN ACOSTA;;MARTINEZ JUANA GALLAR;;YAGUE ANGELA SESTO;;MARTINEZ CARLOS BELMONTE;;ANTON ANA ISABEL JIMENEZ;;GOMEZ MARIA CONCEPCION JIMENEZ,SYLENTIS S.A.U (2008-06-19),https://lens.org/075-705-998-379-254,Granted Patent,yes,74,3,23,23,162,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,C12N15/113;;A61K48/00,514/44;;536/24.5;;536/24.31;;536/24.1,104,98,048-116-857-026-485;;037-101-743-841-229;;018-351-655-903-314;;016-670-235-376-074;;004-876-714-261-109;;024-791-615-880-37X;;054-717-576-027-490;;127-499-707-102-782;;029-841-616-932-068;;015-110-000-063-426;;051-790-948-257-863;;008-596-497-168-15X;;015-791-854-840-002;;026-906-570-644-874;;073-877-006-888-362;;017-948-174-671-191;;038-650-283-063-54X;;016-670-235-376-074;;037-881-958-632-918;;050-081-159-568-433;;068-055-612-027-809;;070-559-745-008-813;;036-341-427-408-956;;048-476-043-023-540;;061-959-179-393-580;;076-335-008-410-445;;007-473-082-027-180;;012-131-826-518-371;;013-637-266-289-148;;051-155-171-598-024;;085-536-450-369-315;;074-144-289-094-762;;011-180-431-880-08X;;070-485-518-615-77X;;003-553-403-022-183;;038-905-409-033-488;;006-969-066-512-437;;059-393-958-757-089;;034-469-385-219-320;;074-254-924-910-683;;094-818-911-071-776;;075-807-879-420-178;;014-212-840-212-085;;018-020-177-526-297;;057-628-171-622-974;;007-927-814-709-034;;094-447-689-125-285;;082-574-129-498-602;;019-813-393-689-185;;018-351-655-903-314;;074-260-569-859-262;;009-554-033-172-004;;006-985-077-371-81X;;005-769-478-094-873;;060-125-111-836-499;;015-006-559-510-258;;014-149-416-523-301;;001-233-720-196-173;;024-067-966-595-688;;020-322-866-684-253;;033-904-152-697-222;;134-212-771-085-289;;056-698-178-560-988;;021-394-716-962-587;;027-028-534-728-333;;005-787-067-218-228;;051-108-083-786-111;;016-094-939-365-290;;069-583-513-457-200;;047-755-491-547-132;;147-961-594-910-603;;074-082-840-909-599;;006-481-966-958-742;;128-718-535-034-368;;006-993-964-891-969;;022-079-725-465-829;;022-171-593-993-575;;044-691-797-011-307;;043-635-448-141-899;;108-440-308-249-554;;042-078-438-061-953;;063-572-417-149-193;;006-387-120-444-19X;;040-194-733-946-522;;006-985-077-371-81X;;038-542-876-994-157;;000-961-724-555-881;;098-345-430-281-439;;041-209-801-983-743;;006-212-893-997-904;;068-065-590-292-861;;006-218-654-219-563;;001-258-556-941-020;;024-804-360-750-433;;009-777-064-743-138;;037-049-705-363-283;;023-405-381-876-110;;008-552-200-019-416,10.1016/j.jmb.2005.03.011;;15843020;;10.1124/jpet.104.079855;;15615864;;10.1093/nar/gkg409;;12799446;;pmc162243;;10.1038/35078175;;11373658;;10.1016/s1046-2023(02)00023-3;;12054897;;16450253;;10.1097/ijg.0b013e31814b990d;;18344762;;8225868;;10.1016/j.bihy.2009.04.003;;8603880;;10.1002/cbic.200300708;;14523910;;10.1089/108729001753411326;;11838637;;10.1016/s0021-9258(19)85352-8;;7688725;;10752959;;15544492;;10.2174/1389201043376643;;10.1002/bies.10046;;11835276;;10.1517/17425247.5.5.567;;18491982;;10.1038/35078175;;11373658;;10.1016/j.exer.2005.01.028;;15862180;;15579465;;10.1074/jbc.m411233200;;pmc1483217;;10.1001/archopht.1965.00970040250024;;14318504;;12742391;;10.1016/s1350-9462(03)00018-1;;10655601;;10.1038/35000102;;11926811;;10.1021/bi0122112;;10.1126/science.1068999;;11910072;;8103041;;10.1007/s00417-004-1025-5;;15864617;;11401512;;10.1006/bbrc.2001.4624;;10.1073/pnas.171251798;;11481446;;pmc55523;;19359485;;pmc2678451;;10.1073/pnas.0812317106;;17768383;;10930321;;10.1006/exer.2000.0866;;7795397;;10.1177/112067219500500104;;10.1016/j.pharmthera.2008.04.002;;18562011;;pmc1771149;;10.1136/bjo.86.6.676;;12034692;;10.1038/sj.onc.1206920;;14647459;;pmc1940047;;16565384;;10.1167/iovs.05-0736;;10.1038/35078107;;11373684;;11726523;;10.1093/emboj/20.23.6877;;pmc125328;;11157775;;10.1101/gad.862301;;pmc312613;;3038771;;6783588;;10.1016/j.addr.2006.07.020;;17097190;;9486653;;10.1038/35888;;pmc147101;;10.1093/nar/25.22.4429;;9358149;;12594334;;pmc151407;;10.1073/pnas.0437841100;;11232238;;10.1023/a:1009664109241;;10670462;;10.1083/jcb.200111033;;11781331;;pmc2173595;;10.1093/nar/gkg409;;12799446;;pmc162243;;10.1038/35052556;;11253050;;15867947;;10.1111/j.1527-3466.2005.tb00156.x;;11224713;;10.1097/00055735-200104000-00002;;11935151;;10.1007/s00125-001-0747-8;;10.1016/j.lfs.2008.11.016;;19087880;;10.1046/j.1432-1033.2003.03555.x;;12694176;;15603251;;10.1097/00061198-199608000-00004;;8795767;;pmc314054;;10.1136/bmj.328.7431.97;;14715605;;pmc314518;;14726349;;10.1136/bmj.328.7432.156;;pmc1618707;;10.1016/s0002-9440(10)63267-1;;15579459;;434053;;10.1016/0002-9394(79)90191-0;;10.1038/nature04303;;16258535;;19279343;;10.1056/nejmra0804630;;pmc3700399;;3006859;;10.1111/j.1476-5381.1986.tb10827.x;;pmc1916554;;10.1007/bf02456527;;5092520;;10.1517/17425247.2.1.3;;16296732;;18155315;;pmc2293332;;10.1016/j.addr.2007.10.004;;10.1073/pnas.1231012100;;12782788;;pmc165852;;10.1016/s0014-5793(03)01505-9;;14759517;;10.1167/iovs.03-0934;;15671302;;7543465;;12749673;;10.1177/112067210301303s04;;10.1101/gad.981002;;pmc152352;;11959843;;10.1124/jpet.103.058669;;14600249;;11274082;;12789138;;12434301;;10.1076/ceyr.24.5.325.8519;;10.1038/nbt915;;14647331;;10942157;;10.1097/00005344-200008000-00005;;10.3109/02713689508998409;;7587308;;16552252;;pmc317199;;10617568;;10.1101/gad.13.24.3191;;pmc7094730;;10.1016/j.febslet.2005.08.004;;16115631;;11224713;;10.1097/00055735-200104000-00002;;18771873;;10.1016/j.jpba.2008.06.028;;16043860;;10.1167/iovs.05-0075;;10.1016/j.exer.2004.11.012;;15862169;;9192637;;10.1073/pnas.94.13.6752;;pmc21230;;pmc1319205;;10.1038/sj.embor.embor865;;12776180;;10.1038/35000016;;10655585;;10.1042/bst0250509;;9191145;;14740992;;10.1016/s0896-1549(03)00067-1;;10.1128/jvi.77.16.8957-8951.2003;;12885912;;pmc167245;;15120486;;10.1016/j.tips.2004.03.002;;pmc7108327;;16478693;;10.1016/s1359-6446(05)03668-8;;pmc53506;;10.1073/pnas.87.4.1516;;2154750;;10.1074/jbc.m307250200;;12890669,"Schubert et al. J. Mol. Biol. May 2005, vol. 348: 883-893.;;Gavva et al. (J. of Pharmacology & Experimental Therapeutics 2005, vol. 313:474-484).;;Grunweller, et al. (2003, Nuc. Acids Res., v.31 :3185-93).;;Bass (2001, Nature, v.411:428-9).;;Elbashir, et al. (2002, Methods, v.26 :199-213).;;Fattal et al., ""Antisense Oligonucleotides, Aptamers and siRNA: Promises for the Treatment of Ocular Disease,"" Arch. Soc. Esp. Oftalmol, 8(1), pp. 1-4, 2006.;;Ghate et al., ""Barriers to Glaucoma Drug Delivery,"" J. Glaucoma, 17(2), pp. 147-156, Mar. 2008.;;Gonzalez et al., ""Reduction of Capsaicin-Induced Ocular Pain and Neurogenic Inflammation by Calcium Antagonists,"" Investigative Ophthalmology & Visual Science, 34(12), pp. 3329-3335, Nov. 1993.;;Nie et al., ""The Potential Therapeutic of siRNA Eye Drops in Ocular Diseases,"" Bioscience Hypotheses, 2, pp. 223-225, 2009.;;Abrams et al., ""Comparison of Three Tonometers for Measuring Intraocular Pressure in Rabbits,"" Invest Ophthalmol Vis Sci. Apr. 1996, 37(5):940-944.;;Achenbach et al., Oligonucleotide-Based Knockdown Technologies: Antisense Versus RNA Interference, ChemBioChem., 4, pp. 928-935, 2003.;;Akashi et al., ""Suppression of Gene Expression by RNA Interference in Cultured Plant Cells,"" Antisense Nucleic Acid Drug Dev, 2001, 11(6):359-367.;;Amaratunga et al., ""Inhibition of Kinesin Synthesis and Rapid Anterograde Axonal Transport in Vivo by an Antisense Oligonucleotide,"" The Journal of Biological Chemistry, 268(23) pp. 17427-17430, Aug. 15, 1993.;;Ambati et al., ""Transscleral Delivery of Bioactive Protein to the Choroid and Retina,"" Investigative Ophthalmology & Visual Science, vol. 41, No. 5, pp. 1186-1191 , Apr. 2000.;;Ambion, ""The Basics: RNase Control,"" printout from website >, dated 2004, retrieved on Sep. 17, 2009.;;Ambion, Tech Notes 10(4) and siRNA Target Finder (http://www.ambion.com/techlib/misc/siRNA-finder.html, available to the public) retrieved on May 1, 2008, siRNA target hit for SEQ ID No. 139 included.;;Banan et al., ""The Ins and Outs of RNAi in Mammalian Cells,"" Current Pharmaceutical Biotechnology, 5, pp. 441-450, 2004.;;Banerjee et al., ""Control of Developmental Timing by Small Temporal RNAs: a Paradigm for RNA-mediated Regulation of Gene Expression,"" Bioessays, 2002, 24(2):119-129.;;Barar J. et al., ""Ocular novel drug delivery"" impacts of membranes and barriers, Expert Opin. Drug Deliv., 5(5): 567-81, 2008.;;Bass, ""The Short Answer,"" Nature, vol. 411, pp. 428-429, 2001.;;Bhattacharya et al., ""Cochlin Deposits in the Trabecular Meshwork of the Glaucomatous DBA/2J mouse,"" Exp Eye Res., May 2005 80(5):741-744.;;Bhattacharya et al., ""Proteomics Reveal Cochlin Deposits Associated with Glaucomatous Trabecular Meshwork,"" J. Biol. Chem., Feb. 2005b, 18;280(7):6080-6084, Epub Dec. 3, 2004.;;Bill, ""Movement of Albumin and Dextran,"" Arch. Opthal., vol. 74, pp. 248-252, Aug. 1965.;;Borrás, ""Gene Expression in the Trabecular Meshwork and the Influence of Intraocular Pressure,"" Progress in Retinal and Eye Research, 22, 435-463, 2003.;;Bosher et al., ""RNA Interference: Genetic Wand and Genetic Watchdog."" Nat Cell Biol, 2000, 2(2):E31-6.;;Braasch et al., ""Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,"" Biochemistry, 2002, 41(14):4503-4510.;;Brummelkamp et al., ""A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,"" Science, American Association for the Advancement of Science, 2002, 296(5567):550-553.;;Busch et al., ""Adenylyl Cyclase in Human and Bovine Trabecular Meshwork,"" Investigative Ophthalmology & Visual Science, 34(10), pp. 3028-3034, Sep. 1993.;;Bunce et al., ""Associations between the deletion polymorphism of the angiotensin 1-converting enzyme gene and ocular signs of primary open-angle glaucoma,"" Graefes Arch Clin Exp Ophthalmol., Apr. 2005 243(4):294-299. Epub Oct. 13, 2004.;;Caballero et al., ""Inefficient Processing of an Olfactomedin-Deficient Myocilin Mutant: Potential Physiological Relevance to Glaucoma,"" Biochemical and Biophysical Research Communications, 282, 662-670, 2001.;;Caplen et al., ""Specific inhibition of Gene Expression by Small Double Stranded RNAs in Invertebrate and Vertebrate Systems,"" Proc. Natl. Acad. Sci. USA, 2001,98: 9742-9747.;;Cho et al., ""Small Interfering RNA-Induced TLR3 Activation Inhibits Blood and Lymphatic Vessel Growth,"" PNAS, pp. 1-6, Dec. 5, 2008.;;Comes N. and Borrás T, ""Functional delivery of synthetic naked siRNA to the human trabecular meshwork in perfused organ cultures,"" Molec. Vision, 13: 1363-74, 2007.;;Costagliola et al., ""Effect of Oral Losartan Potassium Administration on Intraocular Pressure in Normotensive and Glaucomatous Human Subjects,"" Exp Eye Res., Aug. 2000, 71(2):167-171.;;Costagliola et al., ""Effect of Oral Captopril (SQ 14225) on Intraocular Pressure in Man,"" Eur. J. Opthalmol, Jan. 1995, 5(1):19-25.;;Crooke et al., ""Nucleotides in Ocular Secretions: Their Role in Ocular Physiology,"" Pharmacology & Therapeutics, 119, pp. 55-73, 2008.;;Cullinane et al., ""Renin-angiotensin System Expression and Secretory Function in Cultured human Ciliary Cody Nonpigmented Epithelium,"" Br J Ophthalmol. Jun. 2002, 86(6):6766-83.;;Denkert et al., ""Induction of G0/G1 Cell Cycle Arrest in Ovarian Carcinoma Cells by the Ant-Inflammatory Drug NS-398, but not by COX-2-Specific RNA Interference,"" Oncogene, 2003, 22:8653-8661.;;Diffen, DNA vs. RNA-Difference and Comparison, retrieved from > on May 21, 2009.;;Diskin et al., ""Detection of Differentially Expressed Glycogenes in Trabecular Meshwork of Eyes with Primary Open-Angle Glaucoma,"" Investigative Opthalmology & Visual Science, Apr. 2006, 47(4):1491-1499.;;Elabashir et al., ""Duplexes of 21-Nucleotide RNAs mediate RNA interference in Cultured Mammalian Cells,"" Nature, May 24, 2001, 411(6836):494-498.;;Elbashir et al., ""Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila melanogaster Embryo Lysate,"" EMBO Journal, vol. 20, No. 23, pp. 6877-6888, 2001.;;Elbashir et al., ""RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,"" Genes Dev, 2001, 15(2):188-200.;;Elena et al., ""Autoradiographic Localization of Beta-Adrenergic Receptors in Rabbit Eye,"" Investigative Ophthalmology & Visual Science, 28, pp. 1436-1441, Aug. 1987.;;Epstein et al., ""Effect of Iodoacetamide Perfusion on Outflow Facility and Metabolism of the Trabecular Meshwork,"" Invest. Ophthalmol. Vis. Sci., 625-631, May 1981.;;Fattal et al., ""Ocular Delivery of Nucleic Acids: Antisense Oligonucleotides, Aptamers and siRNA,"" Advanced Drug Delivery Reviews, 2006, 58:1203-1223.;;Fire et al., ""Potent and Specific Genetic Interference by Double Stranded RNA in a Caenorhabditis elegans,"" Nature, 1998, 391(6669):806-11.;;Freier et al., ""The Ups and Downs of Nucleic Acid Duplex Stability: Structure-Stability Studies on Chemically-Modified DNA:RNA Duplexes,"" Nucleic Acids Research, 25(22), pp. 4429-4443, 1997.;;Ge et al., ""RNA Interference of Influenza Virus Production by Directly Targeting mRNA for Degradation and Indirectly Inhibiting all Viral RNA Transcription,"" Proc Natl Acad Sci USA., 2003, 100(5):2718-2723.;;Gil et al., ""Induction of Apoptosis by the dsRNA-dependent Protein Kinase (PKR): Mechanism of Action,"" Apoptosis, 2000, 5(2):107-114.;;Gonzalez et al., ""Genes Upregulated in the Human Trabecular Meshwork in Response to Elevated Intraocular Pressure,"" Investigative Opthalmology & Visual Science, Feb. 2000, 41(2):352-361.;;Grosshans et al., ""Micro-RNAs: Small is Plentiful,"" J Cell Bioi, 2002, 156(1):17-21.;;Grunweller et al., ""Comparison of Different Antisense Strategies in Mammalian Cells Using Locked Nucleic Acids, 2' O-methyl RNA,"" Nucleic Acids Research, vol. 31, No. 12, pp. 3185-3193, Jun. 15, 2003.;;Hammond et al., ""Post-Transcriptional Gene Silencing by Double-Standed RNA,"" Nature, 2001, 2:110-119.;;Hara et al., ""Bunazosin, a Selective Alpha1-Adrenoceptor Antagonist, as an Anti-glaucoma Drug: Effects on Ocular Circulation and Retinal Neuronal Damage,"" Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.;;Herkel et al., ""Update on Topical Carbonic Anhydrase Inhibitors,"" Current Opinion in Ophthamology, Apr. 2001, 12(2):88-93.;;Hogeboom et al., ""Angiotensin Converting Enzyme Inhibiting Therapy is Associated with Lower Vitreous Vascular Endothelial Growth Factor Concentrations in Patients with Proliferative Diabetic Retinopathy,"" Diabetologia, vol. 45, pp. 203-209, 2002.;;Horinouchi et al., ""Pharmacological Evaluation of Ocular beta-Adrenoceptors in Rabbit by Tissue Segment Binding Method,"" Life Sciences, 84, pp. 181-187, 2009.;;Jens Kurreck, ""Antisense Technologies,"" Eur. J. Biochem., 270, pp. 1628-1644, 2003.;;Jens Kurreck, ""Antisense and RNA Interference Approaches to Target Validation in Pain Research,"" Current Opinion in Drug Discovery & Development, 7(2), pp. 179-187, 2004.;;Kaplan et al., ""Aqueous Humor Flow in Unilateral Carotid Stenosis,"" Journal of Glaucoma, 5, pp. 237-240, 1996.;;Khaw et al., ""Glaucoma-1: Diagnosis,"" BMJ, 2004a, 328:97-99.;;Khaw et al., ""Glaucoma-2: Treatment,"" BMJ, 2004, 328:156-158.;;Kim et al., ""Inhibition of Ocular Angiogenesis by Sirna Targeting Vascular Endothelial Growth Factor Pathway Genes Therapeutics Strategy for Herpetic Stromal Keratititis,"" American Journal of Pathology, Dec. 2004, 165(6):2177-285.;;Krohn et al., ""Transcorneal Flux of Topical Pilocarpine to the Human Aqueous,"" Am. J. Ophthalmol., 87(1), pp. 50-56, Jan. 1979, Abstract retrieved from > on Nov. 9, 2009.;;Krutzfeldt et al., ""Silencing of microRNAs in vivo with 'Antagomirs',"" Nature, 2005, 438(7068):685-689.;;Kwon et al., ""Primary Open-Angle Glaucoma,"" The New England Journal of Medicine, 360(11), pp. 1113-1124, Mar. 12, 2009.;;Lograno et al., ""Receptor-Responses in Fresh Human Ciliary Muscle,"" Br. J. Pharmac., 87, pp. 379-385, 1986.;;Madsen, ""Ocular Finding in 123 Patients with Proliferative Diabetic Retinopathy,"" Documenta Ophthalmologica, Advances in ophthalmology, May 14, 1971, 29(2):345-349.;;Mahato et al., ""Modulation of Gene Expression by Antisense and Antigene Oligodeoxynucleotides and Small Interfering RNA,"" Expert Opinion on Drug Delivery, Jan. 2005, 2(1):3-28.;;Meade et al., ""Enhancing the Cellular Uptake of siRNA Duplexes Following Noncovalent Packaging with Protein Transduction Domain Peptides,"" Advanced Drug Delivery Reviews, 60, pp. 530-536, 2008.;;Miller et al., ""Allele-specific Silencing of Dominant Disease Genes,"" Proceedings of the National Academy of Sciences of USA, Jun. 10, 2003, 100(12):7195-7200.;;Muratovska et al., ""Conjugate for Efficient Delivery of Short Interfering RNA (siRNA) into Mammalian Cells,"" FEBS Letters, 558, pp. 63-68, 2004.;;Okabe et al., ""Effect of Benzalkonium Chloride on Transscleral Drug Delivery,"" Investigative Ophthalmology & Visual Science, vol. 46, No. 2, pp. 703-708 , Feb. 2005.;;Olsen et al., ""Human Scleral Permeability: Effects of Age, Cryotherapy, Transscleral Diode Laser, and Surgical Thinning,"" Investigative Ophthalmology & Visual Science, vol. 36, No. 9. pp. 1893-1903, Aug. 1995.;;Osborne et al., ""Some Current Ideas on the Pathogenesis and the Role of Neuroprotection in Glaucomatous Optic Neuropathy,"" Eur J Ophthalmol., Apr. 2003, 13Suppl. 3:S19-26.;;Paddison et al., ""Short hairpin RNAs (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells,"" Genes Dev, 2002, 16(8):948-958.;;Pintor et al., ""Adenosine Tetraphosphate, Ap4, a Physiological Regulator of Intraocular Pressure in Normotensive Rabbit Eyes,"" The Journal of Pharmacology and Experimental Therapeutics, vol. 308, No. 2, pp. 468-473, 2004.;;Rao et al., ""Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632,"" Investigative Opthalmology & Visual Science, Apr. 2001, 42(5): 1029-1037.;;Reich et al., ""Small Interfering RNA (siRNA) Targeting VEGF effectively Inhibits Ocular Neovascularization in a Mouse Model,"" Molecular Vision, 2003, 9:210-216.;;Sakaguchi et al., ""Chymase and Angiotensin Converting Enzyme Activities in a Hamster Model of Glaucoma Filtering Surgery,"" Curr Eye Res., May 2002, 24(5):325-331.;;Scherer et al., ""Approaches for the Sequence-Specific Knockdown of mRNA,"" Nat. Biotechnology, 2003, 21(12):1457-1465.;;Shah et al., ""Oculohypotensive Effect of Angiotensin-Converting Enzyme Inhibitors in Acute and Chronic Models of Glaucoma,"" J Cardiovasc Pharmacol. Aug. 2000, 36(2):169-175.;;Stamer et al., ""Isolation and Culture of Human Trabecular Meshwork Cells by Extracellular Matrix Digestion,"" Current Eye Research, pp. 611-617, Jan. 10, 1995.;;Tan et al., ""Recent Developments in Understanding the Pathophysiology of Elevated Intraocular Pressure,"" Current Opinion in Opthalmology, vol. 17, pp. 168-174, 2006.;;Tuschl et al., ""Targeted mRNA degradation by double-stranded RNA in vitro,"" Genes Dev., 1999, 13(24):3191-3197.;;Uprichard et al., The Therapeutic Potential of RNA Interference, FEBS Letters, Oct. 31, 2005 579(26):5996-6007.;;U. Herkel et al, Update on topical carbonic anhydrase inhibitors, Curr. Opthalmol., vol. 12 (2), p. 88-93, Apr. 2001, XP002375306.;;Valls et al., ""Validation of a Device for Transcorneal Drug Permeation Measure,"" Journal of Pharmaceutical and Biomedical Analysis, 48, pp. 657-663, 2008.;;Vittal et al., ""Changes in Gene Expression by Trabecular Meshword Cells in Response to Mechanical Stretching,"" Investigative Opthalmology & Visual Science, Aug. 2005, 46(8):2857-2868.;;Wang et al., Effect of C5-088, an Angiotensin AT1 Receptor Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes, Exp Eye Res., May 2005 80(5):629-632. Epub Jan 4, 2005.;;Wax et al., ""Vacuolar H+ -ATPase in Ocular Ciliary Epithelium,"" Proc. Natl. Acad. Sci., vol. 94, pp. 6752-6757, Jun. 1997.;;Wetering et al., ""Specific Inhibition of Gene Expression Using a Stably Integrated, Inducible Small-Interfering-RNA Vector,"" EMBO Reports, Jun. 2003, 4(6):609-615.;;Wianny et al., ""Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development,"" Nat Cell Biol, 2000, 2(2):70-75.;;Williams BR, ""Role of the Double-Stranded RNA-activated Protein kinase (PKR) in Cell Regulation,"" Biochem Soc Trans, 1997, 25(2):509-513.;;Wirtz et al., ""The Genetic Loci of Open-Angle Glaucoma,"" Ophthalmol. Clin. North Am. 2003 16:505-514.;;Wiznerowicz et al., ""Conditional Suppression of Cellular Genes: Lentivirus Vector-Mediated Drug-Inducible RNA Interference,"" Journal of Virology, Aug. 2003, 77(16):8957-8961.;;Woodward et al., ""The Inflow and Outflow of Anti-Glaucoma Drugs,"" Trends in Pharmacological Sciences, May 2004, 25(5):238-241.;;Xie et al., ""Harnessing in vivo siRNA Delivery for Drug Discovery and Therapeutic Development,"" Drug Discovery Today, Jan. 2006, 11(1-2):67-73.;;Yang-Feng et al., ""Chromosomal Organization of Adrenergic Receptor Genes,"" PNAS, 1990, 87:1516-1520.;;Yang et al., ""Early Growth Response Gene 1 Modulates Androgen Receptor Signaling in Prostate Carcinoma Cells,"" The Journal of Biological Chemistry, 278(41), pp. 39906-39911, 2003.;;Office Action dated Jul. 14, 2008 in corresponding U.S. Appl. No. 11/360,305.;;Office Action dated Jan. 29, 2009 in corresponding U.S. Appl. No. 11/360,305.;;Office Action dated Nov. 12, 2008 in corresponding U.S. Appl. No. 11/574,169.",ACTIVE
166,DK,T3,DK 1937281 T3,136-997-273-172-14X,2011-05-02,2011,DK 06794999 T,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,Modulering af TRPV-ekspressionsniveauer,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/136-997-273-172-14X,Granted Patent,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
167,AU,A1,AU 2006/305657 A1,106-211-263-625-699,2007-04-26,2007,AU 2006/305657 A,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,Modulation of TRPV expression levels,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ANTON ANA ISABEL JIMENEZ;;BOJ MARIA DEL CARMEN ACOSTA;;GOMEZ MARIA CONCEPCION JIMENEZ;;MARTINEZ CARLOS BELMONTE;;YAGUE ANGELA SESTO;;MARTINEZ JUANA GALLAR,,https://lens.org/106-211-263-625-699,Patent Application,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
168,CO,A1,CO 2022011606 A1,125-513-450-086-232,2024-02-26,2024,CO 2022011606 A,2022-08-17,CO 2022011606 A,2022-08-17,Método para medir e identificar entes biológicos a partir del aumento de la sensibilidad de la dispersión de luz láser,"El método propuesto, provee una solución al problema planteado a partir del uso de nanopartículas metálicas que se adhieren a los entes biológicos que serán objeto de análisis, recubriéndolos, disminuyendo su transmisión y aumentando su reflexión. Ello permite, conociendo el tamaño de la nanopartícula, calcular de manera exacta el tamaño del ente biológico al que se adhiere.",UNIV SIMON BOLIVAR,PACHECO LUGO LISANDRO ALFONSO;;NAVARRO QUIROZ ELKIN ANTONIO;;ACOSTA HOYOS ANTONIO;;GALÁN FREYLE NATALY;;PACHECO LONDOÑO LEONARDO CARLOS;;DÍAZ MAURICIO;;BELLO YESIT,,https://lens.org/125-513-450-086-232,Patent Application,no,0,0,1,1,0,,G01N21/00;;G01N15/00;;G01N33/00;;G01S13/00,,0,0,,,,PENDING
169,CA,C,CA 2626181 C,185-412-668-272-672,2014-03-18,2014,CA 2626181 A,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/ or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/185-412-668-272-672,Granted Patent,no,0,0,23,23,162,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
170,CN,A,CN 113574322 A,031-047-965-340-945,2021-10-29,2021,CN 202080024133 A,2020-03-18,ES 201930269 A;;EP 2020057393 W,2019-03-25,HOB AND METHOD,"A hob (1) comprising a top sheet (2) comprising an electric cooking zone (4a -4d), a port (7a) and a gas burner (9) arranged on the top sheet (2) and releasably connected to the port (7a), the port (7a) being configured to supply the gas burner (9) with fuel gas.",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;JUSTE PALLARES JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/031-047-965-340-945,Patent Application,no,7,0,4,4,0,F24C7/067;;F24C15/10;;F24C3/085;;F24C3/126;;F24C1/04;;F24C15/2042;;F24C3/08;;F24C7/06;;F24C15/007;;F24C1/04;;F24C1/04,F24C3/08;;F24C1/04;;F24C3/12;;F24C7/06;;F24C15/10,,0,0,,,,PENDING
171,JP,A,JP 2013074902 A,116-917-081-137-00X,2013-04-25,2013,JP 2013007528 A,2013-01-18,GB 0521351 A,2005-10-20,CONTROL OF LEVEL OF TRPV EXPRESSION,"PROBLEM TO BE SOLVED: To provide a means for the treatment and/or prevention of the condition that contains the abnormality of eyes and follicle and relates to TRPV1 of a high level.SOLUTION: To interfere in one or two or more splicing forms of the mRNA expression of a TRPV1 gene is targeted, and can be caused by the use of a double stranded nucleic acid component called siNA or a low molecular weight interference NA. A modified nucleic acid that is siNA and desirably siRNA or a similar chemical compound is included in the range.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/116-917-081-137-00X,Patent Application,no,4,0,23,23,162,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,C12N15/113;;A61K31/7105;;A61K31/712;;A61K31/7125;;A61K31/713;;A61P27/02;;A61P43/00,,0,0,,,,PENDING
172,EP,A1,EP 3948085 A1,044-137-651-360-522,2022-02-09,2022,EP 20713234 A,2020-03-18,ES 201930269 A;;EP 2020057393 W,2019-03-25,HOB AND METHOD,,BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;JUSTE PALLARES JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/044-137-651-360-522,Patent Application,yes,0,0,4,4,0,F24C7/067;;F24C15/10;;F24C3/085;;F24C3/126;;F24C1/04;;F24C15/2042;;F24C3/08;;F24C7/06;;F24C15/007;;F24C1/04;;F24C1/04,F24C3/08;;F24C1/04;;F24C3/12;;F24C7/06;;F24C15/10,,0,0,,,,PENDING
173,HK,A1,HK 1120741 A1,105-115-032-508-894,2009-04-09,2009,HK 08113880 A,2008-12-23,GB 2006050342 W;;GB 0521351 A,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS TRPV,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/105-115-032-508-894,Patent Application,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K/;;A61P/;;C12N15/113,,0,0,,,,PENDING
174,CY,T1,CY 1111384 T1,138-155-425-673-51X,2015-08-05,2015,CY 111100350 T,2011-04-05,EP 06794999 A;;GB 0521351 A,2005-10-20,ΔΙΑΜΟΡΦΩΣΗ ΤΩΝ ΕΠΙΠΕΔΩΝ ΕΚΦΡΑΣΗΣ TOY TRPV,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMÉNEZ GÓMEZ MARIA CONCEPCIÓN;;BELMONTE MARTINEZ CARLOS;;JIMÉNEZ ANTÓN ANA ISABEL,,https://lens.org/138-155-425-673-51X,Granted Patent,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
175,ES,T3,ES 2323080 T3,039-101-028-430-925,2009-07-06,2009,ES 05729588 T,2005-03-18,CU 20040051 A,2004-03-18,COMPOSICIONES VACUNALES OBTENIDAS A PARTIR DE STREPTOMYCES.,"La presente invención se relaciona con el campo de la inmunología, específicamente con el control de enfermedades infecciosas causadas por micobacterias, basado en el uso de vacunas para la prevención de estas enfermedades. Con la presente invención se desarrollaron vacunas basadas en el uso de cepas vivas de Streptomyces expresando o no antígenos de M. tuberculosis, las cuales demostraron su capacidad protectora frente al reto con BCG y M. tuberculosis después de ser administradas por distintas vías. Forma parte de la presente invención el uso de cepas de Streptomyces para la expresión de antígenos heterólogos de interés vacunal.",INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,SARMIENTO GARCIA SAN MIGUEL MARIA ELENA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD,,https://lens.org/039-101-028-430-925,Granted Patent,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,0,0,,,,ACTIVE
176,ES,T3,ES 2358538 T3,149-599-132-979-730,2011-05-11,2011,ES 06794999 T,2006-10-20,GB 0521351 A,2005-10-20,MODULACION DE NIVELES DE EXPRESION DE TRPV.,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/149-599-132-979-730,Granted Patent,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
177,ES,A1,ES 2784539 A1,002-498-032-439-952,2020-09-28,2020,ES 201930269 A,2019-03-25,ES 201930269 A,2019-03-25,"Countertop and method (Machine-translation by Google Translate, not legally binding)","The present invention refers to a hob (1), which comprises a top plate (2) comprising an electric cooking zone (4a-4d), a port (7a), and a gas burner (9) arranged on top plate (2) and detachably connected to port (7a), where port (7a) is configured to supply gas (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA SA;;BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;JUSTE PALLARES JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/002-498-032-439-952,Patent Application,no,4,0,4,4,0,F24C7/067;;F24C15/10;;F24C3/085;;F24C3/126;;F24C1/04;;F24C15/2042;;F24C3/08;;F24C7/06;;F24C15/007;;F24C1/04;;F24C1/04,F24C3/08;;F24C7/06;;F24C15/00,,0,0,,,,DISCONTINUED
178,PT,E,PT 1937281 E,038-165-711-429-765,2011-03-29,2011,PT 06794999 T,2006-10-20,GB 0521351 A,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,BOJ MARIA DEL CARMEN ACOSTA;;MARTINEZ JUANA GALLAR;;YAGUE ANGELA SESTO;;GOMEZ MARIA CONCEPCION JIMENEZ;;MARTINEZ CARLOS BELMONTE;;ANTON ANA ISABEL JIMENEZ,,https://lens.org/038-165-711-429-765,Granted Patent,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
179,AT,T1,AT E493994 T1,033-755-903-334-881,2011-01-15,2011,AT 06794999 T,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,MODULATION DER TRPV-EXPRESSIONSMENGEN,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GAMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTAN ANA ISABEL,,https://lens.org/033-755-903-334-881,Granted Patent,no,0,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,C12N15/113,,0,0,,,,ACTIVE
180,WO,A1,WO 2020/193299 A1,093-855-687-192-43X,2020-10-01,2020,EP 2020057393 W,2020-03-18,ES 201930269 A,2019-03-25,HOB AND METHOD,"A hob (1) comprising a top sheet (2) comprising an electric cooking zone (4a -4d), a port (7a) and a gas burner (9) arranged on the top sheet (2) and releasably connected to the port (7a), the port (7a) being configured to supply the gas burner (9) with fuel gas.",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;JUSTE PALLARES JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/093-855-687-192-43X,Patent Application,yes,5,0,4,4,0,F24C7/067;;F24C15/10;;F24C3/085;;F24C3/126;;F24C1/04;;F24C15/2042;;F24C3/08;;F24C7/06;;F24C15/007;;F24C1/04;;F24C1/04,F24C3/08;;F24C1/04;;F24C3/12;;F24C7/06;;F24C15/10,,0,0,,,,PENDING
181,EP,B1,EP 1937281 B1,168-296-199-569-93X,2011-01-05,2011,EP 06794999 A,2006-10-20,GB 2006050342 W;;GB 0521351 A,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU,ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/168-296-199-569-93X,Granted Patent,yes,4,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,4,0,,,"CHRISTOPH T ET AL: ""RNA interference approaches for target validation in pain research"" JOURNAL OF NEUROCHEMISTRY, vol. 94, no. Suppl. 2, August 2005 (2005-08), page 142, XP002429499 & 20TH BIENNIAL MEETING OF THE INTERNATIONAL-SOCIETY-FOR-NEUROCHEMISTRY /EUROPEAN-SOCIETY-FOR-NEUROCHEM; INNSBRUCK, AUSTRIA; AUGUST 21 -26, 2005 ISSN: 0022-3042;;GRÜNWELLER A ET AL: ""Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA"" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 31, no. 12, 15 June 2003 (2003-06-15), pages 3185-3193, XP002286510 ISSN: 0305-1048;;SCHUBERT S ET AL: ""Local RNA Target Structure Influences siRNA Efficacy: Systematic Analysis of Intentionally Designed Binding Regions"" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 348, no. 4, 13 May 2005 (2005-05-13), pages 883-893, XP004849589 ISSN: 0022-2836;;CHRISTOPH ET AL: ""Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo"" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 350, no. 1, 10 November 2006 (2006-11-10), pages 238-243, XP005676323 ISSN: 0006-291X",ACTIVE
182,ES,A1,ES 2393869 A1,048-874-381-174-935,2012-12-28,2012,ES 200931298 A,2009-12-30,EP 09382275 A,2009-12-10,"Domestic appliance with control handle. (Machine-translation by Google Translate, not legally binding)","Domestic appliance with control handle. To perfect a domestic appliance having a functional field (10) and at least one control handle (20; 20 '), installed in the functional field area (10), with a base (24; 24') and a front side (22; 22 '), in such a way that the control handle (20; 20') remains uninfluenced by the operation of the functional field, in particular, it is not heated through the operation of the functional field, it is proposed that the front side (22; 22 ') of the control handle (20; 20') - is arranged in a plane with the surface (12) of the functional field (10), or - is displaced with respect to the plane of the surface (12) of the functional field (10) in the direction towards the base (24; 24 '). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/048-874-381-174-935,Patent Application,no,5,0,2,2,0,F24C3/124;;G05G1/087,G05G1/08;;F24C3/12,,0,0,,,,ACTIVE
183,ES,B1,ES 2393869 B1,160-591-545-233-971,2013-11-12,2013,ES 200931298 A,2009-12-30,EP 09382275 A,2009-12-10,APARATO DOMESTICO CON MANILLA DE MANDO.,,BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/160-591-545-233-971,Granted Patent,no,0,0,2,2,0,F24C3/124;;G05G1/087,G05G1/08;;F24C3/12,,0,0,,,,ACTIVE
184,WO,A1,WO 2020/193300 A1,051-645-860-778-612,2020-10-01,2020,EP 2020057395 W,2020-03-18,ES 201930270 A,2019-03-25,GAS HOB,"A gas hob (1) comprising a top sheet (2), a port (6a), a gas burner (7) arranged on the top sheet (2) and releasably connected to the port (6a), the port (6a) being configured to supply the gas burner (7) with fuel gas, and an extraction unit (10) configured to extract fumes, the extraction unit (10) being retractable into the top sheet (2).",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;KLEINLEIN PHILIPP;;LOPEZ ORTIZ ALBERTO;;MARSCH ALEXANDER;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/051-645-860-778-612,Patent Application,yes,5,1,4,4,0,F24C15/2042;;F24C15/2092;;F24C3/126;;F24C3/085;;F24C15/001;;F24C3/082;;F23K5/005;;F23K5/007;;F24C3/008;;F24C3/085;;F24C15/107;;F24C15/2042;;F24C15/2092,F24C3/12;;F24C3/08;;F24C15/20,,0,0,,,,PENDING
185,EP,A1,EP 2267372 A1,044-704-256-245-020,2010-12-29,2010,EP 10166082 A,2010-06-16,ES 200930577 A;;EP 09382103 A;;EP 10166082 A,2009-06-25,Gas cooking hob,"Die Erfindung betrifft ein Gaskochfeld mit zumindest einem Gasbrenner (1) sowie einer Kochfeld-Abdeckung (7), zwischen der und einem Kochfeld-Boden (11) zumindest ein, insbesondere elektrisch betätigbares Funktionselement (17, 19) angeordnet ist, das mittels eines Wärmeschutzelements (29) vor thermischer Beschädigung während des Gasbrenner-Betriebs geschützt ist. Erfindungsgemäß ist das Wärmeschutzelement (29) mit der von einer Sichtseite der Abdeckung (7) abgewandten Unterseite (31) der Abdeckung (7) in Anlage und/oder daran befestigt.
",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/044-704-256-245-020,Patent Application,yes,11,4,2,3,0,F24C3/126;;F24C15/101;;F24C15/34,F24C15/34;;F24C3/12;;F24C15/10,,0,0,,,,ACTIVE
186,ES,A1,ES 2384716 A1,146-352-671-315-50X,2012-07-11,2012,ES 200930577 A,2009-08-07,EP 09382103 A,2009-06-25,"Cooking field to gas. (Machine-translation by Google Translate, not legally binding)","Gas cooking range. The invention relates to a gas cooking field with at least one gas burner (1), as well as a cooking field cover (7), between which and a cooking field base (11) is arranged at less a functional element (17, 19), in particular, electrically operable, which is protected by a thermal protection element (29) against thermal deterioration during operation of the gas burner. According to the invention, the thermal protection element (29) is in contact with and/or is fixed to the underside (31) of the cover (7) set aside from a viewing side of the cover (7). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALMARES ALMUDENA,,https://lens.org/146-352-671-315-50X,Patent Application,no,5,0,1,3,0,F24C3/126,F24C3/12;;F24C15/10;;F24C15/34,,0,0,,,,DISCONTINUED
187,ES,T3,ES 2605613 T3,035-859-044-573-719,2017-03-15,2017,ES 10173940 T,2010-08-25,ES 200930831 A;;EP 09382167 A,2009-09-09,Campo de cocción de gas así como cocina de gas con campo de cocción de gas correspondiente,"Campo de cocción de gas (100'), que comprende: - al menos una superficie de soporte (50) de vidrio o vitrocerámica, - al menos un quemador de gas para la preparación de al menos una llama, en el que el quemador de gas está dispuesto, al menos por secciones, en una escotadura de la superficie de soporte (50), - un soporte de fijación de toberas (30), que soporta una tobera de quemador (32), - una cubeta de cocción dispuesta debajo de la superficie de soporte (50), - al menos un dispositivo de protección del calor (10') dispuesto entre la llama y la superficie de soporte (50) para evitar un recalentamiento de la superficie de soporte (50) en la zona de la llama y - al menos un elemento de fijación (40', 40'') para la fijación del dispositivo de protección del calor (10) en la superficie de soporte (50), en el que - el elemento de fijación (40', 40'') está en contacto directo y/o está unido directamente con el dispositivo de protección del calor (10'), - el campo de cocción de gas (100') presenta como elemento de fijación (40', 40'') al menos un elemento de sujeción (40, 40''), que fija el dispositivo de protección del calor (10') en la superficie de soporte (50) y se extiende a través de la escotadura de la placa de soporte (50) en la dirección de la cubeta de cocción, - el campo de cocción de gas (100') presenta de forma complementaria al elemento de sujeción (40') que se extiende a través de la escotadura de la superficie de soporte (50) al menos un elemento de sujeción (40'') que se extiende esencialmente horizontal, que está dispuesto al menos por secciones en el lado inferior (56), alejado del dispositivo de protección del calor (10'), de la superficie de soporte (50) y al menos por secciones entre el dispositivo de protección del calor (10') y un soporte de fijación de las toberas (30) del quemador de gas, que está dispuesto debajo del dispositivo de protección del calor (10') y configurado para la fijación de una tobera de quemador (32), y - el elemento de sujeción (40''), que se extiende esencialmente horizontal, colabora con el elemento de sujeción (40'), que se extiende a través de la escotadura de la superficie de soporte (50), de tal manera que sobre el dispositivo de protección del calor (10') actúa una fuerza dirigida en la dirección de la superficie de soporte (50), caracterizado porque - el elemento de sujeción (40'), que se extiende a través de la escotadura de la superficie de soporte (50), se forma por al menos dos patas de sujeción (40') distanciadas entre sí, asociadas al dispositivo de protección del calor (10') y que se extienden en la dirección de la cubeta de cocción, y - el elemento de sujeción (40'') que se extiende esencialmente horizontal para la recepción de las patas de sujeción (40') presenta, respectivamente, una escotadura (42) con al menos una zona (44) que rodea las escotaduras (42), en el que las escotaduras (42) y las zonas (44) que rodean las escotaduras (42) están configuradas de tal forma que - las zonas (42) que rodean las escotaduras (42) se pueden colocar sobre las patas de sujeción (40'), en particular se pueden presionar en las patas de sujeción (40') y - las zonas (44) que rodean las escotaduras (42), colocadas sobre las patas de sujeción (40'), son giratorias en la dirección de las escotaduras (42), de manera que las patas de sujeción (40') se disponen en las escotaduras (42).",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/035-859-044-573-719,Granted Patent,no,0,0,2,5,0,F23D2900/14064;;F23D14/06;;F24C3/085;;F24C15/10,F24C3/08,,0,0,,,,ACTIVE
188,EP,A1,EP 3948086 A1,067-596-796-490-528,2022-02-09,2022,EP 20713235 A,2020-03-18,ES 201930270 A;;EP 2020057395 W,2019-03-25,GAS HOB,,BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;KLEINLEIN PHILIPP;;LOPEZ ORTIZ ALBERTO;;MARSCH ALEXANDER;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/067-596-796-490-528,Patent Application,yes,0,0,4,4,0,F24C15/2042;;F24C15/2092;;F24C3/126;;F24C3/085;;F24C15/001;;F24C3/082;;F23K5/005;;F23K5/007;;F24C3/008;;F24C3/085;;F24C15/107;;F24C15/2042;;F24C15/2092,F24C3/08;;F24C3/12;;F24C15/20,,0,0,,,,PENDING
189,ES,A2,ES 2397899 A2,118-497-839-472-392,2013-03-12,2013,ES 201031650 A,2010-11-10,ES 201031650 A,2010-11-10,"Gas rotary switch and cooking point with said switch (Machine-translation by Google Translate, not legally binding)","Gas rotary switch and cooking point with said switch. Gas rotary switch (1) with a piezoelectric element (4), and a casing (5) rotatable about an axis (3), and movable in the direction of the axis (3), next to which a toothed surface is provided ( 2), where, by pressing the housing (5) inward in the direction of the axis (3), a tension between the piezoelectric element (4) and the toothed surface (2), and a rotation of the housing (5) in the pressed-in state causes an alternative stress of the piezoelectric element (4) and, with it, an alternative electrical voltage next to the piezoelectric element (4), which is transmissible at a spark gap. (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA,PALACIOS VALDUEZA LUIS ANTONIO;;LOPEZ ORTIZ ALBERTO;;HERRERA ESTRADA PEDRO;;DE CARLOS NEGRO AINHOA;;ACOSTA HERRERO LUIS;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/118-497-839-472-392,Patent Application,no,0,0,4,4,0,,F24C3/10;;F23Q3/00,,0,0,,,,ACTIVE
190,EP,B1,EP 2267372 B1,035-546-698-077-071,2019-03-06,2019,EP 10166082 A,2010-06-16,ES 200930577 A;;EP 09382103 A;;EP 10166082 A,2009-06-25,Gas cooking hob,,BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/035-546-698-077-071,Granted Patent,yes,8,0,2,3,0,F24C3/126;;F24C15/34;;F24C15/101,F24C3/12;;F24C15/34;;F24C15/10,,0,0,,,,ACTIVE
191,EP,A3,EP 2295868 A3,154-787-239-389-502,2013-01-09,2013,EP 10173940 A,2010-08-25,ES 200930831 A;;EP 09382167 A;;EP 10173940 A,2009-09-09,Gas range and gas hob with associated gas range,"Um ein Gaskochfeld (100; 100'; 100"") aufweisend 
- mindestens eine tragende Fläche (50) aus Glas oder Glaskeramik, 
- mindestens einen Gasbrenner zur Bereitstellung mindestens einer Flamme, 
- mindestens eine zwischen der Flamme und der tragenden Fläche (50) angeordnete Wärmeschutzvorrichtung (10; 10'; 10"") zum Verhindern einer Überhitzung der tragenden Fläche (50) im Bereich der Flamme und 
- mindestens ein Fixierelement (40; 40', 40""; 40""') zur Befestigung der Wärmeschutzvorrichtung (10; 10'; 10"") an der tragenden Fläche (50) 
 
sowie einen Gasherd mit mindestens einem vorgenannten Gaskochfeld (100; 100'; 100"") so weiterzubilden, dass die Wärmeschutzvorrichtung (10; 10'; 10"") besonders dicht an der tragenden Fläche des Gaskochfelds anliegt, wird vorgeschlagen, dass das Fixierelement (40; 40', 40""; 40""') mit der Wärmeschutzvorrichtung (10; 10'; 10"") direkt in Kontakt steht und/oder direkt verbunden ist.
",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/154-787-239-389-502,Search Report,yes,4,1,3,5,0,F24C3/085,F24C3/08,,0,0,,,,ACTIVE
192,ES,A1,ES 2784618 A1,017-358-905-837-790,2020-09-29,2020,ES 201930270 A,2019-03-25,ES 201930270 A,2019-03-25,"GAS HOB (Machine-translation by Google Translate, not legally binding)","Gas hob. The present invention refers to a gas hob (1), which comprises an upper plate (2), a port (6a), a gas burner (7) arranged on the upper plate (2) and detachably connected to the port (6a), where the port (6a) is configured to supply fuel gas to the gas burner (7), and an extraction unit (10) configured to extract vapors, where the extraction unit (10) is retractable to the inside the top plate (2). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA SA;;BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;KLEINLEIN PHILIPP;;LOPEZ ORTIZ ALBERTO;;MARSCH ALEXANDER;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,,https://lens.org/017-358-905-837-790,Patent Application,no,4,0,4,4,0,F24C15/2042;;F24C15/2092;;F24C3/126;;F24C3/085;;F24C15/001;;F24C3/082;;F23K5/005;;F23K5/007;;F24C3/008;;F24C3/085;;F24C15/107;;F24C15/2042;;F24C15/2092,F24C15/00;;F24C3/08,,0,0,,,,DISCONTINUED
193,EP,A3,EP 2295867 A3,019-870-573-275-79X,2017-12-06,2017,EP 10173934 A,2010-08-25,ES 200930832 A;;EP 09382168 A;;EP 10173934 A,2009-09-09,Gas range and gas stove with associated gas range,"Um ein Gaskochfeld (100; 102; 100'; 102'), aufweisend 
- ein Gehäuse mit mindestens einer Bodenfläche (40) und mindestens einer die Bodenfläche (40) umrandenden Seitenfläche, 
- mindestens eine auf der Seitenfläche angeordnete und zum Abdecken des Gehäuses ausgebildete Abdeckfläche (50) aus Glas oder Glaskeramik und 
- mindestens einen Gasbrenner mit mindestens einem an der Abdeckfläche (50) mechanisch befestigten Bereich (72), sowie einen Gasherd mit mindestens einem vorgenannten Gaskochfeld (100; 102; 100'; 102') so weiterzubilden, dass die Düsenhalterung (70; 70') flexibel gegenüber Montageintoleranzen des Gaskochfelds (100; 102; 100'; 102') sowie gegenüber, beispielsweise durch Gasexplosionen des Gasbrenners verursachten, Druckschwankungen ist und dennoch auf einfache Weise zuverlässig im Gaskochfeld (100; 102; 100'; 102') befestigbar ist, wird vorgeschlagen, dass der Gasbrenner mindestens eine zur Halterung einer Brennerdüse (60) ausgebildete Düsenhalterung (70; 70') aufweist, wobei die Düsenhalterung (70; 70') mindestens einen am Gehäuse befestigten Bereich (76; 76') aufweist, der mittels mindestens eines mechanischen Fixierelements (10, 20, 30; 10, 20, 32; 10', 20, 30; 10', 20, 32) mit horizontalem Spiel am Gehäuse befestigt ist, wobei das Fixierelement (10, 20, 30; 10, 20, 32; 10', 20, 30; 10', 20, 32) 
- mindestens ein erstes Verbindungselement (10; 10'), 
- mindestens ein weiteres Verbindungselement (20) mit mindestens einem mit dem ersten Verbindungselement (10; 10') formschlüssig und/oder kraftschlüssig verbindbaren Grundkörper (22) und 
- mindestens ein zwischen dem ersten Verbindungselement (10; 10') und dem weiteren Verbindungselement (20) angeordnetes elastisches Element (30, 32), beispielsweise mindestens eine Feder, aufweist.
",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/019-870-573-275-79X,Search Report,yes,8,0,2,3,0,F24C3/085,F24C3/08,,0,0,,,,DISCONTINUED
194,ES,R1,ES 2397899 R1,100-173-506-826-450,2013-03-21,2013,ES 201031650 A,2010-11-10,ES 201031650 A,2010-11-10,Interruptor giratorio de gas y punto de cocción con dicho interruptor,"Interruptor giratorio de gas y punto de cocción con dicho interruptor. Interruptor giratorio de gas (1) con un elemento piezoeléctrico (4), y una carcasa (5) giratoria alrededor de un eje (3), y desplazable en dirección del eje (3), junto a la cual está prevista una superficie dentada (2), donde, presionando hacia dentro la carcasa (5) en dirección del eje (3), es generable una tensión entre el elemento piezoeléctrico (4) y la superficie dentada (2), y un giro de la carcasa (5) en el estado presionado hacia dentro provoca un esfuerzo alternativo del elemento piezoeléctrico (4) y, con ello, una tensión eléctrica alternativa junto al elemento piezoeléctrico (4), la cual es transmisible a una distancia de chispa.",BSH ELECTRODOMESTICOS ESPANA,PALACIOS VALDUEZA LUIS ANTONIO;;LOPEZ ORTIZ ALBERTO;;HERRERA ESTRADA PEDRO;;DE CARLOS NEGRO AINHOA;;ACOSTA HERRERO LUIS;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/100-173-506-826-450,Unknown,no,3,0,4,4,0,,F24C3/10;;F23Q3/00,,0,0,,,,ACTIVE
195,ES,A1,ES 2385408 A1,199-552-771-342-301,2012-07-24,2012,ES 200930831 A,2009-10-09,EP 09382167 A,2009-09-09,"Cooking field to gas and gas kitchen with a cooking field to gas of such type. (Machine-translation by Google Translate, not legally binding)","Gas cooking range and gas range. To perfect a gas cooking range (100; 100 '; 100' '), that presents - at least one support surface (50) of glass or glass-ceramic, - at least one gas burner for the provision of at least one flame, - at least one thermal protection device (10; 10 '; 10 "") disposed between the flame and the support surface (50) to prevent overheating of the support surface (50) in the area of the flame, and - at least one fixing element (40; 40 '; 40 ""; 40""') for fixing the thermal protection device (10; 10 '; 10 "") to the support surface (50), As well as a gas cooker with at least one gas cooking range (100; 100 '; 100 "") mentioned above in such a way that the thermal protection device (10; 10'; 10"") is in contact with the support surface of the gas cooking field in a particularly hermetic manner, it is proposed that the fixing element (40; 40 '; 40 ""; 40""') be directly in contact and/or be directly connected to the device of thermal protection (10; 10 '; 10' '). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/199-552-771-342-301,Patent Application,no,2,1,2,5,0,F23D14/06;;F24C3/085;;F24C15/10;;F23D2900/14064,F23D14/06;;F24C3/08;;F24C15/10,,0,0,,,,DISCONTINUED
196,ES,A9,ES 2397899 A9,100-391-163-984-128,2014-02-13,2014,ES 201031650 A,2010-11-10,ES 201031650 A,2010-11-10,Interruptor giratorio de gas y punto de cocción con dicho interruptor,,BSH ELECTRODOMESTICOS ESPANA,PALACIOS VALDUEZA LUIS ANTONIO;;LOPEZ ORTIZ ALBERTO;;HERRERA ESTRADA PEDRO;;DE CARLOS NEGRO AINHOA;;ACOSTA HERRERO LUIS;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/100-391-163-984-128,Unknown,no,0,0,4,4,0,,F24C3/10;;F23Q3/00,,0,0,,,,ACTIVE
197,ES,B1,ES 2397899 B1,045-032-473-034-585,2014-02-11,2014,ES 201031650 A,2010-11-10,ES 201031650 A,2010-11-10,Interruptor giratorio de gas y punto de cocción con dicho interruptor,,BSH ELECTRODOMESTICOS ESPANA,PALACIOS VALDUEZA LUIS ANTONIO;;LOPEZ ORTIZ ALBERTO;;HERRERA ESTRADA PEDRO;;DE CARLOS NEGRO AINHOA;;ACOSTA HERRERO LUIS;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/045-032-473-034-585,Granted Patent,no,0,0,4,4,0,,,,0,0,,,,ACTIVE
198,EP,B1,EP 2295868 B1,095-565-925-242-787,2016-10-26,2016,EP 10173940 A,2010-08-25,ES 200930831 A;;EP 09382167 A;;EP 10173940 A,2009-09-09,Gas range and gas hob with associated gas range,,BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/095-565-925-242-787,Granted Patent,yes,4,0,3,5,0,F24C3/085,F24C3/08,,0,0,,,,ACTIVE
199,US,A1,US 2022/0163210 A1,153-169-427-885-963,2022-05-26,2022,US 202017437062 A,2020-03-08,ES 201930270 A;;EP 2020057395 W,2019-03-25,GAS HOB,"A gas hob comprising a top sheet, a port, a gas burner arranged on the top sheet and releasably connected to the port, the port being configured to supply the gas burner with fuel gas, and an extraction unit configured to extract fumes, the extraction unit being retractable into the top sheet.",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;GUTIERREZ HUMARA MELCA;;KLEINLEIN PHILIPP;;LOPEZ ORTIZ ALBERTO;;MARSCH ALEXANDER;;PALACIOS VALDUEZA LUIS ANTONIO;;PELAYO ALONSO CARLOS;;PLACER MARURI EMILIO,BSH HAUSGERAETE GMBH (2021-08-10),https://lens.org/153-169-427-885-963,Patent Application,yes,5,0,4,4,0,F24C15/2042;;F24C15/2092;;F24C3/126;;F24C3/085;;F24C15/001;;F24C3/082;;F23K5/005;;F23K5/007;;F24C3/008;;F24C3/085;;F24C15/107;;F24C15/2042;;F24C15/2092,F24C3/00;;F23K5/00;;F24C3/08;;F24C15/10;;F24C15/20,,0,0,,,,PENDING
200,EP,A2,EP 2295867 A2,102-934-384-311-462,2011-03-16,2011,EP 10173934 A,2010-08-25,ES 200930832 A;;EP 09382168 A;;EP 10173934 A,2009-09-09,Gas range and gas stove with associated gas range,"Um ein Gaskochfeld (100; 102; 100'; 102'), aufweisend 
- ein Gehäuse mit mindestens einer Bodenfläche (40) und mindestens einer die Bodenfläche (40) umrandenden Seitenfläche, 
- mindestens eine auf der Seitenfläche angeordnete und zum Abdecken des Gehäuses ausgebildete Abdeckfläche (50) aus Glas oder Glaskeramik und 
- mindestens einen Gasbrenner mit mindestens einem an der Abdeckfläche (50) mechanisch befestigten Bereich (72), sowie einen Gasherd mit mindestens einem vorgenannten Gaskochfeld (100; 102; 100'; 102') so weiterzubilden, dass die Düsenhalterung (70; 70') flexibel gegenüber Montageintoleranzen des Gaskochfelds (100; 102; 100'; 102') sowie gegenüber, beispielsweise durch Gasexplosionen des Gasbrenners verursachten, Druckschwankungen ist und dennoch auf einfache Weise zuverlässig im Gaskochfeld (100; 102; 100'; 102') befestigbar ist, wird vorgeschlagen, dass der Gasbrenner mindestens eine zur Halterung einer Brennerdüse (60) ausgebildete Düsenhalterung (70; 70') aufweist, wobei die Düsenhalterung (70; 70') mindestens einen am Gehäuse befestigten Bereich (76; 76') aufweist, der mittels mindestens eines mechanischen Fixierelements (10, 20, 30; 10, 20, 32; 10', 20, 30; 10', 20, 32) mit horizontalem Spiel am Gehäuse befestigt ist, wobei das Fixierelement (10, 20, 30; 10, 20, 32; 10', 20, 30; 10', 20, 32) 
- mindestens ein erstes Verbindungselement (10; 10'), 
- mindestens ein weiteres Verbindungselement (20) mit mindestens einem mit dem ersten Verbindungselement (10; 10') formschlüssig und/oder kraftschlüssig verbindbaren Grundkörper (22) und 
- mindestens ein zwischen dem ersten Verbindungselement (10; 10') und dem weiteren Verbindungselement (20) angeordnetes elastisches Element (30, 32), beispielsweise mindestens eine Feder, aufweist.
",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/102-934-384-311-462,Patent Application,yes,5,0,2,3,0,F24C3/085,F24C3/08,,0,0,,,,DISCONTINUED
201,ES,A1,ES 2390715 A1,160-634-989-761-502,2012-11-15,2012,ES 200930832 A,2009-10-09,EP 09382168 A,2009-09-09,"Gas cooking field and gas kitchen with gas cooking field of such type (Machine-translation by Google Translate, not legally binding)","Gas cooking range and gas range. The gas burner of the gas cooking range and gas cooker has at least one nozzle support (70; 70 ') configured for holding a burner nozzle (60), wherein the nozzle support (70; 70 ') has at least one area (76; 76') fixed to the housing by means of at least one mechanical fastening element (10, or 10 ', 20, 30) with horizontal clearance, wherein the fixing element (10; or, 10 ', 20, 30) presents - at least one first connection element (10; 10 '), - at least one other connecting element (20) with at least one base body (22) that can be joined to the first connecting element (10; 10 ') in a positive and/or forceful manner, and - at least one elastic element (30), arranged between the first connecting element (10; 10 ') and the other connecting element (20). (Machine-translation by Google Translate, not legally binding)",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;PALACIOS VALDUEZA LUIS ANTONIO;;DE CARLOS NEGRO AINHOA;;PLACER MARURI EMILIO;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/160-634-989-761-502,Patent Application,no,3,0,1,3,0,F23D14/06;;F24C3/085,F23D14/06;;F24C3/08,,0,0,,,,DISCONTINUED
202,ES,A1,ES 2458215 A1,123-816-762-559-911,2014-04-30,2014,ES 201200608 A,2012-06-04,ES 201200608 A,2012-06-04,METHOD FOR GENERATING PIECEWISE-AFFINE MULTIVARIABLE FUNCTIONS WITH ON-LINE COMPUTATION OF THE SEARCH TREE AND DEVICE FOR IMPLEMENTING SAME,"The invention relates to a method for generating piecewise-affine multivariable functions, comprising the on-line computation of the search tree in order to locate the input value in the polytopes of the partition, and the subsequent generation of the corresponding affine function. The invention also relates to a configurable and programmable device for generating piecewise-affine multivariable functions, formed by an architecture having four functional blocks, namely a control unit block (1), a tree memory block, a parameter memory block and an arithmetic unit block, as well as having at least three operating modes that can be selected using different values of a bus (config): writing of the tree memory, writing of the parameter memory and evaluating the affine function. The device can also have a fourth operating mode, i.e. the test mode.",UNIV SEVILLA;;CONSEJO SUPERIOR INVESTIGACION,ACOSTA JIMENEZ ANTONIO JOSÉ;;BATURONE CASTILLO MARÍA ILUMINADA;;CASTRO RAMIREZ JAVIER;;JIMENEZ FERNANDEZ CARLOS JES S;;BROX JIMENEZ PIEDAD;;MARTINEZ RODRIGUEZ MACARENA CRISTINA,,https://lens.org/123-816-762-559-911,Patent Application,no,0,0,7,7,0,G06F1/02;;G06F17/175;;G05B15/02;;G06F16/9027;;G06F16/9027;;G06F16/951;;G06F16/951;;G06F17/175;;G06N20/00;;G06N20/00,G06F17/10,,0,0,,,,INACTIVE
203,EP,A2,EP 2295868 A2,128-140-803-180-081,2011-03-16,2011,EP 10173940 A,2010-08-25,ES 200930831 A;;EP 09382167 A;;EP 10173940 A,2009-09-09,Gas range and gas hob with associated gas range,"Um ein Gaskochfeld (100; 100'; 100"") aufweisend 
- mindestens eine tragende Fläche (50) aus Glas oder Glaskeramik, 
- mindestens einen Gasbrenner zur Bereitstellung mindestens einer Flamme, 
- mindestens eine zwischen der Flamme und der tragenden Fläche (50) angeordnete Wärmeschutzvorrichtung (10; 10'; 10"") zum Verhindern einer Überhitzung der tragenden Fläche (50) im Bereich der Flamme und 
- mindestens ein Fixierelement (40; 40', 40""; 40""') zur Befestigung der Wärmeschutzvorrichtung (10; 10'; 10"") an der tragenden Fläche (50) 
 
sowie einen Gasherd mit mindestens einem vorgenannten Gaskochfeld (100; 100'; 100"") so weiterzubilden, dass die Wärmeschutzvorrichtung (10; 10'; 10"") besonders dicht an der tragenden Fläche des Gaskochfelds anliegt, wird vorgeschlagen, dass das Fixierelement (40; 40', 40""; 40""') mit der Wärmeschutzvorrichtung (10; 10'; 10"") direkt in Kontakt steht und/oder direkt verbunden ist.
",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/128-140-803-180-081,Patent Application,yes,6,4,3,5,0,F24C3/085,F24C3/08,,0,0,,,,ACTIVE
204,US,B1,US 11670155 B1,075-951-971-365-438,2023-06-06,2023,US 202217736761 A,2022-05-04,US 202217736761 A;;US 202016749649 A;;US 201962796413 P,2019-01-24,Systems and methods for detecting water events in vehicles,Systems and methods of the present disclosure include a vehicle water detection system that includes a housing configured to be disposed within a vehicle. The vehicle water detection system also includes a water-activated battery disposed within the housing and configured to produce an electrical voltage upon contact with water. The vehicle water detection system further includes an electronic circuitry disposed within the housing and configured to detect a water event occurring in the vehicle based at least in part on the electrical voltage.,USAA,ACOSTA STEFANIE JEAN;;CHAVEZ CARLOS JP;;DZIUK JANELLE DENICE;;GAETA MICHAEL JOSEPH;;HUGGAR STACY CALLAWAY;;KREBS EMILY KATHLEEN;;POLLACK JEFFREY NEAL;;RUIZ MITZI,,https://lens.org/075-951-971-365-438,Granted Patent,yes,4,0,2,2,0,G07C5/008;;G07C5/0841;;G01M3/16;;B60R16/02;;G08B21/20;;G08B21/20;;B60R2021/0016;;B60R21/00;;G01F23/185,G08B21/20;;B60R21/00;;G01F23/18,,0,0,,,,ACTIVE
205,US,B1,US 11525755 B1,111-761-189-536-301,2022-12-13,2022,US 202016800891 A,2020-02-25,US 202016800891 A;;US 201962811379 P,2019-02-27,Fluid storage water monitor,"A water detection system for a fluid storage system includes a housing configured to be disposed in fluid communication with a fluid storage vessel, a water-activated battery disposed within the housing and configured to produce an electrical voltage upon contact with water, and an electronic circuit disposed within the housing and configured to detect water above a threshold within the fluid storage vessel based at least in part on the electrical voltage.",USAA,HUGGAR STACY CALLAWAY;;KREBS EMILY KATHLEEN;;POLLACK JEFFREY NEAL;;CHAVEZ CARLOS J P;;ACOSTA STEFANIE JEAN;;DZIUK JANELLE DENICE;;RUIZ MITZI;;GAETA MICHAEL JOSEPH,UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) (2022-11-01);;UIPCO LLC (2020-05-05),https://lens.org/111-761-189-536-301,Granted Patent,yes,13,0,1,1,0,G01M3/40;;G08B21/20;;G01F23/0007;;G01M3/40;;G08B21/20;;G01F23/802,G08B21/20;;G01F23/80;;G01M3/40,,2,0,,,"US 10,309,860 B1, 06/2019, Billman et al. (withdrawn);;U.S. Appl. No. 15/636,317, filed Jun. 28, 2017, Bradly Jay Billman.",ACTIVE
206,US,B1,US 11348440 B1,026-295-974-690-252,2022-05-31,2022,US 202016749649 A,2020-01-22,US 202016749649 A;;US 201962796413 P,2019-01-24,Systems and methods for detecting water events in vehicles,Systems and methods of the present disclosure include a vehicle water detection system that includes a housing configured to be disposed within a vehicle. The vehicle water detection system also includes a water-activated battery disposed within the housing and configured to produce an electrical voltage upon contact with water. The vehicle water detection system further includes an electronic circuitry disposed within the housing and configured to detect a water event occurring in the vehicle based at least in part on the electrical voltage.,USAA,ACOSTA STEFANIE JEAN;;CHAVEZ CARLOS J P;;DZIUK JANELLE DENICE;;GAETA MICHAEL JOSEPH;;HUGGAR STACY CALLAWAY;;KREBS EMILY KATHLEEN;;POLLACK JEFFREY NEAL;;RUIZ MITZI,UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) (2022-03-17);;UIPCO LLC (2020-01-15),https://lens.org/026-295-974-690-252,Granted Patent,yes,4,1,2,2,0,G07C5/008;;G07C5/0841;;G01M3/16;;B60R16/02;;G08B21/20;;G08B21/20;;B60R2021/0016;;B60R21/00;;G01F23/185,G08B21/20;;B60R21/00;;G01F23/18,,0,0,,,,ACTIVE
207,WO,A3,WO 2007/045930 A3,032-445-174-530-38X,2007-07-12,2007,GB 2006050342 W,2006-10-20,GB 0521351 A,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/ or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU;;WILLIAMS GARETH OWEN;;ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,WILLIAMS GARETH OWEN;;ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/032-445-174-530-38X,Search Report,yes,4,0,23,23,0,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,4,3,018-351-655-903-314;;048-116-857-026-485;;102-915-930-640-164,10.1093/nar/gkg409;;12799446;;pmc162243;;10.1016/j.jmb.2005.03.011;;15843020;;16996476;;10.1016/j.bbrc.2006.09.037,"CHRISTOPH T ET AL: ""RNA interference approaches for target validation in pain research"", JOURNAL OF NEUROCHEMISTRY, vol. 94, no. Suppl. 2, August 2005 (2005-08-01), & 20TH BIENNIAL MEETING OF THE INTERNATIONAL-SOCIETY-FOR-NEUROCHEMISTRY /EUROPEAN-SOCIETY-FOR-NEUROCHEM; INNSBRUCK, AUSTRIA; AUGUST 21 -26, 2005, pages 142, XP002429499, ISSN: 0022-3042;;GRÜNWELLER A ET AL: ""Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA"", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 31, no. 12, 15 June 2003 (2003-06-15), pages 3185 - 3193, XP002286510, ISSN: 0305-1048;;SCHUBERT S ET AL: ""Local RNA Target Structure Influences siRNA Efficacy: Systematic Analysis of Intentionally Designed Binding Regions"", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 348, no. 4, 13 May 2005 (2005-05-13), pages 883 - 893, XP004849589, ISSN: 0022-2836;;CHRISTOPH ET AL: ""Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 350, no. 1, 10 November 2006 (2006-11-10), pages 238 - 243, XP005676323, ISSN: 0006-291X",PENDING
208,CA,A1,CA 2626181 A1,000-204-287-663-439,2007-04-26,2007,CA 2626181 A,2006-10-20,GB 0521351 A;;GB 2006050342 W,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SA,WILLIAMS GARETH OWEN;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;GALLAR MARTINEZ JUANA;;ACOSTA BOJ MARIA DEL CARMEN;;JIMENEZ ANTON ANA ISABEL;;SESTO YAGUE ANGELA,,https://lens.org/000-204-287-663-439,Patent Application,no,0,0,23,23,162,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,A61K31/713;;A61P17/14;;A61P27/02;;C12N15/113,,0,0,,,,ACTIVE
209,HK,A1,HK 1222112 A1,167-820-238-347-048,2017-06-23,2017,HK 16110469 A,2016-09-02,CU 2014000003 W;;CU 20130086 A,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CIG,CABAL MIRABAL CARLOS ALBERTO CA;;GONZLEZ DALMAU EVELIO RAFAEL ER;;FLORES DAZ LUIS MANUEL LM;;BERLANGA ACOSTA JORGE AMADOR JA;;HERRERA MARTINEZ LUIS SATURNINO LS,,https://lens.org/167-820-238-347-048,Patent Application,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B/;;A61G/;;A61N/,,0,0,,,,PENDING
210,WO,A2,WO 2007/045930 A2,072-295-968-676-639,2007-04-26,2007,GB 2006050342 W,2006-10-20,GB 0521351 A,2005-10-20,MODULATION OF TRPV EXPRESSION LEVELS,"The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/ or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.",SYLENTIS SAU;;WILLIAMS GARETH OWEN;;ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,WILLIAMS GARETH OWEN;;ACOSTA BOJ MARIA DEL CARMEN;;GALLAR MARTINEZ JUANA;;SESTO YAGUE ANGELA;;JIMENEZ GOMEZ MARIA CONCEPCION;;BELMONTE MARTINEZ CARLOS;;JIMENEZ ANTON ANA ISABEL,,https://lens.org/072-295-968-676-639,Patent Application,yes,0,9,23,23,162,A61K31/713;;C12N15/1138;;C12N2310/14;;A61P17/00;;A61P17/14;;A61P27/00;;A61P27/02;;A61P27/04;;A61P43/00;;C12N15/1138;;C12N2310/14;;A61K31/713,C12N15/113,,3,3,089-315-410-576-21X;;001-079-201-835-006;;074-254-924-910-683,10.1172/jci19478;;10.1172/jci200419478;;15085194;;pmc385397;;15793280;;pmc1602392;;10.1016/s0002-9440(10)62320-6;;11157775;;10.1101/gad.862301;;pmc312613,"RUBERTE ET AL.: ""Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease"", J CLIN INVEST., vol. 113, no. 8, April 2004 (2004-04-01), pages 1149 - 57;;BODO ET AL.: ""A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1íTRPV1) signaling in human hair growth control"", AM J PATHOL., vol. 166, no. 4, April 2005 (2005-04-01), pages 985 - 98;;ELBASHIR ET AL., GENES DEV, vol. 15, 2001, pages 188",PENDING
211,EP,A2,EP 2202463 A2,004-759-758-367-797,2010-06-30,2010,EP 09178243 A,2009-12-08,ES 200900077 A,2008-12-29,Gas cooking hob,"Um ein Gaskochfeld (100) mit 
- einem oberen Tragelement (40), in dem mindestens eine Gaskochstelle (20) angeordnet ist, und 
- einem mit dem oberen Tragelement (40) verbundenen unteren Tragelement (50), das zum Stützen des oberen Tragelements (40) mindestens ein zumindest bereichsweise im Gaskochfeld (100) angeordnetes und sich vertikal zum oberen Tragelement (40) hin erstreckendes Stützelement (10) aufweist, 
 
so weiterzubilden, dass das obere Tragelement (40) eine besonders hohe Biegesteifigkeit aufweist und zuverlässig plan auf dem unteren Tragelement (50) aufliegt, wird vorgeschlagen, dass an der dem unteren Tragelement (50) zugewandten Seite des oberen Tragelements (40) mindestens ein sich im Wesentlichen horizontal erstreckendes Versteifungselement (42) zum Versteifen des oberen Tragelements (40) angeordnet ist, wobei das Versteifungselement (42) sich auf dem Stützelement (10) abstützt.
",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/004-759-758-367-797,Patent Application,yes,0,1,4,4,0,F24C15/08;;F24C15/10;;F24C3/008,F24C15/10,,0,0,,,,DISCONTINUED
212,ES,B1,ES 2382063 B1,119-257-081-033-17X,2013-05-07,2013,ES 200900077 A,2008-12-29,ES 200900077 A,2008-12-29,PLACA DE COCCION A GAS,,BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/119-257-081-033-17X,Granted Patent,no,0,0,4,4,0,F24C15/08;;F24C15/10;;F24C3/008,F24C15/08,,0,0,,,,INACTIVE
213,EP,B1,EP 2469172 B1,132-034-702-372-047,2018-02-21,2018,EP 11193143 A,2011-12-13,ES 201031891 A,2010-12-21,Gas hotplate with automatic control,,BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/132-034-702-372-047,Granted Patent,yes,7,0,5,5,0,F24C3/126;;F23N5/203;;F23N5/00,F24C3/12;;F23N5/20,,0,0,,,,ACTIVE
214,EP,A1,EP 2240723 A1,166-605-661-414-924,2010-10-20,2010,EP 09709112 A,2009-01-19,EP 2009050558 W;;ES 200800393 A,2008-02-04,GAS HOB AND GAS BURNER FOR A GAS HOB OF THIS TYPE,,BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/166-605-661-414-924,Patent Application,yes,1,0,6,6,0,F23Q3/006;;F23Q9/045;;F24C3/103;;F23Q3/008,F24C3/10;;F23Q3/00,,1,0,,,See also references of WO 2009098117A1,DISCONTINUED
215,ES,A1,ES 2349992 A1,129-141-653-234-507,2011-01-14,2011,ES 200800393 A,2008-02-04,ES 200800393 A,2008-02-04,GAS HOB AND GAS BURNER FOR A GAS HOB OF THIS TYPE,"The invention relates to a gas burner for a gas hob with an associated ignition electrode (13) for igniting the gas burner (1). An adjusting device (15) is allocated to the electrode, said device allowing the operating position of the ignition electrode (13) to be adjusted vertically (z) in relation to gas outlet openings (7) of the gas burner (1).",BSH ELECTRODOMESTICOS ESPANA,VERDEJA GALNARES ALMUDENA;;PALACIOS VALDUEZA LUIS ANTONIO;;HERRERA ESTRADA PEDRO;;DE CARLOS NEGRO AINHOA;;LOPEZ ORTIZ ALBERTO;;LEON GARCIA JOSE;;ACOSTA HERRERO LUIS;;PLACER MARURI EMILIO,,https://lens.org/129-141-653-234-507,Patent Application,no,5,0,6,6,0,F23Q3/006;;F23Q9/045;;F24C3/103;;F23Q3/008,F24C3/10;;F23Q3/00;;F23Q9/04,,0,0,,,,INACTIVE
216,MX,A,MX 2010014333 A,105-897-445-931-200,2012-06-20,2012,MX 2010014333 A,2010-12-20,MX 2010014333 A,2010-12-20,PROCESS FOR THE SUPERFICIAL MODIFICATION OF INORGANIC NANOPARTICLES WITH COMPOUNDS OF THE SPIROORTHOCARBONATE-TYPE USING ULTRASOUND.,"The present invention refers to a process for the superficial modification of inorganic matter, specially metallic or metallic oxide nanoparticles with compounds of the spiroorthocarbonate-type compounds with alcohol functionality which present compatibility with said nanoparticles, so that when the polymerization is performed, the material is provided with antishrinking or volume expanding properties, once the material is processed for any desired application. The superficial modifiers used for the present invention are the spiroorthocarbonate mono and difunctional alcohol, SOC DIOL and HSOC OL. The ultrasound induction at a predetermined time depends on the characteristics to be obtained in the final product, allowing the nanoparticles to have a better dispersion when these are incorporated in any compound.",CT DE INVESTIG EN QUIMICA APLICADA,DUARTE MARIA LYDIA BERLANGA;;ORTA CARLOS ALBERTO AVILA;;FERNANDEZ OLIVERIO SANTIAGO RODRIGUEZ;;GALINDO REBECA BETANCOURT;;URBINA BERTHA ALICIA PUENTE;;MENDOZA LILIANA ELIZABETH ROMO;;ORTIZ RICARDO ACOSTA,,https://lens.org/105-897-445-931-200,Patent Application,no,0,0,2,2,0,,C08G18/28;;A61K41/00;;C08G18/32;;C09D175/04,,0,0,,,,ACTIVE
217,CN,B,CN 101983306 B,019-568-101-402-861,2013-07-24,2013,CN 200980104111 A,2009-01-19,EP 2009050558 W;;ES 200800393 A,2008-02-04,Gas hob and gas burner for a gas hob of this type,,BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,"BSH HOME APPLIANCES CO., LTD. (2015-06-24)",https://lens.org/019-568-101-402-861,Granted Patent,no,0,0,6,6,0,F23Q3/006;;F23Q9/045;;F24C3/103;;F23Q3/008,F24C3/10;;F23Q3/00,,0,0,,,,ACTIVE
218,EP,A3,EP 2202463 A3,184-804-762-116-904,2017-06-21,2017,EP 09178243 A,2009-12-08,ES 200900077 A,2008-12-29,Gas cooking hob,"Um ein Gaskochfeld (100) mit 
- einem oberen Tragelement (40), in dem mindestens eine Gaskochstelle (20) angeordnet ist, und 
- einem mit dem oberen Tragelement (40) verbundenen unteren Tragelement (50), das zum Stützen des oberen Tragelements (40) mindestens ein zumindest bereichsweise im Gaskochfeld (100) angeordnetes und sich vertikal zum oberen Tragelement (40) hin erstreckendes Stützelement (10) aufweist, 
 
so weiterzubilden, dass das obere Tragelement (40) eine besonders hohe Biegesteifigkeit aufweist und zuverlässig plan auf dem unteren Tragelement (50) aufliegt, wird vorgeschlagen, dass an der dem unteren Tragelement (50) zugewandten Seite des oberen Tragelements (40) mindestens ein sich im Wesentlichen horizontal erstreckendes Versteifungselement (42) zum Versteifen des oberen Tragelements (40) angeordnet ist, wobei das Versteifungselement (42) sich auf dem Stützelement (10) abstützt.
",BSH HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/184-804-762-116-904,Search Report,yes,4,0,4,4,0,F24C15/10;;F24C3/008;;F24C15/08,F24C15/10;;F24C3/00,,0,0,,,,DISCONTINUED
219,CN,A,CN 101983306 A,034-529-204-420-220,2011-03-02,2011,CN 200980104111 A,2009-01-19,EP 2009050558 W;;ES 200800393 A,2008-02-04,Gas hob and gas burner for a gas hob of this type,"The invention relates to a gas burner for a gas hob with an associated ignition electrode (13) for igniting the gas burner (1). An adjusting device (15) is allocated to the electrode, said device allowing the operating position of the ignition electrode (13) to be adjusted vertically (z) in relation to gas outlet openings (7) of the gas burner (1).",BSH BOSCH SIEMENS HAUSGERAETE,LUIS ACOSTA HERRERO;;AINHOA DE CARLOS NEGRO;;PEDRO HERRERA ESTRADA;;JOSE LEON GARCIA;;ALBERTO LOPEZ ORTIZ;;ANTONIO PALACIOS VALDUEZA LUIS;;EMILIO PLACER MARURI;;ALMUDENA VERDEJA GALNARES,"BSH HOME APPLIANCES CO., LTD. (2015-06-24)",https://lens.org/034-529-204-420-220,Patent Application,no,0,3,6,6,0,F23Q3/006;;F23Q9/045;;F24C3/103;;F23Q3/008,F24C3/10;;F23Q3/00,,0,0,,,,ACTIVE
220,ES,B1,ES 2349992 B1,177-140-300-855-064,2011-11-11,2011,ES 200800393 A,2008-02-04,ES 200800393 A,2008-02-04,CAMPO DE COCCION A GAS ASI COMO QUEMADOR DE GAS PARA TAL CAMPO DE COCCION A GAS,,BSH ELECTRODOMESTICOS ESPANA,VERDEJA GALNARES ALMUDENA;;PALACIOS VALDUEZA LUIS ANTONIO;;HERRERA ESTRADA PEDRO;;DE CARLOS NEGRO AINHOA;;LOPEZ ORTIZ ALBERTO;;LEON GARCIA JOSE;;ACOSTA HERRERO LUIS;;PLACER MARURI EMILIO,,https://lens.org/177-140-300-855-064,Granted Patent,no,0,0,6,6,0,F23Q3/006;;F23Q9/045;;F24C3/103;;F23Q3/008,F24C3/10;;F23Q3/00;;F23Q9/04,,0,0,,,,INACTIVE
221,ES,R1,ES 2407592 R1,172-411-330-505-890,2013-06-28,2013,ES 201031891 A,2010-12-21,ES 201031891 A,2010-12-21,Punto de cocción a gas con un mando automático,"Punto de cocción a gas con un mando automático. El objeto de la invención es un punto de cocción a gas con, al menos, un quemador de gas (2), un dispositivo de mando (9), y una instalación, que está en conexión de efecto con el dispositivo de mando (9), para conectar y desconectar secuencialmente de manera automática llamas en el quemador de gas (2). Según la invención, el dispositivo de mando (9) presenta una instalación para cocinar automáticamente de manera asistida por programa. El dispositivo de mando (9) está configurado de tal modo que, al menos, uno de los programas de cocción predeterminados prescribe la utilización de un quemador de gas (2) determinado, y una duración de ciclo determinada para el conectar y desconectar secuencialmente llamas en el quemador de gas (2). Al menos, un programa de cocción predeterminado está definido como programa de descongelación.",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/172-411-330-505-890,Unknown,no,7,0,5,5,0,F24C3/126;;F23N5/00;;F23N5/203,F23N5/00;;F23N5/26;;F24C3/12,,0,0,,,,DISCONTINUED
222,WO,A1,WO 2009/098117 A1,092-501-910-114-561,2009-08-13,2009,EP 2009050558 W,2009-01-19,ES 200800393 A,2008-02-04,GAS HOB AND GAS BURNER FOR A GAS HOB OF THIS TYPE,"The invention relates to a gas burner for a gas hob with an associated ignition electrode (13) for igniting the gas burner (1). An adjusting device (15) is allocated to the electrode, said device allowing the operating position of the ignition electrode (13) to be adjusted vertically (z) in relation to gas outlet openings (7) of the gas burner (1).",BSH BOSCH SIEMENS HAUSGERAETE;;ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/092-501-910-114-561,Patent Application,yes,3,4,6,6,0,F23Q3/006;;F23Q9/045;;F24C3/103;;F23Q3/008,F24C3/10;;F23Q3/00,,1,0,,,See also references of EP 2240723A1,PENDING
223,EP,A3,EP 2469172 A3,071-631-325-268-598,2015-03-11,2015,EP 11193143 A,2011-12-13,ES 201031891 A,2010-12-21,Gas hotplate with automatic control,"Gegenstand der Erfindung ist eine Gaskochstelle mit mindestens einem Gasbrenner (2), einer Steuervorrichtung (9) und einer mit der Steuervorrichtung (9) in Wirkverbindung stehenden Einrichtung zum selbsttätigen sequentiellen Ein- und Ausschalten von Flammen an dem Gasbrenner (2). Erfindungsgemäß weist die Steuervorrichtung (9) eine Einrichtung zum programmunterstützten automatischen Kochen auf. Die Steuervorrichtung (9) ist derart konfiguriert, dass zumindest eines der vorgegebenen Kochprogramme die Benutzung eines bestimmten Gasbrenners (2) und eine bestimmte Zyklusdauer für das sequentielle Ein- und Ausschalten von Flammen an dem Gasbrenner (2) vorschreibt. Zumindest ein vorgegebenes Kochprogramm ist als Auftauprogramm definiert.
",BSH BOSCH & SIEMENS HAUSGERAETE GMBH,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/071-631-325-268-598,Search Report,yes,7,0,5,5,0,F24C3/126;;F23N5/203;;F23N5/00,F24C3/12;;F23N5/20,,0,0,,,,ACTIVE
224,ES,A1,ES 2382063 A1,130-127-447-302-876,2012-06-05,2012,ES 200900077 A,2008-12-29,ES 200900077 A,2008-12-29,Gas cooking hob,"The hob (100) has a lower carrier element (50) i.e. cooking hob cavity, connected with an upper carrier element (40) i.e. cooking hob cover plate, and comprising a support element i.e. supporting screw (10), for supporting the upper element. The support element is sectionally arranged at the hob and vertically extends towards the upper element. A reinforcing element e.g. strip (42), is arranged at a side of the upper element, extends horizontally and reinforces the upper element, where the side is turned towards the lower element. The reinforcing element is supported on the support element.",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/130-127-447-302-876,Patent Application,no,3,0,4,4,0,F24C15/08;;F24C15/10;;F24C3/008,F24C15/08,,0,0,,,,INACTIVE
225,EP,A2,EP 2469172 A2,014-014-865-423-738,2012-06-27,2012,EP 11193143 A,2011-12-13,ES 201031891 A,2010-12-21,Gas hotplate with automatic control,"Gegenstand der Erfindung ist eine Gaskochstelle mit mindestens einem Gasbrenner (2), einer Steuervorrichtung (9) und einer mit der Steuervorrichtung (9) in Wirkverbindung stehenden Einrichtung zum selbsttätigen sequentiellen Ein- und Ausschalten von Flammen an dem Gasbrenner (2). Erfindungsgemäß weist die Steuervorrichtung (9) eine Einrichtung zum programmunterstützten automatischen Kochen auf. Die Steuervorrichtung (9) ist derart konfiguriert, dass zumindest eines der vorgegebenen Kochprogramme die Benutzung eines bestimmten Gasbrenners (2) und eine bestimmte Zyklusdauer für das sequentielle Ein- und Ausschalten von Flammen an dem Gasbrenner (2) vorschreibt. Zumindest ein vorgegebenes Kochprogramm ist als Auftauprogramm definiert.
",BSH BOSCH SIEMENS HAUSGERAETE,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,BSH HAUSGERAETE GMBH (2015-03-25),https://lens.org/014-014-865-423-738,Patent Application,yes,0,5,5,5,0,F24C3/126;;F23N5/203;;F23N5/00,F23N5/20;;F24C3/12,,0,0,,,,ACTIVE
226,ES,A2,ES 2407592 A2,139-385-657-109-440,2013-06-13,2013,ES 201031891 A,2010-12-21,ES 201031891 A,2010-12-21,Gas hotplate with automatic control,"The zone e.g. hob plate (1), has switching on-and off unit automatically and sequentially switching on and off flames (3) at a gas burner (2) and operatively connected with a control device (9). The control device includes a program-aided automatic cooking unit, and a user interface (10) i.e. indicating display, for adjusting a predetermined cooking program i.e. defrosting program. The control device is arranged such that the predetermined cooking program prescribes an application of the predetermined gas burner and predetermined cycle duration for switching on and off the flame at the burner.",BSH ELECTRODOMESTICOS ESPANA,ACOSTA HERRERO LUIS;;DE CARLOS NEGRO AINHOA;;HERRERA ESTRADA PEDRO;;LEON GARCIA JOSE;;LOPEZ ORTIZ ALBERTO;;PALACIOS VALDUEZA LUIS ANTONIO;;PLACER MARURI EMILIO;;VERDEJA GALNARES ALMUDENA,,https://lens.org/139-385-657-109-440,Patent Application,no,0,0,5,5,0,F24C3/126;;F23N5/00;;F23N5/203,F24C3/12,,0,0,,,,DISCONTINUED
227,MX,B,MX 341359 B,136-914-662-641-660,2016-07-08,2016,MX 2010014333 A,2010-12-20,MX 2010014333 A,2010-12-20,PROCESS FOR THE SUPERFICIAL MODIFICATION OF INORGANIC NANOPARTICLES WITH COMPOUNDS OF THE SPIROORTHOCARBONATE-TYPE USING ULTRASOUND.,"The present invention refers to a process for the superficial modification of inorganic matter, specially metallic or metallic oxide nanoparticles with compounds of the spiroorthocarbonate-type compounds with alcohol functionality which present compatibility with said nanoparticles, so that when the polymerization is performed, the material is provided with antishrinking or volume expanding properties, once the material is processed for any desired application. The superficial modifiers used for the present invention are the spiroorthocarbonate mono and difunctional alcohol, SOC DIOL and HSOC OL. The ultrasound induction at a predetermined time depends on the characteristics to be obtained in the final product, allowing the nanoparticles to have a better dispersion when these are incorporated in any compound.",CENTRO DE INVESTIG EN QUIM APLICADA,MARIA LYDIA BERLANGA DUARTE;;CARLOS ALBERTO AVILA ORTA;;OLIVERIO SANTIAGO RODRIGUEZ FERNANDEZ;;REBECA BETANCOURT GALINDO;;BERTHA ALICIA PUENTE URBINA;;LILIANA ELIZABETH ROMO MENDOZA;;RICARDO ACOSTA ORTIZ,,https://lens.org/136-914-662-641-660,Granted Patent,no,0,0,2,2,0,,C09C1/04;;C01G9/02;;C08G18/32;;C09C1/40;;C09C3/04,,0,0,,,,ACTIVE
228,ES,B1,ES 2340647 B1,194-618-612-749-304,2011-04-12,2011,ES 200800901 A,2008-03-18,ES 200800901 A,2008-03-18,ELEMENTO DE MANDO Y ELEMENTO DE RESORTE PARA LA FIJACION DEL ELEMENTODE MANDO,,BSH ELECTRODOMESTICOS ESPANA,VERDEJA GALNARES ALMUDENA;;PALACIOS VALDUEZA LUIS ANTONIO;;HERRERA ESTRADA PEDRO;;DE CARLOS NEGRO AINHOA;;LOPEZ ORTIZ ALBERTO;;LEON GARCIA JOSE;;ACOSTA HERRERO LUIS;;PLACER MARURI EMILIO,,https://lens.org/194-618-612-749-304,Granted Patent,no,0,0,2,2,0,G05G1/12,G05G1/12,,0,0,,,,INACTIVE
229,US,B1,US 11792038 B1,166-068-571-051-962,2023-10-17,2023,US 202016821246 A,2020-03-17,US 202016821246 A;;US 201962820068 P,2019-03-18,Systems and methods to determine activity via wireless and sound signals,"A system includes a transceiver configured to receive one or more Wi-Fi signals associated with a structure, and a processor having computer-executable instructions. When executed, the instructions are configured to cause the processor to perform operations that include receiving the one or more Wi-Fi signals via the transceiver, comparing the one or more Wi-Fi signals with a signal profile, and determining whether an anomaly activity is occurring in the structure based on comparison between the one or more Wi-Fi signals and the signal profile.",USAA,HUGGAR STACY CALLAWAY;;KREBS EMILY KATHLEEN;;POLLACK JEFFREY NEAL;;CHAVEZ CARLOS JP;;ACOSTA STEFANIE JEAN;;DZIUK JANELLE DENICE;;RUIZ MITZI;;GAETA MICHAEL JOSEPH;;MOREY AGATHA MARIA,UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA) (2023-05-08);;UIPCO LLC (2020-05-29),https://lens.org/166-068-571-051-962,Granted Patent,yes,1,1,1,1,0,H04L67/125;;H04L12/2823;;H04L2012/2841;;H04L2012/2849;;H04L12/2823;;H04L2012/2841;;H04L2012/2849;;H04L67/125,H04L12/28;;H04L67/125,,1,1,104-939-611-119-944,10.1109/access.2018.2812887,"Hongbo Jiang, Chao Cai, Xiaoqiang Ma, Yang Yang, Jiangchuan Liu, Smart Home Based on WiFi Sensing: A Survey, Mar. 28, 2018, IEEE Access, Volume 6.",ACTIVE
230,WO,A1,WO 2017/068499 A1,109-428-479-551-787,2017-04-27,2017,IB 2016056261 W,2016-10-19,CO 15251031 A,2015-10-21,MOBILE DEVICE FOR GEOREFERENCING AND MONITORING AIR QUALITY AND GREENHOUSE GASES,"The invention relates to a mobile device for georeferencing and monitoring air quality and greenhouse gases in the atmosphere/troposphere and on the earth's surface, which comprises various modules provided with respective means for communicating, measuring, processing and sending data to land stations, to perform real-time remote analysis and thus predict possible negative effects in various zones.",UNIV DE SAN BUENAVENTURA MEDELLÍN;;UNIV DE MEDELLÍN,CÁRDENAS TORRES ANDRÉS MAURICIO;;VALENCIA HERNANDEZ GERMÁN MAURICIO;;ECHEVERRI LONDOÑO CARLOS ALBERTO;;GÓMEZ GÓMEZ BEATRIZ LILIANA;;MAYA VASCO GABRIEL JAIME;;VELASQUEZ SIERRA EVER ALBERTO;;ACOSTA RAMIREZ HERNAN ALEJANDRO,,https://lens.org/109-428-479-551-787,Patent Application,yes,4,3,1,1,0,G01N33/00,G01N33/00,,0,0,,,,PENDING
231,CO,U1,CO 7590060 U1,073-783-106-992-688,2016-04-29,2016,CO 15251031 U,2015-10-21,CO 15251031 U,2015-10-21,Equipo móvil para la georeferenciación y monitoreo de la calidad del aire de los gases efecto invernadero,"RESUMEN Un equipo móvil para la georeferenciación y monitoreo de la calidad del aire y de los gases efecto invernadero tanto en la atmósfera/tropósfera como en la superficie terrestre, que comprende diferentes módulos provistos de respectivas disposiciones de comunicación, de medición, de procesamiento y de envío de datos a estaciones terrestres para llevar a cabo el análisis remoto en tiempo real y así predecir posibles efectos negativos en diferentes zonas.",UNIV DE MEDELLIN;;UNIV DE SAN BUENAVENTURA SECCIONAL MEDELLÍN,VALENCIA HERNANDEZ GERMAN MAURICIO;;CARDENAS TORRES ANDRES MAURICIO;;GÓMEZ GÓMEZ BEATRIZ LILIANA;;ACOSTA RAMIREZ HERNAN ALEJANDRO;;VELASQUEZ SIERRA EVER ALBERTO;;ECHEVERRI LONDOÑO CARLOS ALBERTO;;MAYA VASCO GABRIEL JAIME,,https://lens.org/073-783-106-992-688,Unknown,no,0,0,1,1,0,,G01S13/02,,0,0,,,,PENDING
232,AT,T1,AT E419868 T1,125-801-545-207-38X,2009-01-15,2009,AT 05729588 T,2005-03-18,CU 20040051 A,2004-03-18,VAKZINE-ZUSAMMENSETZUNGEN AUS STREPTOMYCES,,INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,SARMIENTO GARCIA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN;;RAMOS MORI ASTRID,,https://lens.org/125-801-545-207-38X,Granted Patent,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04,,0,0,,,,INACTIVE
233,CU,A1,CU 23011 A1,175-532-565-357-052,2004-12-17,2004,CU 20000242 A,2000-11-03,CU 20000242 A,2000-11-03,MÉTODO DE OBTENCIÓN DE ESTRUCTURAS ANTIGÉNICAS QUEMÉTODO DE OBTENCIÓN DE ESTRUCTURAS ANTIGÉNICAS QUE POTENCIAN LA REACTIVIDAD CRUZADA ESPECÍFICA Y SU POTENCIAN LA REACTIVIDAD CRUZADA ESPECÍFICA Y SU USO EN FORMULACIONES USO EN FORMULACIONES,"La presente invención se relaciona con el método pLa presente invención se relaciona con el método para la obtención de estructuras antigiénicas de alara la obtención de estructuras antigiénicas de alta reactividad cruzada, capaces de potenciar la reta reactividad cruzada, capaces de potenciar la respuesta inmune a antíjenos peptídios administradosspuesta inmune a antíjenos peptídios administrados par vía sistémica y/o mucosal, generando potentes par vía sistémica y/o mucosal, generando potentes respuestas inmunes así coma estructuras químicas respuestas inmunes así coma estructuras químicas resultantes de la aplicación de este método, formuresultantes de la aplicación de este método, formulaciones obtenidas a partir de dichas estructuras laciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtenciy uso de las mismas. El método describe la obtención de nuevas estructuras dendriméricas. Partiendo ón de nuevas estructuras dendriméricas. Partiendo de la selección y síntesis de dendrímeros, que posde la selección y síntesis de dendrímeros, que posteriormente son acoplados a moléculas portadoras. teriormente son acoplados a moléculas portadoras. Las estructuras resultantes pueden utilizarse convLas estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulación donde enientemente adyuvadas o en una formulación donde pueden introducirse varios antígenos de este tipo,pueden introducirse varios antígenos de este tipo, encontrándose un efecto sinérgico entre estos com encontrándose un efecto sinérgico entre estos componentes con respecto a la reactividad cruzada y lponentes con respecto a la reactividad cruzada y la inmunogenicidad de la respuesta obtenida. Ademása inmunogenicidad de la respuesta obtenida. Además la preparación puede contener, estabilizadores y la preparación puede contener, estabilizadores y preservos. Las estructuras antigénicas resultantespreservos. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como son aplicables en la industria farmacéutica como formulaciones vacúnales tanto para uso humano comoformulaciones vacúnales tanto para uso humano como veterinario y coma parte de sistemas de diagnósti veterinario y coma parte de sistemas de diagnóstico. co.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS DUARTE CANO CARLOS;;IGLESIAS PEREZ ENRIQUE IGLESIAS PEREZ ENRIQUE;;CRUZ RICONDO LUIS JAVIER CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR AGUILAR RUBIDO JULIO CE;;GARAY PEREZ HILDA ELISA GARAY PEREZ HILDA ELISA;;REYES ACOSTA OSVALDO REYES ACOSTA OSVALDO;;GUILLEN NIETO GERARDO ENRIQUE GUILLEN NIETO GERARD;;MUZIO GONZALEZ VERENA LUCILA MUZIO GONZALEZ VERENA;;PENTON ARIAS EDUARDO PENTON ARIAS EDUARDO,,https://lens.org/175-532-565-357-052,Limited Patent,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K31/74;;A61K31/785;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K39/39;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
234,MX,A,MX 2022004620 A,186-161-565-369-482,2022-04-29,2022,MX 2022004620 A,2022-04-18,MX 2022004620 A,2022-04-18,FOOD ADDITIVE WITH HIGH FIBER CONTENT FOR WHOLE DIETS OF SMALL RUMINANTS.,"The present invention relates to the field of food products, particularly fodder as animal feed. It aims to increase the nutritional value of vegetable fibers used as a food additive. Also, it uses agro-industrial by-products as additive ingredients for animal feed for ruminant nutrition, enabling good consumption, digestibility, and weight gain. Additionally, it provides a food additive with a high fiber content for integral diets of small ruminants, containing an exhausted substrate from a Pleurotus spp fungus culture, including a mixture in equal parts of cob, grass, and coffee pulp.",INSTITUTO NAC DE INVESTIGACIONES FORESTALES AGRICOLAS Y PECUARIAS,AGUILAR MARCELINO LILIANA;;SÁNCHEZ VÁZQUEZ JOSÉ ERNESTO;;SANDOVAL CASTRO CARLOS ALFREDO;;TORRES ACOSTA JUAN FELIPE DE JESÚS;;MANCILLA MONTELONGO MARÍA GABRIELA;;GÓNZALEZ PECH PEDRO GERALDO;;CASTAÑEDA RAMIREZ GLORIA SARAHI,,https://lens.org/186-161-565-369-482,Patent Application,no,0,0,1,1,0,,A23K10/30;;A23K50/10,,0,0,,,,PENDING
235,ES,Y,ES 1247685 Y,114-434-682-830-783,2020-09-02,2020,ES 202030711 U,2020-04-24,ES 202030711 U,2020-04-24,Textil para mascarillas reutilizables,,ONDYTEC 2018 S L,FRANCÉS VILAPLANA JAVIER;;GRAU LLOPIS CARLOS;;HERRERO MONZÓN ANA;;GÓMEZ ACOSTA RUBÉN;;VERCET SAIZ MARIA DEL MAR;;FRANCÉS FALIP AITANA;;FRANCÉS FALIP JAVIER;;SOLÉ CABANES ANTONIO;;YAMILY VILLALOBOS ARAPA SHIRLEY,,https://lens.org/114-434-682-830-783,Limited Patent,no,0,0,2,2,0,,D03D1/00;;A41D13/11;;A62B17/04;;D03D11/00;;D03D13/00,,0,0,,,,ACTIVE
236,US,A1,US 2020/0083155 A1,175-180-801-145-259,2020-03-12,2020,US 201816128284 A,2018-09-11,US 201816128284 A,2018-09-11,ELECTRICAL ROUTING COMPONENT LAYOUT FOR CROSSTALK REDUCTION,"Apparatuses, systems and methods associated with electrical routing layout of printed circuit boards and integrated circuit substrates are disclosed herein. In embodiments, an apparatus includes a first electrically conductive path that extends through a region, wherein the first electrically conductive path includes a first pad located at a surface of the region, a first via that extends through the region, and a first trace that extends in a first direction. The apparatus further includes a second electrically conductive path that extends through the region, wherein the second electrically conductive path includes a second pad located at the surface and adjacent to the first pad, a second via that extends through the region, and a second trace that extends in a second direction. Other embodiments may be described and/or claimed.",INTEL CORP,ENRIQUEZ SHIBAYAMA RAUL;;BODDU VIJAYA;;PEREZ ACOSTA LUIS NATHAN;;GALARZA MEDINA FRANCISCO JAVIER;;XIAO KAI;;ROSALES-GALVAN LUIS;;LEE BEOM-TAEK;;LIZALDE MORENO CARLOS ALBERTO;;HERNANDEZ SOSA GAUDENCIO;;LIU MO,INTEL CORPORATION (2018-07-25),https://lens.org/175-180-801-145-259,Patent Application,yes,14,0,1,1,0,H05K1/114;;H01L23/49838;;H05K1/0228;;H05K1/0245;;H05K2201/09409;;H05K2201/09609;;H01L23/49838;;H01L23/49816;;H05K1/0245;;H05K1/114;;H05K2201/09236;;H01L2223/6616;;H05K2201/09409;;H05K2201/09609;;H01L2223/6638,H01L23/498;;H05K1/02;;H05K1/11,,0,0,,,,PENDING
237,CL,A1,CL 2020002882 A1,182-508-924-688-181,2021-06-11,2021,CL 2020002882 A,2020-11-06,CO 2018006379 A,2018-06-20,Dispositivo para la interrupción y reconexión automática de circuitos de media tensión instalable en bases intercambiables,"La presente invención se relaciona con dispositivos instalables en bases intercambiables que efectúan la interrupción y posterior reconexión automática de circuitos de media tensión. El dispositivo aquí revelado detecta si se presenta una falla en el circuito eléctrico y efectúa automáticamente la interrupción y posterior reconexión después de un tiempo que depende de las características de la falla detectada y de la configuración del dispositivo. El diseño del dispositivo atenúa el desgaste de los contactos del interruptor de vacío y alarga su vida útil. El dispositivo además se caracteriza por obtener información detallada acerca de las características eléctricas de la línea de media tensión, por ser autoalimentado y porque almacena energía eléctrica, por lo que puede mantener su operación aun cuando no haya corriente en la línea.",CELSA S A S,CÁRDENAS BOTERO JUAN JOSÉ;;DOMÍNGUEZ JARAMILLO SERGIO FERNANDO;;ECHEVERRI ESCOBAR DIVIER ADOLFO;;GONZÁLEZ ELORZA LUZ ADRIANA;;LOPEZ GONZALEZ DANIEL;;PACHON NIÑO KEVIN ANDRES;;ZAPATA ACOSTA CARLOS ALBERTO;;OSORIO RODRIGUEZ CINDY,,https://lens.org/182-508-924-688-181,Patent Application,no,0,0,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H01H33/66;;H01H75/00,,0,0,,,,PENDING
238,ES,U,ES 1247685 U,059-276-068-788-083,2020-06-12,2020,ES 202030711 U,2020-04-24,ES 202030711 U,2020-04-24,"Reusable Face Mask Textile (Machine-translation by Google Translate, not legally binding)","Reusable mask fabric characterized in that it comprises in warp a plurality of polyester multifilaments, with a title range between 75 Dtex and 350 Dtex, while in weft it comprises a plurality of polyethylene or polypropylene multifilaments, with a title range between 150 Dtex and 700 Dtex, the resulting density being both warp and weft is between 10 and 70 threads/cm. (Machine-translation by Google Translate, not legally binding)",ONDYTEC 2018 S L,FRANCÉS VILAPLANA JAVIER;;GRAU LLOPIS CARLOS;;HERRERO MONZÓN ANA;;GÓMEZ ACOSTA RUBÉN;;VERCET SAIZ MARIA DEL MAR;;FRANCÉS FALIP AITANA;;FRANCÉS FALIP JAVIER;;SOLÉ CABANES ANTONIO;;YAMILY VILLALOBOS ARAPA SHIRLEY,,https://lens.org/059-276-068-788-083,Patent Application,no,0,0,2,2,0,,D03D1/00;;A41D13/11;;A62B17/04;;D03D11/00;;D03D13/00,,0,0,,,,ACTIVE
239,BR,A2,BR 112020023046 A2,057-223-900-922-227,2021-04-13,2021,BR 112020023046 A,2019-06-18,IB 2019055104 W;;CO 2018006379 A,2018-06-20,dispositivo para a interrupção e reconexão automática de circuitos de média tensão instalável em bases intercambiáveis,"""dispositivo para a interrupção e reconexão automática de circuitos de média tensão instalável em bases intercambiáveis"". que detecta a ocorrência de qualquer falha no circuito elétrico e realiza automaticamente a interrupção e posterior reconexão após um tempo que vai depender das características da falha detectada e da configuração do dispositivo. o desenho do dispositivo reduz o desgaste dos contatos do interruptor de vácuo e prolonga sua vida útil. o dispositivo também se caracteriza por obter informações detalhadas sobre as características elétricas da linha de média tensão, por ser autoalimentado e por armazenar energia elétrica, e, por isso, pode manter seu funcionamento mesmo quando não houver energia na linha.",CELSA S A S,CARLOS ALBERTO ZAPATA ACOSTA;;CINDY MISHELL OSORIO RODRIGUEZ;;DANIEL LOPEZ GONZALEZ;;DIVIER ADOLFO ECHEVERRI ESCOBAR;;JUAN JOSÉ CÁRDENAS BOTERO;;KEVIN ANDRES PACHON NIÑO;;LUZ ADRIANA GONZÁLEZ ELORZA;;SERGIO FERNANDO DOMÍNGUEZ JARAMILLO,,https://lens.org/057-223-900-922-227,Patent Application,no,0,0,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H02H3/06;;H01H33/66;;H01H75/00,,0,0,,,,PENDING
240,CO,A1,CO 2018006379 A1,064-615-538-836-356,2018-07-10,2018,CO 2018006379 A,2018-06-20,CO 2018006379 A,2018-06-20,Dispositivo para la interrupción y reconexión automática de circuitos de media tensión instalable en bases intercambiables,"RESUMEN [001] La presente invención se relaciona con dispositivos instalables en bases intercambiables que efectúan la interrupción y posterior reconexión automática de circuitos de media tensión. El dispositivo aquí revelado detecta si se presenta una falla en el circuito eléctrico y efectúa automáticamente la interrupción y posterior reconexión después de un tiempo que depende de las características de la falla detectada y de la configuración del dispositivo. El diseño del dispositivo atenúa el desgaste de los contactos del interruptor de vacío y alarga su vida útil. El dispositivo además se caracteriza por obtener información detallada acerca de las características eléctricas de la línea de media tensión, por ser autoalimentado y porque almacena energía eléctrica, por lo que puede mantener su operación aun cuando no haya corriente en la línea.",CELSA S A S,CÁRDENAS BOTERO JUAN JOSÉ;;DOMÍNGUEZ JARAMILLO SERGIO FERNANDO;;GONZÁLEZ ELORZA LUZ ADRIANA;;ECHEVERRI ESCOBAR DIVIER ADOLFO;;LOPEZ GONZALEZ DANIEL;;OSORIO RODRIGUEZ CINDY MISHELL;;PACHON NIÑO KEVIN ANDRES;;ZAPATA ACOSTA CARLOS ALBERTO,,https://lens.org/064-615-538-836-356,Patent Application,no,0,0,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H01H37/00;;H01H37/06;;H01H85/00;;H01H85/28,,0,0,,,,PENDING
241,WO,A1,WO 2019/244034 A1,184-451-970-267-116,2019-12-26,2019,IB 2019055104 W,2019-06-18,CO 2018006379 A,2018-06-20,DEVICE FOR THE AUTOMATIC INTERRUPTION AND RECONNECTION OF MEDIUM-VOLTAGE CIRCUITS WHICH CAN BE INSTALLED IN INTERCHANGEABLE BASES,"The present invention relates to devices which can be installed in interchangeable bases and which interrupt and subsequently automatically reconnect medium-voltage circuits. The device disclosed herein detects whether there is a fault in the electric circuit and effects automatic interruption and subsequent reconnection after a time that depends on the characteristics of the detected fault and on the device configuration. The design of the device reduces the wear of the contacts of the vacuum interrupter and lengthens its useful life. In addition, the device is characterised in that it obtains detailed information regarding the electrical characteristics of the medium-voltage line, is self-powering and stores electrical energy, thereby allowing the device to keep operating even when there is no current in the line.",CELSA S A S,CÁRDENAS BOTERO JUAN JOSÉ;;DOMÍNGUEZ JARAMILLO SERGIO FERNANDO;;ECHEVERRI ESCOBAR DIVIER ADOLFO;;GONZÁLEZ ELORZA LUZ ADRIANA;;LOPEZ GONZALEZ DANIEL;;PACHON NIÑO KEVIN ANDRES;;ZAPATA ACOSTA CARLOS ALBERTO;;OSORIO RODRIGUEZ CINDY MISHELL,,https://lens.org/184-451-970-267-116,Patent Application,yes,5,3,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H01H33/66;;H01H75/00;;H02H3/06,,0,0,,,,PENDING
242,PE,A1,PE 20201439 A1,056-624-227-350-513,2020-12-09,2020,PE 2020001855 A,2019-06-18,CO 2018006379 A;;IB 2019055104 W,2018-06-20,DISPOSITIVO PARA LA INTERRUPCION Y RECONEXION AUTOMATICA DE CIRCUITOS DE MEDIA TENSION INSTALABLE EN BASES INTERCAMBIABLES,"La presente invencion se relaciona con dispositivos instalables en bases intercambiables que efectuan la interrupcion y posterior reconexion automatica de circuitos de media tension. El dispositivo aqui revelado detecta si se presenta una falla en el circuito electrico y efectua automaticamente la interrupcion y posterior reconexion despues de un tiempo que depende de las caracteristicas de la falla detectada y de la configuracion del dispositivo. El diseno del dispositivo atenua el desgaste de los contactos del interruptor de vacio y alarga su vida util. El dispositivo ademas se caracteriza por obtener informacion detallada acerca de las caracteristicas electricas de la linea de media tension, por ser autoalimentado y porque almacena energia electrica, por lo que puede mantener su operacion aun cuando no haya corriente en la linea.",CELSA S A S,CARDENAS BOTERO JUAN JOSE;;DOMINGUEZ JARAMILLO SERGIO FERNANDO;;ECHEVERRI ESCOBAR DIVIER ADOLFO;;GONZALEZ ELORZA LUZ ADRIANA;;LOPEZ GONZALEZ DANIEL;;PACHON NINO KEVIN ANDRES;;ZAPATA ACOSTA CARLOS ALBERTO;;OSORIO RODRIGUEZ CINDY MISHELL,,https://lens.org/056-624-227-350-513,Patent Application,no,0,0,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H01H75/00;;H01H33/66;;H02H3/06,,0,0,,,,PENDING
243,US,A1,US 2020/0412122 A1,156-573-976-289-21X,2020-12-31,2020,US 201916976722 A,2019-06-18,CO 2018006379 A;;IB 2019055104 W,2018-06-20,DEVICE FOR THE AUTOMATIC INTERRUPTION AND RECONNECTION OF MEDIUM-VOLTAGE CIRCUITS WHICH CAN BE INSTALLED IN INTERCHANGEABLE BASES,"The present invention relates to devices which can be installed in interchangeable bases and which interrupt and subsequently automatically reconnect medium-voltage circuits. The device disclosed herein detects whether there is a fault in the electric circuit and effects automatic interruption and subsequent reconnection after a time that depends on the characteristics of the detected fault and on the device configuration. The design of the device reduces the contact wear of vacuum switch and lengthens the useful life thereof. The device is further characterized in that it gathers detailed information regarding electrical characteristics of medium-voltage line; it is self-powering and stores electrical power, thereby allowing the device to keep operating even when there is no current in the line.",CELSA S A S,CÁRDENAS BOTERO JUAN JOSÉ;;DOMÍNGUEZ JARAMILLO SERGIO FERNANDO;;ECHEVERRI ESCOBAR DIVIER ADOLFO;;GONZÁLEZ ELORZA LUZ ADRIANA;;LOPEZ GONZALEZ DANIEL;;PACHON NIÑO KEVIN ANDRES;;ZAPATA ACOSTA CARLOS ALBERTO;;OSORIO ROGRIGUEZ CINDY MISHELL,CELSA S.A.S (2018-06-12),https://lens.org/156-573-976-289-21X,Patent Application,yes,7,1,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H02H3/08;;H01H71/24;;H02H1/00,,0,0,,,,ACTIVE
244,US,B2,US 11764564 B2,032-270-519-378-060,2023-09-19,2023,US 201916976722 A,2019-06-18,CO 2018006379 A;;IB 2019055104 W,2018-06-20,Device for the automatic interruption and reconnection of medium-voltage circuits which can be installed in interchangeable bases,"The present invention relates to devices which can be installed in interchangeable bases and which interrupt and subsequently automatically reconnect medium-voltage circuits. The device disclosed herein detects whether there is a fault in the electric circuit and effects automatic interruption and subsequent reconnection after a time that depends on the characteristics of the detected fault and on the device configuration. The design of the device reduces the contact wear of vacuum switch and lengthens the useful life thereof. The device is further characterized in that it gathers detailed information regarding electrical characteristics of medium-voltage line; it is self-powering and stores electrical power, thereby allowing the device to keep operating even when there is no current in the line.",CELSA S A S,CÁRDENAS BOTERO JUAN JOSÉ;;DOMÍNGUEZ JARAMILLO SERGIO FERNANDO;;ECHEVERRI ESCOBAR DIVIER ADOLFO;;GONZÁLEZ ELORZA LUZ ADRIANA;;LOPEZ GONZALEZ DANIEL;;PACHON NIÑO KEVIN ANDRES;;ZAPATA ACOSTA CARLOS ALBERTO;;OSORIO ROGRIGUEZ CINDY MISHELL,CELSA S.A.S (2018-06-12),https://lens.org/032-270-519-378-060,Granted Patent,yes,21,0,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H02H3/08;;H01H71/24;;H02H1/00;;H02H9/02,,0,0,,,,ACTIVE
245,MX,A,MX 2020013048 A,108-907-602-884-686,2021-02-26,2021,MX 2020013048 A,2019-06-18,CO 2018006379 A;;IB 2019055104 W,2018-06-20,DEVICE FOR THE AUTOMATIC INTERRUPTION AND RECONNECTION OF MEDIUM-VOLTAGE CIRCUITS WHICH CAN BE INSTALLED IN INTERCHANGEABLE BASES.,"The present invention relates to devices which can be installed in interchangeable bases and which interrupt and subsequently automatically reconnect medium-voltage circuits. The device disclosed herein detects whether there is a fault in the electric circuit and effects automatic interruption and subsequent reconnection after a time that depends on the characteristics of the detected fault and on the device configuration. The design of the device reduces the wear of the contacts of the vacuum interrupter and lengthens its useful life. In addition, the device is characterised in that it obtains detailed information regarding the electrical characteristics of the medium-voltage line, is self-powering and stores electrical energy, thereby allowing the device to keep operating even when there is no current in the line.",CELSA S A S,CÁRDENAS BOTERO JUAN JOSÉ;;DOMÍNGUEZ JARAMILLO SERGIO FERNANDO;;ECHEVERRI ESCOBAR DIVIER ADOLFO;;GONZÁLEZ ELORZA LUZ ADRIANA;;LOPEZ GONZALEZ DANIEL;;PACHON NIÑO KEVIN ANDRES;;ZAPATA ACOSTA CARLOS ALBERTO;;OSORIO RODRIGUEZ CINDY MISHELL,,https://lens.org/108-907-602-884-686,Patent Application,no,0,0,8,8,0,H02H3/06;;H01H71/24;;H01H71/24;;H02H1/0007;;H02H3/08,H01H75/00;;H01H33/66;;H02H3/06,,0,0,,,,PENDING
246,MX,A,MX 2015017839 A,011-905-892-338-571,2017-06-19,2017,MX 2015017839 A,2015-12-18,MX 2015017839 A,2015-12-18,DOUBLE STEERABLE VESSEL.,"The present invention consists of a double steerable vessel, constituted by an aerodynamic and hydrodynamic profile between two balloons and a mechanical connection and load structure. This section possesses a structure that allows joining the balloons and distributing the vessel loads efficiently. The invention also enables to house the control systems and those relating to their handling and exploitation functions. Additionally, it possesses the capability to vary its altitude due to it support fluid chamber with a modular ballast compression manifold system, serving as an aid to save lifting fluid. This dual steerable vessel is capable of maintaining and generating a self-contained, autonomous navigation plan according to the application required, as well as the use of all of its functions in the form of manual control. The present invention belongs to the field of aeronautics and marine navigation.",UNIV AUTONOMA DE NUEVO LEON *,MAX SALVADOR HERNANDEZ;;SIMON MARTINEZ MARTINEZ;;JULIO MARTINEZ TORRES;;IVAN ESTEBAN MORALES NIÑO;;GENRRY ROSSVIER CAVAZOS ALMAGUER;;JORGE ALBERTO GONZALEZ GUEVARA;;VICTOR MAXIMO ARREDONDO SOLIS;;JOSE VALENTIN GUZMAN GONZALEZ;;RENE MAURICIO CHAVEZ RODRIGUEZ;;ARMANDO ACOSTA PEREZ;;JOEL GONZALEZ MARROQUIN;;JOSE RUBEN MORONES IBARRA;;MARCO ANTONIO SANROMÁN RESÉNDIZ;;CARLOS ULISES ACOSTA MUÑIZ,,https://lens.org/011-905-892-338-571,Patent Application,no,0,1,1,1,0,,B64B1/06;;B64B1/08;;B64B1/34,,0,0,,,,PENDING
247,WO,A3,WO 2002/036160 A3,056-616-434-795-590,2003-05-30,2003,CU 0100007 W,2001-11-01,CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH;;CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/056-616-434-795-590,Search Report,yes,1,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,2,1,015-688-221-013-431,10.1159/000024268;;10592465,"NAKANO ET AL.: ""Antigen-specific, Ig E-selective unresponsiveness induced by antigen-liposome conjugates"", INT. ARCH. ALLERGY IMMUNOL., vol. 120, no. 3, November 1999 (1999-11-01), XP002209693;;See also references of EP 1334727A2",PENDING
248,BR,A,BR 0107424 A,181-093-619-939-097,2002-10-15,2002,BR 0107424 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,"Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma","""MéTODO PARA OBTENçãO DE ESTRUTURAS ANTIGêNICAS, ESTRUTURA ANTIGêNICA, USO DA MESMA, FORMULAçãO DE VACINA, E, USO DA MESMA"". A presente invenção está relacionada com um método para se obter estruturas antigênicas com alta reatividade cruzada, capazes de intensificar a resposta imune a antígenos peptídicos sistêmica e/ou mucosicamente administrados, e às estruturas químicas obtidas com dito método e as formulações obtidas a partir de ditas estruturas e seus usos. O método descreve a obtenção de novas estruturas dendriméricas a partir da seleção e síntese de dendrímeros, que são ligados subseq³entemente a moléculas portadoras. As estruturas resultantes podem ser usadas convenientemente adjuvadas ou em uma formulação na qual diversos antígenos deste tipo podem ser introduzidos, um efeito sinergístico acontecendo entre esses componentes em relação à reatividade cruzada e à imunogenicidade da resposta obtida. A preparação pode também conter estabilizadores e agentes conservantes. As estruturas antigênicas resultantes podem ser usadas na indústria farmacêutica como formulações de vacina para uso em seres humanos e animais e como parte de sistemas de diagnóstico.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/181-093-619-939-097,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,DISCONTINUED
249,US,B2,US 10993888 B2,000-310-302-970-592,2021-05-04,2021,US 201816228014 A,2018-12-20,US 201816228014 A;;US 201762608254 P;;US 201762608271 P,2017-12-20,Fluorescent nanoparticle compositions for dental bonded restorations,Fluorescent nanoparticle compositions and methods of used for dental bonded restorations are provided herein.,UNIV RES INST INC AUGUSTA,GIANNINI MARCELO;;PACHECO RAFAEL ROCHA;;RUEGGEBERG FREDERICK ALLEN;;MONTERO JORGE RODRIGO SOTO;;MARTINEZ EDUARDO DAVID;;FLORES ALI FRANCISCO GARCIA;;LANCELLOTTI AILLA CARLA ROCHA ACOSTA;;LESSEUX GUILHERME GORGEN;;RETTORI CARLOS;;URBANO RICARDO RODRIGUES,UNIVERSITY OF CAMPINAS (2018-04-02);;AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC (2019-01-29);;AUGUSTA UNIVERSITY (2019-01-24),https://lens.org/000-310-302-970-592,Granted Patent,yes,6,0,2,2,0,C08L33/02;;A61K6/842;;A61K6/17;;C08L33/02;;A61K6/17;;A61K6/842;;A61K6/887;;C01F17/265;;C09K11/7773,A61K6/842;;A61K6/17;;A61K6/887;;C01F17/265;;C08L33/02;;C09K11/77,,4,3,002-264-242-258-728;;005-351-442-339-375;;081-463-516-706-928,10.1021/ja060212h;;16683808;;21264435;;10.1039/c0nr00823k;;pmc3236245;;10.1021/jp2114863,"Mai et al., “High-Quality Sodium Rare-Earth Fluoride Nanocrystals: Controlled Synthesis and Optical Properties,” J. Am. Chem. Soc. 128,6426-6436 (2006).;;Liu et al., “Monodisperse, size-tunable and highly efficient β-NaYF4:Yb,Er(Tm) up-conversion luminescent nanospheres: controllable synthesis and their surface modifications,” J. Mater. Chem. 19, 3546-3553 (2009).;;Zhang, Hua et al., “Composition Tuning the Upconversion Emission in NaYF4:Yb/Tm Hexaplate Nanocrystals”, Nanoscale, 3:963-966 (2011).;;Zou, Peng et al., “Up-Conversion Luminescence of NaYF4:Yb3+/Er3+ Nanoparticles Embedded into PVP Nanotubes with Controllable Diameters”, J. Phys. Chem. C, 116(9) 5787-5791 (2012).",ACTIVE
250,AR,A1,AR 031182 A1,019-950-212-914-592,2003-09-10,2003,AR P010105120 A,2001-11-01,CU 20000242 A,2000-11-03,METODO DE OBTENCION DE ESTRUCTURAS ANTIGENICAS QUE POTENCIAN LA REACTIVIDAD CRUZADA ESPECIFICA Y SU USO EN FORMULACIONES,"La presente se relaciona con el método para la obtencion de estructuras antigénicas de alta reactividad cruzada, capaces de potenciar la respuesta inmune a antígenos peptídicos administrados por vía sistémica y/o mucosal, generando potentes respuestas inmunes así como estructuras químicas resultantes de la aplicacion de este método, formulaciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtencion de nuevas estructuras dendriméricas. Partiendo de la seleccion y síntesis de dendrímeros, que posteriormente son acoplados a moléculas portadoras. Las estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulacion donde pueden introducirse varios antígenos de este tipo, encontrándose un efecto sinérgico entre estos componentes con respecto a la reactividad cruzada y la inmunogenicidad de la respuesta obtenida. Además, la preparacion puede contener, estabilizadores y preservativos. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como formulaciones vacunales tanto para uso humano como veterinario y como parte de sistemas de diagnostico.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/019-950-212-914-592,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,PENDING
251,AU,B2,AU 2002/214938 B2,080-419-429-201-37X,2006-04-13,2006,AU 2002/214938 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,Method for obtaining antigenic structures enhancing specific cross reactivity,,CT INGENIERIA GENETICA BIOTECNOLOGIA,CANO CARLOS DUARTE;;PEREZ ENRIQUE IGLESIAS;;PEREZ HILDA ELISA GARAY;;NIETO GERARDO ENRIQUE GUILLEN;;RICONDO LUIS JAVIER CRUZ;;ARIAS EDUARDO PENTON;;ACOSTA OSVALDO REYES;;RUBIDO JULIO CESAR AGUILAR;;GONZALEZ VERENA LUCILA MUZIO,,https://lens.org/080-419-429-201-37X,Granted Patent,no,1,1,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,A61K39/12;;C12P21/02;;A61K/;;A61K39/00;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
252,AU,A,AU 2002/014938 A,082-742-286-151-32X,2002-05-15,2002,AU 2002/014938 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,Method for obtaining antigenic structures enhancing specific cross reactivity,,CT INGENIERIA GENETICA BIOTECH,RICONDO LUIS JAVIER CRUZ;;RUBIDO JULIO CESAR AGUILAR;;PEREZ ENRIQUE IGLESIAS;;ACOSTA OSVALDO REYES;;PEREZ HILDA ELISA GARAY;;GONZALEZ VERENA LUCILA MUZIO;;NIETO GERARDO ENRIQUE GUILLEN;;CANO CARLOS DUARTE;;ARIAS EDUARDO PENTON,,https://lens.org/082-742-286-151-32X,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,PENDING
253,CN,A,CN 1446094 A,156-361-019-338-687,2003-10-01,2003,CN 01803978 A,2001-11-01,CU 20000242 A,2000-11-03,Method for obtaining antigenic structures enhancing specific cross reactivity,,CENTO DE INGENIERIA GENETICA Y,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/156-361-019-338-687,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
254,MX,A,MX PA03003849 A,022-412-523-911-428,2004-10-15,2004,MX PA03003849 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY.,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/022-412-523-911-428,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,DISCONTINUED
255,WO,A2,WO 2002/036160 A2,035-295-181-352-524,2002-05-10,2002,CU 0100007 W,2001-11-01,CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH;;CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/035-295-181-352-524,Patent Application,yes,0,0,21,21,59,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,PENDING
256,BR,A2,BR 102017027647 A2,083-660-910-554-809,2019-07-09,2019,BR 102017027647 A,2017-12-20,BR 102017027647 A,2017-12-20,nanopartículas com propriedades ópticas de fluorescência e uso,"esta invenção descreve nanopartículas com propriedades ópticas de fluorescência, as quais compreendem nanocristais de nayf4 dopadas com terras raras (er, yb e tm). estas nanopartículas apresentam tamanho de partícula que varia de 100 a 200 nm e atuam em comprimentos de onda específicos, preferencialmente em luz azul (?460 nm) e luz violeta (?400 nm), a fim de aumentar o grau de conversão de materiais restauradores odontológicos.",AUGUSTA UNIV;;UNIV ESTADUAL CAMPINAS UNICAMP,AILLA CARLA ROCHA ACOSTA LANCELLOTTI;;ALI FRANCISCO GARCIA FLORES;;CARLOS RETTORI;;EDUARDO DAVID MARTÍNEZ;;FREDERICK ALLEN RUEGGEBERG;;GUILHERME GORGEN LESSEUX;;JORGE RODRIGO SOTO MONTERO;;MARCELO GIANNINI;;RAFAEL ROCHA PACHECO;;RICARDO RODRIGUES URBANO,,https://lens.org/083-660-910-554-809,Patent Application,no,0,0,2,2,0,,A61K6/16;;A61K6/80;;B82Y5/00,,0,0,,,,ACTIVE
257,MX,A,MX 2020008620 A,091-405-494-030-441,2021-03-25,2021,MX 2020008620 A,2020-08-18,MX 2020008620 A,2020-08-18,COMPOSITION BASED ON A DEGRADED SUBSTRATE OF P. OSTREATUS FOR CONTROLLING HAEMONCHUS CONTORTUS AND THE OBTAINING PROCESS THEREOF.,"The present invention relates to a nematicidal extract obtained from the exhausted or degraded substrate of the edible fungus Pleurotus ostreatus, as well as its production process. Said extract allows controlling the hatching of eggs of the parasite Haemonchus Contortus and its larval stage. Also, the present invention relates to a pharmaceutical composition comprising the nematicidal extract and one or more pharmaceutically acceptable excipients. Further, it can be subjected to a silica gel column fractionation with the solvent system hexane and the ethyl acetate for showing that the fractions obtained with the solvent in the ratio 3:1 to 4:1 preserve the nematicidal activity.",INSTITUTO NAC DE INVESTIGACIONES FORESTALES AGRICOLAS Y PECUARIAS,AGUILAR MARCELINO LILIANA;;GONZÁLEZ CORTAZAR MANASÉS;;MENDOZA DE GIVES PEDRO;;CASTAÑEDA RAMÍREZ GLORIA SARAHÍ;;PINEDA ALEGRÍA JESÚS ANTONIO;;SÁNCHEZ VÁZQUEZ JOSÉ ERNESTO;;SANDOVAL CASTRO CARLOS ALFREDO;;TORRES ACOSTA JUAN FELIPE DE JESÚS,,https://lens.org/091-405-494-030-441,Patent Application,no,0,0,1,1,0,,A01N65/00;;A01P5/00;;A61K36/74;;A61P33/00,,0,0,,,,PENDING
258,BR,B1,BR 102017027647 B1,192-301-760-525-531,2022-05-31,2022,BR 102017027647 A,2017-12-20,BR 102017027647 A,2017-12-20,Nanopartículas com propriedades ópticas de fluorescência e uso,"esta invenção descreve nanopartículas com propriedades ópticas de fluorescência, as quais compreendem nanocristais de nayf4 dopadas com terras raras (er, yb e tm). estas nanopartículas apresentam tamanho de partícula que varia de 100 a 200 nm e atuam em comprimentos de onda específicos, preferencialmente em luz azul (?460 nm) e luz violeta (?400 nm), a fim de aumentar o grau de conversão de materiais restauradores odontológicos.",AUGUSTA UNIV;;UNIV ESTADUAL CAMPINAS UNICAMP,AILLA CARLA ROCHA ACOSTA LANCELLOTTI;;ALI FRANCISCO GARCIA FLORES;;RETTORI CARLOS;;EDUARDO DAVID MARTÍNEZ;;FREDERICK ALLEN RUEGGEBERG;;GUILHERME GORGEN LESSEUX;;JORGE RODRIGO SOTO MONTERO;;GIANNINI MARCELO;;RAFAEL ROCHA PACHECO;;RICARDO RODRIGUES URBANO,,https://lens.org/192-301-760-525-531,Granted Patent,no,0,0,2,2,0,,A61K6/16;;A61K6/80;;B82Y5/00,,0,0,,,,ACTIVE
259,US,A1,US 2019/0183742 A1,100-890-327-499-732,2019-06-20,2019,US 201816228014 A,2018-12-20,US 201816228014 A;;US 201762608254 P;;US 201762608271 P,2017-12-20,Fluorsecent Nanoparticle Compositions for Dental Bonded Restorations,Fluorescent nanoparticle compositions and methods of used for dental bonded restorations are provided herein.,UNIV RES INST INC AUGUSTA,GIANNINI MARCELO;;PACHECO RAFAEL ROCHA;;RUEGGEBERG FREDERICK ALLEN;;MONTERO JORGE RODRIGO SOTO;;MARTINEZ EDUARDO DAVID;;FLORES ALI FRANCISCO GARCIA;;LANCELLOTTI AILLA CARLA ROCHA ACOSTA;;LESSEUX GUILHERME GORGEN;;RETTORI CARLOS;;URBANO RICARDO RODRIGUES,UNIVERSITY OF CAMPINAS (2018-04-02);;AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC (2019-01-29);;AUGUSTA UNIVERSITY (2019-01-24),https://lens.org/100-890-327-499-732,Patent Application,yes,0,0,2,2,0,C08L33/02;;A61K6/842;;A61K6/17;;C08L33/02;;A61K6/17;;A61K6/842;;A61K6/887;;C01F17/265;;C09K11/7773,A61K6/00;;A61K6/04;;A61K6/083,,0,0,,,,ACTIVE
260,CA,A1,CA 2427539 A1,065-872-809-077-712,2003-05-01,2003,CA 2427539 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFICCROSS REACTIVITY,"The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH,REYES ACOSTA OSVALDO;;IGLESIAS PEREZ ENRIQUE;;GARAY PEREZ HILDA ELISA;;AGUILAR RUBIDO JULIO CESAR;;PENTON ARIAS EDUARDO;;CRUZ RICONDO LUIS JAVIER;;GUILLEN NIETO GERARDO ENRIQUE;;MUZIO GONZALEZ VERENA LUCILA;;DUARTE CANO CARLOS,,https://lens.org/065-872-809-077-712,Patent Application,no,0,0,21,21,59,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,DISCONTINUED
261,EA,B1,EA 005313 B1,165-878-006-875-190,2004-12-30,2004,EA 200300535 A,2001-11-01,CU 20000242 A;;CU 0100007 W,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"1. Method for obtaining antigenic structures able to enhance the specific cross reactivity comprising the steps: A) selection of the epitope of interest; B) obtaining of dendrimeric structures with the epitopes selected in (A), using a method of synthesis selected from the following group: 1) synthesis on a nucleus of aspartic acid or lysine; 2) synthesis on a nucleus of organic molecules and 3) direct coupling of peptides on a dendrimeric nucleus, the B and T-cell epitopes can be mixed on the same nucleus; C) conjugation of one or various dendrimeric structures obtained in (B), to one or various carrier molecules using a method of coupling selected from the group consisting in: 1) conjugation using glutaraldehyde, 2) using succinic anhydride, 3) using the ester of the beta -maleimidopropionic-N-hidroxisucci-nimidic acid (MPS), and 4) any method avoiding the use of spacer agents with aromatic side chains; D) mixture of conjugates obtained in the step (C) including the addition of the CD4-binding peptide or a conjugate containing it; and E) adjuvation of the resulting formulation in alum or a any other convenient adjuvant. 2. Method according to claim 1, wherein peptides contained in the structures obtained from step (B) belong to regions from the Human Immunodeficiency virus type 1 or 2. 3. Method according to claim 2, wherein peptides contained in the structures obtained from the step (B) belong to variable regions from the Human Immunodeficiency virus type 1 or 2. 4. Method according to claim 3, wherein peptides contained in the structures obtained from the step (B) belong to the third variable region (V3) from the Human Immunodeficiency Virus 1 or 2. 5. Method for according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to the Hepatitis B Virus. 6. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to the Hepatitis C Virus. 7. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to Dengue Virus. 8. Method according to claim 1, wherein the oligomers contained in the structures obtained from the step (B) belong to polysaccharidic regions from Neisseria meningitidis. 9. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) are mimetic peptides of antigenic polyssacharides. 10. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to antigenic regions from a microorganism or a pathogen. 11. Method according to claim 1, wherein peptides contained in the structures obtained from the step (B) belong to self-antigens. 12. Method according to claim 11, wherein peptides contained in the structures obtained from the step (B) belong to the Gonadotropine Releasing Hormone. 13. Method according to claim 1, wherein the carrier molecule from the step (C) is the Hepatitis B surface antigen, HBsAg. 14. Method according to claim 1, wherein the carrier molecule from the step (C) is the p64K protein from Neisseria meningitidis. 15. Method according to claim 1, wherein the carrier molecule from the step (C) is the core protein from the Human Inmunodeficiency Virus. 16. Method according to claim 1, wherein the-carrier molecule from the step (C) is the hepatitis b core antigen or the Hepatitis C core antigen. 17. Method according to claim 1, wherein the carrier molecule from the step (C) is a polysaccharide. 18. Method according to claim 17, wherein the carrier molecule from the step (C) is a dextran. 19. Method according to claim 1, wherein the carrier molecule and the dendrimeric structure from the step (C) are coupled covalently, electrostatically or by hydrophobicity. 20. Antigenic structure able to enhance the specific cross reactivity comprising dendrimeric antigenic epitopes coupled to carrier proteins. 21. Antigenic structure according to claim 20 wherein the epitopes from the dendrimeric region have peptidic or oligosaccharidic nature. 22. Antigenic structure according to claim 21 wherein the epitopes of peptidic nature are peptidic consensus of variable regions selected from subtypes, subgroups, serotypes or other kind of associations. 23. Antigenic structure according to claim 21 wherein the epitopes of peptidic nature are peptidic libraries from peptidic sequences selected from microorganisms or mimetic peptides. 24. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to the Human Immunodeficiency Virus 1 or 2. 25. Antigenic structure according to claims 24 wherein the epitopes from the dendrimeric peptidic regions belong to variable regions from the Human Immunodeficiency Virus 1 or 2. 26. Antigenic structure according to claim 25 wherein the epitopes from the dendrimeric peptidic regions belong to the V3 variable region from the Human Immunodeficiency Virus 1 or 2. 27. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to regions from the Hepatitis B Virus. 28. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to regions from the Hepatitis C Virus. 29. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to regions from Dengue Virus. 30. Antigenic structure according to claim 21 wherein the epitopes from the dendrimeric peptidic regions belong to polysaccharidic antigens from Neisseria meningitidis. 31. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions are mimetic peptides from polysaccharidic or proteic antigens. 32. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to microorganisms or pathogens. 33. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to self-antigens. 34. Antigenic structure according to claims 21 to 23 wherein the epitopes from the dendrimeric peptidic regions belong to the Gonadotropine Releasing Hormone. 35. Antigenic structure according to claim 20 wherein the carrier molecule is the Hepatitis B Surface Antigen, HBsAg. 36. Antigenic structure according to claim 20 wherein the carrier molecule is the p64K protein from Neisseria meningitidis. 37. Antigenic structure according to claim 20 wherein the carrier molecule is the HIV nucleocapside antigen. 38. Antigenic structure according to claim 20 wherein the carrier molecule is the HBV nucleocapside antigen (HBcAg). 39. Antigenic structure according to claim 20 wherein the carrier molecule is a polysaccharide. 40. Antigenic structure according to claim 39 wherein the carrier molecule is a dextran. 41. Use of the antigenic structure according to claims 20 to 40 in a diagnostic system. 42. Use of the antigenic structure according to claims 20 to 40 in preventive and therapeutic vaccines. 43. Vaccine formulation comprising the antigenic structure of claims 20 to 40 adsorbed or adjuvated conveniently. 44. Vaccine formulation according to claim 43 for systemic or mucosal use. 45. Use of vaccine formulations of claims 43 and 44 to prevent infectious diseases, autoimmunity or cancer. 46. Use of vaccine formulations of claims 43 and 44 to treat infectious diseases, autoimmunity or cancer.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY PEREZ HILDA ELISA;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENTON ARIAS EDUARDO,,https://lens.org/165-878-006-875-190,Granted Patent,no,0,1,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
262,HK,A1,HK 1058154 A1,185-574-033-309-648,2004-05-07,2004,HK 04101011 A,2004-02-13,CU 0100007 W;;CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,,CT INGENIERIA GENETICA BIOTECH,RICONDO LUIS JAVIER CRUZ;;RUBIDO JULIO CESAR AGUILAR;;PEREZ ENRIQUE IGLESIAS;;ACOSTA OSVALDO REYES;;PEREZ HILDA ELISA GARAY;;GONZALEZ VERENA LUCILA MUZIO;;NIETO GERARDO ENRIQUE GUILLEN;;CANO CARLOS DUARTE;;ARIAS EDUARDO PENTON,,https://lens.org/185-574-033-309-648,Patent Application,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P/;;A61P31/00;;A61P31/18;;A61P35/00;;C07K/;;C07K7/08;;C07K14/00;;C07K14/16;;C08G/;;C08G83/00,,0,0,,,,DISCONTINUED
263,ES,T3,ES 2604702 T3,131-062-963-692-876,2017-03-08,2017,ES 11720370 T,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,Método para inhibir la replicación del VIH en células de mamíferos y humanos,"La presente invención describe un método para inhibir la replicación del virus de la inmunodeficiencia humana (VIH) mediante la modulación negativa o alteración del citoesqueleto, específicamente de proteínas que forman parte de los filamentos intermedios del citoesqueleto, más específicamente de las proteínas vimentina y/o queratina-10. La intervención sobre la estructura de estas proteínas causa una inhibición de la replicación del virus en células humanas. La invención se relaciona además con el uso de agentes, que comprenden péptidos y/o ARN interferentes y/o compuestos lipídicos, y producen la modulación negativa o alteración del citoesqueleto celular, para prevenir o tratar la infección por el VIH. La invención proporciona medios y métodos para alterar la estructura del citoesqueleto/filamento de la célula, lo que interfiere con la infección por VIH de las células humanas y que puede incluso ser inhibida completamente. El citoesqueleto es alterado al reducir la cantidad de vimentina y/o queratina-10 (por ejemplo, por control transcripcional utilizando ARN interferentes) o mediante el uso de péptidos que alteran el citoesqueleto.",CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA,FERNANDEZ ORTEGA CELIA;;RAMIREZ SUAREZ ANNA;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR;;CASTELLANOS SERRA LILA;;DUARTE CANO CARLOS;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/131-062-963-692-876,Granted Patent,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K38/17;;A61P31/18;;C12N15/113,,0,0,,,,ACTIVE
264,DE,D1,DE 602005012252 D1,094-979-165-298-510,2009-02-26,2009,DE 602005012252 T,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,VAKZINE-ZUSAMMENSETZUNGEN AUS STREPTOMYCES,,INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,SARMIENTO GARCIA SAN MIGUEL;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,,https://lens.org/094-979-165-298-510,Granted Patent,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,0,0,,,,ACTIVE
265,WO,A1,WO 2005/087259 A1,165-226-282-897-501,2005-09-22,2005,CU 2005000002 W,2005-03-18,CU 20040051 A,2004-03-18,VACCINE COMPOSITIONS WHICH ARE OBTAINED FROM STREPTOMYCES,"The invention relates to the field of immunology and, more specifically, to the control of infectious diseases caused by microbacteria, which is based on the use of vaccines for the prevention of said diseases. The inventive vaccines have been developed with the use of live strains of Streptomyces, which may or may not express antigens of M. tuberculosis, and have demonstrated their protective capacity against the threat of BCG and M. tuberculosis after being administered by different routes. The invention also relates to the use of strains of Streptomyces for the expression of heterologous antigens of vaccinal interest.",INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA;;SARMIENTO GARCIA SAN MIGUEL MA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,SARMIENTO GARCIA SAN MIGUEL MA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,,https://lens.org/165-226-282-897-501,Patent Application,yes,2,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04,,2,1,035-648-418-366-715,11888162;;10.1139/w01-133,"DATABASE WPI Section Ch Week 200379, Derwent World Patents Index; Class B04, AN 2003-849754, XP002334575, KIM C J ET AL.: ""Microorganism Streptomyces sp. amlk-335 producing cyclo(proline-phenylalanine) and cyclo(leucine-proline) useful for preparing an antimicrobial and anticancer composition"";;DONALD TREMBLAY ET AL.: ""High-level hetrologous expression and secretion in Streptomyces lividans of two major antigenic proteins from Mycobacterium tuberculosis"", CANADIAN JOURNAL OF MICROBIOLOGY, vol. 48, 2002, pages 43 - 48, XP002334573",PENDING
266,MY,A,MY 137709 A,158-713-504-253-336,2009-02-27,2009,MY PI20015012 A,2001-10-30,CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES OF HIGH CROSS REACTIVITY AND THEIR USE IN FORMULATIONS,"THE PRESENT INVENTION IS RELATED TO A METHOD FOR OBTAINING NEW ANTIGENIC STRUCTURES, ABLE TO ENHANCE THE IMMUNE RESPONSE TO PEPTIDIC ANTIGENS ADMINISTERED SYSTEMICALLY AND/OR MUCOSALLY, GENERATING STRONG IMMUNE RESPONSES AS WELL AS CHEMICAL STRUCTURES RESULTING FROM THE APPLICATION OF THE METHOD, FORMULATIONS OBTAINED AND THEIR USES. @THE METHOD DESCRIBED IN THE PRESENT INVENTION ENABLES THE OBTENTION OF NEW ANTIGENIC STRUCTURES. STARTING FROM THE SELECTION AND SYNTHESIS OF DENDRIMERS, THEY ARE COUPLED TO CARRIER. THE RESULTING STRUCTURES CAN BE USED ADJUVATED CONVENIENTLY OR IN A FORMULATION OF VARIOUS ANTIGENS. A SYNERGISTIC EFFECT CAN BE FOUND IN THE CROSSREACTIVITY AND IMMUNOGENICITY. FUTHERMORE, THE FORMULATIONS CAN CONTAIN STABILIZERS AND PRESERVES. @THE ANTIGENIC STRUCTURES OF THE PRESENT INVENTION CAN BE USED IN THE PHARMACEUTICAL INDUSTRY AS VACCINE FORMULATIONS TO PREVENT OR TO TREAT DISEASES IN HUMANS AND ANIMALS, AS WELL AS IN THE DEVELOPMENT OF DIAGNOSTIC SYSTEMS.",CT INGENIERIA GENETICA BIOTECH,JAVIER CRUZ RICONDO LUIS;;AGUILAR RUBIDO JULIO CESAR;;ENRIQUE IGLESIAS PEREZ;;OSVALDO REYES ACOSTA;;ELISA GARAY PEREZ HILDA;;LUCILA MUZIO GONZALEZ VERENA;;ENRIQUE GUILL XC N NIETO GERARDO;;CARLOS DUARTE CANO;;EDUARDO PENTON ARIAS,,https://lens.org/158-713-504-253-336,Granted Patent,no,0,0,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,0,0,,,,EXPIRED
267,BR,A,BR PI0508160 A,010-819-259-982-17X,2007-08-07,2007,BR PI0508160 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,composições de vacina obtidas a partir de streptomyces,"COMPOSIçõES DE VACINA OBTIDAS A PARTIR DE STREPTOMYCES. O presente invento se refere ao campo da imunologia e, mais especificamente, ao controle de doenças infecciosas causadas por micobactérias, que é baseado no uso de vacinas para a prevenção de ditas doenças. A vacina de acordo com o presente invento foi desenvolvida com o uso de cepas vivas de STREPTOMYCES, que podem ou não expressar antígenos de M. tuberculosais, e demonstraram sua capacidade protetora contra a ameaça de BCG e M. tuberculosais após serem administrados por rotas diferentes. O presente invento também se refere ao uso de cepas de STREPTOMYCES para a expressão de antígenos heterólogos de interesse de vacina.",INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,MIGUEL MARIA ELENA SARMIENTO G;;DOMINGUEZ ARMANDO ACOSTA;;PLOUS CARLOS ROMAN VALLIN;;ARZUAGA NESTY OLIVARES;;HERNANDEZ YAMILE LOPEZ;;VALDES CARIDAD RODRIGUEZ;;BENITEZ MAXIMO MARTINEZ;;MESA LEONORA GONZALEZ;;BOURZAC JUAN FRANCISCO INFANTE;;MORI ASTRID RAMOS,,https://lens.org/010-819-259-982-17X,Patent Application,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,0,0,,,,DISCONTINUED
268,AU,A1,AU 2005/221262 A1,188-124-717-205-912,2005-09-22,2005,AU 2005/221262 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,Vaccine compositions which are obtained from Streptomyces,,INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,HERNANDEZ YAMILE LOPEZ;;BOURZAC JUAN FRANCISCO INFANTE;;MESA LEONORA GONZALEZ;;PLOUS CARLOS ROMAN VALLIN;;MORI ASTRID RAMOS;;ARZUAGA NESTY OLIVARES;;VALDES CARIDAD RODRIGUEZ;;DOMINGUEZ ARMANDO ACOSTA;;BENITEZ MAXIMO MARTINEZ;;MIGUEL MARIA ELENA SARMIENTO G,,https://lens.org/188-124-717-205-912,Patent Application,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04,,0,0,,,,DISCONTINUED
269,CA,A1,CA 2559633 A1,120-750-376-927-044,2005-09-22,2005,CA 2559633 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,VACCINE COMPOSITIONS WHICH ARE OBTAINED FROM STREPTOMYCES,,INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;RAMOS MORI ASTRID;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;SARMIENTO GARCIA SAN MIGUEL MA;;ACOSTA DOMINGUEZ ARMANDO;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO,,https://lens.org/120-750-376-927-044,Patent Application,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,0,0,,,,INACTIVE
270,EP,B1,EP 1743651 B1,182-630-635-198-070,2009-01-07,2009,EP 05729588 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,VACCINE COMPOSITIONS WHICH ARE OBTAINED FROM STREPTOMYCES,,INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,SARMIENTO GARCIA SAN MIGUEL MA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,,https://lens.org/182-630-635-198-070,Granted Patent,yes,2,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,2,0,,,"DATABASE WPI Section Ch, Week 200379 Derwent Publications Ltd., London, GB; Class B04, AN 2003-849754 XP002334575 KIM C J ET AL.: ""Microorganism Streptomyces sp. amlk-335 producing cyclo(proline-phenylalanine) and cyclo(leucine-proline) useful for preparing an antimicrobial and anticancer composition"" & KR 2003 055 089 A (KOREA RES INST BIOSCIENCE & BIOTECHNOLOG) 2 July 2003 (2003-07-02);;DONALD TREMBLAY ET AL.: ""High-level hetrologous expression and secretion in Streptomyces lividans of two major antigenic proteins from Mycobacterium tuberculosis"" CANADIAN JOURNAL OF MICROBIOLOGY, vol. 48, 2002, pages 43-48, XP002334573",ACTIVE
271,EP,A1,EP 1743651 A1,173-985-675-407-697,2007-01-17,2007,EP 05729588 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,VACCINE COMPOSITIONS WHICH ARE OBTAINED FROM STREPTOMYCES,"The present invention relates to the filed of immunology and, more specifically, to the control of infectious diseases caused by microbacteria, which is based on the use of vaccines for the prevention of said diseases. The inventive vaccines have been developed with the use of live strains of Streptomyces, which may or may not express antigens of M. tuberculosis, and have demonstrated their protective capacity against the threat of BCG and M. tuberculosis after being administered by different routes. The invention also relates to the use of strains of Streptomyces for the expression of heterologous antigens of vaccinal interest.",INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,SARMIENTO GARCIA SAN MIGUEL MA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,,https://lens.org/173-985-675-407-697,Patent Application,yes,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,0,0,,,,ACTIVE
272,MX,A,MX 2013015224 A,187-944-643-095-956,2016-05-26,2016,MX 2013015224 A,2013-12-19,MX 2013015224 A,2013-12-19,PROCESS FOR THE PREPARATION OF A THERMOPLASTIC ELASTOMER FORMULATION REINFORCED WITH TIRE POWDER.,"The present disclosure is related to a process for the preparation of a thermoplastic elastomer formulation reinforced with tire powder, wherein the tire powder acts as a reinforcing agent as a result of a superficial modification. The formulations include the addition of a crosslinking agent that promotes an increase in the formulations strength while the Young's module is substantially dependent on the superficial modification of the tire powder, thereby obtaining an improvement of up to 207% in the module. The formulations obtained by the process of the present invention are reprocessable and can be used in the automotive or the construction industries, among other applications.",CT DE INVESTIG EN QUIMICA APLICADA,ORTA CARLOS ALBERTO AVILA;;VELAZQUEZ MARIA GUADALUPE NEIRA;;MORONES PABLO GONZALEZ;;HERNANDEZ ERNESTO HERNANDEZ;;ACOSTA YADIRA KARINA REYES;;CESPEDES ROSA IDALIA NARRO;;FERNANDEZ OLIVERIO SANTIAGO RODRIGUEZ;;GAMEZ JOSE FRANCISCO HERNANDEZ;;AGUIÑAGA MARIA ELENA RAMOS,,https://lens.org/187-944-643-095-956,Patent Application,no,0,0,1,1,0,Y02W30/62,C08J11/06;;C08L23/06;;C08L23/16,,0,0,,,,PENDING
273,KR,A,KR 20070026454 A,087-040-492-474-555,2007-03-08,2007,KR 20067021156 A,2006-10-12,CU 20040051 A,2004-03-18,VACCINE COMPOSITIONS WHICH ARE OBTAINED FROM STREPTOMYCES,"The invention relates to the field of immunology and, more specifically, to the control of infectious diseases caused by microbacteria, which is based on the use of vaccines for the prevention of said diseases. The inventive vaccines have been developed with the use of live strains of Streptomyces, which may or may not express antigens of M. tuberculosis, and have demonstrated their protective capacity against the threat of BCG and M. tuberculosis after being administered by different routes. The invention also relates to the use of strains of Streptomyces for the expression of heterologous antigens of vaccinal interest. ® KIPO & WIPO 2007",INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,SARMIENTO GARCIA SAN MIGUEL MA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,,https://lens.org/087-040-492-474-555,Patent Application,no,0,3,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/04;;A61K39/00;;A61P37/00,,0,0,,,,DISCONTINUED
274,MX,A,MX 9707071 A,087-820-041-678-863,1997-11-29,1997,MX 9707071 A,1997-01-17,CU 9700001 W;;CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS.,"The present invention relates to biotechnology and genetic engineering, particularly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an oppropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 aminoacids of the antigen P64k of Neisseria meningitidis B:4 :P1.15. In particular, use is made of a recombinant plasmide containing said sequence, under the control of the triptophane promotor of E. coli and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.",CT INGENIERIA GENETICA BIOTECH,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGU RICARDO DE LA CARIDAD;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL,,https://lens.org/087-820-041-678-863,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
275,MX,A,MX 2017014763 A,194-908-372-319-334,2019-05-20,2019,MX 2017014763 A,2017-11-17,MX 2017014763 A,2017-11-17,MATERIALS FOR THE PRODUCTION OF ELECTROCHEMICAL SENSORS AND THE MANUFACTURING PROCESS.,"The present disclosure is related to a process for the treatment of urea suspensions and mixtures of urea with different nanometric materials in non-polar organic solvents, under thermal treatment conditions in an autoclave; the process is carried out in a temperature range that goes from 200°C to 300°C, using time intervals ranging from two to 24 hours. The methodology allows the preparation in a high performance single step of the compounds of nanometric materials with oxidized graphitic carbon nitrides; offering advantages over traditional thermolysis methods that achieve low yields (<10%) of unoxidized material and avoids the need to perform subsequent steps to achieve oxidation and doping. The use of the compounds as a raw material for the manufacture of electrochemical sensor prototypes to detect micromolar amounts of hydrogen peroxide is also described.",CENTRO DE INVESTIGACION EN QUIM APLICADA,SALVADOR FERNANDEZ TAVIZON;;CARLOS ALBERTO GALLARDO VEGA;;MANUEL EDUARDO MARTINEZ CARTAGENA;;JORGE ROMERO GARCÍA;;URIEL ALEJANDRO SIERRA GÓMEZ;;EDGAR CUARA DÍAZ;;JESUS ALFONSO MERCADO SILVA;;JOSÉ ROMÁN TORRES LUBIÁN;;TAMARA PIÑA KRASNOHIRA;;DIANA MORALES ACOSTA,,https://lens.org/194-908-372-319-334,Patent Application,no,0,2,1,1,0,,C01B21/06,,0,0,,,,PENDING
276,MX,A,MX PA06010616 A,115-385-301-321-407,2007-07-04,2007,MX PA06010616 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,VACCINE COMPOSITIONS WHICH ARE OBTAINED FROM STREPTOMYCES.,"The invention relates to the field of immunology and, more specifically, to the control of infectious diseases caused by microbacteria, which is based on the use of vaccines for the prevention of said diseases. The inventive vaccines have been developed with the use of live strains of Streptomyces, which may or may not express antigens of M. tuberculosis, and have demonstrated their protective capacity against the threat of BCG and M. tuberculosis after being administered by different routes. The invention also relates to the use of strains of Streptomyces for the expression of heterologous antigens of vaccinal interest.",INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,ACOSTA DOMINGUEZ ARMANDO;;SARMIENTO GARCIA SAN MIGUEL MARIA ELENA;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,,https://lens.org/115-385-301-321-407,Patent Application,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,0,0,,,,ACTIVE
277,CA,C,CA 2559633 C,107-115-605-184-632,2011-09-06,2011,CA 2559633 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,VACCINE COMPOSITIONS OBTAINED FROM STREPTOMYCES,"The invention relates to the field of immunology and, more specifically, to the control of infectious diseases caused by microbacteria, which is based on the use of vaccines for the prevention of said diseases. The inventive vaccines have been developed with the use of live strains of Streptomyces, which may or may not express antigens of M. tuberculosis, and have demonstrated their protective capacity against the threat of BCG and M. tuberculosis after being administered by different routes. The invention also relates to the use of strains of Streptomyces for the expression of heterologous antigens of vaccinal interest.",INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUERO S;;CT DE QUIMICA FARMACEUTICA,SARMIENTO GARCIA SAN MIGUEL MARIA ELENA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN;;OLIVARES ARZUAGA NESTY;;LOPEZ HERNANDEZ YAMILE;;RODRIGUEZ VALDES CARIDAD;;MARTINEZ BENITEZ MAXIMO;;GONZALEZ MESA LEONORA;;INFANTE BOURZAC JUAN FRANCISCO;;RAMOS MORI ASTRID,,https://lens.org/107-115-605-184-632,Granted Patent,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/04;;A61P15/00;;A61P35/00;;A61P37/00,,0,0,,,,INACTIVE
278,MX,A,MX 2021002741 A,167-171-492-906-59X,2021-06-23,2021,MX 2021002741 A,2021-03-08,MX 2021002741 A,2021-03-08,COMPOSITION BASED ON DEGRADED SUBSTRATE OF PLEUROTUS DJAMOR FOR CONTROLLING HAEMONCHUS CONTORTUS AND THE OBTAINING PROCESS THEREOF.,"The present invention relates to a nematicidal extract obtained from the exhausted or degraded substrate of the edible fungus Pleurotus Djamor and the production process thereof. Said extract allows controlling the hatching of eggs of the parasite Haemonchus Contortus, the larval stage of the parasite H. Contortus, and both. Also, it comprises the nematicidal extract and one or more pharmaceutically acceptable excipients subjected to a silica gel column fractionation with the hexane-ethyl acetate solvent system, showing that the fractions obtained with said solvent preserve the nematicidal activity.",INSTITUTO NAC DE INVESTIGACIONES FORESTALES AGRICOLAS Y PECUARIAS,GONZÁLEZ CORTÁZAR MANASÉS;;AGUILAR MARCELINO LILIANA;;ZAMILPA ÁLVAREZ ALEJANDRO;;PINEDA ALEGRÍA JESÚS ANTONIO;;SÁNCHEZ VÁZQUEZ JOSÉ ERNESTO;;SANDOVAL CASTRO CARLOS ALFREDO;;TORRES ACOSTA JUAN FELIPE DE JESÚS;;MANCILLA MONTELONGO MARÍA GABRIELA;;CASTAÑEDA RAMÍREZ GLORIA SARAHI,,https://lens.org/167-171-492-906-59X,Patent Application,no,0,0,1,1,0,,A61K36/07;;A01P5/00;;A61K31/185,,0,0,,,,PENDING
279,US,A1,US 2007/0292452 A1,117-146-282-387-471,2007-12-20,2007,US 59322505 A,2005-03-18,CU 20040051 A;;CU 2005000002 W,2004-03-18,Vaccine Compositions Which Are Obtained From Streptomyces,"The present invention relates to the field of immunology, specifically to the control of infectious diseases caused by mycobacteria using vaccines developed from live strains of Streptomyces , expressing or not antigens of M. tuberculosis , which demonstrated their protective capacity against challenge with BCG and M. tuberculosis after being administered by different routes.",MIGUEL MARIA ELENA SARMIENTO G;;DOMI NGUEZ ARMANDO ACOSTA;;PLOUS CARLOS ROMAN V;;ARZUAGA NEST O;;HERNANDEZ YAMILE L;;VALDES CARIDAD R;;BENITEZ MAXIMO M;;MESA LEONORA G;;BOURZAC JUAN FRANCISCO I;;MORI ASTRID R,MIGUEL MARIA ELENA SARMIENTO G;;DOMI NGUEZ ARMANDO ACOSTA;;PLOUS CARLOS ROMAN V;;ARZUAGA NEST O;;HERNANDEZ YAMILE L;;VALDES CARIDAD R;;BENITEZ MAXIMO M;;MESA LEONORA G;;BOURZAC JUAN FRANCISCO I;;MORI ASTRID R,,https://lens.org/117-146-282-387-471,Patent Application,yes,1,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/02;;A61K39/00;;A61K39/04;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00,424/203.1;;424/234.1,0,0,,,,DISCONTINUED
280,EP,A2,EP 1334727 A2,054-611-976-348-124,2003-08-13,2003,EP 01983427 A,2001-11-01,CU 0100007 W;;CU 20000242 A,2000-11-03,METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY,"The present invention is related to a method for obtaining antigenic structures with high cross reactivity, able to enhance the immune response to peptidic antigens administered systemically and/or mucosally, as well as with the chemical structures obtained from this method, and with formulations obtained and their uses. The method described in the present invention enables the obtaining of new antigenic structures, starting from the selection and synthesis of dendrimers, which are coupled to carrier molecules. The resulting structures can be used adjuvated conveniently or in a formulation of various antigens. A synergistic effect can be found in the cross reactivity and immunogenicity. Furthermore, the formulations may contain stabilizers and preserves. The antigenic structures of the present invention can be used in the pharmaceutical industry as vaccine formulations to prevent or to treat diseases in humans and animals, as well as in the development of diagnostic systems.",CT INGENIERIA GENETICA BIOTECH,CRUZ RICONDO LUIS JAVIER;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;REYES ACOSTA OSVALDO;;GARAY P REZ HILDA ELISA;;MUZIO GONZ LEZ VERENA LUCILA;;GUILL N NIETO GERARDO ENRIQUE;;DUARTE CANO CARLOS;;PENT N ARIAS EDUARDO,,https://lens.org/054-611-976-348-124,Patent Application,yes,1,1,21,21,0,A61K39/12;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/292;;A61K39/385;;A61K47/646;;A61K2039/545;;A61K2039/6031;;A61K2039/6075;;A61K2039/645;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P43/00;;C07K7/08;;C08G83/003;;C12N2730/10134;;C12N2740/16034;;C12N2770/24234;;Y02A50/30,C12P21/02;;A61K/;;A61K39/00;;A61K39/12;;A61K39/21;;A61K39/29;;A61K39/385;;A61K47/48;;A61P31/00;;A61P31/18;;A61P35/00;;C07K7/08;;C07K14/00;;C07K14/16;;C08G83/00,,6,4,170-782-665-410-754;;011-325-090-999-852;;022-217-950-107-369;;030-969-890-444-663,10.1002/(sici)1099-1387(200005)6:5<217::aid-psc242>3.0.co;2-u;;10.1002/(sici)1099-1387(200005)6:5<217::aid-psc242>3.3.co;2-l;;10823490;;10.1016/0264-410x(95)00072-9;;8578819;;10596755;;10.1016/s1050-3862(99)00019-4;;1925584;;10.1126/science.1925584;;10.1126/science.254.5029.285,"CRUZ L.J.: ""Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice."", J PEPT SCI., vol. 6, no. 5, May 2000 (2000-05-01), pages 217-24;;RAJADHYAKSHA M. ET AL: ""Immunological evaluation of three generations of anti-idiotype vaccine: study of B and T cell responses following priming with anti-idiotype, anti-idiotype peptide and its MAP structure."", VACCINE, vol. 13, no. 15, 1 January 1995 (1995-01-01), BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, pages 1421 - 1426, XP004057451;;CANO C.A.: ""The multi-epitope polypeptide approach in HIV-1 vaccine development"", GENETC ANALYSIS: BIOMOLECULAR ENGINEERING, vol. 15, no. 3-5, November 1999 (1999-11-01), pages 149-153, XP009079077, DOI: doi:10.1016/S1050-3862(99)00019-4;;WANG C.Y. ET AL: ""Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen"", SCIENCE, vol. 254, no. 285, 1991, pages 285-254;;""Trilateral Project B3b: Mutual understanding in search and examination - Report on Comparative study on biotechnology patent practices; Theme: Comparative study on ?reach-through claims?"", SAN FRANCISCO, CALIFORNIA; NOVEMBER 5-9, 2001, 5 November 2001 (2001-11-05), Retrieved from the Internet <URL:http://www.trilateral.net/projects/biotechnology/reach_through_claims/B3b_reachthrough_text.pdf>;;See also references of WO 0236160A3",DISCONTINUED
281,CU,A1,CU 23460 A1,051-551-056-111-481,2009-12-01,2009,CU 20040051 A,2004-03-18,CU 20040051 A,2004-03-18,COMPOSICIONES VACUNALES OBTENIDAS A PARTIR DE STREPTOMYCES,"La presente invención se relaciona con el campo de la inmunología, específicamente con composiciones vacunales a partir de Streptomyces para la prevención de enfermedades infecciosas, tumorales, alérgicas y autoinmunes. Las composiciones vacunales comprenden una o más cepas salvajes del género Streptomyces o cepas mutantes o recombinantes expresando antígenos heterólogos derivados de las mismas, específicamente pueden emplearse cepas vivas de Streptomyces lividans, Sterptomyces coelicolor y Streptomyces Sp.",INST FINLAY CT DE INVESTIGACIO;;CT DE QUIMICA FARMACEUTICA,GONZALEZ MESA LEONORA;;RAMOS MORI ASTRID;;RODRIGUEZ VALDES CARIDAD;;OLIVARES ARZUAGA NESTY;;MARTINEZ BENITEZ MAXIMO BERTO;;INFANTE BOURZAC JUAN FRANCISCO;;LOPEZ HERNANDEZ YAMILE;;SARMIENTO GARCIA SAN MIGUEL MARIA ELENA;;ACOSTA DOMINGUEZ ARMANDO;;VALLIN PLOUS CARLOS ROMAN,,https://lens.org/051-551-056-111-481,Limited Patent,no,0,0,18,18,0,A61K39/00;;A61K39/04;;A61K2039/523;;A61P15/00;;A61P15/18;;A61P31/04;;A61P31/06;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/08;;A61K39/04;;A61K39/00;;A61K39/00;;A61K2039/523;;A61K39/04,A61K39/00;;A61K39/02;;A61K39/04;;A61P31/06;;A61P35/00;;A61P37/00,,0,0,,,,EXPIRED
282,BR,A2,BR 112012025092 A2,011-596-862-926-94X,2017-01-10,2017,BR 112012025092 A,2011-04-01,CU 2011000001 W;;CU 20100056 A,2010-04-01,método para inibir a replicação do hiv em células de mamíferos e em seres humanos,"método para inibir a replicação do hiv em células de mamíferos e em seres humanos. a presente invenção refere-se a um método para inibir a replicação do vírus da imunodeficiência humana (hiv) por meio da modulação negativa ou alteração do citoesqueleto, especificamente de proteínas que fazem parte dos filamentos intermediários do citoesqueleto, mais especifiamente das proteínas vimentina e/ou queratina-10. a invenção sobre a estrutura dessas proteínas causa uma inibição da replicação do vírus em células humanas. a invenção também se refere ao uso de agentes que compreendem peptídeos e/ou rna interferentes e/ou compostos lipídicos, e produzem a modulação negativa ou alteração do citoesqueleteo celular, para a prevenção ou tratamento da infecção pelo hiv. a invenção provê meios e métodos para alterar a estrutura do citoesqueleto/filamento da célula, o que interfere na infeção pelo hiv das células humanas e que pode inclusive ser inibido completamente. o citoesqueleto é alterado ao reduzir a quantidade de vitamina e/ou queratina-10 (por exemplo, por meio do controle transcricional ao utilziar rna interferentes) ou por meio do uso de peptídeos que alteram o citoesqueleto.",CT INGENIERIA GENETICA BIOTECH,SUAREZ ANNA CARIDYS RAMIREZ;;CANO CARLOS ANTONIO DUARTE;;ORTEGA CELIA BERTA FERNANDEZ;;LEYVA LEONOR MARGARITA NAVEA;;SERRA LILA ROSA CASTELLANOS;;ECHEVARRIA MARTA DUBED;;ACOSTA OSVALDO REYES;;GOMEZ RAIMUNDO UBIETA;;GUERRERO TAIMI EMELIA PANEQUE;;CAMA VIVIANA FALCON,,https://lens.org/011-596-862-926-94X,Patent Application,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K38/17;;A61K31/5575;;A61K31/7105;;A61P31/18;;C07C405/00;;C07K14/47;;C12N15/113,,0,0,,,,ACTIVE
283,MY,A,MY 141912 A,015-537-291-761-39X,2010-07-30,2010,MY PI20064171 A,2006-09-19,MY PI20064171 A,2006-09-19,VACCINE COMPOSITIONS OBTAINED FROM STREPTOMYCES,"THE INVENTION RELATES TO FIELD OF IMMUNOLOGY AND MORE SPECIFICALLY TO THE CONTROL OF INFECTIOUS DISEASES CAUSED BY MICROBACTERIA WHICH IS BASED ON THE USE OF VACCINES FOR THE PREVENTION OF SAID DISEASES. THE INVENTIVE VACCINES HAVE BEEN DEVELOPED WITH THE USE OF LIVE STRAINS OF STRPTOMYCES, WHICH MAYOR MAY NOT EXPRESS ANTIGENS OF M. TUBERCULOSIS AND HAVE DEMONSTRATED THEIR PROTECTIVE CAPACITY AGAINST THE THREAT BCG AND M.TUBERCULOSIS AFTER BEING ADMINISTRATED BY DIFFERENT ROUTES. THE INVENTION ALSO RELATES TO THE USE OF STRAINS OF STREPTOMYCES FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS OF VACCINAL INTEREST.",INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS;;CT DE QUIMICA FARMACEUTICA,MIGUEL MARIA ELENA SARMIENTO GARCIA SAN;;MESA LEONORA GONZALEZ;;DOMINGUEZ ARMANDO ACOSTA;;PLOUS CARLOS ROMAN VALLIN;;ARZUAGA NESTY OLIVARES;;HERNANDEZ YAMILE LOPEZ;;VALDES CARIDAD RODRIGUEZ;;BENITEZ MAXIMO BERTO MARTINEZ;;BOURZAC JUAN FRANCISCO INFANTE;;MORI ASTRID RAMOS,,https://lens.org/015-537-291-761-39X,Granted Patent,no,0,0,1,1,0,,A61K39/00,,0,0,,,,ACTIVE
284,MX,A,MX 2018002972 A,080-863-144-735-651,2019-09-10,2019,MX 2018002972 A,2018-03-09,MX 2018002972 A,2018-03-09,DEVICE FOR THE AUTOMATIC DETERMINATION OF FOAM TEXTURE.,"The present disclosure is related to a device, hereinafter referred to as Texturometer (TM), to automatically determine, qualitatively and quantitatively, the texture of foams composed of fluids and gases, both in the laboratory and in the field. All of the above is carried out as follows: a) Obtain digital micrographs of foams, preferably with high resolution; and b) Treat digital micrographs, using a graphical interface and a computer program, to automatically determine their textural properties: integration of the shape, average size and distribution of sizes of diameters of the bubbles in the foam. The present invention is used in different industries, but in particular in the oil industry; where the foam is used for prevention and control of conflagrations, recovery processes, drilling, distillation, fractionation, fracturing, acidification, gas mobility, clogging, derivation and other applications.",MEXICANO INST PETROL,FLORENTINO LEYTE GUERRERO;;DAVID VELÁZQUEZ CRUZ;;GALICIA MABEL ACOSTA GARATE;;ALEJANDRO ORTEGA RODRÍGUEZ;;RICARDO TAPIA HERRERA;;CARLOS ARTURO GONZALEZ LÓPEZ;;MANUEL ANTONIO CHI CHIM;;RODRIGO BUERHEND OROZCO;;FEDERICO GUTIERREZ CORIA;;NOÉ ESTÉVEZ LEAL;;ISIDRO RAÚL CANO MARTÍNEZ,,https://lens.org/080-863-144-735-651,Patent Application,no,0,0,1,1,0,,G06T15/04;;C08J9/28,,0,0,,,,PENDING
285,WO,A3,WO 2015/025255 A3,084-921-727-454-745,2015-05-28,2015,IB 2014063934 W,2014-08-15,CO 13196767 A,2013-08-20,"ORTHODONTIC TOOL FOR THE PLACEMENT, POSITIONING AND ATTACHING OF BRACKETS ON THE VESTIBULAR SURFACE OF THE TOOTH","The invention relates to an orthodontic tool for the placement, positioning and attaching of brackets using a direct or indirect method, said tool comprising two parts: a body for manipulating the device (1) and a point (2). The shape of the body (1) is compatible with the hand and offers the user control and comfort when arranging the bracket (100) on the target - the target being the mesiodistal centre of the dental piece or tooth - at a predetermined height (202), resulting in precision and accuracy.",UNIV NAC DE COLOMBIA,GARCÍA ACOSTA GABRIEL;;LANGE MORALES KAREN;;PUENTES LAGOS DAVID ERNESTO;;PARADA PARADA SARA ESTELA;;RUÍZ ORTIZ MANUEL RICARDO;;GARZÓN PACHECO ANA MARÍA;;LEÓN CASTELLANOS WILLIAM RICARDO;;ÁLVAREZ JUAN RICARDO;;VANEGAS MATA CARLOS JULIO;;NUÑEZ VILORIA JHON WALTHER,,https://lens.org/084-921-727-454-745,Search Report,yes,8,0,4,4,0,A61C7/146;;A61C7/146;;A61C7/02;;A61C7/02,A61C7/02,,0,0,,,,PENDING
286,US,A1,US 2016/0302888 A1,075-592-303-073-956,2016-10-20,2016,US 201414913307 A,2014-08-15,CO 13196767 A;;IB 2014063934 W,2013-08-20,"ORTHODONTIC TOOL FOR THE PLACEMENT, POSITIONING AND ATTACHING OF BRACKETS ON THE VESTIBULAR SURFACE OF THE TOOTH","The invention relates to an orthodontic tool for the placement, positioning and attaching of brackets using a direct or indirect method, said tool comprising two parts: a body for manipulating the device ( 1 ) and a point ( 2 ). The shape of the body ( 1 ) is compatible with the hand and offers the user control and comfort when arranging the bracket ( 100 ) on the target—the target being the mesiodistal centre of the dental piece or tooth—at a predetermined height ( 202 ), resulting in precision and accuracy.",UNIV NAC DE COLOMBIA,GARCÍA ACOSTA GABRIEL;;LANGE MORALES KAREN;;PUENTES LAGOS DAVID ERNESTO;;PARADA PARADA SARA ESTELA;;RUIZ ORTIZ MANUEL RICARDO;;GARZÓN PACHECO ANA MARÍA;;LEÓN CASTELLANOS WILLIAM RICARDO;;ÁLVAREZ JUAN RICARDO;;VANEGAS MATA CARLOS JULIO;;NUÑEZ VILORIA JHON WALTHER,UNIVERSIDAD NACIONAL DE COLOMBIA (2016-03-09),https://lens.org/075-592-303-073-956,Patent Application,yes,8,5,4,4,0,A61C7/146;;A61C7/146;;A61C7/02;;A61C7/02,A61C7/14,,0,0,,,,DISCONTINUED
287,MX,B,MX 369635 B,004-736-274-596-145,2019-10-17,2019,MX 2015017291 A,2015-12-14,MX 2015017291 A,2015-12-14,INSULATION SYSTEM AND METHOD FOR SUPERSTRUCTURE BASES.,"The present disclosure is related to an insulation system for superstructure bases, characterized in that the same comprises at least one foundation slab, a plate or a bottom base defining a smooth flat top surface arranged on the firm ground or on another structure which in turn has to be arranged on the firm ground; a top plate disposed on said foundation slab, plate or bottom base, comprising a flat, smooth lower surface and defining at least one hydraulic cavity in the overlapping surface of said upper plate, foundation slab, plate or lower base, capable of containing a pressurized working fluid injected through hydraulic apertures in a pipe provided with said pressurized working fluid, wherein said pipe is embedded or housed in said top plate or foundation slab and connected to a pressurized working fluid reservoir. The upper plate is connected to the ground or to a structure fixed to the ground or to the foundation slab, plate or bottom base by means of a damping element. A meth od is also presented, an isolation unit allowing implementing the method, and a shuttering allowing building the same in a simple and economic way.",INST TECNOLOGICO Y DE ESTUDIOS SUPERIORES DE OCCIDENTE A C,DAVID VARGAS DEL RIO;;RAFAEL VARGAS BERRUETA;;CARLOS ALONSO GRANDE ALDANA;;LUIS EDGARDO REYNOSO ÁLVAREZ;;LUIS ABRAHAM GARCÍA LEAL;;ALAN RODRÍGUEZ ACOSTA;;NAYAR CUITLAHUAC GUTIÉRREZ ASTUDILLO;;RAÚL ARTURO GARCÍA HUERTA;;CÉSAR REAL DIEZ MARTÍNEZ;;ALFREDO CUEVA ZEPEDA,,https://lens.org/004-736-274-596-145,Granted Patent,no,0,0,2,2,0,,E04H9/02;;E04B1/98,,0,0,,,,ACTIVE
288,WO,A2,WO 2015/025255 A2,177-304-015-394-674,2015-02-26,2015,IB 2014063934 W,2014-08-15,CO 13196767 A,2013-08-20,"ORTHODONTIC TOOL FOR THE PLACEMENT, POSITIONING AND ATTACHING OF BRACKETS ON THE VESTIBULAR SURFACE OF THE TOOTH","The invention relates to an orthodontic tool for the placement, positioning and attaching of brackets using a direct or indirect method, said tool comprising two parts: a body for manipulating the device (1) and a point (2). The shape of the body (1) is compatible with the hand and offers the user control and comfort when arranging the bracket (100) on the target - the target being the mesiodistal centre of the dental piece or tooth - at a predetermined height (202), resulting in precision and accuracy.",UNIV NAC DE COLOMBIA,GARCÍA ACOSTA GABRIEL;;LANGE MORALES KAREN;;PUENTES LAGOS DAVID ERNESTO;;PARADA PARADA SARA ESTELA;;RUÍZ ORTIZ MANUEL RICARDO;;GARZÓN PACHECO ANA MARÍA;;LEÓN CASTELLANOS WILLIAM RICARDO;;ÁLVAREZ JUAN RICARDO;;VANEGAS MATA CARLOS JULIO;;NUÑEZ VILORIA JHON WALTHER,,https://lens.org/177-304-015-394-674,Patent Application,yes,0,2,4,4,0,A61C7/146;;A61C7/146;;A61C7/02;;A61C7/02,A61C8/00,,0,0,,,,PENDING
289,MX,A,MX 2015017291 A,054-896-457-470-082,2017-06-13,2017,MX 2015017291 A,2015-12-14,MX 2015017291 A,2015-12-14,INSULATION SYSTEM AND METHOD FOR SUPERSTRUCTURE BASES.,"The present disclosure is related to an insulation system for superstructure bases, characterized in that the same comprises at least one foundation slab, a plate or a bottom base defining a smooth flat top surface arranged on the firm ground or on another structure which in turn has to be arranged on the firm ground; a top plate disposed on said foundation slab, plate or bottom base, comprising a flat, smooth lower surface and defining at least one hydraulic cavity in the overlapping surface of said upper plate, foundation slab, plate or lower base, capable of containing a pressurized working fluid injected through hydraulic apertures in a pipe provided with said pressurized working fluid, wherein said pipe is embedded or housed in said top plate or foundation slab and connected to a pressurized working fluid reservoir. The upper plate is connected to the ground or to a structure fixed to the ground or to the foundation slab, plate or bottom base by means of a damping element. A meth od is also presented, an isolation unit allowing implementing the method, and a shuttering allowing building the same in a simple and economic way.",INST TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE OCCIDENTE A C,DAVID VARGAS DEL RIO;;RAFAEL VARGAS BERRUETA;;CARLOS ALONSO GRANDE ALDANA;;LUIS EDGARDO REYNOSO ÁLVAREZ;;LUIS ABRAHAM GARCÍA LEAL;;ALAN RODRÍGUEZ ACOSTA;;NAYAR CUITLAHUAC GUTIÉRREZ ASTUDILLO;;RAÚL ARTURO GARCÍA HUERTA;;CÉSAR REAL DIEZ MARTÍNEZ;;ALFREDO CUEVA ZEPEDA,,https://lens.org/054-896-457-470-082,Patent Application,no,0,0,2,2,0,,E04B1/00,,0,0,,,,ACTIVE
290,DK,T3,DK 0816506 T3,111-972-502-386-136,2001-05-21,2001,DK 97901516 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,System til ekspression af heterologe antigener som fusionsproteiner,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO AVENID;;MARTIN DUNN ALEJANDRO MIGUEL A,,https://lens.org/111-972-502-386-136,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
291,ES,A1,ES 2590217 A1,143-619-803-802-838,2016-11-18,2016,ES 201500365 A,2015-05-18,ES 201500365 A,2015-05-18,"Inhibitor of vibrations in elongated objects subjected to impacts, blows and any type of thrust (Machine-translation by Google Translate, not legally binding)","Inhibitor of vibrations in elongated objects subjected to impacts, blows and any type of thrust. It consists of an element, called redistribution of internal mass, based on an internal system of masses distributed along the object, through which it is possible to move the center of percussion along the same, making it match the vibration node, as consequence of the change of the center of the masses. The invention optimizes the physicochemical and technical-structural parameters in order to reduce the damaging effects for the users, produced by the manipulation of elongated instruments as a consequence of the torsional and vibrational effects that take place. The sectors to which they are directed are the sports sector, as well as that of the public security forces and corps, armed forces, private security, port police, customs surveillance and similar. (Machine-translation by Google Translate, not legally binding)",UNIV CADIZ,FERNANDEZ ZACARIAS FRANCISCO;;AYUSO VILACIDES JESÚS;;RUIZ RODRIGUEZ LUIS RAMÓN;;ALVAREZ SAURA JOSÉ ANGEL;;DIAZ VAZQUEZ JOSÉ ENRIQUE;;HERNANDEZ MOLINA RICARDO;;FERREIRO GONZALEZ MARTA;;SAUCEDO MORALES AGUSTÍN;;LORENTE ACOSTA JOSÉ ANTONIO;;VERA JIMENEZ JOSÉ CARLOS;;RUIZ GONZALEZ ANTONIO,,https://lens.org/143-619-803-802-838,Patent Application,no,5,0,2,2,0,A63B60/02;;A63B60/42;;A63B60/54;;F41B15/02,A63B60/02;;A63B60/42;;A63B60/54;;F41B15/02,,0,0,,,,ACTIVE
292,ES,B1,ES 2590217 B1,041-824-310-383-756,2017-09-05,2017,ES 201500365 A,2015-05-18,ES 201500365 A,2015-05-18,"Inhibidor de vibraciones en objetos alargados sometidos a impactos, golpes y cualquier tipo de empuje",,UNIV CADIZ,FERNANDEZ ZACARIAS FRANCISCO;;AYUSO VILACIDES JESÚS;;RUIZ RODRIGUEZ LUIS RAMÓN;;ALVAREZ SAURA JOSÉ ANGEL;;DIAZ VAZQUEZ JOSÉ ENRIQUE;;HERNANDEZ MOLINA RICARDO;;FERREIRO GONZALEZ MARTA;;SAUCEDO MORALES AGUSTÍN;;LORENTE ACOSTA JOSÉ ANTONIO;;VERA JIMENEZ JOSÉ CARLOS;;RUIZ GONZALEZ ANTONIO,,https://lens.org/041-824-310-383-756,Granted Patent,no,0,0,2,2,0,A63B60/02;;A63B60/42;;A63B60/54;;F41B15/02,A63B60/02;;A63B60/42;;A63B60/54;;F41B15/02,,0,0,,,,ACTIVE
293,CO,A1,CO 7200060 A1,078-665-716-731-359,2015-02-27,2015,CO 13196767 A,2013-08-20,CO 13196767 A,2013-08-20,"Herramienta ortodóntica para ubicar, posicionar y adosar brackets en la superficie vestibular del diente","Herramienta ortodóntica para ubicar, posicionar y adosar brackets en la superficie vestibular del diente, por el método directo e indirecto, CARACTERIZADA PORQUE consta de dos partes ensambladas: un cuerpo para manipulación del dispositivo (1) y una punta (2); la morfología del cuerpo (1) permite que el usuario tenga control, seguridad, confort y compatibilidad con la mano en el momento de colocar el bracket en el objetivo, que es el centro meso-distal del diente a una altura predeterminada y la punta (2) que consta de: elemento porta-bracket (3), proyector de luz (4), filamento (5) y guía incisal (6), que operan sinérgicamente, aseguran la colocación del bracket en sentido horizontal y vertical, y permiten el ajuste de los componentes del tratamiento como torque y angulación mesodistal, para garantizar exactitud y precisión en la colocación del bracket.",UNIV NAC DE COLOMBIA,GARCIA ACOSTA GABRIEL;;LAGE MORALES KAREN;;PUENTES LAGOS DAVID E;;PARADA PARADA SARA ESTELA;;RUIZ ORTIZ MANUEL RICARDO;;GARZON PACHECO ANA MARÍA;;LEON CASTELLANOS WILLIAM RICARDO;;ALVAREZ R JUAN RICARDO;;VANEGAS MATA CARLOS JULIO;;NUÑEZ VILORIA JHON WALTHER,,https://lens.org/078-665-716-731-359,Patent Application,no,0,0,4,4,0,A61C7/146;;A61C7/146;;A61C7/02;;A61C7/02,A61C7/14,,0,0,,,,PENDING
294,CO,A1,CO 2022006045 A1,137-968-097-156-127,2022-06-10,2022,CO 2022006045 A,2022-05-09,CO 2022006045 A,2022-05-09,Robot para inspecciones seguras en espacios confinados,"La presente solicitud se refiere a un dispositivo robótico móvil para el monitoreo de espacios confinados. En particular, la presente invención se refiere a un dispositivo robótico que cuenta con un brazo modular extensible tipo tijera a lo largo del cual se fijan mangueras que cuentan con puntos de inhalación o succión que están controlados por válvulas y por donde ingresan muestras de gases, las cuales son transportadas por dichas mangueras hasta un módulo de medición de gases. El dispositivo robótico mantiene comunicación en tiempo real con el exterior y es capaz de resistir atmósferas altamente corrosivas y que pueden llegar a ser explosivas.",ENEL COLOMBIA S A E S P,GROSSO PERALTA JUAN CARLOS;;SAENZ OSPINA HURID YAMILE;;SIERRA TORRES SANDRA PATRICIA;;ACERO ZULUAGA JUAN DIEGO;;PARRADO MORALES ANA MARCELA;;BUITRAGO LOZANO LUIS JAVIER;;GRANADOS ANDRADE MAYRA ROCIO;;ROJAS CERQUERA OSCAR;;VARELA RINCÓN JAIME;;DÍAZ RIVERA MIGUEL ANGEL;;OLIVEROS CARLOS ALFONSO;;DIAZ CABALLERO OSCAR ANDRES;;PALOMARES GUTIERREZ ANA MARÍA;;VASQUEZ MARTÍN FELIPE;;ACOSTA WILMAR ARMANDO,,https://lens.org/137-968-097-156-127,Patent Application,no,0,0,1,1,0,,B25J5/00;;B25J9/00;;B25J11/00;;B25J19/00;;B62D55/065;;F17D5/02;;G01M3/04;;G01N1/26;;G05D1/02,,0,0,,,,PENDING
295,BR,B1,BR 9704641 B1,180-408-257-424-818,2010-03-09,2010,BR 9704641 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,"proteìna de fusão, vetor de expressão de proteìnas de fusão em e. coli, cepa recombinante e composição de vacina.",,,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGUEZ RICARDO DE LA CARIDAD;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN;;VAZQUEZ DIOGENES QUITANA,,https://lens.org/180-408-257-424-818,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,C12N15/62;;G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
296,US,B1,US 6921809 B1,129-270-120-927-352,2005-07-26,2005,US 61292500 A,2000-07-10,CU 1996010 A;;CU 9700001 W,1996-01-17,Monoclonal antibody to the stabilizer peptide of the P64K antigen of Neisseria meningitidis,"The present invention related to biotechnology and genetic engineering, particularly the expression of proteins of viral origin in microorganisms through their fusion by applying recombinant DNA technology to bacterial peptides. The present invention provides an effcient process for the expression in Escherichia coli of heterlogous proteins as fusion peptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations. What is essentially used is a stabilizing sequence derived from the first 47 amino acids of the antigen P64k of Neisseria meningitides B:4:P1.15. In particular, use is made of a recombinant plasmid containing said sequence, under the control of the tryptophane promoter of E. coli and of the terminator of the transcription of the phage T4, including restrictions sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest.",CT INGENIERIA GENETICA BIOTECH,CANO CARLOS ANTONIO DURATE;;NIETO ENRIQUE GERARDO GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ LUIS EMILIO CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIQUEZ CARMEN ELENA GOMEZ;;RODRIQUEZ RECARDO DE LA CARIDI;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN,,https://lens.org/129-270-120-927-352,Granted Patent,yes,1,0,33,33,29,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;G01N33/569;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,530/387.9;;530/387.1;;530/388.1;;530/388.4;;424/139.1;;424/150.1;;424/130.1;;424/141.1,2,0,,,"Niebla et al. In: Neisseria 94. Proceedings of the Ninth International Pathogenic Neisseria Conference. (Ed) Evans et al. Winchester, England, Sep. 26-30, 1994, pp. 85-86.;;Nazabal et al. In: Neisseria 94. Proceedings of the Ninth International Pathogenic Neisseria Conference. (Ed) Evans et al. Sep. 26-30, Winchester, England, pp. 98-99, 1994.",EXPIRED
297,AU,B2,AU 2011/235369 B2,025-730-753-636-081,2015-12-24,2015,AU 2011/235369 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,Method for inhibiting HIV replication in mammal and human cells,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECNOLOGIA,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/025-730-753-636-081,Granted Patent,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,7,7,032-353-621-170-585;;139-919-188-174-285;;034-235-038-782-379;;075-044-825-480-092;;010-379-797-525-48X;;042-317-613-150-01X;;016-251-453-054-608,10.1006/bbrc.1993.2555;;7505575;;18790770;;10.1158/1535-7163.mct-08-0450;;16291835;;10.1681/asn.2005030329;;pmc2120965;;8769421;;10.1083/jcb.134.4.971;;10.1096/fj.09-151639;;20097873;;pmc2874471;;10.1096/fj.08-124982;;19299483;;pmc2717765;;10.1007/bf02628654;;8993755,"STEINERT P.M. et al., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1993, Vol. 197 No. 2,;;PACCIONE, R.J. et al., 'Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility', Mol Cancer Ther. 2008, Vol 7, pages 2894-2903;;STAMATAKIS, K. et al., 'Identification of Novel Protein Targets for Modification by 15-Deoxy-?12,14 -Prostaglandin J2 in Mesangial Cells Reveals Multiple Interactions with the Cytoskeleton', J Am Soc Nephrol. 2006, Vol 17, pages 89-98;;GOLDMAN, R.D. et al., 'The Function of Intermediate Filaments in Cell Shape and Cytoskeletal Integrity', The Journal of Cell Biology. 1996, Vol. 134 No. 4, pages 971-983;;MENDEZ, M.G. et al., 'Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition', The FASEB Journal. 2010, Vol. 25. pages 1838-1851;;KALANTARI, P. et al.,'15-Deoxy-?12,14 -prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification', The FASEB Journal. 2009, Vol. 23, pages 2366-2373;;FERNANDEZ-ORTEGA, C. et al., 'Inhibition of in vitro HIV infection by dialysable leucocyte extracts', Biotherapy. 1996, Vol. 9, pages 33-40",INACTIVE
298,CA,A1,CA 2794930 A1,120-352-428-392-704,2011-10-06,2011,CA 2794930 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/120-352-428-392-704,Patent Application,no,0,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,0,0,,,,ACTIVE
299,CN,A,CN 102884075 A,140-917-771-449-430,2013-01-16,2013,CN 201180023063 A,2011-04-01,CU 2011000001 W;;CU 20100056 A,2010-04-01,Method for inhibiting HIV replication in mammal and human cells,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/140-917-771-449-430,Patent Application,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,7,6,010-379-797-525-48X;;042-317-613-150-01X;;032-353-621-170-585;;016-251-453-054-608;;034-235-038-782-379;;075-044-825-480-092,10.1096/fj.09-151639;;20097873;;pmc2874471;;10.1096/fj.08-124982;;19299483;;pmc2717765;;10.1006/bbrc.1993.2555;;7505575;;10.1007/bf02628654;;8993755;;16291835;;10.1681/asn.2005030329;;pmc2120965;;8769421;;10.1083/jcb.134.4.971,"M.G.MENDEZ ET AL: ""Vimentin induces changes in cell shape,motility,and adhesion during the epithelial to mesenchymal transtition"", <THE FASEB JOURNAL>, 22 January 2010 (2010-01-22);;FORTIER,A.M.: ""NP_0033721.2"", <NCBI>, 28 March 2010 (2010-03-28);;P.KALANTARI ET AL: ""15-Deoxy-12,14-prostaglandin Ja inhibits HIV-1 transactivating protein,Tat,through covalent modification"", <THE FASEB JOURNAL>, 1 August 2009 (2009-08-01);;STEINERT P M ET AL: ""Concurrence between the Molecular Overlap Regions in Keratin INtermediate Filaments and the Locations of Keratin Mutations in Genodermatoses"", <BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS>, 15 December 1993 (1993-12-15);;FERNANDEZ-ORTEGA C: ""Inhibition of in vitro HIV infection by dialysabel leucocyte extracts"", <BIOTHERAPY>, 1 January 1996 (1996-01-01);;STAMATAKIS KONSTANTINOS ET AL: ""Identification of novel protien targets for modification by 15-deoxy-Delta(12,14)-rostaglandin J(2) in mesangial cells reveals multiple interactions with the cytoskeleton"", <JOURNAL OF THE AMERRICAN SOCIETIY OF NEPHROLOGY>, 31 January 2006 (2006-01-31);;R.D.GOLDMAN: ""The function of intermediate filaments in cell shape and cytoskeletal integrity"", <THE JOURNAL OF CELL BIOLOGY>, 1 August 1996 (1996-08-01)",ACTIVE
300,US,B2,US 9205128 B2,121-903-286-630-934,2015-12-08,2015,US 201113637845 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,Method for inhibiting HIV replication in mammal and human cells,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",FERNANDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUÁREZ ANNA CARIDYS;;CASANOVA DIONNE CASILLAS;;PANEQUE GUERRERO TAIMI EMELIA;;GÓMEZ RAIMUNDO UBIETA;;ECHEVARRIA MARTA DUBED;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;CAMA VIVIANA FALCÓN;;ACOSTA OSVALDO REYES;;CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUÁREZ ANNA CARIDYS;;CASANOVA DIONNE CASILLAS;;PANEQUE GUERRERO TAIMI EMELIA;;GÓMEZ RAIMUNDO UBIETA;;ECHEVARRIA MARTA DUBED;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;CAMA VIVIANA FALCÓN;;ACOSTA OSVALDO REYES,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2013-01-04),https://lens.org/121-903-286-630-934,Granted Patent,yes,6,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K38/10;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/17;;A61K45/06;;C07K14/47;;C12N5/0783;;C12N15/113,,31,24,117-057-748-742-523;;036-797-023-113-786;;133-633-057-246-101;;016-601-169-811-533;;047-021-528-310-006;;057-792-660-552-916;;035-790-025-859-655;;117-296-629-798-047;;016-251-453-054-608;;075-044-825-480-092;;042-317-613-150-01X;;041-378-860-150-554;;139-919-188-174-285;;095-614-841-679-779;;068-381-634-623-162;;034-235-038-782-379;;032-353-621-170-585;;046-650-479-211-102;;005-358-319-990-738;;038-927-160-067-62X;;045-057-644-738-052;;010-379-797-525-48X;;074-280-275-997-377;;016-601-169-811-533,10.1007/978-1-349-02718-7;;9841417;;10.1126/science.282.5389.642;;10.1016/s0022-2836(02)00945-2;;12441114;;8822624;;10.1089/vim.1996.9.73;;10.1111/j.1728-4457.2008.00217.x;;12370191;;10.1074/jbc.m205636200;;pmc2704048;;19649357;;10.2471/blt.09.067330;;7763812;;10.1016/0167-7799(93)90115-p;;10.1007/bf02628654;;8993755;;pmc2120965;;8769421;;10.1083/jcb.134.4.971;;10.1096/fj.08-124982;;19299483;;pmc2717765;;pmc2721701;;10.1093/jac/dkn455;;18984648;;18790770;;10.1158/1535-7163.mct-08-0450;;10.1016/j.molbrainres.2004.10.023;;15710248;;11160829;;pmc30574;;10.1091/mbc.12.1.143;;16291835;;10.1681/asn.2005030329;;10.1006/bbrc.1993.2555;;7505575;;pmc373388;;10.1093/nar/gkh247;;14769950;;19908203;;10.1002/psc.1192;;7929196;;10.1016/s0021-9258(17)31502-8;;10.1016/s0021-9258(19)37628-8;;2459124;;10.1096/fj.09-151639;;20097873;;pmc2874471;;10.1124/mi.2.3.158;;14993376;;8822624;;10.1089/vim.1996.9.73,"Rudinger, Peptide Hormones, JA Parsons, Ed., 1976, pp. 1-7.;;SIGMA, 2004, pp. 1-2.;;Berendsen, A Glimpae of the Holy Grail?, Science, 1998, 282, pp. 642-643.;;Voet et al, Biochemistry, John Wiley & Sons Inc., 1995, pp. 235-241.;;Ngo et al, Computational Complexity, Protein Structure Protection, and the Levinthal Paradox, 1994, pp. 491-494.;;Bradley et al., Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat, J. Mol. BioL (2002) 324, 373-386.;;T. V. Khakhulin, Intermediate Vimentin Filaments Involved in Type I Human Immunodeficiency Virus Replication, Academy of Sciences Reports, vol. 368, No. 5, 1999, pp. 706-708.;;UniProt Protein Database, Protein Accession Q6EIY9, Keratin, type II cytoskeletal 1, accessed on Nov. 5, 2014.;;UniProt Protein Database, Protein Accession P08670, Vimentin, accessed on Nov. 5, 2014.;;Elaine Thomas, Anti-idiotypic Antibody to the V3 Domain of gpl20 Binds to Vimentin: A Possible Role of Intermediate Filaments in the Early Steps of HIV-1 Infection Cycle, Viral Immunology, vol. 9, No. 2, 1996, pp. 73-87.;;Bongaarts, John, et al., ""Has the HIV Epidemic Peaked?"", Population and Development Review 34 (2): pp. 199-204, Jun. 2008.;;Blanco, Raquel, et al., ""Cell Killing by HIV-1 Protease"", Journal of Bio. Chem., vol. 278, No. 2, Issue of Jan. 10, pp. 1086-1093, 2003.;;De Cock, Kevin, et al., ""Preventing HIV transmission with antiretrovirals"", Bulletin of the World Health Organization 2009, 87:488-488 (machine translation).;;Findeis, Mark. A., et al., ""Targeted delivery of DNA for gene therapy via receptors"", Elsevier Science Publishers Ltd, May 1993, vol. 11, pp. 202-205.;;Fernandez-Ortega C., et al., ""Inhibition of in vitro HIV infection by dialysable leucocyte extracts"", Kluwer Academic Publishers, Netherlands, Biotherapy 9: 33-40, 1996.;;Goldman, Robert D., et al., ""The Function of Intermediate Filaments in Cell Shape and Cytoskeletal Integrity"", The Rockefeller University Press, The Journal of Cell Biology, vol. 134, No. 4, Aug. 1996 pp. 971-983.;;Iglesias, Enrique, ""Therapies and Clinical Trials with Vaccine Candidates Against HIV-1"" Biotecnologia Aplicada 2009, vol. 26, No. 3., pp. 190-198.;;Kalantari, Parisa, et al., ""15-Deoxy-12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification"", The FASEB Journal, vol. 23, No. 8, Aug. 2009, pp. 2366-2373.;;Marsden, Matthew D. et al., ""Eradication of HIV: current challenges and new directions"", Journal of Antimicrobial Chemotherapy, 2009, vol. 63, pp. 7-10.;;Paccione, Rachel J., et al., ""Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility"", Molecular Cancer Therapeutics, vol. 7, No. 9, Sep. 2008, pp. 2894-2903.;;Pocernich, Chava B., et al., ""Proteomics analysis of human astrocytes expressing the HIV protein Tat"", Molecular Brain Research, Elsevier Science BV, Amsterdam, NL, vol. 133, No. 2, Feb. 2005, pp. 307-316.;;Shoeman, Robert L., et al., ""Amino-terminal Polypeptides of Vimentin Are Responsible for the Changes in Nuclear Architecture Associated with Human Immunodeficiency Virus Type 1 Protease Activity in Tissue Culture Cells"", Molecular Biology of the Cell, vol. 12, pp. 143-154, Jan. 2001.;;Stamatakis, Konstantinos, et al., ""Identification of Novel Protein Targets for Modification by 15-Deoxy-12,14-Prostaglandin J2 in Mesangial Cells Reveals Multiple Interactions with the Cytoskeleton"", J. Am. Soc. Nephrol., vol. 17, No. 1, Jan. 2006, pp. 89-98.;;Steinert, Peter M., ""Concurrence between the Molecular Overlap Regions in Keratin Intermediate Filaments and the Locations of Keratin Mutations in Genodermatoses"", Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL., vol. 197, No. 2, Dec. 1993, pp. 840-848.;;Ui-Tei, Kumiko, et al, ""Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference"", Oxford University Press, Nucleic Acids Research, 2004, vol. 32, No. 3, pp. 936-948.;;Vallespi, Maribel G., ""Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF32-51 region"", J. Pept. Sci. 2010; vol. 16, pp. 40-47.;;Wu, Rui-Yun, et al., ""LIM Domain Recognition of a Tyrosine-containing Tight Turn"", The Journal of Biological Chemistry, vol. 269, No. 40, Issue of Oct. 7, pp. 25085-25090, 1994.;;Zhou, Xiao-Mei, et al., ""The Complete Sequence of the Human Intermediate Filament Chain Keratin 10"", The Journal of Biological Chemistry, vol. 263, No. 30, Issue of Oct. 25, pp. 15584-15589, 1988.;;Mendez, Melissa G., et al., ""Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition"", The FASEB Journal, vol. 24, No. 6, Jan. 22, 2010, pp. 1838-1851.;;Tuschl, Thomas, et al., ""Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy"", Molecular Interventions, Jun. 2002, vol. 2, Issue 3, pp. 159-167.;;Thomas, EK, et al., ""Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle"", Viral Immunology, vol. 9, No. 2, 1996, pp. 73-87. (Abstract only).",ACTIVE
301,US,B2,US 10434137 B2,134-675-275-687-097,2019-10-08,2019,US 201514943106 A,2015-11-17,US 201514943106 A;;CU 20100056 A;;US 201313637845 A;;CU 2011000001 W,2010-04-01,Method for inhibiting HIV replication in mammal and human cells,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.",CT INGENIERIA GENETICA BIOTECNOLOGIA,FERNANDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,CENTRO DE INGENIERÍA GENETICA Y BIOTECNOLOGÍA (2013-01-04),https://lens.org/134-675-275-687-097,Granted Patent,yes,8,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C12N15/113;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/17;;A61K45/06;;C07K14/47;;C12N5/0783,,33,25,004-876-714-261-109;;047-021-528-310-006;;057-792-660-552-916;;035-790-025-859-655;;117-296-629-798-047;;016-251-453-054-608;;075-044-825-480-092;;042-317-613-150-01X;;041-378-860-150-554;;139-919-188-174-285;;095-614-841-679-779;;068-381-634-623-162;;034-235-038-782-379;;032-353-621-170-585;;046-650-479-211-102;;005-358-319-990-738;;038-927-160-067-62X;;045-057-644-738-052;;010-379-797-525-48X;;074-280-275-997-377;;016-601-169-811-533;;117-057-748-742-523;;036-797-023-113-786;;133-633-057-246-101;;016-601-169-811-533,10.1016/s1046-2023(02)00023-3;;12054897;;10.1111/j.1728-4457.2008.00217.x;;12370191;;10.1074/jbc.m205636200;;pmc2704048;;19649357;;10.2471/blt.09.067330;;7763812;;10.1016/0167-7799(93)90115-p;;10.1007/bf02628654;;8993755;;pmc2120965;;8769421;;10.1083/jcb.134.4.971;;10.1096/fj.08-124982;;19299483;;pmc2717765;;pmc2721701;;10.1093/jac/dkn455;;18984648;;18790770;;10.1158/1535-7163.mct-08-0450;;10.1016/j.molbrainres.2004.10.023;;15710248;;11160829;;pmc30574;;10.1091/mbc.12.1.143;;16291835;;10.1681/asn.2005030329;;10.1006/bbrc.1993.2555;;7505575;;pmc373388;;10.1093/nar/gkh247;;14769950;;19908203;;10.1002/psc.1192;;7929196;;10.1016/s0021-9258(17)31502-8;;10.1016/s0021-9258(19)37628-8;;2459124;;10.1096/fj.09-151639;;20097873;;pmc2874471;;10.1124/mi.2.3.158;;14993376;;8822624;;10.1089/vim.1996.9.73;;10.1007/978-1-349-02718-7;;9841417;;10.1126/science.282.5389.642;;10.1016/s0022-2836(02)00945-2;;12441114;;8822624;;10.1089/vim.1996.9.73,"Sayda M. Elbashir, Analysis of gene function in somatic mammalian cells using small interfering RNAs, Methods 26 (2002) 199-213.;;Bongaarts, John, et al., “Has the HIV Epidemic Peaked?”, Population and Development Review 34 (2): pp. 199-204, Jun. 2008.;;Blanco, Raquel, et al., “Cell Killing by HIV-1 Protease”, Journal of Bio. Chem., vol. 278, No. 2, Issue of Jan. 10, pp. 1086-1093, 2003.;;De Cock, Kevin, et al., “Preventing HIV transmission with antiretrovirals”, Bulletin of the World Health Organization 2009, 87:488-488 (machine translation).;;Findeis, Mark. A., et al., “Targeted delivery of DNA for gene therapy via receptors”, Elsevier Science Publishers Ltd, May 1993, vol. 11, pp. 202-205.;;Fernandez-Ortega C., et al., “Inhibition of in vitro HIV infection by dialysable leucocyte extracts”, Kluwer Academic Publishers, Netherlands, Biotherapy 9: 33-40, 1996.;;Goldman, Robert D., et al., “The Function of Intermediate Filaments in Cell Shape and Cytoskeletal Integrity”, The Rockefeller University Press, The Journal of Cell Biology, vol. 134, No. 4, Aug. 1996 pp. 971-983.;;Iglesias, Enrique, “Therapies and Clinical Trials with Vaccine Candidates Against HIV-1” Biotecnologia Aplicada 2009, vol. 26, No. 3., pp. 190-198.;;Kalantari, Parisa, et al., “15-Deoxy-12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification”, The FASEB Journal, vol. 23, No. 8, Aug. 2009, pp. 2366-2373.;;Marsden, Matthew D. et al., “Eradication of HIV: current challenges and new directions”, Journal of Antimicrobial Chemotherapy, 2009, vol. 63, pp. 7-10.;;Paccione, Rachel J., et al., “Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility”, Molecular Cancer Therapeutics, vol. 7, No. 9, Sep. 2008, pp. 2894-2903.;;Pocernich, Chava B., et al., “Proteomics analysis of human astrocytes expressing the HIV protein Tat”, Molecular Brain Research, Elsevier Science BV, Amsterdam, NL, vol. 133, No. 2, Feb. 2005, pp. 307-316.;;Shoeman, Robert L., et al., “Amino-terminal Polypeptides of Vimentin Are Responsible for the Changes in Nuclear Architecture Associated with Human Immunodeficiency Virus Type 1 Protease Activity in Tissue Culture Cells”, Molecular Biology of the Cell, vol. 12, pp. 143-154, Jan. 2001.;;Stamatakis, Konstantinos, et al., “Identification of Novel Protein Targets for Modification by 15-Deoxy-12,14-Prostaglandin J2 in Mesangial Cells Reveals Multiple Interactions with the Cytoskeleton”, J. Am. Soc. Nephrol., vol. 17, No. 1, Jan. 2006, pp. 89-98.;;Steinert, Peter M., “Concurrence between the Molecular Overlap Regions in Keratin Intermediate Filaments and the Locations of Keratin Mutations in Genodermatoses”, Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, Fl., vol. 197, No. 2, Dec. 1993, pp. 840-848.;;Ui-Tei, Kumiko, et al, “Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference”, Oxford University Press, Nucleic Acids Research, 2004, vol. 32, No. 3, pp. 936-948.;;Vallespi, Maribel G., “Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF32-51 region”, J. Pept. Sci. 2010; vol. 16, pp. 40-47.;;Wu, Rui-Yun, et al., “LIM Domain Recognition of a Tyrosine-containing Tight Turn”, The Journal of Biological Chemistry, vol. 269, No. 40, Issue of Oct. 7, pp. 25085-25090, 1994.;;Zhou, Xiao-Mei, et al., “The Complete Sequence of the Human Intermediate Filament Chain Keratin 10”, The Journal of Biological Chemistry, vol. 263, No. 30, Issue of Oct. 25, pp. 15584-15589, 1988.;;Mendez, Melissa G., et al., “Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition”, The FASEB Journal, vol. 24, No. 6, Jan. 22, 2010, pp. 1838-1851.;;Tuschl, Thomas, et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy”, Molecular Interventions, Jun. 2002, vol. 2, Issue 3, pp. 159-167.;;Thomas, Ek, et al., “Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle”, Viral Immunology, vol. 9, No. 2, 1996, pp. 73-87. (Abstract only).;;Alberts, B., et al., “Molecular Biology of the Cell”, 4th ed. 2002, Garland Publishing, New York.;;Rudinger, Peptide Hormones, JA Parsons, Ed. 1976, pp. 1-7.;;SIGMA, 2004, pp. 1-2.;;Berendsen, A Glimpae of the Holy Grail?, Science, 1998, 282, pp. 642-643.;;Voet et al., Biochemistry, John Wiley & Sons, Inc., 1995, pp. 235-241.;;Ngo et al., Computational Complexity, Protein structure Protection and the Levinthal Paradox, 1994, pp. 491-494.;;Bradley et al., Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alaine Substitutions in Each Repeat, J. Mol. Biol (2002) 324, pp. 373-386.;;T.V. Khakhulin, Intermediate Vimentin Filaments Involved in Type I Human Immunodeficiency Virus Replication, Academy of Sciences Reports, vol. 368, No. 5, 1999, pp. 706-708.;;UniProt Protein Database, Protein Accession Q6EIY9, Keratin, type II cytoskeletal 1, accessed on Nov. 5, 2014.;;UniProt Protein Database, Protein Accession Po8670, Vimentin, accessed on Nov. 5, 2014.;;Elaine Thomas, Anti-idiotypic Antibody to the V3 Domain of gpl20 Binds to Vimentin: A Possible Role of Intermediate Filaments in the Early Steps of HIV-1 Infection Cycle, Viral Immunology, vol. 9, No. 2, 1996, pp. 73-87.",ACTIVE
302,CA,C,CA 2794930 C,189-837-692-272-268,2019-05-21,2019,CA 2794930 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",CT INGENIERIA GENETICA BIOTECNOLOGIA,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/189-837-692-272-268,Granted Patent,no,0,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,0,0,,,,ACTIVE
303,CU,B1,CU 23896 B1,103-943-749-718-267,2013-05-31,2013,CU 20100056 A,2010-04-01,CU 20100056 A,2010-04-01,MÉTODO PARA INHIBIR LA REPLICACIÓN DEL VIH EN CÉLULAS DE MAMÍFEROS,"La presente invención describe un método para inhibir la replicación del virus de la inmunodeficiencia humana (VIH) mediante la modulación negativa o alteración del citoesqueleto, específicamente de proteínas que forman parte de los filamentos intermedios del citoesqueleto, más específicamente de las proteínas vimentina y/o queratina-10. La intervención sobre la estructura de estas proteínas causa una inhibición de la replicación del virus en células humanas. La invención se relaciona además con el uso de agentes, que comprenden péptidos y/o ARN de interferentes y/o compuestos lipídicos, y producen la modulación negativa o alteración del citoesqueleto celular, para prevenir o tratar la infección por el VIH. La invención proporciona medios y métodos para alterar la estructura del citoesqueleto/filamento de la célula, lo que interfiere con la infección por VIH de las células humanas y que puede incluso ser inhibida completamente. El citoesqueleto es alterado al reducir la cantidad de vimentina y/o queratina-10 (por ejemplo, por control transcripcional utilizando ARN interferentes) o mediante el uso de péptidos que alteran el citoesqueleto.",CT DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA,FERNÁNDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUÁREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GÓMEZ RAIMUNDO;;DUBED ECHEVARRÍA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCÓN CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/103-943-749-718-267,Unknown,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K39/00;;C12N7/04,,0,0,,,,ACTIVE
304,CU,A7,CU 20100056 A7,163-065-391-799-313,2012-06-21,2012,CU 20100056 A,2010-04-01,CU 20100056 A,2010-04-01,MÉTODO PARA INHIBIR LA REPLICACIÓN DEL VIH EN CÉLULAS DE MAMÍFEROS,"La presente invención describe un método para inhibir la replicación del virus de la inmunodeficiencia humana (VIH) mediante la modulación negativa o alteración del citoesqueleto celular, específicamente de proteínas que forman parte de los filamentos intermedios del citoesqueleto, más específicamente de las proteínas vimentina y queratina 10. La intervención sobre la estructura de estas proteínas causa una inhibición de la replicación del virus en células humanas. La invención se relaciona además con el uso de agentes, que comprenden péptidos y/o ARN de interferencia y/o compuestos lipídicos, y producen la modulación negativa o alteración del citoesqueleto celular, para prevenir o tratar la infección por el VIH.",CT INGENIERIA GENETICA BIOTECH,NAVEA LEYVA LEONOR MARGARITA;;DUBED ECHEVARRIA MARTA;;PANEQUE GUERRERO TAIMI EMELIA;;CASILLAS CASANOVA DIONNE;;RAMIREZ SUAREZ ANNA CARIDYS;;FERNANDEZ ORTEGA CELIA BERTA;;UBIETA GOMEZ RAIMUNDO;;DUARTE CANO CARLOS ANTONIO;;REYES ACOSTA OSVALDO;;CASTELLANOS SERRA LILA ROSA;;FALCON CAMA VIVIANA,,https://lens.org/163-065-391-799-313,Patent Application,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C12N7/04;;A61K39/00,,0,0,,,,ACTIVE
305,KR,A,KR 20130027016 A,192-232-906-560-844,2013-03-14,2013,KR 20127028726 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,,CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/192-232-906-560-844,Patent Application,no,2,4,34,34,24,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C12N5/10;;C12N15/113;;C12N15/49;;C12N15/63,,2,2,042-317-613-150-01X;;034-235-038-782-379,10.1096/fj.08-124982;;19299483;;pmc2717765;;16291835;;10.1681/asn.2005030329,"FASEB J., Vol. 23, No. 8, pp. 2366-2373 (2009.08.)*;;J. Am., Soc. Nephrol., Vol. 17, pp. 89-98 (2006.)*",ACTIVE
306,AU,A1,AU 2011/235369 A1,060-346-231-666-69X,2012-11-01,2012,AU 2011/235369 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,Method for inhibiting HIV replication in mammal and human cells,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/060-346-231-666-69X,Patent Application,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,0,0,,,,INACTIVE
307,WO,A9,WO 2011/120474 A9,120-581-548-799-153,2012-03-22,2012,CU 2011000001 W,2011-04-01,CU 20100056 A,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH;;FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/120-581-548-799-153,Search Report,yes,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,0,0,,,,PENDING
308,MY,A,MY 161923 A,015-820-497-052-680,2017-05-15,2017,MY PI2012700711 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD TO INHIBIT HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA,FERNANDEZ ORTEGA CELIA BERTA;;FALCÓN CAMA VIVIANA;;REYES ACOSTA OSVALDO;;RAMÍREZ SUÁREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GÓMEZ RAIMUNDO;;DUBED ECHEVARRÍA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO,,https://lens.org/015-820-497-052-680,Granted Patent,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K38/17;;A61P31/18;;C12N15/113,,0,0,,,,ACTIVE
309,ZA,B,ZA 201207761 B,044-804-295-759-313,2013-06-26,2013,ZA 201207761 A,2012-10-16,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,,CT INGENIERIA GENETICA BIOTECNOLOGIA,FERNANDEZ ORTEGA CELIA BERTA;;CASILLAS CASANOVA DIONNE;;UBIETA GOMEZ RAIMUNDO;;NAVEA LEYVA LEONOR MARGARITA;;DUARTE CANO CARLOS ANTONIO;;REYES ACOSTA OSVALDO;;RAMIREZ SUAREZ ANNA CARIDYS;;PANEQUE GUERRERO TAIMI EMELIA;;DUBED ECHEVARRIA MARTA;;CASTELLANOS SERRA LILA ROSA;;FALCON CAMA VIVIANA,,https://lens.org/044-804-295-759-313,Granted Patent,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K/;;A61P/;;C07C/;;C07K/;;C12N/,,0,0,,,,ACTIVE
310,AU,B2,AU 722317 B2,121-149-587-457-467,2000-07-27,2000,AU 1997/015396 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,System for the expression of heterologous antigens as fusion proteins,,CIGB,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGEZ RICARDO DE LA CARIDAD;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN,,https://lens.org/121-149-587-457-467,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
311,BR,B1,BR 112012025092 B1,152-816-031-835-291,2022-03-22,2022,BR 112012025092 A,2011-04-01,CU 2011000001 W;;CU 20100056 A,2010-04-01,Uso de um peptídeo capaz de romper os filamentos intermediários do citoesqueleto em uma célula de mamífero,"método para inibir a replicação do hiv em células de mamíferos e em seres humanos. a presente invenção refere-se a um método para inibir a replicação do vírus da imunodeficiência humana (hiv) por meio da modulação negativa ou alteração do citoesqueleto, especificamente de proteínas que fazem parte dos filamentos intermediários do citoesqueleto, mais especificamente das proteínas vimentina e/ou queratina-10. a invenção sobre a estrutura dessas proteínas causa uma inibição da replicação do vírus em células humanas. a invenção também se refere ao uso de agentes que compreendem peptídeos e/ou rna interferentes e/ou compostos lipídicos, e produzem a modulação negativa ou alteração do citoesqueleto celular, para a prevenção ou tratamento da infecção pelo hiv. a invenção provê meios e métodos para alterar a estrutura do citoesqueleto/filamento da célula, o que interfere na infeção pelo hiv das células humanas e que pode inclusive ser inibido completamente. o citoesqueleto é alterado ao reduzir a quantidade de vitamina e/ou queratina-10 (por exemplo, por meio do controle transcricional ao utilizar rna interferentes) ou por meio do uso de peptídeos que alteram o citoesqueleto.",CT INGENIERIA GENETICA BIOTECNOLOGIA,ANNA CARIDYS RAMÍREZ SUÁREZ;;CARLOS ANTONIO DUARTE CANO;;CELIA BERTA FERNANDEZ ORTEGA;;DIONE CASILLAS CASANOVA;;LEONOR MARGARITA NAVEA LEYVA;;LILA ROSA CASTELLANOS SERRA;;MARTA DUBED ECHEVARRÍA;;OSVALDO REYES ACOSTA;;RAIMUNDO UBIETA GÓMEZ;;TAIMI EMELIA PANEQUE GUERRERO;;VIVIANA FALCÓN CAMA,,https://lens.org/152-816-031-835-291,Granted Patent,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K38/17;;A61K31/5575;;A61K31/7105;;A61P31/18;;C07C405/00;;C07K14/47;;C12N15/113,,0,0,,,,ACTIVE
312,CA,A1,CA 2214840 A1,175-579-576-980-403,1997-07-24,1997,CA 2214840 A,1997-01-17,CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"The present invention relates to biotechnology and genetic engineering, particul arly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterotogous prot eins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in a oppropriate fo rm for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence de rived from the first 47 aminoacids of the antigen P64k of Neisseria meningitidis B:4 :P1.15. In particular, use is made of a recombinant p lasmide containing said sequence, under the control of the triptophane promotor of E. coli and of the terminator of the transcription of th e phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The proce ss of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and i n any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.",CIGB,NAZABAL GALVEZ CONSUELO;;QUINTANA VAZQUEZ DIOGENES;;CARPIO MUNOZ EMILIO LUIS;;MARTIN DUNN ALEJANDRO MIGUEL;;LEAL ANGULO MARIA DE JESUS;;GOMEZ RODRIGUEZ CARMEN ELENA;;DUARTE CANO CARLOS ANTONIO;;ALVAREZ ACOSTA ANABEL;;SILVA RODRIGUEZ RICARDO DE LA;;GUILLEN NIETO GERARDO ENRIQUE,,https://lens.org/175-579-576-980-403,Patent Application,no,0,0,33,33,21,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,DISCONTINUED
313,CZ,A3,CZ 291097 A3,126-713-633-234-042,1998-11-11,1998,CZ 291097 A,1997-01-17,CU 1996010 A,1996-01-17,EXPRESSION SYSTEM OF HETEROLOGOUS PROTEINS AS FUSED PROTEINS,,CIGB,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGUEZ RICARDO DE LA;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/126-713-633-234-042,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,PENDING
314,JP,A,JP 2016121172 A,141-328-773-977-537,2016-07-07,2016,JP 2016019305 A,2016-02-03,CU 20100056 A,2010-04-01,METHODS FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"PROBLEM TO BE SOLVED: To provide uses of drugs for preventing or treating Human Immunodeficiency Virus (HIV) infection.SOLUTION: The present invention relates to a method to inhibit replication of Human Immunodeficiency Virus (HIV) by negatively modulating or altering the cytoskeleton, in particular, the proteins forming the intermediate cytoskeletal filaments (IF), more particularly, vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention also relates to the use of an agent comprising a peptide and/or interfering RNA and/or a lipidic compound, where the agent produces a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cellular cytoskeleton/filament structure, thereby the infection of human cells by HIV is prevented and further the virus is completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 or by using peptides that disrupt the cytoskeleton.SELECTED DRAWING: Figure 1",CENTRO DE INGENIERIA GENETICA Y BIOTECHNOLOGIA,CELIA BERTA FERNANDEZ ORTEGA;;ANNA CARIDYS RAMIREZ SUAREZ;;DIONNE CASILLAS CASANOVA;;TAIMI EMELIA PANEQUE GUERRERO;;RAIMUNDO UBIETA GOMEZ;;MARTA DUBED ECHEVARRIA;;LEONOR MARGARITA NAVEA LEYVA;;LILA ROSA CASTELLANOS SERRA;;CARLOS ANTONIO DUARTE CANO;;VIVIANA FALCON CAMA;;OSVALDO REYES ACOSTA,,https://lens.org/141-328-773-977-537,Patent Application,no,1,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K45/00;;A61K31/5575;;A61K31/713;;A61K38/00;;A61K48/00;;A61P31/18;;C12N7/00,,0,0,,,,ACTIVE
315,EP,B1,EP 2554550 B1,003-099-306-398-632,2016-09-07,2016,EP 11720370 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,,CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUÁREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GÓMEZ RAIMUNDO;;DUBED ECHEVARRÍA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCÓN CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/003-099-306-398-632,Granted Patent,yes,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K38/17;;A61P31/18;;C12N15/113,,1,1,094-773-188-439-343,10.1096/fasebj.13.9002.s261;;10619140,"GOLDMAN R D ET AL: ""Intermediate filaments: dynamic processes regulating their assembly, motility, and interactions with other cytoskeletal systems."", FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY DEC 1999, vol. 13 Suppl 2, December 1999 (1999-12-01), pages S261 - S265, ISSN: 0892-6638",ACTIVE
316,AR,A1,AR 080818 A1,037-183-529-206-859,2012-05-09,2012,AR P110101094 A,2011-03-31,CU 20100056 A,2010-04-01,METODO PARA INHIBIR LA REPLICACION DEL VIH EN CELULAS DE MAMIFEROS Y EN HUMANOS,"Un método para inhibir la replicacion del virus de la inmunodeficiencia humana (VIH) mediante la modulacion negativa o alteracion del citoesqueleto, específicamente de proteínas que forman parte de los filamentos intermedios del citoesqueleto, más específicamente de las proteínas vimentina y/o queratina-10. La intervencion sobre la estructura de estas proteínas causa una inhibicion de la replicacion del virus en células humanas. Además el uso de agentes, que comprenden péptidos y/o ARN interferentes y/o compuestos lipídicos, y producen la modulacion negativa o alteracion del citoesqueleto celular, para prevenir o tratar la infeccion por el VIH. Medios y métodos para alterar la estructura del citoesqueleto/filamento de la célula, lo que interfiere con la infeccion por VIH de las células humanas y que puede incluso ser inhibida completamente. El citoesqueleto es alterado al reducir la cantidad de vimentina y/o queratina-10 (por ejemplo, por control transcripcional utilizando ARN interferentes) o mediante el uso de péptidos que alteran el citoesqueleto. Reivindicacion 22: Una composicion farmacéutica para la prevencion o el tratamiento de la infeccion por el VIH que comprende un agente que altera los FI del citoesqueleto y un vehículo o excipiente farmacéuticamente aceptable. Reivindicacion 23: La composicion de acuerdo a la reivindicacion 22 donde dicho agente se selecciona del grupo compuesto por polipéptidos, péptidos, ácidos nucleicos y compuestos químicos que alteran los FI. Reivindicacion 24: La composicion de acuerdo a la reivindicacion 23 donde dicho agente es un péptido que se selecciona del grupo de los péptidos identificados como SEQ ID Ns:1 a la SEQ ID Ns:10, y homologos de los mismos. Reivindicacion 25: La composicion de acuerdo a la reivindicacion 23 donde dicho agente es un ARN interferente (iRNA) o un oligonucleotido antisentido dirigido a los genes de vimentina y/o de la queratina 10. Reivindicacion 28: La composicion de acuerdo a la reivindicacion 27 donde dicho compuesto lipídico es la prostaglandina ciclopentano 15 deoxy-delta-12.14-PGJ2.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANANA CARIDYS;;CASILLAS CASANOVAS DIONEA;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBET ECHEVERRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS A;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/037-183-529-206-859,Patent Application,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,,,0,0,,,,PENDING
317,EP,A1,EP 2554550 A1,126-720-002-793-900,2013-02-06,2013,EP 11720370 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/126-720-002-793-900,Patent Application,yes,0,1,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K38/17;;A61P31/18;;C12N15/113,,0,0,,,,ACTIVE
318,BR,A,BR 9704641 A,195-541-948-950-822,1998-06-09,1998,BR 9704641 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,Sistema de expressão de antígenos heterólogos como proteínas de fusão,,INGENIERIA GENETIC Y BIOTECNOL,MARTIN DUNN ALEJANDRO MIGUEL;;LEAL ANGULO MARIA DE JESUS;;NAZABAL GALVEZ CONSUELO;;QUITANA VAZQUEZ DIOGENES;;SILVA RODRIGUEZ RICARDO DE LA;;DUARTE CANO CARLOS ANTONIO;;GOMEZ RODRIGUEZ CARMEN ELENA;;CARPIO MUNOZ EMILIO LUIS;;ALVAREZ ACOSTA ANABEL;;GUILLEN NIETO GERARDO ENRIQUE,,https://lens.org/195-541-948-950-822,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
319,US,A1,US 2016/0106810 A1,043-264-859-079-866,2016-04-21,2016,US 201514943096 A,2015-11-17,US 201514943096 A;;CU 20100056 A;;US 201313637845 A;;CU 2011000001 W,2010-04-01,Method for Inhibiting HIV Replication in Mammal and Human Cells,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",CT DE INGENIERÍA GENETICA Y BIOTECHNOLOGÍA,FERNANDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/043-264-859-079-866,Patent Application,yes,0,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K38/17;;A61K38/10,,1,0,,,"NIH, Challenges in Desigining HIV Vaccines, accessed on 7/20/2016.",DISCONTINUED
320,US,A1,US 2016/0129073 A1,056-773-538-582-089,2016-05-12,2016,US 201514943089 A,2015-11-17,US 201514943089 A;;CU 20100056 A;;US 201313637845 A;;CU 2011000001 W,2010-04-01,Method for Inhibiting HIV Replication in Mammal and Human Cells,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",CT DE INGENIERÍA GENETICA Y BIOTECNOLOGÍA,FERNANDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/056-773-538-582-089,Patent Application,yes,1,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K38/10;;A61K31/713;;C12N15/113,,5,4,005-727-920-678-578;;057-892-052-074-779;;035-790-025-859-655;;034-224-515-616-08X,10.1007/s002800050932;;10321513;;10.1091/mbc.9.10.2933;;9763453;;pmc25570;;pmc2704048;;19649357;;10.2471/blt.09.067330;;10.1038/nri2021;;17259969,"Nannan Panday Vinodh, Paclitaxel in the treatment of human immunodedefciency virus 1-associatedKaposi's sarcoma Â± drug-drug interactions with protease inhibitorsand a nonnucleoside reverse transcriptase inhibitor: a case report study, Cancer Chemother Pharmacol (1999) 43: 516Â±519.;;Chu JJ, Taxol induces concomitant hyperphosphorylation and reorganization of vimentin intermediate filaments in 9L rat brain tumor cells, J Cell Biochem. 1998 Mar 15Í¾68(4):47283.;;Katherine B. Pryzwansky, Chemotactic Peptide-induced Changes of Intermediate Filament Organization in Neutrophils during Granule Secretion: Role of Cyclic Guanosine Monophosphate, Molecular Biology of the Cell Vol. 9, 2933-2947, October 1998.;;Kevin M De Cock, Preventing HIV transmission withantiretrovirals, Bulletin of the World Health Organization, published online 2007.;;Daniel D. Billadeau, Regulation of T-cell activation bythe cytoskeleton, Nature Reviews, Immunology, volume 7, 2007.",DISCONTINUED
321,WO,A8,WO 2011/120474 A8,132-346-743-717-93X,2012-11-15,2012,CU 2011000001 W,2011-04-01,CU 20100056 A,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH;;FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/132-346-743-717-93X,Amended Application,yes,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,0,0,,,,PENDING
322,US,A1,US 2013/0130971 A1,093-275-898-263-487,2013-05-23,2013,US 201113637845 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,Method for Inhibiting HIV Replication in Mammal and Human Cells,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO;;CT DE INGENIERAA GENATICA Y BIOTECNOLOGAA,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2013-01-04),https://lens.org/093-275-898-263-487,Patent Application,yes,0,5,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,A61K38/10;;A61K31/19;;A61K31/7105;;A61K31/713;;A61K38/17;;A61K45/06;;C12N5/0783,514/3.8;;435/375;;536/24.5;;562/503;;530/326;;X514 44  A;;514/573;;530/324,10,5,117-057-748-742-523;;036-797-023-113-786;;133-633-057-246-101;;037-609-393-437-003;;016-601-169-811-533,10.1007/978-1-349-02718-7;;9841417;;10.1126/science.282.5389.642;;10.1016/s0022-2836(02)00945-2;;12441114;;10613270;;8822624;;10.1089/vim.1996.9.73,"Rudinger, Peptide Hormones, JA Parsons, Ed., 1976, pages 1-7.;;SIGMA, 2004, pages 1-2.;;Berendsen, A Glimpae of the Holy Grail?, Science, 1998, 282, pages 642-643.;;Voet et al, Biochemistry, John Wiley & Sons Inc., 1995, pages 235-241.;;Ngo et al, Computational Complexity, Protein Structure Protection, and the Levinthal Paradox, 1994, pages 491-494.;;Bradley et al., Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat, J. Mol. BIoL (2002) 324, 373-386.;;T. V. Khakhulin, INTERMEDIATE VIMENTIN FILAMENTS INVOLVED IN TYPE I HUMANIMMUNODEFICIENCY VIRUS REPLICATION, Academy of Sciences Reports, Vol. 368, No. 5, 1999, pages 706-708.;;UniProt Protein Database, Protein Accession Q6EIY9, Keratin, type II cytoskeletal 1, accessed on 11/5/2014.;;UniProt Protein Database, Protein Accession P08670, Vimentin, accessed on 11/5/2014.;;Elaine Thomas, Anti-idiotypic Antibody to the V3 Domain of gpl20 Binds to Vimentin: A Possible Role of IntermediateFilaments in the Early Steps of HIV-1 Infection Cycle, VIral Immunology, Volume 9, Number 2, 1996, pages 73-87.",ACTIVE
323,WO,A1,WO 2011/120474 A1,000-138-813-970-752,2011-10-06,2011,CU 2011000001 W,2011-04-01,CU 20100056 A,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH;;FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,,https://lens.org/000-138-813-970-752,Patent Application,yes,6,1,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,31,24,016-251-453-054-608;;042-317-613-150-01X;;034-235-038-782-379;;139-919-188-174-285;;010-379-797-525-48X;;075-044-825-480-092;;032-353-621-170-585;;016-601-169-811-533;;037-609-393-437-003;;095-614-841-679-779;;041-378-860-150-554;;163-472-353-889-068;;057-792-660-552-916;;068-381-634-623-162;;045-057-644-738-052;;074-280-275-997-377;;016-601-169-811-533;;117-296-629-798-047;;016-251-453-054-608;;046-650-479-211-102;;075-044-825-480-092;;032-353-621-170-585;;005-358-319-990-738;;034-235-038-782-379,10.1007/bf02628654;;8993755;;10.1096/fj.08-124982;;19299483;;pmc2717765;;16291835;;10.1681/asn.2005030329;;18790770;;10.1158/1535-7163.mct-08-0450;;10.1096/fj.09-151639;;20097873;;pmc2874471;;pmc2120965;;8769421;;10.1083/jcb.134.4.971;;10.1006/bbrc.1993.2555;;7505575;;8822624;;10.1089/vim.1996.9.73;;10613270;;10.1016/j.molbrainres.2004.10.023;;15710248;;pmc2721701;;10.1093/jac/dkn455;;18984648;;10.1201/9780203833445;;12370191;;10.1074/jbc.m205636200;;11160829;;pmc30574;;10.1091/mbc.12.1.143;;10.1016/s0021-9258(19)37628-8;;2459124;;10.1124/mi.2.3.158;;14993376;;8822624;;10.1089/vim.1996.9.73;;7763812;;10.1016/0167-7799(93)90115-p;;10.1007/bf02628654;;8993755;;pmc373388;;10.1093/nar/gkh247;;14769950;;pmc2120965;;8769421;;10.1083/jcb.134.4.971;;10.1006/bbrc.1993.2555;;7505575;;19908203;;10.1002/psc.1192;;16291835;;10.1681/asn.2005030329,"FERNANDEZ-ORTEGA C ET AL: ""Inhibition of in vitro HIV infection by dialysable leucocyte extracts"", BIOTHERAPY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 9, no. 1-3, 1 January 1996 (1996-01-01), pages 33 - 40, XP008138600, ISSN: 0921-299X;;P. KALANTARI ET AL: ""15-Deoxy- 12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification"", THE FASEB JOURNAL, vol. 23, no. 8, 1 August 2009 (2009-08-01), pages 2366 - 2373, XP055001499, ISSN: 0892-6638, DOI: 10.1096/fj.08-124982;;STAMATAKIS KONSTANTINOS ET AL: ""Identification of novel protein targets for modification by 15-deoxy-Delta(12,14)-prostaglandin J(2) in mesangial cells reveals multiple interactions with the cytoskeleton"", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 17, no. 1, January 2006 (2006-01-01), pages 89 - 98, XP055001886, ISSN: 1046-6673;;R. J. PACCIONE ET AL: ""Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility"", MOLECULAR CANCER THERAPEUTICS, vol. 7, no. 9, 1 September 2008 (2008-09-01), pages 2894 - 2903, XP055001822, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-08-0450;;M. G. MENDEZ ET AL: ""Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition"", THE FASEB JOURNAL, vol. 24, no. 6, 22 January 2010 (2010-01-22), pages 1838 - 1851, XP055001818, ISSN: 0892-6638, DOI: 10.1096/fj.09-151639;;R. D. GOLDMAN: ""The function of intermediate filaments in cell shape and cytoskeletal integrity"", THE JOURNAL OF CELL BIOLOGY, vol. 134, no. 4, 1 August 1996 (1996-08-01), pages 971 - 983, XP055001618, ISSN: 0021-9525, DOI: 10.1083/jcb.134.4.971;;STEINERT P M ET AL: ""Concurrence between the Molecular Overlap Regions in Keratin Intermediate Filaments and the Locations of Keratin Mutations in Genodermatoses"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 197, no. 2, 15 December 1993 (1993-12-15), pages 840 - 848, XP024766778, ISSN: 0006-291X, [retrieved on 19931215], DOI: DOI:10.1006/BBRC.1993.2555;;THOMAS ELAINE KINNEY ET AL: ""Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: A possible role of intermediate filaments in the early steps of HIV-1 infection cycle"", VIRAL IMMUNOLOGY, vol. 9, no. 2, 1996, pages 73 - 87, XP055001881, ISSN: 0882-8245;;KHAKHULINA T V ET AL: ""Vimentin intermediate filaments are involved in human immunodeficiency virus type I replication"", DOKLADY AKADEMII NAUK. ROSSIJSKA AKADEMI NAUK, NAUKA, MOSCOW, RU, vol. 368, no. 5, 1 October 1999 (1999-10-01), pages 706 - 708, XP008138850, ISSN: 0869-5652;;POCERNICH C B ET AL: ""Proteomics analysis of human astrocytes expressing the HIV protein Tat"", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 133, no. 2, 18 February 2005 (2005-02-18), pages 307 - 316, XP025297363, ISSN: 0169-328X, [retrieved on 20050218], DOI: DOI:10.1016/J.MOLBRAINRES.2004.10.023;;DE COCK K; CROWLEY SP; LO YR; GRANICH RM; WILLIAMS BG, BOLETIN DE LA ORGANIZACIÓN MUNDIAL DE LA SALUD, vol. 87, 2009, pages 488 - 488;;DE COCK K; CROWLEY SP; LO YR; GRANICH RM; WILLIAMS BG, BOLETIN DE LA ORGANIZACI6N MUNDIAL DE LA SALUD, vol. 87, 2009, pages 488 - 489;;BONGAARTS J; BUETTNER T; HEILIG G; PELLETIER F., POPUL DEV REV, vol. 34, 2008, pages 199 - 224;;DE COCK K; CROWLEY SP; LO YR; GRANICH RM; WILLIAMS BG, BOLETIN DE LA ORGANIZACIÓN MUNDIAL DE LA SALUD, vol. 87, 2009, pages 488 - 489;;IGLESIAS E, BIOTECNOLOGIA APLICADA, vol. 26, 2009, pages 189 - 194;;MARSDEN MD; ZACK JA, J ANTIMICROB CHEMOTH, vol. 63, 2009, pages 7 - 10;;ALBERTS B; JOHNSON A; LEWIS J; RAFF M; ROBERTS K; WALTER P: ""Molecular Biology of the Cell"", 2002, GARLAND PUBLISHING;;BLANCO R; CARRASCO L; VENTOSO I, J BIOL CHEM, vol. 278, 2003, pages 1086 - 1093;;SHOEMAN RL; HUTTERMANN C; HARTIG R; TRAUB P, MOL BIOL CELL, vol. 12, 2001, pages 143 - 154;;ZHOU XM, J BIOL CHEM, vol. 263, 1988, pages 15584 - 9;;""Remington's Pharmaceutical Sciences"", 1991, MACK PUB. CO.;;TUSCHL; BORKHARDT, MOLECULAR INTERVENTIONS, vol. 2, 2002, pages 158;;THOMAS EK; CONNELLY RJ; PENNATHUR S; DUBROUSKY L; HAFFAR OK; BUKRINSKY MI, VIRAL IMMUNOL, vol. 9, 1996, pages 73 - 87;;FINDEIS ET AL., TRENDS IN BIOTECHNOL., vol. 11, 1993, pages 202 - 205;;WU ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 542 - 46;;FERN6NDEZ-ORTEGA C; DUBED M; RUIBAL I; VILARRUBIA OL; MENENDEZ JC; NAVEA L ET AL., BIOTHERAPY, vol. 9, 1996, pages 33 - 40;;UI-TEI K; NAITO Y; TAKAHASHI F; HARAGUCHI T ET AL., NUCLEIC ACIDS RESEARCH, vol. 32, 2004, pages 936 - 948;;GOLDMAN RD; KHUON S; HAO CHOU Y; OPAL P; STEINERT PM, J CELL BIOL, vol. 134, 1996, pages 971 - 983;;STEINERT PM; YANG JM; BALE SJ; COMPTON JG, BBRC, vol. 197, 1993, pages 840 - 848;;VALLESPI MG; FERNANDEZ JR; TORRENS; GARCIA I; GARAY H; MENDOZA O ET AL., J PEPTIDE SCIENCE, vol. 16, 2009, pages 40 - 47;;STAMATAKIS K; SANCHEZ-GOMEZ FJ; PEREZ-SAIA D, J AM SOC NEPHROL, vol. 17, 2006, pages 89 - 98",PENDING
324,PT,E,PT 816506 E,052-627-629-662-956,2001-06-29,2001,PT 97901516 T,1997-01-17,CU 1996010 A,1996-01-17,SISTEMA PARA A EXPRESSAO DE ANTIGENIOS HETEROLOGOS COMO PROTEINAS DE FUSAO,,CT INGENIERIA GENETICA BIOTECH,CANO CARLOS ANTONIO DUARTE;;NIETO GERARDO ENRIQUE GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ EMILIO LUIS CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIGUEZ CARMEN ELENA GOMEZ;;RODRIGUEZ RICARDO DE LA CARIDA;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN,,https://lens.org/052-627-629-662-956,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
325,MX,A,MX 2012011424 A,125-311-304-233-083,2012-11-06,2012,MX 2012011424 A,2011-04-01,CU 20100056 A;;CU 2011000001 W,2010-04-01,METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL AND HUMAN CELLS.,"The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate filaments, and more specifically the proteins vimentin and/or keratin-10. Intervening in the structure of said proteins inhibits replication of the virus in human cells. The invention likewise relates to the use of agents, which include peptides and/or interfering RNA and/or lipid compounds, and negatively modulates or alters the cell cytoskeleton, in order to prevent or treat HIV infection. The invention provides the means and methods for altering the structure of the cell cytoskeleton/filament, which disrupts the HIV infection in human cells; the virus can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin-10 (for example, by interfering RNA transcription control) or by using peptides that alter the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH,REYES ACOSTA OSVALDO;;UBIETA GOMEZ RAIMUNDO;;CASTELLANOS SERRA LILA ROSA;;FALCON CAMA VIVIANA;;FERNANDEZ ORTEGA CELIA BERTA;;RAMIREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;DUARTE CANO CARLOS ANTONIO,,https://lens.org/125-311-304-233-083,Patent Application,no,0,0,34,34,0,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C07K14/47;;A61K31/5575;;A61K31/7105;;A61K38/17;;A61P31/18;;C07C405/00;;C12N15/113,,0,0,,,,PENDING
326,US,A1,US 2016/0108404 A1,175-718-872-698-135,2016-04-21,2016,US 201514943106 A,2015-11-17,US 201514943106 A;;CU 20100056 A;;US 201313637845 A;;CU 2011000001 W,2010-04-01,Method for Inhibiting HIV Replication in Mammal and Human Cells,"The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ ORTEGA CELIA BERTA;;RAMÍREZ SUAREZ ANNA CARIDYS;;CASILLAS CASANOVA DIONNE;;PANEQUE GUERRERO TAIMI EMELIA;;UBIETA GOMEZ RAIMUNDO;;DUBED ECHEVARRIA MARTA;;NAVEA LEYVA LEONOR MARGARITA;;CASTELLANOS SERRA LILA ROSA;;DUARTE CANO CARLOS ANTONIO;;FALCON CAMA VIVIANA;;REYES ACOSTA OSVALDO,CENTRO DE INGENIERÍA GENETICA Y BIOTECNOLOGÍA (2013-01-04),https://lens.org/175-718-872-698-135,Patent Application,yes,1,0,34,34,12,A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;A61P31/18;;A61P43/00;;A61K31/19;;A61K31/5575;;A61K31/7105;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K38/1748;;A61K45/06;;C12N5/0636;;C12N15/113;;C12N15/1132;;A61K31/5575;;A61K31/7105;;C07K14/47;;C07K14/4741;;C12N15/113;;C12N2310/14;;A61K38/1748;;A61K31/19;;A61K31/713;;A61K38/10;;A61K38/1709;;A61K45/06;;C12N5/0636;;C12N15/1132;;C12N15/1131;;C12N2310/531;;C12N2320/31,C12N15/113,,1,0,,,"Sayda M. Elbashir, Analysis of gene function in somatic mammalian cells using small interfering RNAs, Methods 26 (2002) 199â213.",ACTIVE
327,EA,B1,EA 000307 B1,079-432-573-661-769,1999-04-29,1999,EA 199700244 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"1. Fusion protein, containing peptide stabilizer representing a modified N-terminal part of 47 aminoacids of the antigen P64K of Neisseria meningitidis B:4:P1.15 having structure 2. Fusion protein according to Claim 1, characterized in that heterologous protein is a protein of external membrane of Neisseria meningitidis. 3. Fusion protein according to Claim 2, characterized in that the protein of external membrane of Neisseria meningitidis is a protein PorA or Opc(5c) of Neisseria meningitidis. 4. Fusion protein according to Claim 1, characterized in that heterologous protein is a multiepitopic polypeptide, including various copies of the central part of the variable region 3 (v3) gp 120 VIH-1. 5. Fusion protein according to Claim 1, characterized in that the multiepitopic polypeptide is a polypeptide TAB 4 or TAB 9. 6. Vector of expression of fusion protein according to Claim 1 in E. Coli, continuing the sequence of sensing, comprising the following constructive elements: - sequence of nucleotides, coding peptide-stabilizer representing a modified N-terminal part of 47 aminoacids of the antigen P64K of Neisseria meningitidis B:4:P1.15 having structure: and being under the control of the triptophane promotor of E. coli - sites of restrictions Xbal, EcoRVand BamHl localized after the sequence of nucleotides, coding peptide-stabilizer; - DNA fragment, coding heterologous protein or polypeptide built-in by said sites; - the terminator of the transcription of the phage T4, arranged behind the DNA fragment, coding for heterologous protein or polypeptide; - gen of resistance against ampicillin as a selective marker gen. 7. Vector of expression according to Claim 6, characterized in that DNA fragment codes for protein of external membrane of Neisseria meningitidis. 8. Vector of expression according to Claim 6, characterized in that DNA fragment codes for heterologous polypeptide, which is multiepitopic polypeptide, including various copies of the central part of the variable region 3 (v3) of protein gp 120 VIH-1 9. Vector of expression according to Claim 7, characterized in that represents vector pM-80. 10. Vector of expression according to Claim 7, characterized in that represents vector pM-82. 11. Vector of expression according to Claim 7, characterized in that represents vector pTAB9. 12. Recombinant plasmide of Escherichia coli transformed by vector of expression according to any of 6-11 Claims and used to prepare fusion protein according to any of 1-5 Claims. 13. Vaccine preparation, characterized in that constituting fusion protein according to 1-5 Claims and appropriate adjuvant.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUEOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/079-432-573-661-769,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;G01N33/569;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
328,WO,A1,WO 1997/026359 A1,161-671-325-238-494,1997-07-24,1997,CU 9700001 W,1997-01-17,CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"The present invention relates to biotechnology and genetic engineering, particularly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an oppropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 aminoacids of the antigen P64k of Neisseria meningitidis B:4 :P1.15. In particular, use is made of a recombinant plasmide containing said sequence, under the control of the triptophane promotor of E. coli and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.",CIGB;;DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/161-671-325-238-494,Patent Application,yes,2,19,33,33,21,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;G01N33/569;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,2,1,048-786-274-866-581,7567952;;10.1002/prot.340210404,"GERARDO GUILLÉN ET AL.: ""Cloning, expression and characterization of the P64k outer membrane protein from N. meningitidis"", BIOTECNOLOGÍA APLICADA, vol. 12, no. 2, 1995, pages 72, XP000671542;;BRINGAS R ET AL: ""A Lipoamide Dehydrogenase From Neisseria meningitidis has a Lipoyl Domain."", PROTEINS STRUCTURE FUNCTION AND GENETICS 21 (4). 1995. 303-306. ISSN: 0887-3585, XP000671539",PATENTED
329,EP,A1,EP 0816506 A1,141-293-689-327-374,1998-01-07,1998,EP 97901516 A,1997-01-17,CU 9700001 W;;CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"The present invention relates to biotechnology and genetic engineering, particularly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in  Escherichia coli  of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 aminoacids of the antigen P64k of  Neisseria meningitidis  B:4 :P1.15. In particular, use is made of a recombinant plasmide containing said sequence, under the control of the triptophane promotor of  E. coli  and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in  E. coli .",CIGB,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/141-293-689-327-374,Patent Application,yes,0,2,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
330,US,A,US 6146635 A,184-435-044-274-894,2000-11-14,2000,US 93091797 A,1997-09-16,CU 1996010 A;;CU 9700001 W,1996-01-17,System for the expression of heterologous antigens as fusion proteins,"The present invention relates to biotechnology and genetic engineering, particularly the expression of proteins of viral origin in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 amino acids of the antigen P64k of Neisseria meningitidis B:4:P1.15. In particular, use is made of a recombinant plasmid containing said sequence, under the control of the tryptophane promotor of E. coli and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.",CT INGENIERIA GENETICA BIOTECH,CANO CARLOS ANTONIO DURATE;;NIETO ENRIQUE GERARDO GUILLEN;;ACOSTA ANABEL ALVAREZ;;MUNOZ LUIS EMILIO CARPIO;;VAZQUEZ DIOGENES QUINTANA;;RODRIQUEZ CARMEN ELENA GOMEZ;;DE LA CARIDID SIVA RODRIGUEZ R;;GALVEZ CONSUELO NAZABAL;;ANGULO MARIA DE JESUS LEAL;;DUNN ALEJANDRO MIGUEL MARTIN,CENTRO DE INGIENERIA GENETICA Y BIOTECNOLOGIA (CIGB) (1997-09-04),https://lens.org/184-435-044-274-894,Granted Patent,yes,3,59,33,33,19,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;G01N33/569;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,424/192.1;;424/185.1;;424/190.1;;424/208.1;;424/250.1;;424/249.1;;424/184.1;;530/350;;530/825;;530/820,3,0,,,"Niebla et al. In: Neisseria 94, Proceedings of the Ninth International Pathogenic Neisseria Conference, (Ed) Evans et al. Winchester, England, Sep. 26 30, 1994.;;Guillen et al. Biotechnol. Apl. 12: 72, 1995.;;Guillen et al. Biotechnol. Apl. 13: 271 275, 1996.",EXPIRED
331,CU,B1,CU 24373 B1,075-788-598-470-899,2018-11-06,2018,CU 20150132 A,2015-09-24,CU 20150132 A,2015-09-24,MARCO ESTEREOTÁXICO PARA EXTREMIDADES,"<p>La presente invención se relaciona con un marco estereotáxico para las extremidades, que garantiza la posición fija y reproducible de la extremidad, logrando mantener las mismas condiciones geométricas de los dispositivos de medición o tratamiento respecto a la extremidad, o parte de ella, durante el estudio o la terapia. El marco comprende un soporte de posicionamiento y fijación de la extremidad y un sistema de medición o tratamiento, que incluye un lugar geométrico donde se ubica el dispositivo de medición o tratamiento, lo que garantiza que la posición relativa de dicho dispositivo respecto a la región de la extremidad bajo examen o tratamiento sea reproducible.</p>",CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA BIOCUBAFARMA,BERLANGA ACOSTA JORGE AMADOR;;CABAL MIRABAL CARLOS ALBERTO;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;FLORES DÍAZ LUIS MANUEL;;GONZÁLEZ BLANCO SONIA;;GONZÁLEZ DALMAU EVELIO RAFAEL;;GUILLÉN NIETO GERARDO ENRIQUE;;HERRERA MARTÍNEZ LUIS SATURNINO;;ORAMAS DÍAZ LEONARDO;;UBIETA GÓMEZ RAIMUNDO,,https://lens.org/075-788-598-470-899,Unknown,no,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B5/107,,0,0,,,,PENDING
332,US,A1,US 2018/0256112 A1,175-280-526-810-485,2018-09-13,2018,US 201615762479 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The present invention is related to a stereotaxic frame for extremities that ensures that the extremity position is fixed and reproducible; keeping the same geometric conditions of the measurement or treatment devices regards the extremity, or part thereof, during the study or therapy. The frame comprises a positioning and fixing holder for the extremity and a measuring or treatment system, that includes a geometric locus where the measurement or treatment device is allocated, ensuring that the relative position of said device regards the region of the extremity under examination or treatment is reproducible.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;GUILLÉN NIETO GERARDO ENRIQUE;;FLORES DÍAZ LUIS MANUEL;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GÓMEZ RAIMUNDO,CENTRO DE INGENIERÍA GENÉTICA Y BIOTECHNOLOGÍA (2018-05-16),https://lens.org/175-280-526-810-485,Patent Application,yes,0,1,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B5/00;;A61B5/01;;A61B5/107;;A61B90/14,,0,0,,,,DISCONTINUED
333,AR,A1,AR 106079 A1,186-898-252-423-536,2017-12-13,2017,AR P160102858 A,2016-09-20,CU 20150132 A,2015-09-24,MARCO ESTEREOTÁXICO PARA EXTREMIDADES,"Marco estereotáxico para las extremidades, que garantiza la posición fija y reproducible de la extremidad, logrando mantener las mismas condiciones geométricas de los dispositivos de medición o tratamiento respecto a la extremidad, o parte de ella, durante el estudio o la terapia. El marco comprende un soporte de posicionamiento y fijación de la extremidad y un sistema de medición o tratamiento, que incluye un lugar geométrico donde se ubica el dispositivo de medición o tratamiento, lo que garantiza que la posición relativa de dicho dispositivo respecto a la región de la extremidad bajo examen o tratamiento sea reproducible.",CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA,RAIMUNDO UBIETA GMEZ;;SONIA GONZALEZ BLANCO;;ORESTES LUCIO CABAAS RODRGUEZ;;LUIS MANUEL FLORES DAS;;GERARDO ENRIQUE GUILLN NIETO;;JOS IGNACIO FERNNDEZ MONTEQUN;;JORGE AMADOR BERLANGA ACOSTA;;LUIS SATURNINO HERRERA MARTNEZ;;LEONARDO ORAMAS DIAZ;;EVELIO RAFAEL GONZLEZ DALMAU;;CARLOS ALBERTO CABAL MIRABAL,,https://lens.org/186-898-252-423-536,Patent Application,no,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B5/00;;A43D1/02;;A61B5/107,,0,0,,,,PENDING
334,EP,A1,EP 3354224 A1,033-584-083-502-865,2018-08-01,2018,EP 16794498 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The present invention is related to a stereotaxic frame for extremities that ensures that the extremity position is fixed and reproducible; keeping the same geometric conditions of the measurement or treatment devices regards the extremity, or part thereof, during the study or therapy. The frame comprises a positioning and fixing holder for the extremity and a measuring or treatment system, that includes a geometric locus where the measurement or treatment device is allocated, ensuring that the relative position of said device regards the region of the extremity under examination or treatment is reproducible.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;GUILLÉN NIETO GERARDO ENRIQUE;;FLORES DÍAZ LUIS MANUEL;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GÓMEZ RAIMUNDO,,https://lens.org/033-584-083-502-865,Patent Application,yes,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B90/10;;A43D1/02;;A61B5/00;;A61B5/107,,0,0,,,,DISCONTINUED
335,WO,A1,WO 2017/050302 A1,057-820-470-931-961,2017-03-30,2017,CU 2016050002 W,2016-09-22,CU 20150132 A,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The invention relates to a stereotactic frame for limbs, which guarantees a fixed and reproducible position for the limb, maintaining the same geometric conditions for the measurement or treatment devices in relation to the limb, or part thereof, during examination or therapy. The frame comprises a support for positioning and securing the limb and a measurement or treatment system, including a geometric location at which the measurement or treatment device is positioned, thereby ensuring that the position of the device relative to the region of the limb being examined or treated can be reproduced.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;GUILLÉN NIETO GERARDO ENRIQUE;;FLORES DÍAZ LUIS MANUEL;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GÓMEZ RAIMUNDO,,https://lens.org/057-820-470-931-961,Patent Application,yes,16,1,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B90/10;;A43D1/02;;A61B5/00;;A61B5/107,,1,0,,,"WANG L ET AL., DIABETES SCI AND TECHNOL, 2015, pages 1 - 8",PENDING
336,DE,T2,DE 69703813 T2,163-736-671-349-346,2001-08-09,2001,DE 69703813 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIETAGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JES S;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/163-736-671-349-346,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
337,AU,A,AU 1997/015396 A,004-643-422-668-700,1997-08-11,1997,AU 1997/015396 A,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,System for the expression of heterologous antigens as fusion proteins,,CT INGENIERIA GENETICA BIOTECNOLOGIA,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/004-643-422-668-700,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
338,AT,T1,AT E198491 T1,105-780-084-003-10X,2001-01-15,2001,AT 97901516 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/105-780-084-003-10X,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,DISCONTINUED
339,WO,A1,WO 1998/023754 A1,113-673-674-202-690,1998-06-04,1998,CU 9700006 W,1997-11-25,CU 1996107 A,1996-11-25,PROCESS FOR THE EXPRESSION OF GENES OF THE DENGUE VIRUSES,"The present invention relates to the field of biotechnology and to recombinant DNA techniques and particularly to a process for the expression of the gene which codes for the protein of the envelope of the dengue viruses serotypes 2 and 4 in methylotrophic yeasts of the genus Pichia. The objective is to obtain an immunogene for human vaccination. For the dengue serotype 2 virus, we started from the genic sequence which codes for the protein E of the virus, from the strain A 15 isolated during the dengue fever epidemic and haemorrhagic dengue which occurred in Cuba in 1981. In the case of the serotype 4 dengue virus, we started from the genic sequence which codes for the protein E of the virus from the strain 814669 isolated during the dengue fever epidemy which occurred in Dominica in 1981.",CIGB;;INST DE MEDICINA TROPICAL PEDR;;SARIOL CURBELO CARLOS AUGUSTO;;MUNE JIMENEZ MAYRA;;GUZMAN TIRADO MARIA GUADALUPE;;GUILLEN NIETO GERARDO ENRIQUE;;VAZQUEZ VILLASUSO VALEXYS;;RODRIGUEZ DIAZ RAYNER;;VAZQUEZ RAMUDO SUSANA;;VAZQUEZ CAMPOS RAYSA;;MARQUEZ PERERA GABRIEL JESUS;;GARCIA SUAREZ JOSE;;ROSARIO DOMINGUEZ DELFINA ESPE;;ALVAREZ ACOSTA ANABEL,SARIOL CURBELO CARLOS AUGUSTO;;MUNE JIMENEZ MAYRA;;GUZMAN TIRADO MARIA GUADALUPE;;GUILLEN NIETO GERARDO ENRIQUE;;VAZQUEZ VILLASUSO VALEXYS;;RODRIGUEZ DIAZ RAYNER;;VAZQUEZ RAMUDO SUSANA;;VAZQUEZ CAMPOS RAYSA;;MARQUEZ PERERA GABRIEL JESUS;;GARCIA SUAREZ JOSE;;ROSARIO DOMINGUEZ DELFINA ESPE;;ALVAREZ ACOSTA ANABEL,,https://lens.org/113-673-674-202-690,Patent Application,yes,1,6,5,5,15,A61K39/00;;C07K14/005;;C12N7/00;;C12N2710/24162;;C12N2770/24122;;Y02A50/30,A61K39/00;;C07K14/18;;C12N1/21;;C12N7/04;;C12N15/40,,3,3,137-177-864-406-692;;055-814-806-213-194;;008-431-290-746-914,2714651;;10.1016/0378-1119(89)90266-7;;9266980;;10.1099/0022-1317-78-8-1861;;10.1128/jvi.71.7.5366-5374.1997;;pmc191775;;9188607,"IRIE K ET AL: ""SEQUENCE ANALYSIS OF CLONED DENGUE VIRUS TYPE 2 GENOME (NEW GUINEA -C STRAIN)"", GENE, vol. 75, 1989, pages 197 - 211, XP000601610;;SUGRUE, R. J. ET AL.: ""Expression of the Dengue virus structural proteins in Pichia pastoris leads to generation of virus-like particles"", JOURNAL OF GENERAL VIROLOGY., vol. 78, no. 8, August 1997 (1997-08-01), READING GB, pages 1861 - 1866, XP002061637;;POLO, S. ET AL.: ""Infectious RNA transcripts from full-length Dengue virus type 2 cDNA clones made in yeast"", JOURNAL OF VIROLOGY., vol. 71, no. 7, July 1997 (1997-07-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 5366 - 5374, XP002061638",PENDING
340,AU,A,AU 1998/053973 A,005-389-068-498-512,1998-06-22,1998,AU 1998/053973 A,1997-11-25,CU 1996107 A;;CU 9700006 W,1996-11-25,Process for the expression of genes of the dengue viruses,,CT INGENIERIA GENETICA BIOTECNOLOGIA;;INST DE MEDICINA TROPICAL PEDRO KOURI IPK,CURBELO CARLOS AUGUSTO SARIOL;;JIMENEZ MAYRA MUNE;;TIRADO MARIA GUADALUPE GUZMAN;;NIETO GERARDO ENRIQUE GUILLEN;;VILLASUSO VALEXYS VAZQUEZ;;DIAZ RAYNER RODRIGUEZ;;RAMUDO SUSANA VAZQUEZ;;CAMPOS RAYSA VAZQUEZ;;PERERA GABRIEL JESUS MARQUEZ;;SUAREZ JOSE GARCIA;;DOMINGUEZ DELFINA ESPERANZA RO;;ACOSTA ANABEL ALVAREZ,,https://lens.org/005-389-068-498-512,Patent Application,no,0,0,5,5,0,A61K39/00;;C07K14/005;;C12N7/00;;C12N2710/24162;;C12N2770/24122;;Y02A50/30,A61K39/00;;C07K14/18;;C12N1/21;;C12N7/04;;C12N15/40,,0,0,,,,DISCONTINUED
341,HU,A2,HU P9800730 A2,033-218-478-771-066,1998-07-28,1998,HU P9800730 A,1997-01-17,CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,"A találmány tárgya heterőlóg prőteinek mikrőbiális gazdasejtekbentörténő expresszáltatása, rekőmbináns DNS technőlógia alkalmazásával.A találmány szerint a heterőlóg pőlipeptideket bakteriálispőlipeptidekkel fűziőnálva expreszálják.A találmány tárgyát közelebbről a Neisseria meningitidis B:4:P1.15P64K-antigénjének első 47 aminősavából származtatőtt stabilizátőrpeptidet tartalmazó fúziós prőteinek képezik, tővábbá eljárásőkheterőlóg prőteinek fúziós fehérjeként történő előállítására, atalálmány szerinti fúziós prőteinek alkalmazásával.A találmány szerinti megőldás alkalmas heterőlóg prőteinek mikrőbiálisgazdasejtekben történő expresszáltatására.ŕ",CIGB,ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;DUARTE CANO CARLOS ANTONIO;;GOMEZ RODRIGUEZ CARMEN ELENA;;GUILLEN NIETO GERARDO ENRIQUE;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL;;NAZABAL GALVEZ CONSUELO;;QUINTANA VAZQUEZ DIOGENES;;SILVA RODRIGEZ RICARDO DE LA C,,https://lens.org/033-218-478-771-066,Patent Application,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,PENDING
342,CU,A1,CU 22666 A1,182-107-045-211-144,2001-04-27,2001,CU 1996107 A,1996-11-25,CU 1996107 A,1996-11-25,"PROCEDIMIENTO PARA LA EXPRESIÓN DE GENES DE LOS VIRUS DEL DENGUE EN LA LEVADURA PICHIA PASTORIS, ADNS RECOMBINANTES Y MICROORGANISMOS TRANSFORMADOS","La presente invención se relaciona con la rama de la biotecnología y con las técnicas de ADN recombinante y en particular con un procedimiento para la expresión del gen que codifica para la proteína de la envoltura de los virus del dengue seropositivos 2 y 4 en levaduras metilotróficas del genero Pichia. El objetivo es obtener un inmunógeno para vacunación en humanos. Para el virus dengue serotipo 2 se partió de la secuencia génica que codifica para la peoteína E del virus, a partir de la cepa A 15 aislada durante la epidemia de fiebre del dengue y dengue hemorrágico ocurrida en Cuba en el ano 1981. En el caso del virus Dengue serotipo 4 se partió de la secuencia génica que codifica para la proteína E del virus, a partir de la cepa 814669 aislada durante la epidemia de fiebre del dengue ocurrida en Dominica en el ano 1981.",INST DE MEDICINA TROPICAL PEDRO KOURI;;CT INGENIERIA GENETICA BIOTECH,RODRIGUEZ DIAZ RAYNER;;ROSARIO DOMINGUEZ DELFINA ESPERANZA;;MARQUEZ PERERA GABRIEL JESUS;;VAZQUEZ CAMPOS RAISA;;VAZQUEZ VILLASUSO VALEXYS;;GUZMAN TIRADO MARIA GUADALUPE;;MUNE JIMENEZ MAYRA;;ALVAREZ ACOSTA ANABEL;;SARIOL CURBELO CARLOS AUGUSTO;;VAZQUEZ RAMUDO SUSANA;;GUILLEN NIETO GERARDO ENRIQUE;;GARCIA SUAREZ JOSE,,https://lens.org/182-107-045-211-144,Limited Patent,no,0,0,5,5,0,A61K39/00;;C07K14/005;;C12N7/00;;C12N2710/24162;;C12N2770/24122;;Y02A50/30,A61K39/00;;A61K39/12;;C07K14/18;;C12N1/21;;C12N7/04;;C12N15/40,,0,0,,,,EXPIRED
343,EP,B1,EP 0816506 B1,182-455-858-668-353,2001-01-03,2001,EP 97901516 A,1997-01-17,CU 9700001 W;;CU 1996010 A,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/182-455-858-668-353,Granted Patent,yes,2,1,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,2,0,,,"BIOTECNOLOG A APLICADA, vol. 12, no. 2, 1995, page 72 XP000671542 GERARDO GUILL N ET AL.: ""Cloning, expression and characterization of the P64k outer membrane protein from N. meningitidis"";;PROTEINS STRUCTURE FUNCTION AND GENETICS 21 (4). 1995. 303-306. ISSN: 0887-3585, XP000671539 BRINGAS R ET AL: ""A Lipoamide Dehydrogenase From Neisseria meningitidis has a Lipoyl Domain.""",EXPIRED
344,KR,A,KR 20180056684 A,183-951-632-276-567,2018-05-29,2018,KR 20187010736 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,사지용 정위 고정 프레임,"본 발명은 사지 위치를 고정 및 재현 가능하도록 하여 조사 또는 치료 중에 사지 또는 그의 일부에 대한 측정 또는 치료 기기의 동일한 기하학적 조건을 유지하게 하는 사지용 정위 고정 프레임에 관한 것이다. 상기 프레임은 사지용 위치 조정 및 고정 홀더와, 측정 또는 치료 기기가 할당되어 있는 기하학적 궤적을 포함하는 측정 또는 치료 시스템을 포함하여 검사 또는 치료 중에 사지의 영역에 대한 상기 기기의 상대적 위치를 재현할 수 있게 한다.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNANDEZ MONTEQUIN JOSE IGNACIO;;GUILLEN NIETO GERARDO ENRIQUE;;FLORES DIAZ LUIS MANUEL;;CABANAS RODRIGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GOMEZ RAIMUNDO,,https://lens.org/183-951-632-276-567,Patent Application,no,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B5/00;;A61B5/107;;A61B90/10,,0,0,,,,PENDING
345,CA,A1,CA 2999084 A1,017-151-775-577-725,2017-03-30,2017,CA 2999084 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The invention relates to a stereotactic frame for limbs, which guarantees a fixed and reproducible position for the limb, maintaining the same geometric conditions for the measurement or treatment devices in relation to the limb, or part thereof, during examination or therapy. The frame comprises a support for positioning and securing the limb and a measurement or treatment system, including a geometric location at which the measurement or treatment device is positioned, thereby ensuring that the position of the device relative to the region of the limb being examined or treated can be reproduced.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNANDEZ MONTEQUIN JOSE IGNACIO;;GUILLEN NIETO GERARDO ENRIQUE;;FLORES DIAZ LUIS MANUEL;;CABANAS RODRIGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GOMEZ RAIMUNDO,,https://lens.org/017-151-775-577-725,Patent Application,no,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B90/10;;A43D1/02;;A61B5/00;;A61B5/107,,0,0,,,,DISCONTINUED
346,BR,A,BR 9713540 A,101-868-857-166-607,2000-10-24,2000,BR 9713540 A,1997-11-25,CU 1996107 A;;CU 9700006 W,1996-11-25,Procedimento para a expressão do gene do vìrus da dengue,"Patente de Invenção: <B>""PROCEDIMENTO PARA A EXPRESSãO DE GENES DO VìRUS DA DENGUE""<D>. A presente invenção está no campo da biotecnologia e refere-se a técnicas de DNA recombinantes, em particular a um procedimento para a expressão do gene que codifica a proteína do envelope do vírus da dengue sorotipo 2 e 4 em levedura metilotrófica de gênero Pichia. O objetivo técnico é desenvolver um sistema para a expressão eficiente do gene que codifica a proteína do envelope do vírus da dengue sorotipo 2 e 4 para obter um imunógeno para vacinação humana. A seq³ência genética que codifica a proteína E do vírus foi o ponto de partida do vírus da dengue sorotipo 2, retirada da cepa A 15 isolada durante as epidemias de febre de dengue e dengue hemorrágica em Cuba, 1981. Para o vírus da dengue sorotipo 4 o ponto de partida foi seq³ência genética que codifica a proteína E do vírus tirada da cepa 814669 isolada durante a epidemia de febre da dengue na República Dominicana em 1981.",CT INGENIERIA GENETICA BIOTECH;;INST DE MEDICINA TROPICAL PEDR,CURBELO CARLOS AUGUSTO SARIOL;;JIMENEZ MAYRA MUNE;;TIRADO MARIA GUADALUPE GUZMAN;;NIETO GERARDO ENRICO GUILHEN;;VILLASUSO VALEXYS VAZQUEZ;;DIAZ RAYNER RODRIGUEZ;;RAMUDO SUSANA VAZQUEZ;;CAMPOS RAYSA VAZQUEZ;;PERERA GABRIEL JESUS MARQUEZ;;SUAREZ JOSE GARCIA;;DOMINGUEZ DELFINA ESPERANZA RO;;ACOSTA ANABEL ALVAREZ,,https://lens.org/101-868-857-166-607,Patent Application,no,0,0,5,5,0,A61K39/00;;C07K14/005;;C12N7/00;;C12N2710/24162;;C12N2770/24122;;Y02A50/30,A61K39/00;;C07K14/18;;C12N1/21;;C12N7/04;;C12N15/40,,0,0,,,,DISCONTINUED
347,DE,D1,DE 69703813 D1,161-204-541-501-987,2001-02-08,2001,DE 69703813 T,1997-01-17,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIETAGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JES S;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/161-204-541-501-987,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;G01N33/569;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
348,GR,T3,GR 3035690 T3,105-987-702-883-529,2001-07-31,2001,GR 20010400539 T,2001-04-02,CU 1996010 A;;CU 9700001 W,1996-01-17,SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS,,CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;GUILLEN NIETO GERARDO ENRIQUE;;ALVAREZ ACOSTA ANABEL;;CARPIO MUNOZ EMILIO LUIS;;QUINTANA VAZQUEZ DIOGENES;;GOMEZ RODRIGUEZ CARMEN ELENA;;SILVA RODRIGEZ RICARDO DE LA C;;NAZABAL GALVEZ CONSUELO;;LEAL ANGULO MARIA DE JESUS;;MARTIN DUNN ALEJANDRO MIGUEL,,https://lens.org/105-987-702-883-529,Granted Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;G01N33/569;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
349,CU,A7,CU 20150132 A7,163-535-845-424-799,2017-05-10,2017,CU 20150132 A,2015-09-24,CU 20150132 A,2015-09-24,MARCO ESTEREOTÁXICO PARA EXTREMIDADES,"La presente invención se relaciona con un marco estereotáxico para las extremidades, que garantiza la posición fija y reproducible de la extremidad, logrando mantener las mismas condiciones geométricas de los dispositivos de medición o tratamiento respecto a la extremidad, o parte de ella, durante el estudio o la terapia. El marco comprende un soporte de posicionamiento y fijación de la extremidad y un sistema de medición o tratamiento, que incluye un lugar geométrico donde se ubica el dispositivo de medición o tratamiento, lo que garantiza que la posición relativa de dicho dispositivo respecto a la región de la extremidad bajo examen o tratamiento sea reproducible.",CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA (BIOCUBAFARMA),CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;ORAMAS DÍAZ LEONARDO;;HERRERA MARTÍNEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;GUILLÉN NIETO GERARDO ENRIQUE;;FLORES DÍAZ LUIS MANUEL;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;GONZÁLEZ BLANCO SONIA;;UBIETA GÓMEZ RAIMUNDO,,https://lens.org/163-535-845-424-799,Patent Application,no,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B5/107,,0,0,,,,PENDING
350,CA,A1,CA 2542680 A1,155-405-937-728-815,2005-04-28,2005,CA 2542680 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,,CT INGENIERIA GENETICA BIOTECH,ACOSTA RIVERO NELSON;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;GARCIA GONZALEZ DAYMIR;;AGUILAR RUBIDO JULIO CESAR;;UBIETA GOMEZ RAIMUNDO;;HERRERA MARTINEZ LUIS SATURNIN;;LOVAINA MATO YADIRA;;IGLESIAS PEREZ ENRIQUE;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;DUENAS CARRERA SANTIAGO;;ALVAREZ OBREGON JULIO CESAR,,https://lens.org/155-405-937-728-815,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/39;;A61K39/21;;A61K39/29;;A61K39/295;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
351,AU,A1,AU 2004/281098 A1,184-464-888-417-085,2005-04-28,2005,AU 2004/281098 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,Pharmaceutical compositions for therapeutic use,,CT INGENIERIA GENETICA BIOTECH,PEREZ ENRIQUE IGLESIAS;;MARTINEZ LUIS SATURNINO HERRER;;CARRERA SANTIAGO DUENAS;;RIVERO NELSON ACOSTA;;CANO CARLOS DUARTE;;MATO YADIRA LOBAINA;;VANLANDSHOOT PETER;;NIETO GERARDO ENRIQUE GUILLEN;;GOMEZ RAIMUNDO UBIETA;;RUBIDO JULIO CESAR AGUILAR;;GONZALEZ VERENA LUCILA MUZIO;;GONZALEZ DAYMIR GARCIA;;OBREGON JULIO CESAR ALVAREZ,,https://lens.org/184-464-888-417-085,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,C12P21/02;;A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02,,0,0,,,,INACTIVE
352,AU,B2,AU 2004/281098 B2,020-963-463-706-112,2009-06-25,2009,AU 2004/281098 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,Pharmaceutical compositions for therapeutic use,,CT INGENIERIA GENETICA BIOTECNOLOGIA,PEREZ ENRIQUE IGLESIAS;;MARTINEZ LUIS SATURNINO HERRERA;;CARRERA SANTIAGO DUENAS;;RIVERO NELSON ACOSTA;;CANO CARLOS DUARTE;;MATO YADIRA LOBAINA;;VANLANDSHOOT PETER;;NIETO GERARDO ENRIQUE GUILLEN;;GOMEZ RAIMUNDO UBIETA;;RUBIDO JULIO CESAR AGUILAR;;GONZALEZ VERENA LUCILA MUZIO;;GONZALEZ DAYMIR GARCIA;;OBREGON JULIO CESAR ALVAREZ,,https://lens.org/020-963-463-706-112,Granted Patent,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,INACTIVE
353,WO,A1,WO 2005/037311 A1,091-645-384-180-070,2005-04-28,2005,CU 2004000011 W,2004-10-20,CU 20030240 A,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,"The invention relates to therapeutic vaccines against pathogens which cause chronic diseases. More specifically, the invention relates to the use of the hepatitis B virus surface antigen (HBsAg) which is produced by recombinant means from Pichia pastoris, by way of a main component, in order to obtain pharmaceutical compositions for therapeutic purposes. The inventive compositions can comprise a combination of the hepatitis B antigen and other coadministered antigens. The aforementioned formulations can generate a strong lymphoproliferative response and cytotoxic T lymphocytes, as well as a significant specific antibody response. In this way, said formulations are very effective for the treatment of the above-mentioned diseases in humans.",CT INGENIERIA GENETICA BIOTECH;;AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOVAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOVAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/091-645-384-180-070,Patent Application,yes,6,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,10,10,014-680-069-455-653;;015-857-934-045-841;;057-206-031-740-178;;041-510-512-838-745;;055-008-872-424-17X;;028-251-769-423-217;;049-909-210-178-361;;088-072-146-165-824;;014-680-069-455-653;;051-433-308-735-163,12794712;;10.1002/jmv.10425;;10.1016/s0168-1656(99)00201-1;;10682276;;10.1016/s0264-410x(02)00393-6;;12477434;;7678639;;10.1002/jmv.1890390113;;10.1016/s0140-6736(94)91384-6;;7914291;;7791465;;10.1016/s0140-6736(95)91126-x;;9658616;;10.1016/s0168-8278(01)00028-9;;11451177;;12794712;;10.1002/jmv.10425;;11237755;;10.1006/bbrc.2001.4449,"VANLANDSCHOOT PETER ET AL: ""Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity."", JOURNAL OF MEDICAL VIROLOGY, vol. 70, no. 4, August 2003 (2003-08-01), pages 513 - 519, XP002316328, ISSN: 0146-6615;;HARDY E ET AL: ""Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris"", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 77, no. 2-3, February 2000 (2000-02-01), pages 157 - 167, XP004185816, ISSN: 0168-1656;;MICHEL M-L: ""Towards immunotherapy for chronic hepatitis B virus infections"", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, 19 December 2002 (2002-12-19), pages A83 - A88, XP004397477, ISSN: 0264-410X;;MANCINI M ET AL.: ""Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg transgenic mice: a possible way of circumventing ''nonresponse'' to HBsAg"", J MED VIROL., vol. 39, 1993, pages 67 - 74;;POL S ET AL., LANCET, 1994, pages 342;;WEN Y-M ET AL., LANCET, vol. 345, 1995, pages 1575 - 1576;;POL S ET AL., ACTA GASTROENTEROLOGICA BELGICA, vol. 61, 1998, pages 228 - 33;;POL S ET AL., J HEPATOL, vol. 34, 2001, pages 917 - 21;;VALANDSCHOOT P ET AL., J. MED VIROL, vol. 70, 2003, pages 513 - 519;;LORENZO LJ ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 281, no. 4, 2001, pages 962 - 965",PENDING
354,KR,A,KR 20060117920 A,154-730-722-939-810,2006-11-17,2006,KR 20067008110 A,2006-04-27,CU 20030240 A,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,"The invention relates to therapeutic vaccines against pathogens which cause chronic diseases. More specifically, the invention relates to the use of the hepatitis B virus surface antigen (HBsAg) which is produced by recombinant means from Pichia pastoris, by way of a main component, in order to obtain pharmaceutical compositions for therapeutic purposes. The inventive compositions can comprise a combination of the hepatitis B antigen and other coadministered antigens. The aforementioned formulations can generate a strong lymphoproliferative response and cytotoxic T lymphocytes, as well as a significant specific antibody response. In this way, said formulations are very effective for the treatment of the above-mentioned diseases in humans.",CT INGENIERIA GENETICA BIOTECH,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/154-730-722-939-810,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/12;;A61K39/21;;A61K39/29;;A61K39/295;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
355,CU,A1,CU 23405 A1,175-359-440-521-22X,2009-08-04,2009,CU 20030240 A,2003-10-20,CU 20030240 A,2003-10-20,COMPOSICIONES FARMACÉUTICAS PARA USO TERAPÉUTICO,"Vacunas terapéuticas contra patógenos que causan enfermedades crónicas. Uso del antígeno de la superficie del virus de la hepatitis B (HbsAg), producido por vía recombinante a partir de Pichia pastoris, como componente principal, para la obtención de composiciones farmacéuticas con fines terapéuticos. Las mismas pueden comprender la combinación del antígeno de hepatitis b con otros antigenos coadministrados. Estas formulaciones son capaces de generar una potente respuesta linfoproliferativa y de linfocitos T citotóxicos, además de una considerable respuesta de anticuerpos específicos, lo que las hace muy efectivas para el tratamiento de estas enfermedades en humanos.",CT INGENIERIA GENETICA BIOTECH,VANLANDSHOOT PETER;;DUARTE CANO CARLOS;;ALVAREZ OBREGON JULIO CESAR;;UBIETA GOMEZ RAIMUNDO;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;ACOSTA RIVERO NELSON;;DUENAS CARRERA SANTIAGO;;IGLESIAS PEREZ ENRIQUE;;AGUILAR RUBIDO JULIO CESAR;;GUILLEN NIETO GERARDO ENRIQUE;;MUZIO GONZALEZ VERENA LUCILA;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/175-359-440-521-22X,Limited Patent,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,EXPIRED
356,US,A1,US 2007/0275012 A1,020-391-514-208-738,2007-11-29,2007,US 57615804 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,Pharmaceutical Compositions for Therapeutic Use,"The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.",AGUILAR RUBIDO JULIO C;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA L;;GUILLEN NIETO GERARDO E;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO C;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS S,AGUILAR RUBIDO JULIO C;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA L;;GUILLEN NIETO GERARDO E;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO C;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS S,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2006-05-17),https://lens.org/020-391-514-208-738,Patent Application,yes,1,1,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/295;;A61K39/21;;A61K39/29;;A61K39/39;;A61P31/12;;C07K14/02;;C12P21/02,424/202.1,0,0,,,,DISCONTINUED
357,EP,A1,EP 1676587 A1,143-834-628-554-110,2006-07-05,2006,EP 04762299 A,2004-10-20,CU 2004000011 W;;CU 20030240 A,2003-10-20,PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE,"The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in  Picchia pastoris.  The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.",CT INGENIERIA GENETICA BIOTECH,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS SATURNIN,,https://lens.org/143-834-628-554-110,Patent Application,yes,0,2,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
358,ZA,B,ZA 200603126 B,175-842-757-844-473,2007-02-28,2007,ZA 200603126 A,2006-04-19,CU 20030240 A,2003-10-20,Pharmaceutical compositions for therapeutic use,,CT DE INGENIERYA GENUTICA Y BI,CESAR AGUILAR RUBIDO JULIO;;YADIRA LOBAINA MATO;;LUCILA MUZIO GONZSLEZ VERENA;;NELSON ACOSTA RIVERO;;CESAR ALVAREZ OBREGON JULIO;;CARLOS DUARTE CANO;;SATURNINO HERRERA MARTINEZ LUIS;;ENRIQUE IGLESIAS PEREZ;;DAYMIR GARCIA GONZALEZ;;ENRIQUE GUILLUN NIETO GERARDO;;RAIMUNDO UBIETA GOMEZ;;SANTIAGO DUENAS CARRERA;;PETER VANLANDSHOOT,,https://lens.org/175-842-757-844-473,Granted Patent,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K/;;A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,ACTIVE
359,BR,A,BR PI0415654 A,008-206-254-763-898,2006-12-19,2006,BR PI0415654 A,2004-10-20,CU 20030240 A;;CU 2004000011 W,2003-10-20,"composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica","""COMPOSIçõES FARMACêUTICAS PARA USO TERAPêUTICO, USO DO ANTìGENO DE SUPERFìCIE DO VìRUS DA HEPATITE B, E, MéTODO PARA O TRATAMENTO DE INFECçõES POR VìRUS DE PROGRESSãO CRÈNICA"". Vacinas terapêuticas contra patógenos que causam doenças crónicas. O uso do antígeno da superfície do vírus da hepatite B (HBsAg), produzido por via recombinante a partir de Pichia pastoris, como componente principal, para a obtenção de composições farmacêuticas com fins terapêuticos. As mesmas podem compreender a combinação do antígeno de hepatite b com outros antígenos co-administrados. Estas formulações são capazes de gerar uma potente resposta linfoproliferativa e de linfócitos T citotóxicos, além de uma considerável resposta de anticorpos específicos, o que as torna muito efetivas para o tratamento destas doenças em humanos.",CT INGENIERIA GENETICA BIOTECH,RUBIDO JULIO CESAR AGUILAR;;PEREZ ENRIQUE IGLESIAS;;MATO YADIRA LOBAINA;;GONZALES DAYMIR GARCIA;;GONZALEZ VERENA LUCILA MUZIO;;NIETO GERARDO ENRIQUE GUILLEN;;RIVERO NELSON ACOSTA;;GOMEZ RAIMUNDO UBIETA;;OBREGON JULIO CESAR ALVAREZ;;CARRERA SANTIAGO DUE AS;;CANO CARLOS DUARTE;;VANLANDSHOOT PETER;;MARTINEZ LUIS SATURNINO HERRER,,https://lens.org/008-206-254-763-898,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,DISCONTINUED
360,AR,A1,AR 046063 A1,140-975-007-366-141,2005-11-23,2005,AR P040103654 A,2004-10-08,CU 20030240 A,2003-10-20,COMPOSICIONES FARMACEUTICAS PARA USO TERAPEUTICO,"Vacunas terapéuticas contra patógenos que causan enfermedades crónicas. Uso del antígeno de la superficie del virus de la hepatitis B (HBsAg), producido por vía recombinante a partir de Pichia pastoris, como componente principal, para la obtención de composiciones farmacéuticas con fines terapéuticos. Las mismas pueden comprender la combinación del antígeno de hepatitis B con otros antígenos coadministrados. Estas formulaciones son capaces de generar una potente respuesta linfoproliferativa y de linfocitos T citotóxicos, además de una considerable respuesta de anticuerpos específicos, lo que las hace muy efectivas para el tratamiento de estas enfermedades en humanos. Método de tratamiento. Reivindicación 1: Composiciones farmacéuticas para uso terapéutico caracterizadas porque comprenden el antígeno de superficie del Virus de la Hepatitis B producido a partir de levadura por un método de purificación que comprende al menos uno de los pasos siguientes lisado de las células en presencia de un buffer de ruptura que comprende un agente caotrópico; precipitación de contaminantes a pH ácido; sometimiento de la preparación del antígeno a una cromatografía de inmunoafinidad empleando un anticuerpo monoclonal específico para antígeno de superficie del virus de la hepatitis B; y sometimiento del antígeno eluído a un tratamiento térmico a una temperatura entre 30° C y 40° C.",CT INGENIERIA GENETICA BIOTECH,AGUILAR RUBIDO JULIO CESAR;;IGLESIAS PEREZ ENRIQUE;;LOBAINA MATO YADIRA;;GARCIA GONZALEZ DAYMIR;;MUZIO GONZALEZ VERENA LUCILA;;GUILLEN NIETO GERARDO ENRIQUE;;ACOSTA RIVERO NELSON;;UBIETA GOMEZ RAIMUNDO;;ALVAREZ OBREGON JULIO CESAR;;DUENAS CARRERA SANTIAGO;;DUARTE CANO CARLOS A;;VANLANDSHOOT PETER;;HERRERA MARTINEZ LUIS S,,https://lens.org/140-975-007-366-141,Patent Application,no,0,0,16,16,0,A61K39/21;;A61K39/29;;A61K39/292;;A61K2039/55516;;C07K14/005;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/54;;A61K2039/543;;A61K2039/545;;C12N2740/16034;;C12N2770/24234;;A61P31/12;;A61P31/18;;A61K39/39;;A61K39/12;;C07K14/005;;A61K39/292;;A61K39/29;;A61K39/21;;A61K2039/55516;;C12N2730/10122;;C12N2730/10134;;A61K39/12;;A61K2039/70;;A61K2039/545;;C12N2770/24234;;A61K2039/543;;A61K2039/54;;C12N2740/16034,A61K39/21;;A61K39/29;;A61K39/295;;A61K39/39;;C07K14/02;;C12P21/02,,0,0,,,,PENDING
361,CU,A1,CU 22559 A1,068-678-622-381-845,1999-05-03,1999,CU 1996010 A,1996-01-17,CU 1996010 A,1996-01-17,SISTEMA DE EXPRESIÓN DE ANTÍGENOS HETEROLOGOS EN E. COLI COMO PROTEÍNAS DE FUSIÓN,"La presente invención está relacionada con la rama de la biotecnología y la ingeniería genética, particularmente con la expresión de proteínas heterólogas en microorganismos mediante su fusión, usando la tecnología del ADN recombinante, a péptidos bacterianos. El objetivo técnico que se persigue con la solución propuesta es el desarrollo de un procedimiento eficaz para la expresión en Escherichia coli de proteínas heterólogas como polipéptidos de fusión con vistas a su obtención con un alto grado de pureza, en cantidades comercialmente útiles, y de forma que permita su inclusión en preparados vacunales destinados al uso en humanos. Para lograr el mismo se emplea esencialmente una secuencia estabilizadora derivada de los primeros 47 aminoácidos del antígeno P64k de Neisseria meningitidis B:4:P1.15. En particular, se usa un plasmidio recombinante conteniendo dicha secuencia bajo el control del promotor triptófano de E. coli y del terminador de la transcripción del fago T4, incluyendo sitios de restricción que permiten la clonación en fase de fragmentos de ADN codificantes para polipéptidos de interés. El procedimiento objeto de la presente invención es aplicable en la industria farmacéutica, para el desarrollo de sistemas de diagnóstico, de preparados vacunales, y en cualquier situación donde sea necesaria la obtención en grandes cantidades de proteínas heterólogas como polipéptidos de fusión en E. coli.",CT INGENIERIA GENETICA BIOTECH,DUARTE CANO CARLOS ANTONIO;;NAZABAL GALVEZ CONSUELO;;GOMEZ RODRIGUEZ CARMEN ELENA;;CARPIO MUNOZ EMILIO LUIS;;MARTIN DUNN ALEJANDRO MIGUEL;;ALVAREZ ACOSTA ANABEL;;QUINTANA VAZQUEZ DIOGENES;;LEAL ANGULO MARIA DE JESUS;;MONTERO RAMOS MARINIEVE;;SILVA RODRIGUEZ RICARDO DE LA CARIDAD;;GUILLEN NIETO GERARDO ENRIQUE;;MENENDEZ ALARCON ALFREDO,,https://lens.org/068-678-622-381-845,Limited Patent,no,0,0,33,33,0,A61K39/00;;C07K14/005;;C07K14/22;;C07K16/1217;;C07K2319/00;;C07K2319/40;;C07K2319/75;;C12N15/62;;C12N2740/16122;;Y10S530/825;;Y10S530/82;;A61P31/04;;A61P31/12;;C12N15/62;;C07K14/22;;C12N1/20;;C07K14/005;;C07K2319/40;;C12N2740/16122;;C12N15/62;;C07K14/22;;C07K2319/00;;C07K16/1217;;A61K39/00;;C07K2319/75;;Y10S530/825;;Y10S530/82,G01N33/569;;A61K39/00;;A61K39/095;;A61K39/395;;A61K39/40;;A61P31/04;;A61P31/12;;C07K1/22;;C07K14/16;;C07K14/22;;C07K16/00;;C07K16/12;;C07K19/00;;C12N1/21;;C12N15/02;;C12N15/31;;C12N15/48;;C12N15/62;;C12N15/70;;C12P21/02;;C12P21/08;;C12R1/19,,0,0,,,,EXPIRED
